U.S. patent application number 12/865713 was filed with the patent office on 2011-03-03 for hsp90 inhibitors.
This patent application is currently assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED. Invention is credited to Young K. Chen, Eric Wang Co, Prasuna Guntupalli, John David Lawson, Wolfgang Reinhard Ludwig Notz, Jeffrey A. Stafford, Huong-Thu Ton-Nu.
Application Number | 20110053873 12/865713 |
Document ID | / |
Family ID | 40436400 |
Filed Date | 2011-03-03 |
United States Patent
Application |
20110053873 |
Kind Code |
A1 |
Chen; Young K. ; et
al. |
March 3, 2011 |
HSP90 INHIBITORS
Abstract
The invention relates to HSP90 inhibiting compounds consisting
of the formula: (I) wherein the variables are as defined herein.
The invention also relates to pharmaceutical compositions, kits and
articles of manufacture comprising such compounds; methods and
intermediates useful for making the compounds; and methods of using
said compounds. ##STR00001##
Inventors: |
Chen; Young K.; (San Diego,
CA) ; Co; Eric Wang; (San Diego, CA) ;
Guntupalli; Prasuna; (San Diego, CA) ; Lawson; John
David; (Carlsbad, CA) ; Notz; Wolfgang Reinhard
Ludwig; (San Diego, CA) ; Stafford; Jeffrey A.;
(San Diego, CA) ; Ton-Nu; Huong-Thu; (San Diego,
CA) |
Assignee: |
TAKEDA PHARMACEUTICAL COMPANY
LIMITED
Osaka
JP
|
Family ID: |
40436400 |
Appl. No.: |
12/865713 |
Filed: |
January 30, 2009 |
PCT Filed: |
January 30, 2009 |
PCT NO: |
PCT/US09/32728 |
371 Date: |
November 18, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61025725 |
Feb 1, 2008 |
|
|
|
61101595 |
Sep 30, 2008 |
|
|
|
Current U.S.
Class: |
514/27 ;
514/210.18; 514/234.2; 514/249; 514/255.05; 514/264.11; 536/17.4;
544/117; 544/279 |
Current CPC
Class: |
A61P 31/20 20180101;
A61P 19/02 20180101; A61P 9/10 20180101; A61P 37/06 20180101; A61P
25/04 20180101; C07D 401/10 20130101; A61P 25/14 20180101; A61P
25/28 20180101; A61P 35/02 20180101; A61P 35/00 20180101; A61P 1/04
20180101; A61P 17/02 20180101; C07D 239/84 20130101; C07D 401/14
20130101; A61P 37/02 20180101; A61P 7/06 20180101; A61P 17/00
20180101; A61P 17/06 20180101; A61P 31/10 20180101; A61P 35/04
20180101; A61P 27/02 20180101; A61P 43/00 20180101; A61P 31/22
20180101; A61P 29/00 20180101; A61P 9/00 20180101; A61P 11/00
20180101; A61P 21/00 20180101; A61P 37/08 20180101; C07D 487/04
20130101; A61P 31/14 20180101; A61P 19/08 20180101; A61P 25/16
20180101; A61P 11/06 20180101 |
Class at
Publication: |
514/27 ; 544/279;
544/117; 514/210.18; 514/255.05; 514/249; 514/264.11; 514/234.2;
536/17.4 |
International
Class: |
C07D 471/04 20060101
C07D471/04; A61K 31/497 20060101 A61K031/497; A61K 31/4985 20060101
A61K031/4985; A61K 31/519 20060101 A61K031/519; A61K 31/5377
20060101 A61K031/5377; C07H 17/02 20060101 C07H017/02; A61K 31/706
20060101 A61K031/706; A61P 35/00 20060101 A61P035/00; A61P 25/16
20060101 A61P025/16; A61P 25/28 20060101 A61P025/28; A61P 29/00
20060101 A61P029/00; A61P 19/02 20060101 A61P019/02; A61P 9/00
20060101 A61P009/00 |
Claims
1. A compound of formula: ##STR00344## or a tautomer, stereoisomer,
or pharmaceutically acceptable salt thereof, wherein X is O;
R.sub.1 is --L--R.sub.45; R.sub.2 is selected from the group
consisting of hydrogen and methyl; R.sub.3 is of the formula
##STR00345## wherein Ring C is selected from the group consisting
of (C.sub.4-6)aryl or (C.sub.1-5)heteroaryl, each unsubstituted or
substituted with said 1-3 substituents selected from the group
consisting halo, alkoxy, alkyl, amino, alkylamino, haloalkyl, and
haloalkoxy; R.sub.12 is selected from the group consisting of
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
hetero(C.sub.4-12)bicycloaryl, (C.sub.3-12)cycloalkyl, and
hetero(C.sub.2-11)cycloalkyl, each unsubstituted or substituted
with 1-3 substituents; R.sub.4 is selected from the group
consisting of hydrogen, (C.sub.1-6)alkyl, (C.sub.2-6)alkenyl,
(C.sub.2-6)alkynyl, hydroxy(C.sub.1-6)alkyl, amino(C.sub.1-6)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.3-7)cycloalkyl,
(C.sub.5-7)cycloalkenyl, and hetero(C.sub.3-12)cycloalkyl, each
unsubstituted or substituted; R.sub.6 and R.sub.6' are each
independently selected from the group consisting of hydrogen,
halogen, unsubstituted or substituted (C.sub.1-6)alkyl; R.sub.45 is
selected from the group consisting of hydrogen, hydroxyl, halo,
(C.sub.1-3)alkyl, hydroxy(C.sub.1-3)alkyl, (C.sub.1-3)alkoxy,
amino, carbonylamino aminocarbonyl, carbonyl, hydroxylcarbonyl,
(C.sub.4-6)aryl, hetero(C.sub.1-5)aryl, (C.sub.3-6)cycloalkyl, and
hetero(C.sub.3-5)cycloalkyl, each unsubstituted or substituted; L
is (--CR.sub.46R.sub.47--).sub.n; n is 1, 2, 3, 4, or 5; R.sub.46
and R.sub.47 are each independently selected from the group
consisting of hydrogen, hydroxyl, oxo, (C.sub.1-6)alkyl,
hydroxy(C.sub.1-6)alkyl, (C.sub.1-6)alkoxy, amino and
aminocarbonyl, each substituted or unsubstituted.
2-5. (canceled)
6. The compound according to claim 1 consisting of the formula
##STR00346##
7-18. (canceled)
19. The compound according to any one of claim 1 or 6, wherein L is
(--CR.sub.46R.sub.47--).sub.5.
20. The compound according to any one of claim 1 or 6, wherein L is
(--CR.sub.46R.sub.47--).sub.4.
21. The compound according to any one of claim 1 or 6, wherein L is
(--CR.sub.46R.sub.47--).sub.3.
22. The compound according to any one of claim 1 or 6, wherein L is
(--CR.sub.46R.sub.47--).sub.2.
23. The compound according to any one of claim 1 or 6, wherein L is
--CR.sub.46R.sub.47--.
24-29. (canceled)
30. The compound according to any one of claims 1 or 6, wherein
R.sub.1 is selected from the group consisting of ##STR00347##
31-49. (canceled)
50. The compound according to claim 30, wherein R.sub.2 is
hydrogen.
51. The compound according to claim 50, wherein R.sub.2 is
methyl.
52-53. (canceled)
54. The compound according to claim 51, wherein R.sub.4 is
hydrogen.
55-60. (canceled)
61. The compound according to claim 54, wherein R.sub.6 and
R.sub.6' are both hydrogen.
62-75. (canceled)
76. The compound according to claim 61, wherein at least one of the
1-3 substituents on Ring C is selected from the group consisting of
fluoro, methyl, and methoxy.
77-86. (canceled)
87. The compound according to claim 76, wherein R.sub.3 is selected
from the group consisting of ##STR00348##
88-98. (canceled)
100. The compound according to claim 87, where in R.sub.12 is
selected from the group consisting of: ##STR00349## ##STR00350##
##STR00351##
100-112. (canceled)
113. A compound of claim 1 selected from the group consisting of:
(E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-methyl oxime;
(R,E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-di-
hydroquinazolin-5(6H)-one O-methyl oxime;
(S,E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-di-
hydroquinazolin-5(6H)-one O-methyl oxime;
(E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-tert-butyl oxime;
(E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-isobutyl oxime;
(E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-benzyl oxime;
(E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-4-nitrobenzyl oxime;
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-2-methoxyethyl oxime;
(R,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-2-methoxyethyl oxime
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-2-methoxyethyl oxime
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-(R)-2,3-dihydroxypropyl oxime;
(R,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-(R)-2,3-dihydroxypropyl oxime;
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-(R)-2,3-dihydroxypropyl oxime;
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-2-tert-butoxyethyl oxime;
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-3-methoxypropyl oxime;
(E)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydroquinazolin-5(6H)-ylideneaminooxy)acetic acid;
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-(S)-2,3-dihydroxypropyl oxime;
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-2-aminoethyl oxime;
(R,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-2-aminoethyl oxime;
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-2-aminoethyl oxime;
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-pyridin-3-ylmethyl oxime;
(Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-pyridin-3-ylmethyl oxime;
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-3-hydroxy-2-(hydroxymethyl)propyl oxime;
(R,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-3-hydroxy-2-(hydroxymethyl)propyl
oxime;
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-3-hydroxy-2-(hydroxymethyl)propyl
oxime;
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-(S)-3,4-dihydroxybutyl oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O-(R)-2,3-dihydroxypropyl
oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O-(S)-2,3-dihydroxypropyl
oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3-hydroxy-2-(hydroxymethyl)propyl oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(R)-3,4-dihydroxybutyl oxime;
(S)-4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)pheny-
l)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)amino)butane-1-
,2-diol;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-meth-
yl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((R)-1,4-dioxan-2-yl)methyl oxime;
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-morpholin-2-ylmethyl
oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O-(R)-morpholin-2-ylmethyl
oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O-(S)-morpholin-2-ylmethyl
oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2R,3S,4R)-3,4,5-trihydroxytetrahydrofuran-2-yl)methyl oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2R,3S,4R,5R)-3,4-dihydroxy-5-methoxytetrahydrofuran-2-yl)methyl
oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((3aR,4R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-
-4-yl)methyl oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2R,3S,4R,55)-3,4-dihydroxy-5-methoxytetrahydrofuran-2-yl)methyl
oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((3aR,4R,6S,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-
-4-yl)methyl oxime;
(R,Z)-2-amino-7-(3'-(cyclopropylsulfonyl)-5-fluorobiphenyl-2-yl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(S)-2,3-dihydroxypropyl oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2R,3S,4S)-3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2S,4R)-4-hydroxypyrrolidin-2-yl)methyl oxime;
(3R,5S)-1-acetyl-5-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-y-
l)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminoox-
y)methyl)pyrrolidin-3-yl acetate,
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((3R,4S)-3,4-dihydroxycyclopentyl)methyl oxime;
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3,4-dihydroxy-4-methylpentyl oxime;
(R)-4-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phen-
yl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)meth-
yl)oxazolidin-2-one;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O-2-morpholinoethyl oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(tetrahydro-2H-pyran-4-yl)methyl oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((1s,4S)-4-hydroxycyclohexyl)methyl oxime;
(S)-44(Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-met-
hyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-hydroxybut-
anamide;
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-met-
hyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-2-(morpholin-2-yl)ethyl oxime;
(S)-4-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phen-
yl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)meth-
yl)-3-benzyloxazolidin-2-one;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(R)-2-amino-3-hydroxypropyl oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(1-methyl-1H-imidazol-4-yl)methyl oxime;
(R,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazin-2-yl)-4-fluorophenyl)-4-meth-
yl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(S)-3,4-dihydroxybutyl oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(S)-3,4-dihydroxybutyl oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(2-methoxythiazol-4-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(S)-3,4-dihydroxybutyl oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyridol[4,3-d]pyrimidin-5(6H)-one
O-(S)-4,5-dihydroxypentyl oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(S)-3-amino-2-hydroxypropyl oxime;
(S)-5-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-m-
ethyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)methyl)oxaz-
olidin-2-one;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O-3-hydroxypropyl oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O-4-hydroxybutyl oxime;
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-3-hydroxy-2-methoxypropyl
oxime;
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O-(R)-4,5-dihydroxypentyl
oxime;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-(2-hydroxyethyl)--
N-methylacetamide;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N,N-dimethylacetami-
de;
2-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((S)-3-hy-
droxypyrrolidin-1-yl)ethanone;
2-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((R)-3-fluor-
opyrrolidin-1-yl)ethanone;
(S)-4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-hydroxybu-
tanoic acid;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxybutana-
mide;
(S,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl--
7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(R)-3,4-dihydroxybutyl oxime;
(R)-2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)pheny-
l)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hy-
droxy-N,N-dimethylbutanamide;
(S)-2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-N-
,N-dimethylbutanamide;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-1-mor-
pholinobutan-1-one;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-methoxy-N,N-d-
imethylbutanamide;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-c]pyrimidin-5(6H)-ylidene)aminooxy)-N--((S)-2,3-dih-
ydroxypropyl)-N-methylacetamide;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N,N-bis(2-hydroxyet-
hyl)acetamide;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-N,N-bis(2-hydro-
xypropyl)acetamide;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(azetidin-1-yl)et-
hanone;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(pyrrolidi-
n-1-yl)ethanone;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((S)-2-(hydro-
xymethyl)pyrrolidin-1-yl)ethanone;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(4-hydroxypiperid-
in-1-yl)ethanone;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-methyl-N-((6-meth-
ylpyridin-2-yl)methyl)acetamide;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N,N-bis(2-methoxyet-
hyl)acetamide;
(R,Z)-N-(2-amino-2-oxoethyl)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
-yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-c]pyrimidin-5(6H)-ylideneaminoo-
xy)-N-methylacetamide;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((R)-2-(hydro-
xymethyl)pyrrolidin-1-yl)ethanone;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-(2-methoxyethyl)--
N-methylacetamide;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((R)-3-hydrox-
ypyrrolidin-1-yl)ethanone;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((R)-3-hydrox-
ypiperidin-1-yl)ethanone;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((S)-3-hydrox-
ypyrrolidin-1-yl)ethanone;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((S)-3-hydrox-
ypiperidin-1-yl)ethanone;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(3-hydroxyazetidi-
n-1-yl)ethanone;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(3,3-difluoropyrr-
olidin-1-yl)ethanone;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((R)-3-fluoro-
pyrrolidin-1-yl)ethanone;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((S)-3-fluoro-
pyrrolidin-1-yl)ethanone;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(4-methoxypiperid-
in-1-yl)ethanone;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(3,3-difluoroazet-
idin-1-yl)ethanone;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-(3-(methoxyme-
thyl)piperidin-1-yl)ethanone;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-methyl-N-(2-(meth-
ylamino)-2-oxoethyl)acetamide;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-(isoxazol-3-ylmet-
hyl)-N-methylacetamide;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-methyl-N-(thiazol-
-4-ylmethyl)acetamide;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(pyrazin-2-yl)eth-
anone;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4--
methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-(3-(dim-
ethylamino)piperidin-1-yl)ethanone;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-(2-methyltetr-
ahydro-1H-pyrrolo[3,4-c]pyridin-5 (6H ,7H ,7 aH)-yl)ethanone;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-methyl-N-((5-meth-
yl-1H-pyrazol-3-yl)methyl)acetamide;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(2-methyl-6,7-dih-
ydro-3H-imidazo[4,5-c]pyridin-5(4H)-yl)ethanone;
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-(3-(hydroxyme-
thyl)pyrrolidin-1-yl)ethanone;
2-(2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-met-
hyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)acetyl)hexahy-
dropyrrolo[1,2-a]pyrazin-6(7H)-one;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(3-methoxyazetidi-
n-1-yl)ethanone;
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(4,4-difluoropipe-
ridin-1-yl)ethanone;
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-3,4-dihydroxybutyl oxime;
(7R,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazin-2-yl)-4-fluorophenyl)-4-met-
hyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3,4-dihydroxybutyl oxime;
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-meth-
yl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxy-5-methoxytetrahydrofuran-2-yl)methyl oxime;
(7R,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazin-2-yl)-4-fluorophenyl)-4-met-
hyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxy-5-methoxytetrahydrofuran-2-yl)methyl oxime;
5-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)methyl)-3,4-dih-
ydroxydihydrofuran-2(3H)-one;
5-(((Z)-((R)-2-amino-7-(2-(5-amino-6-methoxypyrazin-2-yl)-4-fluorophenyl)-
-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)methyl)-
-3,4-dihydroxydihydrofuran-2(3H)-one;
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime;
(7R,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazin-2-yl)-4-fluorophenyl)-4-met-
hyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime;
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxypyrrolidin-2-yl)methyl oxime;
(7R,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazin-2-yl)-4-fluorophenyl)-4-met-
hyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxypyrrolidin-2-yl)methyl oxime;
(7S,Z)-2-amino-8,8-difluoro-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)--
4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3,4-dihydroxybutyl oxime;
(7S,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazin-2-yl)-4-fluorophenyl-
)-8,8-difluoro-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3,4-dihydroxybutyl oxime;
(7S,Z)-2-amino-8,8-difluoro-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)--
4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime;
(7S,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazin-2-yl)-4-fluorophenyl)-8,8-d-
ifluoro-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime;
(7S,Z)-2-amino-8,8-difluoro-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)--
4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxypyrrolidin-2-yl)methyl oxime;
(7S,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazin-2-yl)-4-fluorophenyl)-8,8-d-
ifluoro-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxypyrrolidin-2-yl)methyl oxime;
(7S,Z)-2-amino-8-fluoro-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3,4-dihydroxybutyl oxime;
(7S,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazin-2-yl)-4-fluorophenyl-
)-8-fluoro-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3,4-dihydroxybutyl oxime;
(7S,Z)-2-amino-8-fluoro-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime;
(7S,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazin-2-yl)-4-fluorophenyl)-8-flu-
oro-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime;
(7S,Z)-2-amino-8-fluoro-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxypyrrolidin-2-yl)methyl oxime;
(7S,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazin-2-yl)-4-fluorophenyl)-8-flu-
oro-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxypyrrolidin-2-yl)methyl oxime;
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-3-amino-4-hydroxybutyl
oxime;
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-4-amino-3-hydroxybutyl
oxime;
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-2-amino-3-hydroxypropyl
oxime; and
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl--
7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3-amino-2-hydroxypropyl oxime.
114. The compound according to any one of claims 1 or 113, wherein
the compound is in the form of a pharmaceutically acceptable
salt.
115. The compound according to any one of claims 1 or 113, wherein
the compound is present as a mixture of stereoisomers.
116. The compound according to any one of claims 1 or 113, wherein
the compound is present as a single stereoisomer.
117. A pharmaceutical composition comprising as an active
ingredient a compound according to any one of claim 1 or 113 and a
pharmaceutical excipient.
118-186. (canceled)
Description
FIELD OF THE INVENTION
[0001] The present invention relates to compounds that may be used
to inhibit heat shock protein 90 (HSP90) as well as compositions of
matter, kits and articles of manufacture comprising these
compounds. The invention also relates to methods for inhibiting
HSP90 and treatment methods using compounds according to the
present invention. In addition, the invention relates to methods of
making the compounds of the present invention, as well as
intermediates useful in such methods. In particular, the present
invention relates to HSP90 inhibitors, compositions of matter, kits
and articles of manufacture comprising these compounds, methods for
inhibiting HSP90, and methods and intermediates useful for making
the inhibitors.
BACKGROUND OF THE INVENTION
[0002] Molecular chaperones maintain the appropriate folding and
conformation of nascent polypeptides. This activity is crucial in
regulating the balance between protein synthesis and degradation.
When a protein is damaged, molecular chaperones may also facilitate
their re-folding or, in the case of irreparably impaired proteins,
their removal by the protein degradation machinery of the
cell.sup.1
[0003] Heat shock proteins (HSPs) were originally defined according
to their increased expression in response to diverse cellular
insults such as elevated temperature as well as exposure to heavy
metals and oxidative stress.sup.1. Most, but not all HSPs are
molecular chaperones that are organized into families according to
their molecular size or function, including HSP100, HSP90, HSP70,
HSP60, HSP40 and small HSPs. The rapid induction of HSP gene
expression is referred to as the heat shock response (HSR) which
confers cytoprotection to repeat exposure of the initial insult
which would otherwise cause lethal molecular damage.sup.2.
Cytoprotection is an example of increased molecular chaperone
expression associated with the functioning of normal cells within
an organism. However, aberrant expression of this family of
proteins can also be associated with several disease states.
[0004] A large body of evidence exists supporting the role of
molecular chaperones in maintaining the cancer phenotype. In
addition, increasing evidence associating molecular chaperone
expression with other disease including but not limited to:
neurodegenerative disorders including Parkinson's, Alzheimer's,
Huntington's and prion-related disease, inflammation and
inflammation related disorders such as pain, headaches, fever,
arthritis, asthma, bronchitis, tendonitis, eczema, inflammatory
bowel disease, and the like, and diseases dependent on angiogenesis
such as, cancer, arthritis, diabetic retinopathy, age associated
macular degeneration (AMD) and infectious diseases in particular
fungal infections, viral diseases including but not limited to
diseases caused by hepatitis B virus (HBV), hepatitis C virus (HCV)
and herpes simplex virus type-1 (HSV-1), cardiovascular and central
nervous system diseases.sup.3,4,5,6,7.
[0005] HSP90 is an abundant molecular chaperone which constitutes
1-2% of total cellular protein. It exerts its chaperone function to
ensure the correct conformation, activity, intracellular
localization and proteolytic turnover of a range of proteins that
are involved in cell growth, differentiation and
survival.sup.3,5,8. Because of the large number of important
signaling proteins with which HSP90 has been shown to associate and
assist in stabilizing (these are generally called HSP90 client
proteins), a rationale exists for the therapeutic use of HSP90
inhibitors for the treatment of a wide range of human diseases (as
discussed above).sup.9.
[0006] HSP90 activity is required for the stability and the
function of many oncogenic client proteins, which contribute to all
of the hallmark traits of malignancy, and thus, HSP90 has been
widely acknowledged as an attractive therapeutic target for the
treatment of cancer.sup.3,4,5,8. These client proteins include:
BCR-ABL, AKT/PKB, C-RAF, CDK4, steroid hormone receptors (estrogen
and androgen), surviving, c-Met, HER-2, and telomerases among
others. Inhibition of HSP90 function leads to the destabilization
and degradation of client proteins via the ubiquitin-proteasome
pathway, resulting in the down-regulation of several signals being
propagated via oncogenic signaling pathways and modulation of all
aspects of the malignant phenotype.sup.3,5,8. Therefore, HSP90
inhibitors have potential to treat cancers driven by numerous
diverse molecular abnormalities and their combinatorial effects
could also reduce the possibility of resistance developing.
[0007] HSP90 is considered to exert its chaperone function via a
cycle which utilizes the coordinated interaction of a number of
co-chaperone proteins that are collectively involved in an
orchestrated, mutually regulatory interplay with ATP/ADP exchange
and ATP hydrolysis by the intrinsic and essential N-terminal ATPase
domain. Crystallographic studies have revealed that several HSP90
inhibitors occupy the N-terminus ATP binding site.sup.10, thereby
inhibiting HSP90 ATPase activity and function.
[0008] The 14-membered macrocyclic antibiotic radicicol was first
demonstrated to have anti-tumor activity in vitro and shown to
reverse the malignant phenotype of v-SRC transformed cells.sup.11.
Subsequently, radicicol was shown using X-ray crystallography to
bind to the N-terminal ATP-binding pocket of HSP90 with high
affinity.sup.10, and to inhibit HSP90 ATPase activity resulting in
the degradation of a number of signaling proteins.sup.12. Although
radicicol inhibits tumor cell growth in vitro, it lacks activity in
vivo, most likely due to its potentially reactive epoxide moiety
and other adverse chemical features that cause instability and
possible toxicity.sup.8,13.
[0009] The benzoquinone ansamycins are a second class of naturally
occurring antibiotics which have been demonstrated to inhibit the
activity of HSP90. The first example is geldanamycin which also
competes with ATP for binding to the N-terminal nucleotide binding
site of HSP90.sup.14. As was the case with radicicol, despite
promising anti-tumor activity in vitro (and in vivo), the
development of geldanamycin into a human therapeutic was stopped
due to compound instability and unacceptable hepatotoxicity at
therapeutic doses.sup.15.
[0010] Analogs of geldanamycin have been pursued with the objective
of finding agents with an improved safety margin for clinical use,
including the derivative 17-allylamino-17-demethoxygeldanamycin
(17-AAG or tanespimycin).sup.16. 17-AAG has similar cellular
effects to geldanamycin, including client protein degradation, and
cell cycle arrest but with improved metabolic stability and lower
toxicity.sup.5,8. Preclinical studies using 17-AAG have shown this
derivative to be highly potent in vitro and to exhibit anti-tumor
activity at non-toxic doses in various human tumor xenograft
models.sup.17,18. Based on its biological activity, 17-AAG has
recently completed several phase I clinical trials with some
encouraging results.sup.9,19. As a result, 17-AAG has now entered
phase II monotherapy clinical trials in various tumor types,
including melanoma and breast.
[0011] There are several possible factors which may reduce the
clinical efficacy of 17-AAG. Preclinical studies have shown that
hepatic metabolism of 17-AAG by cytochrome P450 leads to the
formation of 17-amino-17-demethoxygeldanamycin (17-AG).sup.17.
Although 17-AG retains inhibitory activity, metabolism by CYP3A4 is
likely to be a cause of variable pharmacokinetics. In addition, the
activity of 17-AAG is enhanced by its conversion to the
hydroquinone form, 17-AAGH.sub.2, by the reductase enzyme NQO1 or
DT-diaphorase.sup.17,20. The polymorphic expression of both of
these metabolic enzymes may pose limitations for the clinical use
of 17-AAG across the population.sup.5,8,17. The efficacy of 17-AAG
may be further reduced by its association with the multi-drug
resistance protein MDR1 or P-glycoprotein.sup.17. Finally, 17-AAG
is limited by its poor solubility, cumbersome and complex
formulation and lack of oral bioavailability. Attempts to
reformulate 17-AAG have resulted in clinical trials commencing with
CNF1010 and a cremaphore-based formulation (KOS-953) the latter of
which has shown promising results during the phase I trial in
patients with relapsed-refractory myeloma. The US National Cancer
Institute and Kosan Biosciences have also developed a more water
soluble and potentially orally bioavailable analog of 17-AAG,
17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG or
alvespimycin, which was evaluated in preclinical and clinical
trials.sup.9. 17-AAGH.sub.2, also known as IPI-504, has also
entered clinical trial as a soluble derivative of
17-AAG.sup.21.
[0012] Non-natural product HSP90 inhibitors have recently been
described. One of these contains a 3,4-diarylpyrazole resorcinol
scaffold. These molecules were exemplified by Compound CCT018159,
and analogues CCT0129397/VER-49009 and VER-50589. Treatment of
cancer cells with these HSP90 inhibitors resulted in HSP70
induction, client protein depletion, cytostasis and
apoptosis.sup.22,23,24,25.
[0013] Rational drug design was used by Chiosis et al..sup.26 to
develop a novel class of HSP90 inhibitors with a purine-scaffold.
The first compound to be identified from this series, PU3, bound to
HSP90 with moderate affinity resulting in cellular effects which
are characteristic of HSP90 inhibitors.sup.26. An important feature
of PU3 is that it is more soluble than 17-AAG; however, it is also
significantly less potent against cells than the ansamycins.sup.26.
Subsequent efforts focused on improving the potency of PU3 and led
to the identification of PU24FCl.sup.27. This compound exhibited
biological effects on cells within a concentration range of 2-6
.mu.M.sup.27, and also demonstrated 10-50 times higher affinity for
HSP90 from transformed cells compared to that from normal
tissues.sup.27. Administration of PU24FCl in human breast tumor
xenograft models led to anti-tumor activity without significant
toxicity.sup.27. A more recent study has identified 8-arylsulfanyl,
8-arylsulfoxyl and 8-arylsulfonyl adenine derivatives of the PU
class which exhibit improved water solubility and approximately 50
nM potency in cellular models, together with therapeutic activity
in human tumor xenograft models.sup.28.
[0014] Additional non-natural product small molecule inhibitors of
HSP90 have been identified including 2-amino-quinazolin-5-one
compounds (WO2006113498A2),
2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds
(WO2007041362A1) and quinazolin-oxime derivatives (WO2008142720A2)
which target HSP90 for the prophylaxis or treatment of cell
proliferative diseases. These molecules have reasonable potency and
drug-likeness.
[0015] The preclinical proof-of-concept provide by small molecules
with reasonable drug like properties coupled with the clinical
proof-of-concept for the approach of inhibition of HSP90 activity
achieved with 17-AAG, has generated a high level of interest in
industry to develop additional HSP90 inhibitors with improved drug
like properties that can provide therapeutic benefit to patients
suffering from disease states related to abnormal protein
folding.
[0016] The following publications are referred to in the
background: [0017] 1. J. C. Young, V. R. Agashe, K. Siegers and F.
U. Hartl, Pathways of chaperone-mediated protein folding in the
cytosol, Nat. Rev. Mol. Cell. Biol. 5 (2004), pp. 781-791. [0018]
2. S. D. Westerheide and R. I. Morimoto, Heat shock response
modulators as therapeutic tools for diseases of protein
conformation, J. Biol. Chem. 280 (2005), pp. 33097-33100. [0019] 3.
L. Whitesell and S. L. Lindquist, HSP90 and the chaperoning of
cancer, Nat. Rev. Cancer 5 (2005), pp. 761-772. [0020] 4. S. K.
Calderwood, M. A. Khaleque, D. B. Sawyer and D. R. Ciocca, Heat
shock proteins in cancer: chaperones of tumorigenesis, Trends
Biochem. Sci. 31 (2006), pp. 164-172. [0021] 5. M. V. Powers and P.
Workman, Targeting of multiple signaling pathways by heat shock
protein 90 molecular chaperone inhibitors, Endocr. Relat. Cancer 13
(Suppl. 1) (2006), pp. S125-S135. [0022] 6. A. J. Macario and
Conway de Macario, Sick chaperones, cellular stress, and disease,
N. Engl. J. Med. 353 (2005), pp. 1489-1501. [0023] 7. J. M. Barral,
S. A. Broadley, G. Schaffar and F. U. Hartl, Roles of molecular
chaperones in protein misfolding diseases, Semin. Cell Dev. Biol.
15 (2004), pp. 17-29. [0024] 8. S. Sharp and P. Workman, Inhibitors
of the HSP90 molecular chaperone: current status, Adv. Cancer Res.
95 (2006), pp. 323-348. [0025] 9. S. Pacey, U. Banerji, I. Judson
and P. Workman, Hsp90 inhibitors in the clinic, Handbook Exp.
Pharmacol. 172 (2006), pp. 331-358. [0026] 10. S. M. Roe, C.
Prodromou, R. O'Brien, J. E. Ladbury, P. W. Piper and L. H. Pearl,
Structural basis for inhibition of the Hsp90 molecular chaperone by
the antitumor antibiotics radicicol and geldanamycin, J. Med. Chem.
42 (1999), pp. 260-266. [0027] 11. H. J. Kwon, M. Yoshida, K. Abe,
S. Horinouchi and T. Beppu, Radicicol, an agent inducing the
reversal of transformed phenotypes of src-transformed fibroblasts,
Biosci. Biotechnol. Biochem. 56 (1992), pp. 538-539. [0028] 12. T.
W. Schulte, S. Akinaga, T. Murakata, T. Agatsuma, S. Sugimoto, H.
Nakano, Y. S. Lee, B. B. Simen, Y. Argon, S. Felts, D. O. Toft, L.
M. Neckers and S. V. Sharma, Interaction of radicicol with members
of the heat shock protein 90 family of molecular chaperones, Mol.
Endocrinol. 13 (1999), pp. 1435-1448. [0029] 13. Clarke, P. A.,
Powers, M., and Workman, P. (2006) Inhibition of the molecular
chaperone heat shock protein 90 in cancer: consequences for the
regulation of survival signaling and induction of cell death. In:
Apoptosis and Cancer Therapy (Debatin, K.-M. and Fulda, S., Eds),
pp. 933-959. Wiley-VCH, Weinheim, Germany. [0030] 14. C. Prodromou,
S. M. Roe, R. O'Brien, J. E. Ladbury, P. W. Piper and L. H. Pearl,
Identification and structural characterization of the
ATP/ADP-binding site in the Hsp90 molecular chaperone, Cell 90
(1997), pp. 65-75. [0031] 15. J. G. Supko, R. L. Hickman, M. R.
Grever and L. Malspeis, Preclinical pharmacologic evaluation of
geldanamycin as an antitumor agent, Cancer Chemother. Pharmacol. 36
(1995), pp. 305-315. [0032] 16. R. C. Schnur, M. L. Corman, R. J.
Gallaschun, B. A. Cooper, M. F. Dee, J. L. Doty, M. L. Muzzi, J. D.
Moyer, C. I. DiOrio and E. G. Barbacci, Inhibition of the oncogene
product p185erbB-2 in vitro and in vivo by geldanamycin and
dihydrogeldanamycin derivatives, J. Med. Chem. 38 (1995), pp.
3806-3812. [0033] 17. L. R. Kelland, S. Y. Sharp, P. M. Rogers, T.
G. Myers and P. Workman, DT-Diaphorase expression and tumor cell
sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an
inhibitor of heat shock protein 90, J. Natl. Cancer Inst. 91
(1999), pp. 1940-1949. [0034] 18. U. Banerji, M. Walton, F.
Raynaud, R. Grimshaw, L. Kelland, M. Valenti, I. Judson and P.
Workman, Pharmacokinetic-pharmacodynamic relationships for the heat
shock protein 90 molecular chaperone inhibitor 17-allylamino,
17-demethoxygeldanamycin in human ovarian cancer xenograft models,
Clin. Cancer Res. 11 (2005), pp. 7023-7032. [0035] 19. U. Banerji,
A. O'Donnell, M. Scurr, S. Pacey, S. Stapleton, Y. Asad, L.
Simmons, A. Maloney, F. Raynaud, M. Campbell, M. Walton, S.
Lakhani, S. Kaye, P. Workman and I. Judson, Phase I pharmacokinetic
and pharmacodynamic study of 17-allylamino,
17-demethoxygeldanamycin in patients with advanced malignancies, J.
Clin. Oncol. 23 (2005), pp. 4152-4161. [0036] 20. W. Guo, P.
Reigan, D. Siegel, J. Zirrolli, D. Gustafson and D. Ross, Formation
of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by
NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in
heat shock protein 90 inhibition, Cancer Res. 65 (2005), pp.
10006-10015. [0037] 21. J. R. Sydor, E. Normant, C. S. Pien, J. R.
Porter, J. Ge, L. Grenier, R. H. Pak, J. A. Ali, M. S. Dembski, J.
Hudak, J. Patterson, C. Penders, M. Pink, M. A. Read, J. Sang, C.
Woodward, Y. Zhang, D. S. Grayzel, J. Wright, J. A. Barrett, V. J.
Palombella, J. Adams and J. K. Tong, Development of
17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride
(IPI-504), an anti-cancer agent directed against Hsp90, Proc. Natl.
Acad. Sci. USA 103 (2006), pp. 17408-17413. [0038] 22. K. M.
Cheung, T. P. Matthews, K. James, M. G. Rowlands, K. J. Boxall, S.
Y. Sharp, A. [0039] Maloney, S. M. Roe, C. Prodromou, L. H. Pearl,
G. W. Aherne, E. McDonald and P. Workman, The identification,
synthesis, protein crystal structure and in vitro biochemical
evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors,
Bioorg. Med. Chem. Lett. 15 (2005), pp. 3338-3343. [0040] 23. S. Y.
Sharp, K. Boxall, M. Rowlands, C. Prodromou, S. M. Roe, A. Maloney,
M. Powers, P. A. Clarke, G. Box, S. Sanderson, L. Patterson, T. P.
Matthews, K. M. Cheung, K. Ball, A. Hayes, F. Raynaud, R. Marais,
L. Pearl, S. Eccles, W. Aherne, E. McDonald and P. Workman, In
vitro biological characterization of a novel, synthetic diaryl
pyrazole resorcinol class of heat shock Protein 90 inhibitors,
Cancer Res. 67 (2007), pp. 2206-2216. [0041] 24. B. W. Dymock, X.
Barril, P. A. Brough, J. E. Cansfield, A. Massey, E. McDonald, R.
E. Hubbard, A. Surgenor, S. D. Roughley, P. Webb, P. Workman, L.
Wright and M. J. Drysdale, Novel, potent small-molecule inhibitors
of the molecular chaperone Hsp90 discovered through structure-based
design, J. Med. Chem. 48 (2005), pp. 4212-4215. [0042] 25. S. Y.
Sharp, C. Prodromou, K. Boxall, M. V. Powers, J. L. Holmes, G. Box,
T. P. Matthews, K. M. Cheung, A. Kalusa, K. James, A. Hayes, A.
Hardcastle, B. Dymock, P. A. Brough, X. Barril, J. E. Cansfield, L.
Wright, A. Surgenor, N. Foloppe, R. E. Hubbard, W. Aherne, L.
Pearl, K. Jones, E. McDonald, F. Raynaud, S. Eccles, M. Drysdale
and P. Workman, Inhibition of the heat shock protein 90 molecular
chaperone in vitro and in vivo by novel, synthetic, potent
resorcinylic pyrazole/isoxazole amide analogues, Mol. Cancer. Ther.
6 (2007), pp. 1198-1211. [0043] 26. G. Chiosis, M. N. Timaul, B.
Lucas, P. N. Munster, F. F. Zheng, L. Sepp-Lorenzino and N. Rosen,
A small molecule designed to bind to the adenine nucleotide pocket
of Hsp90 causes Her2 degradation and the growth arrest and
differentiation of breast cancer cells, Chem. Biol. 8 (2001), pp.
289-299. [0044] 27. M. Vilenchik, D. Solit, A. Basso, H. Huezo, B.
Lucas, H. He, N. Rosen, C. Spampinato, P. Modrich and G. Chiosis,
Targeting wide-range oncogenic transformation via PU24FC1, a
specific inhibitor of tumor Hsp90, Chem. Biol. 11 (2004), pp.
787-797. [0045] 28. H. He, D. Zatorska, J. Kim, J. Aguirre, L.
Llauger, Y. She, N. Wu, R. M. Immormino, D. T. Gewirth and G.
Chiosis, Identification of potent water soluble purine-scaffold
inhibitors of the heat shock protein 90, J. Med. Chem. 49 (2006),
pp. 381-390.
SUMMARY OF THE INVENTION
[0046] The present invention relates to compounds that have
activity for inhibiting HSP90. The present invention also provides
compositions, articles of manufacture and kits comprising these
compounds. In addition, the invention relates to methods of making
the compounds of the present invention, as well as intermediates
useful in such methods.
[0047] In one aspect, the invention is directed to compounds having
the formula:
##STR00002##
or a tautomer, stereoisomer, or pharmaceutically acceptable salt
thereof, wherein
[0048] A is NR.sub.4 or CR.sub.5R.sub.5';
[0049] B is CR.sub.7 or N;
[0050] X is O, NR.sub.8 or CR.sub.9R.sub.9';
[0051] R.sub.1 is selected from the group consisting of hydrogen,
carbonyl, hydroxycarbonyl, oxycarbonyl, aminocarbonyl, sulfonyl,
sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, alkoxy(C.sub.1-10)alkyl,
amino(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, carbonylamino(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, hydroxycarbonyl(C.sub.1-10)alkyl,
aminocarbonyl(C.sub.1-10)alkyl, aminosulfonyl(C.sub.1-10)alkyl,
sulfonylamino(C.sub.1-10)alkyl,
(C.sub.1-6)alkylsulfonylamino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted;
[0052] R.sub.2 is selected from the group consisting of hydrogen,
halo, cyano, thio, hydroxy, carbonyloxy, (C.sub.1-10)alkoxy,
(C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy, carbonyl,
oxycarbonyl, aminocarbonyl, amino, (C.sub.1-10)alkylamino,
sulfonamido, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0053] R.sub.3 is selected from the group consisting of hydrogen,
halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy,
(C.sub.1-10)alkoxy, (C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy,
carbonyl, oxycarbonyl, aminocarbonyl, amino,
(C.sub.1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, (C.sub.1-10)alkenyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted with 1-3 substituents, and the substituents on adjacent
atoms may be taken together to form a substituted or unsubstituted
ring;
[0054] R.sub.4 is selected from the group consisting of hydrogen,
carbonyl, oxycarbonyl, amino, (C.sub.1-10)alkylamino, sulfonamido,
sulfonyl, sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.9-12)bicycloalkyl,
hetero(C.sub.3-12)bicycloalkyl, (C.sub.4-12)aryl,
hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl, and
hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0055] R.sub.5 and R.sub.5' are each independently selected from
the group consisting of hydrogen, cyano, carbonyl, oxycarbonyl,
aminocarbonyl, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0056] R.sub.6 and R.sub.6' are each independently selected from
the group consisting of hydrogen, halogen, cyano,
(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted, provided that R.sub.6' is absent when A is
CR.sub.5R.sub.5;
[0057] R.sub.7 is selected from the group consisting of hydrogen,
cyano, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.9-12)bicycloalkyl,
hetero(C.sub.3-12)bicycloalkyl, (C.sub.4-12)aryl,
hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl and
hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0058] R.sub.8 is selected from the group consisting of hydrogen,
(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0059] R.sub.9 and R.sub.9' are each independently selected from
the group consisting of hydrogen, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted; and
[0060] provided that when A is CR.sub.5R.sub.5', B is N, X is O,
R.sub.1 is (C.sub.1-6)alkyl substituted with at least two hydroxyl
groups.
[0061] In another aspect, the invention is directed to salts and
polymorphs of the compounds. Particularly,
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl
oxime benzoate Form A.
[0062] In another aspect, the invention is directed to
pharmaceutical compositions that comprise a HSP90 inhibitor
according to the present invention as an active ingredient.
Pharmaceutical compositions according to the invention may
optionally comprise 0.001%-100% of one or more inhibitors of this
invention. These pharmaceutical compositions may be administered or
coadministered by a wide variety of routes, including for example,
orally, parenterally, intraperitoneally, intravenously,
intraarterially, transdermally, sublingually, intramuscularly,
rectally, transbuccally, intranasally, liposomally, via inhalation,
vaginally, intraocularly, via local delivery (for example by
catheter or stent), subcutaneously, intraadiposally,
intraarticularly, or intrathecally. The compositions may also be
administered or coadministered in slow release dosage forms.
[0063] In another aspect, the invention is directed to kits and
other articles of manufacture for treating disease states
associated with HSP90. In one embodiment, the kit comprises a
composition comprising at least one HSP90 inhibitor of the present
invention in combination with instructions. The instructions may
indicate the disease state for which the composition is to be
administered, storage information, dosing information and/or
instructions regarding how to administer the composition. The kit
may also comprise packaging materials. The packaging material may
comprise a container for housing the composition. The kit may also
optionally comprise additional components, such as syringes for
administration of the composition. The kit may comprise the
composition in single or multiple dose forms.
[0064] In another aspect, the invention is directed to articles of
manufacture that comprise a composition comprising at least one
HSP90 inhibitor of the present invention in combination with
packaging materials. The packaging material may comprise a
container for housing the composition. The container may optionally
comprise a label indicating the disease state for which the
composition is to be administered, storage information, dosing
information and/or instructions regarding how to administer the
composition. The article of manufacture may also optionally
comprise additional components, such as syringes for administration
of the composition. The article of manufacture may comprise the
composition in single or multiple dose forms.
[0065] In yet another aspect of the invention is directed to
methods for preparing compounds, compositions, kits, and articles
of manufacture according to the present invention. For example,
several synthetic schemes are provided herein for synthesizing
compounds according to the present invention.
[0066] In yet other aspect, the invention is directed to methods of
using compounds, compositions, kits and articles of manufacture
according to the present invention.
[0067] In one embodiment, the compounds, compositions, kits and
articles of manufacture are used to inhibit HSP90.
[0068] In another embodiment, the compounds, compositions, kits and
articles of manufacture are used to treat a disease state for which
HSP90 possess activity that contributes to the pathology and/or
symptomology of the disease state.
[0069] In another embodiment, a compound is administered to a
subject wherein HSP90 activity within the subject is altered,
preferably reduced.
[0070] In another embodiment, a prodrug of a compound is
administered to a subject that is converted to the compound in vivo
where it inhibits HSP90.
[0071] In another embodiment, a method of inhibiting HSP90 is
provided that comprises contacting a HSP90 with a compound
according to the present invention.
[0072] In another embodiment, a method of inhibiting HSP90 is
provided that comprises causing a compound according to the present
invention to be present in a subject in order to inhibit HSP90 in
vivo.
[0073] In another embodiment, a method of inhibiting a HSP90 is
provided that comprises administering a first compound to a subject
that is converted in vivo to a second compound wherein the second
compound inhibits HSP90 in vivo. It is noted that the compounds of
the present invention may be the first or second compounds.
[0074] In another embodiment, a therapeutic method is provided that
comprises administering a compound according to the present
invention.
[0075] In another embodiment, a method of treating a condition in a
patient that is known to be mediated by HSP90, or which is known to
be treated by HSP90 inhibitors, comprising administering to the
patient a therapeutically effective amount of a compound according
to the present invention.
[0076] In another embodiment, a method is provided for treating a
disease state for which HSP90 possesses activity that contributes
to the pathology and/or symptomology of the disease state, the
method comprising: causing a compound according to the present
invention to be present in a subject in a therapeutically effective
amount for the disease state.
[0077] In another embodiment, a method is provided for treating a
disease state for which HSP90 possesses activity that contributes
to the pathology and/or symptomology of the disease state, the
method comprising: administering a first compound to a subject that
is converted in vivo to a second compound such that the second
compound is present in the subject in a therapeutically effective
amount for the disease state. It is noted that the compounds of the
present invention may be the first or second compounds.
[0078] In another embodiment, a method is provided for treating a
disease state for which HSP90 possesses activity that contributes
to the pathology and/or symptomology of the disease state, the
method comprising: administering a compound according to the
present invention to a subject such that the compound is present in
the subject in a therapeutically effective amount for the disease
state.
[0079] In another embodiment, a method is provided for using a
compound according to the present invention in order to manufacture
a medicament for use in the treatment of a disease state that is
known to be mediated by HSP90, or that is known to be treated by
HSP90 inhibitors.
[0080] It is noted in regard to all of the above embodiments that
the present invention is intended to encompass all pharmaceutically
acceptable ionized forms (e.g., salts) and solvates (e.g.,
hydrates) of the compounds, regardless of whether such ionized
forms and solvates are specified since it is well known in the art
to administer pharmaceutical agents in an ionized or solvated form.
It is also noted that unless a particular stereochemistry is
specified, recitation of a compound is intended to encompass all
possible stereoisomers (e.g., enantiomers or diastereomers
depending on the number of chiral centers), independent of whether
the compound is present as an individual isomer or a mixture of
isomers. Further, unless otherwise specified, recitation of a
compound is intended to encompass all possible resonance forms and
tautomers. With regard to the claims, the language "compound
comprising the formula," "compound having the formula" and
"compound of the formula" is intended to encompass the compound and
all pharmaceutically acceptable ionized forms and solvates, all
possible stereoisomers, and all possible resonance forms and
tautomers unless otherwise specifically specified in the particular
claim.
[0081] It is further noted that prodrugs may also be administered
which are altered in vivo and become a compound according to the
present invention. The various methods of using the compounds of
the present invention are intended, regardless of whether prodrug
delivery is specified, to encompass the administration of a prodrug
that is converted in vivo to a compound according to the present
invention. It is also noted that certain compounds of the present
invention may be altered in vivo prior to inhibiting HSP90 and thus
may themselves be prodrugs for another compound. Such prodrugs of
another compound may or may not themselves independently have HSP90
inhibitory activity.
BRIEF DESCRIPTION OF THE FIGURES
[0082] FIG. 1 illustrates SEQ ID NO:1 and SEQ ID NO: 2 referred to
in this application.
[0083] FIG. 2 illustrates the powder X-ray diffractogram of
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl
oxime benzoate Form A.
[0084] FIG. 3 shows the differential scanning calorimetry trace and
the thermogravimetric trace of
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl
oxime benzoate Form A.
DEFINITIONS
[0085] Unless otherwise stated, the following terms used in the
specification and claims shall have the following meanings for the
purposes of this Application.
[0086] It is noted that, as used in the specification and the
appended claims, the singular forms "a," "an" and "the" include
plural referents unless the context clearly dictates otherwise.
Further, definitions of standard chemistry terms may be found in
reference works, including Carey and Sundberg "ADVANCED ORGANIC
CHEMISTRY 5.sup.TH ED." Vols. A (2007) and B (2007), Springer
Science+Business Media, New York. Also, unless otherwise indicated,
conventional methods of mass spectroscopy, NMR, HPLC, protein
chemistry, biochemistry, recombinant DNA techniques and
pharmacology, within the skill of the art are employed.
[0087] "*" when appears in a chemical structure, particularly in
radicals, indicates the point of attachment of the radical.
[0088] "Alicyclic" means a moiety comprising a non-aromatic ring
structure. Alicyclic moieties may be saturated or partially
unsaturated with one, two or more double or triple bonds. Alicyclic
moieties may also optionally comprise heteroatoms such as nitrogen,
oxygen and sulfur. The nitrogen atoms can be optionally
quaternerized or oxidized and the sulfur atoms can be optionally
oxidized. Examples of alicyclic moieties include, but are not
limited to moieties with (C.sub.3-8) rings such as cyclopropyl,
cyclohexane, cyclopentane, cyclopentene, cyclopentadiene,
cyclohexane, cyclohexene, cyclohexadiene, cycloheptane,
cycloheptene, cycloheptadiene, cyclooctane, cyclooctene, and
cyclooctadiene.
[0089] "Aliphatic" means a moiety characterized by a straight or
branched chain arrangement of constituent carbon atoms and may be
saturated or partially unsaturated with one, two or more double or
triple bonds.
[0090] "Alkenyl" means a straight or branched, carbon chain that
contains at least one carbon-carbon double bond (--CR.dbd.CR'-- or
--CR.dbd.CR'R'', wherein R, R' and R'' are each independently
hydrogen or further substituents). Examples of alkenyl include
vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl,
2-butenyl, 2-methyl-2-butenyl, and the like. In particular
embodiments, "alkenyl," either alone or represented along with
another radical, can be a (C.sub.2-20)alkenyl, a
(C.sub.2-15)alkenyl, a (C.sub.2-10)alkenyl, a (C.sub.2-5)alkenyl or
a (C.sub.2-3)alkenyl. Alternatively, "alkenyl," either alone or
represented along with another radical, can be a (C.sub.2)alkenyl,
a (C.sub.3)alkenyl or a (C.sub.4)alkenyl.
[0091] "Alkenylene" means a straight or branched, divalent carbon
chain having one or more carbon-carbon double bonds
(--CR.dbd.CR'--, wherein R and R' are each independently hydrogen
or further substituents). Examples of alkenylene include
ethene-1,2-diyl, propene-1,3-diyl, methylene-1,1-diyl, and the
like. In particular embodiments, "alkenylene," either alone or
represented along with another radical, can be a (C.sub.2-20)
alkenylene, a (C.sub.2-15) alkenylene, a (C.sub.2-10) alkenylene, a
(C.sub.2-5) alkenylene or a (C.sub.2-3) alkenylene. Alternatively,
"alkenylene," either alone or represented along with another
radical, can be a (C.sub.2) alkenylene, a (C.sub.3) alkenylene or a
(C.sub.4) alkenylene.
[0092] "Alkoxy" means an oxygen moiety having a further alkyl
substituent. The alkoxy groups of the present invention can be
optionally substituted.
[0093] "Alkyl" represented by itself means a straight or branched,
saturated or unsaturated, aliphatic radical having a chain of
carbon atoms. (C.sub.X)alkyl and (C.sub.X-Y)alkyl are typically
used where X and Y indicate the number of carbon atoms in the
chain. For example, (C.sub.1-6)alkyl includes alkyls that have a
chain of between 1 and 6 carbons (e.g., methyl, ethyl, propyl,
isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, vinyl, allyl,
1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl,
2-methylallyl, ethynyl, 1-propynyl, 2-propynyl, and the like).
Alkyl represented along with another radical (e.g., as in
arylalkyl, heteroarylalkyl and the like) means a straight or
branched, saturated or unsaturated aliphatic divalent radical
having the number of atoms indicated or when no atoms are indicated
means a bond (e.g., (C.sub.6-10)aryl(C.sub.1-3)alkyl includes,
benzyl, phenethyl, 1-phenylethyl, 3-phenylpropyl, 2-thienylmethyl,
2-pyridinylmethyl and the like). In particular embodiments,
"alkyl," either alone or represented along with another radical,
can be a (C.sub.1-20)alkyl, a (C.sub.1-15)alkyl, a
(C.sub.1-10)alkyl, a (C.sub.1-5)alkyl or a (C.sub.1-3)alkyl.
Alternatively, "alkyl," either alone or represented along with
another radical, can be a (C.sub.1)alkyl, a (C.sub.2)alkyl or a
(C.sub.3)alkyl.
[0094] "Alkylene", unless indicated otherwise, means a straight or
branched, saturated or unsaturated, aliphatic, divalent radical.
(C.sub.X)alkylene and (C.sub.X-Y)alkylene are typically used where
X and Y indicate the number of carbon atoms in the chain. For
example, (C.sub.1-6)alkylene includes methylene (--CH.sub.2--),
ethylene (--CH.sub.2CH.sub.2--), trimethylene
(--CH.sub.2CH.sub.2CH.sub.2--), tetramethylene
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--) 2-butenylene
(--CH.sub.2CH.dbd.CHCH.sub.2--), 2-methyltetramethylene
(--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.2--), pentamethylene
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2--) and the like. In
particular embodiments, "alkylene," either alone or represented
along with another radical, can be a (C.sub.1-20)alkylene, a
(C.sub.1-15)alkylene, a (C.sub.1-10)alkylene, a (C.sub.1-5)alkylene
or a (C.sub.1-3)alkylene. Alternatively, "alkylene," either alone
or represented along with another radical, can be a
(C.sub.1)alkylene, a (C.sub.2)alkylene or a (C.sub.3)alkylene.
[0095] "Alkylidene" means a straight or branched, saturated or
unsaturated, aliphatic radical connected to the parent molecule by
a double bond. (C.sub.X)alkylidene and (C.sub.X-Y)alkylidene are
typically used where X and Y indicate the number of carbon atoms in
the chain. For example, (C.sub.1-6)alkylidene includes methylene
(.dbd.CH.sub.2), ethylidene (.dbd.CHCH.sub.3), isopropylidene
(.dbd.C(CH.sub.3).sub.2), propylidene (.dbd.CHCH.sub.2CH.sub.3),
allylidene (.dbd.CH--CH.dbd.CH.sub.2), and the like. In particular
embodiments, "alkylidene," either alone or represented along with
another radical, can be a (C.sub.1-20)alkylidene, a
(C.sub.1-15)alkylidene, a (C.sub.1-10)alkylidene, a
(C.sub.1-5)alkylidene or a (C.sub.1-3)alkylidene. Alternatively,
"alkylidene," either alone or represented along with another
radical, can be a (C.sub.1)alkylidene, a (C.sub.2)alkylidene or a
(C.sub.3)alkylidene.
[0096] "Alkynyl" means a straight or branched, carbon chain that
contains at least one carbon-carbon triple bond (--C.ident.C-- or
--C.ident.CR, wherein R is hydrogen or a further substituent).
Examples of alkynyl include ethynyl, propargyl,
3-methyl-1-pentynyl, 2-heptynyl and the like. In particular
embodiments, "alkynyl," either alone or represented along with
another radical, can be a (C.sub.2-20)alkynyl, a
(C.sub.2-15)alkynyl, a (C.sub.2-10)alkynyl, a (C.sub.2-5)alkynyl or
a (C.sub.2-3)alkynyl. Alternatively, "alkynyl," either alone or
represented along with another radical, can be a (C.sub.2)alkynyl,
a (C.sub.3)alkynyl or a (C.sub.4)alkynyl.
[0097] "Alkynylene" means a straight or branched, divalent carbon
chain having one or more carbon-carbon triple bonds
(--CR.ident.CR'--, wherein R and R' are each independently hydrogen
or further substituents). Examples of alkynylene include
ethyne-1,2-diyl, propyne-1,3-diyl, and the like. In particular
embodiments, "alkynylene," either alone or represented along with
another radical, can be a (C.sub.2-20) alkynylene, a (C.sub.2-15)
alkynylene, a (C.sub.2-10) alkynylene, a (C.sub.2-5) alkynylene or
a (C.sub.2-3) alkynylene. Alternatively, "alkynylene," either alone
or represented along with another radical, can be a (C.sub.2)
alkynylene, a (C.sub.3) alkynylene or a (C.sub.4) alkynylene.
[0098] "Amido" means the radical --C(.dbd.O)--NR--,
--C(.dbd.O)--NRR', --NR--C(.dbd.O)-- and/or --NR--C(.dbd.O)R',
wherein each R and R' are independently hydrogen or a further
substituent.
[0099] "Amino" means a nitrogen moiety having two further
substituents where, for example, a hydrogen or carbon atom is
attached to the nitrogen. For example, representative amino groups
include --NH.sub.2, --NHCH.sub.3, --N(CH.sub.3).sub.2,
--NH((C.sub.1-10)alkyl), --N((C.sub.1-10)alkyl).sub.2, --NH(aryl),
--NH(heteroaryl), --N(aryl).sub.2, --N(heteroaryl).sub.2, and the
like. Optionally, the two substituents together with the nitrogen
may also form a ring. Unless indicated otherwise, the compounds of
the invention containing amino moieties may include protected
derivatives thereof. Suitable protecting groups for amino moieties
include acetyl, tert-butoxycarbonyl, benzyloxycarbonyl, and the
like.
[0100] "Animal" includes humans, non-human mammals (e.g., dogs,
cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the
like) and non-mammals (e.g., birds, and the like).
[0101] "Aromatic" means a moiety wherein the constituent atoms make
up an unsaturated ring system, all atoms in the ring system are
sp.sup.2 hybridized and the total number of pi electrons is equal
to 4n+2. An aromatic ring may be such that the ring atoms are only
carbon atoms or may include carbon and non-carbon atoms (See
"heteroaryl").
[0102] "Aryl" means a monocyclic or polycyclic ring assembly
wherein each ring is aromatic or when fused with one or more rings
forms an aromatic ring assembly. If one or more ring atoms is not
carbon (e.g., N, S), the aryl is a heteroaryl. (C.sub.X)aryl and
(C.sub.X-Y)aryl are typically used where X and Y indicate the
number of carbon atoms in the ring. In particular embodiments,
"aryl," either alone or represented along with another radical, can
be a (C.sub.3-14)aryl, a (C.sub.3-10)aryl, a (C.sub.3-7)aryl, a
(C.sub.8-10)aryl or a (C.sub.5-7)aryl. Alternatively, "aryl,"
either alone or represented along with another radical, can be a
(C.sub.5)aryl, a (C.sub.6)aryl, a (C.sub.7)aryl, a (C.sub.8)aryl, a
(C.sub.9)aryl or a (C.sub.10)aryl.
[0103] "Azaalkyl" means an alkyl, as defined above, except where
one or more of the carbon atoms forming the alkyl chain are
replaced with substituted or unsubstituted nitrogen atoms (--NR--
or --NRR', wherein R and R' are each independently hydrogen or
further substituents). For example, a (C.sub.1-10)azaalkyl refers
to a chain comprising between 1 and 10 carbons and one or more
nitrogen atoms.
[0104] "Bicycloalkyl" means a saturated or partially unsaturated
fused, spiro or bridged bicyclic ring assembly. In particular
embodiments, "bicycloalkyl," either alone or represented along with
another radical, can be a (C.sub.4-15)bicycloalkyl, a
(C.sub.4-10)bicycloalkyl, a (C.sub.6-10)bicycloalkyl or a
(C.sub.8-10)bicycloalkyl. Alternatively, "bicycloalkyl," either
alone or represented along with another radical, can be a
(C.sub.8)bicycloalkyl, a (C.sub.9)bicycloalkyl or a
(C.sub.10)bicycloalkyl.
[0105] "Bicycloaryl" means a fused, spiro or bridged bicyclic ring
assembly wherein at least one of the rings comprising the assembly
is aromatic. (C.sub.X)bicycloaryl and (C.sub.X-Y)bicycloaryl are
typically used where X and Y indicate the number of carbon atoms in
the bicyclic ring assembly and directly attached to the ring. In
particular embodiments, "bicycloaryl," either alone or represented
along with another radical, can be a (a (C.sub.4-15)bicycloaryl, a
(C.sub.4-10)bicycloaryl, a (C.sub.6-10)bicycloaryl or a
(C.sub.8-10)bicycloaryl. Alternatively, "bicycloalkyl," either
alone or represented along with another radical, can be a
(C.sub.8)bicycloaryl, a (C.sub.9)bicycloaryl or a
(C.sub.10)bicycloaryl.
[0106] "Bridging ring" and "bridged ring" as used herein refer to a
ring that is bonded to another ring to form a compound having a
bicyclic or polycyclic structure where two ring atoms that are
common to both rings are not directly bound to each other.
Non-exclusive examples of common compounds having a bridging ring
include borneol, norbornane, 7-oxabicyclo[2.2.1]heptane, and the
like. One or both rings of the bicyclic system may also comprise
heteroatoms.
[0107] "Carbamoyl" means the radical --OC(O)NRR', wherein R and R'
are each independently hydrogen or further substituents.
[0108] "Carbocycle" means a ring consisting of carbon atoms.
[0109] "Carbonyl" means the radical --C(.dbd.O)-- and/or
--C(.dbd.O)R, wherein R is hydrogen or a further substituent. It is
noted that the carbonyl radical may be further substituted with a
variety of substituents to form different carbonyl groups including
acids, acid halides, aldehydes, amides, esters, and ketones.
[0110] "Carboxy" means the radical --C(.dbd.O)--O-- and/or
--C(.dbd.O)--OR, wherein R is hydrogen or a further substituent. It
is noted that compounds of the invention containing carboxy
moieties may include protected derivatives thereof, i.e., where the
oxygen is substituted with a protecting group. Suitable protecting
groups for carboxy moieties include benzyl, tert-butyl, and the
like.
[0111] "Cyano" means the radical --CN.
[0112] "Cycloalkyl" means a non-aromatic, saturated or partially
unsaturated, monocyclic, bicyclic or polycyclic ring assembly.
(C.sub.X)cycloalkyl and (C.sub.X-Y)cycloalkyl are typically used
where X and Y indicate the number of carbon atoms in the ring
assembly. For example, (C.sub.3-10)cycloalkyl includes cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl,
2,5-cyclohexadienyl, bicyclo[2.2.2]octyl, adamantan-1-yl,
decahydronaphthyl, oxocyclohexyl, dioxocyclohexyl, thiocyclohexyl,
2-oxobicyclo[2.2.1]hept-1-yl, and the like. In particular
embodiments, "cycloalkyl," either alone or represented along with
another radical, can be a (C.sub.3-14)cycloalkyl, a
(C.sub.3-10)cycloalkyl, a (C.sub.3-7)cycloalkyl, a
(C.sub.8-10)cycloalkyl or a (C.sub.5-7)cycloalkyl. Alternatively,
"cycloalkyl," either alone or represented along with another
radical, can be a (C.sub.5)cycloalkyl, a (C.sub.6)cycloalkyl, a
(C.sub.7)cycloalkyl, a (C.sub.8)cycloalkyl, a (C.sub.9)cycloalkyl
or a (C.sub.10)cycloalkyl.
[0113] "Cycloalkylene" means a divalent, saturated or partially
unsaturated, monocyclic, bicyclic or polycyclic ring assembly.
(C.sub.X)cycloalkylene and (C.sub.X-Y)cycloalkylene are typically
used where X and Y indicate the number of carbon atoms in the ring
assembly. In particular embodiments, "cycloalkylene," either alone
or represented along with another radical, can be a
(C.sub.3-14)cycloalkylene, a (C.sub.3-10)cycloalkylene, a
(C.sub.3-7)cycloalkylene, a (C.sub.8-10)cycloalkylene or a
(C.sub.5-7)cycloalkylene. Alternatively, "cycloalkylene," either
alone or represented along with another radical, can be a
(C.sub.5)cycloalkylene, a (C.sub.6)cycloalkylene, a
(C.sub.7)cycloalkylene, a (C.sub.8)cycloalkylene, a
(C.sub.9)cycloalkylene or a (C.sub.10)cycloalkylene.
[0114] "Disease" specifically includes any unhealthy condition of
an animal or part thereof and includes an unhealthy condition that
may be caused by, or incident to, medical or veterinary therapy
applied to that animal, i.e., the "side effects" of such
therapy.
[0115] "EC.sub.50" means the molar concentration of an agonist that
produces 50% of the maximal possible effect of that agonist. The
action of the agonist may be stimulatory or inhibitory.
[0116] "Fused ring" as used herein refers to a ring that is bonded
to another ring to form a compound having a bicyclic structure
where the ring atoms that are common to both rings are directly
bound to each other. Non-exclusive examples of common fused rings
include decaling, naphthalene, anthracene, phenanthrene, indole,
furan, benzofuran, quinoline, and the like. Compounds having fused
ring systems may be saturated, partially saturated, carbocyclics,
heterocyclics, aromatics, heteroaromatics, and the like.
[0117] "Halo" means fluoro, chloro, bromo or iodo.
[0118] "Heteroalkyl" means an alkyl, as defined in this
Application, provided that one or more of the atoms within the
alkyl chain is a heteroatom or a carbonyl group. "Heteroalkyl" as
defined herein includes alkyl chain containing oxygen (See
"oxaalkyl"), a carbonyl group (See "oxoalkyl"), sulfur (See
"thioalkyl"), and nitrogen (See "azaalkyl"). Hetero(C.sub.X)alkyl
and hetero(C.sub.X-Y)alkyl are typically used where X and Y
indicate the number of carbon atoms in the chain. In particular
embodiments, "heteroalkyl," either alone or represented along with
another radical, can be a hetero(C.sub.1-20)alkyl, a
hetero(C.sub.1-15)alkyl, a hetero(C.sub.1-10)alkyl, a
hetero(C.sub.1-5)alkyl, a hetero(C.sub.1-3)alkyl or a
hetero(C.sub.1-2)alkyl. Alternatively, "heteroalkyl," either alone
or represented along with another radical, can be a
hetero(C.sub.1)alkyl, a hetero(C.sub.2)alkyl or a
hetero(C.sub.3)alkyl.
[0119] "Heteroaryl" means a monocyclic, bicyclic or polycyclic
aromatic group wherein at least one ring atom is a heteroatom and
the remaining ring atoms are carbon. Monocyclic heteroaryl groups
include, but are not limited to, cyclic aromatic groups having five
or six ring atoms, wherein at least one ring atom is a heteroatom
and the remaining ring atoms are carbon. The nitrogen atoms can be
optionally quaternerized and the sulfur atoms can be optionally
oxidized. Heteroaryl groups of this invention include, but are not
limited to, those derived from furan, imidazole, isothiazole,
isoxazole, oxadiazole, oxazole, 1,2,3-oxadiazole, pyrazine,
pyrazole, pyridazine, pyridine, pyrimidine, pyrroline, thiazole,
1,3,4-thiadiazole, triazole and tetrazole. "Heteroaryl" also
includes, but is not limited to, bicyclic or tricyclic rings,
wherein the heteroaryl ring is fused to one or two rings
independently selected from the group consisting of an aryl ring, a
cycloalkyl ring, a cycloalkenyl ring, and another monocyclic
heteroaryl or heterocycloalkyl ring. These bicyclic or tricyclic
heteroaryls include, but are not limited to, those derived from
benzo[b]furan, benzo[b]thiophene, benzimidazole,
imidazo[4,5-c]pyridine, quinazoline, thieno[2,3-c]pyridine,
thieno[3,2-b]pyridine, thieno[2,3-b]pyridine, indolizine,
imidazo[1,2a]pyridine, quinoline, isoquinoline, phthalazine,
quinoxaline, naphthyridine, quinolizine, indole, isoindole,
indazole, indoline, benzoxazole, benzopyrazole, benzothiazole,
imidazo[1,5-a]pyridine, pyrazolo[1,5-a]pyridine,
imidazo[1,2-a]pyrimidine, imidazo[1,2-c]pyrimidine,
imidazo[1,5-a]pyrimidine, imidazo[1,5-c]pyrimidine,
pyrrolo[2,3-b]pyridine, pyrrolo[2,3-c]pyridine,
pyrrolo[3,2-c]pyridine, pyrrolo[3,2-b]pyridine,
pyrrolo[2,3-d]pyrimidine, pyrrolo[3,2-d]pyrimidine,
pyrrolo[2,3-b]pyrazine, pyrazolo[1,5-a]pyridine,
pyrrolo[1,2-b]pyridazine, pyrrolo[1,2-c]pyrimidine,
pyrrolo[1,2-a]pyrimidine, pyrrolo[1,2-a]pyrazine,
triazo[1,5-a]pyridine, pteridine, purine, carbazole, acridine,
phenazine, phenothiazine, phenoxazine,
1,2-dihydropyrrolo[3,2,1-hi]indole, indolizine, pyrido[1,2-a]indole
and 2(1H)-pyridinone. The bicyclic or tricyclic heteroaryl rings
can be attached to the parent molecule through either the
heteroaryl group itself or the aryl, cycloalkyl, cycloalkenyl or
heterocycloalkyl group to which it is fused. The heteroaryl groups
of this invention can be substituted or unsubstituted. In
particular embodiments, "heteroaryl," either alone or represented
along with another radical, can be a hetero(C.sub.1-13)aryl, a
hetero(C.sub.2-13)aryl, a hetero(C.sub.2-6)aryl, a
hetero(C.sub.3-9)aryl or a hetero(C.sub.5-9)aryl. Alternatively,
"heteroaryl," either alone or represented along with another
radical, can be a hetero(C.sub.3)aryl, a hetero(C.sub.4)aryl, a
hetero(C.sub.5)aryl, a hetero(C.sub.6)aryl, a hetero(C.sub.7)aryl,
a hetero(C.sub.8)aryl or a hetero(C.sub.9)aryl.
[0120] "Heteroatom" refers to an atom that is not a carbon atom.
Particular examples of heteroatoms include, but are not limited to,
nitrogen, oxygen, and sulfur.
[0121] "Heteroatom moiety" includes a moiety where the atom by
which the moiety is attached is not a carbon. Examples of
heteroatom moieties include --NR--, --N.sup.+(O.sup.-).dbd., --O--,
--S-- or --S(O).sub.2--, wherein R is hydrogen or a further
substituent.
[0122] "Heterobicycloalkyl" means bicycloalkyl, as defined in this
Application, provided that one or more of the atoms within the ring
is a heteroatom. For example hetero(C.sub.9-12)bicycloalkyl as used
in this application includes, but is not limited to,
3-aza-bicyclo[4.1.0]hept-3-yl, 2-aza-bicyclo[3.1.0]hex-2-yl,
3-aza-bicyclo[3.1.0]hex-3-yl, and the like. In particular
embodiments, "heterobicycloalkyl," either alone or represented
along with another radical, can be a
hetero(C.sub.1-14)bicycloalkyl, a hetero(C.sub.4-14)bicycloalkyl, a
hetero(C.sub.4-9)bicycloalkyl or a hetero(C.sub.5-9)bicycloalkyl.
Alternatively, "heterobicycloalkyl," either alone or represented
along with another radical, can be a hetero(C.sub.5)bicycloalkyl,
hetero(C.sub.6)bicycloalkyl, hetero(C.sub.7)bicycloalkyl,
hetero(C.sub.8)bicycloalkyl or a hetero(C.sub.9)bicycloalkyl.
[0123] "Heterobicycloaryl" means bicycloaryl, as defined in this
Application, provided that one or more of the atoms within the ring
is a heteroatom. For example, hetero(C.sub.4-12)bicycloaryl as used
in this Application includes, but is not limited to,
2-amino-4-oxo-3,4-dihydropteridin-6-yl, tetrahydroisoquinolinyl,
and the like. In particular embodiments, "heterobicycloaryl,"
either alone or represented along with another radical, can be a
hetero(C.sub.1-14)bicycloaryl, a hetero(C.sub.4-14)bicycloaryl, a
hetero(C.sub.4-9)bicycloaryl or a hetero(C.sub.5-9)bicycloaryl.
Alternatively, "heterobicycloaryl," either alone or represented
along with another radical, can be a hetero(C.sub.5)bicycloaryl,
hetero(C.sub.6)bicycloaryl, hetero(C.sub.7)bicycloaryl,
hetero(C.sub.8)bicycloaryl or a hetero(C.sub.9)bicycloaryl.
[0124] "Heterocycloalkyl" means cycloalkyl, as defined in this
Application, provided that one or more of the atoms forming the
ring is a heteroatom selected, independently from N, O, or S,
Non-exclusive examples of heterocycloalkyl include piperidyl,
4-morpholyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolizinyl,
1,4-diazaperhydroepinyl, 1,3-dioxanyl, 1,4-dioxanyl and the like.
In particular embodiments, "heterocycloalkyl," either alone or
represented along with another radical, can be a
hetero(C.sub.1-13)cycloalkyl, a hetero(C.sub.1-9)cycloalkyl, a
hetero(C.sub.1-6)cycloalkyl, a hetero(C.sub.5-9)cycloalkyl or a
hetero(C.sub.2-6)cycloalkyl. Alternatively, "heterocycloalkyl,"
either alone or represented along with another radical, can be a
hetero(C.sub.2)cycloalkyl, a hetero(C.sub.3)cycloalkyl, a
hetero(C.sub.4)cycloalkyl, a hetero(C.sub.5)cycloalkyl, a
hetero(C.sub.6)cycloalkyl, hetero(C.sub.7)cycloalkyl,
hetero(C.sub.8)cycloalkyl or a hetero(C.sub.9)cycloalkyl.
[0125] "Heterocycloalkylene" means cycloalkylene, as defined in
this Application, provided that one or more of the ring member
carbon atoms is replaced by a heteroatom. In particular
embodiments, "heterocycloalkylene," either alone or represented
along with another radical, can be a
hetero(C.sub.1-13)cycloalkylene, a hetero(C.sub.1-9)cycloalkylene,
a hetero(C.sub.1-6)cycloalkylene, a hetero(C.sub.5-9)cycloalkylene
or a hetero(C.sub.2-6)cycloalkylene. Alternatively,
"heterocycloalkylene," either alone or represented along with
another radical, can be a hetero(C.sub.2)cycloalkylene, a
hetero(C.sub.3)cycloalkylene, a hetero(C.sub.4)cycloalkylene, a
hetero(C.sub.5)cycloalkylene, a hetero(C.sub.6)cycloalkylene,
hetero(C.sub.7)cycloalkylene, hetero(C.sub.8)cycloalkylene or a
hetero(C.sub.9)cycloalkylene.
[0126] "Hydroxy" means the radical --OH.
[0127] "IC.sub.50" means the molar concentration of an inhibitor
that produces 50% inhibition of the target enzyme.
[0128] "Imino" means the radical --CR(.dbd.NR') and/or
--C(.dbd.NR')--, wherein R and R' are each independently hydrogen
or a further substituent.
[0129] "Iminoketone derivative" means a derivative comprising the
moiety --C(NR)--, wherein R is hydrogen or a further
substituent.
[0130] "Isomers" means compounds having identical molecular
formulae but differing in the nature or sequence of bonding of
their atoms or in the arrangement of their atoms in space. Isomers
that differ in the arrangement of their atoms in space are termed
"stereoisomers." Stereoisomers that are not mirror images of one
another are termed "diastereomers" and stereoisomers that are
nonsuperimposable mirror images are termed "enantiomers" or
sometimes "optical isomers." A carbon atom bonded to four
nonidentical substituents is termed a "chiral center." A compound
with one chiral center has two enantiomeric forms of opposite
chirality. A mixture of the two enantiomeric forms is termed a
"racemic mixture." A compound that has more than one chiral center
has 2.sup.n-1 enantiomeric pairs, where n is the number of chiral
centers. Compounds with more than one chiral center may exist as
ether an individual diastereomer or as a mixture of diastereomers,
termed a "diastereomeric mixture." When one chiral center is
present a stereoisomer may be characterized by the absolute
configuration of that chiral center. Absolute configuration refers
to the arrangement in space of the substituents attached to the
chiral center. Enantiomers are characterized by the absolute
configuration of their chiral centers and described by the R- and
S-sequencing rules of Cahn, Ingold and Prelog. Conventions for
stereochemical nomenclature, methods for the determination of
stereochemistry and the separation of stereoisomers are well known
in the art (e.g., see "Advanced Organic Chemistry", 5th edition,
March, Jerry, John Wiley & Sons, New York, 2001).
[0131] "Leaving group" means the group with the meaning
conventionally associated with it in synthetic organic chemistry,
i.e., an atom or group displaceable under reaction (e.g.,
alkylating) conditions. Examples of leaving groups include, but are
not limited to, halo (e.g., F, Cl, Br and I), alkyl (e.g., methyl
and ethyl) and sulfonyloxy (e.g., mesyloxy, ethanesulfonyloxy,
benzenesulfonyloxy and tosyloxy), thiomethyl, thienyloxy,
dihalophosphinoyloxy, tetrahalophosphoxy, benzyloxy, isopropyloxy,
acyloxy, and the like.
[0132] "Linker" refers to a divalent radical which links together
two moieties. A "linker providing X atom separation" between two
other moieties mean that the chain of atoms directly linking the
two other moieties is X atoms in length. When X is given as a range
(e.g., X.sub.1-X.sub.2), then the chain of atoms is at least
X.sub.1 and not more than X.sub.2 atoms in length. It is understood
that the chain of atoms can be formed from a combination of atoms
including, for example, carbon, nitrogen, sulfur and oxygen atoms.
Further, each atom can optionally be bound to one or more
substituents, as valencies allow. In addition, the chain of atoms
can form part of a ring. Accordingly, in one embodiment, a moiety
providing X atom separation between two other moieties (R and R')
can be represented by R-(L).sub.X-R' where each L is independently
selected from the group consisting of CR''R''', NR'''', O, S, CO,
CS, C.dbd.NR''''', SO, SO.sub.2, and the like, where any two or
more of R'', R''', R'''' and R''''' can be taken together to form a
substituted or unsubstituted ring.
[0133] "Nitro" means the radical --NO.sub.2.
[0134] "Oxaalkyl" means an alkyl, as defined above, except where
one or more of the carbon atoms forming the alkyl chain are
replaced with oxygen atoms (--O-- or --OR, wherein R is hydrogen or
a further substituent). For example, an oxa(C.sub.1-10)alkyl refers
to a chain comprising between 1 and 10 carbons and one or more
oxygen atoms.
[0135] "Oxoalkyl" means an alkyl, as defined above, except where
one or more of the carbon atoms forming the alkyl chain are
replaced with carbonyl groups (--C(.dbd.O)-- or --C(.dbd.O)--R,
wherein R is hydrogen or a further substituent). The carbonyl group
may be an aldehyde, ketone, ester, amide, acid or acid halide. For
example, an oxo(C.sub.1-10)alkyl refers to a chain comprising
between 1 and 10 carbon atoms and one or more carbonyl groups.
[0136] "Oxy" means the radical --O-- or --OR, wherein R is hydrogen
or a further substituent. Accordingly, it is noted that the oxy
radical may be further substituted with a variety of substituents
to form different oxy groups including hydroxy, alkoxy, aryloxy,
heteroaryloxy or carbonyloxy.
[0137] "Pharmaceutically acceptable" means that which is useful in
preparing a pharmaceutical composition that is generally safe,
non-toxic and neither biologically nor otherwise undesirable and
includes that which is acceptable for veterinary use as well as
human pharmaceutical use.
[0138] "Pharmaceutically acceptable salts" means salts of compounds
of the present invention which are pharmaceutically acceptable, as
defined above, and which possess the desired pharmacological
activity. Such salts include acid addition salts formed with
inorganic acids such as hydrochloric acid, hydrobromic acid,
sulfuric acid, nitric acid, phosphoric acid, and the like; or with
organic acids such as acetic acid, propionic acid, hexanoic acid,
heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic
acid, lactic acid, malonic acid, succinic acid, malic acid, maleic
acid, fumaric acid, tartaric acid, citric acid, benzoic acid,
o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid,
methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic
acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid,
p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid,
p-toluenesulfonic acid, camphorsulfonic acid,
4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic
acid, 4,4'-methylenebis(3-hydroxy-2-ene-1-carboxylic acid),
3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic
acid, lauryl sulfuric acid, gluconic acid, glutamic acid,
hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid
and the like.
[0139] Pharmaceutically acceptable salts also include base addition
salts which may be formed when acidic protons present are capable
of reacting with inorganic or organic bases. Acceptable inorganic
bases include sodium hydroxide, sodium carbonate, potassium
hydroxide, aluminum hydroxide and calcium hydroxide. Acceptable
organic bases include ethanolamine, diethanolamine,
triethanolamine, tromethamine, N-methylglucamine and the like.
[0140] "Polycyclic ring" includes bicyclic and multi-cyclic rings.
The individual rings comprising the polycyclic ring can be fused,
spiro or bridging rings.
[0141] "Prodrug" means a compound that is convertible in vivo
metabolically into an inhibitor according to the present invention.
The prodrug itself may or may not also have activity with respect
to a given target protein. For example, a compound comprising a
hydroxy group may be administered as an ester that is converted by
hydrolysis in vivo to the hydroxy compound. Suitable esters that
may be converted in vivo into hydroxy compounds include acetates,
citrates, lactates, phosphates, tartrates, malonates, oxalates,
salicylates, propionates, succinates, fumarates, maleates,
methylene-bis-b-hydroxynaphthoates, gentisates, isethionates,
di-p-toluoyltartrates, methanesulfonates, ethanesulfonates,
benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates,
quinates, esters of amino acids, and the like. Similarly, a
compound comprising an amine group may be administered as an amide
that is converted by hydrolysis in vivo to the amine compound.
[0142] "Protected derivatives" means derivatives of inhibitors in
which a reactive site or sites are blocked with protecting groups.
Protected derivatives are useful in the preparation of inhibitors
or in themselves may be active as inhibitors. A comprehensive list
of suitable protecting groups can be found in P. G. M. Wuts and T.
W. Greene, "Greene's Protecting Groups in Organic Synthesis, 4th
edition, John Wiley & Sons, Inc. 2007.
[0143] "Ring" and "ring assembly" means a carbocyclic or a
heterocyclic system and includes aromatic and non-aromatic systems.
The system can be monocyclic, bicyclic or polycyclic. In addition,
for bicyclic and polycyclic systems, the individual rings
comprising the polycyclic ring can be fused, spiro or bridging
rings.
[0144] "Subject" and "patient" includes humans, non-human mammals
(e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine,
deer, and the like) and non-mammals (e.g., birds, and the
like).
[0145] "Substituted or unsubstituted" means that a given moiety may
consist of only hydrogen substituents through available valencies
(unsubstituted) or may further comprise one or more non-hydrogen
substituents through available valencies (substituted) that are not
otherwise specified by the name of the given moiety. For example,
isopropyl is an example of an ethylene moiety that is substituted
by --CH.sub.3. In general, a non-hydrogen substituent may be any
substituent that may be bound to an atom of the given moiety that
is specified to be substituted. Examples of substituents include,
but are not limited to, aldehyde, alicyclic, aliphatic,
(C.sub.1-10)alkyl, alkylene, alkylidene, amide, amino, aminoalkyl,
aromatic, aryl, bicycloalkyl, bicycloaryl, carbamoyl, carbocyclyl,
carboxyl, carbonyl group, cycloalkyl, cycloalkylene, ester, halo,
heterobicycloalkyl, heterocycloalkylene, heteroaryl,
heterobicycloaryl, heterocycloalkyl, oxo, hydroxy, iminoketone,
ketone, nitro, oxaalkyl, and oxoalkyl moieties, each of which may
optionally also be substituted or unsubstituted. In one particular
embodiment, examples of substituents include, but are not limited
to, hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy,
(C.sub.1-10)alkoxy, (C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy,
carbonyl, oxycarbonyl, aminocarbonyl, amino,
(C.sub.1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
(C.sub.1-10)azaalkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl. In addition, the substituent is
itself optionally substituted by a further substituent. In one
particular embodiment, examples of the further substituent include,
but are not limited to, hydrogen, halo, nitro, cyano, thio, oxy,
hydroxy, carbonyloxy, (C.sub.1-10)alkoxy, (C.sub.4-12)aryloxy,
hetero(C.sub.1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl,
amino, (C.sub.1-10)alkylamino, sulfonamido, imino, sulfonyl,
sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, (C.sub.1-10)azaalkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl.
[0146] "Sulfinyl" means the radical --SO-- and/or --SO--R, wherein
R is hydrogen or a further substituent. It is noted that the
sulfinyl radical may be further substituted with a variety of
substituents to form different sulfinyl groups including sulfinic
acids, sulfinamides, sulfinyl esters, and sulfoxides.
[0147] "Sulfonyl" means the radical --SO.sub.2-- and/or
--SO.sub.2--R, wherein R is hydrogen or a further substituent. It
is noted that the sulfonyl radical may be further substituted with
a variety of substituents to form different sulfonyl groups
including sulfonic acids, sulfonamides, sulfonate esters, and
sulfones.
[0148] "Therapeutically effective amount" means that amount which,
when administered to an animal for treating a disease, is
sufficient to effect such treatment for the disease.
[0149] "Thio" denotes replacement of an oxygen by a sulfur and
includes, but is not limited to, --SR, --S-- and .dbd.S containing
groups.
[0150] "Thioalkyl" means an alkyl, as defined above, except where
one or more of the carbon atoms forming the alkyl chain are
replaced with sulfur atoms (--S-- or --S--R, wherein R is hydrogen
or a further substituent). For example, a thio(C.sub.1-10)alkyl
refers to a chain comprising between 1 and 10 carbons and one or
more sulfur atoms.
[0151] "Thiocarbonyl" means the radical --C(.dbd.S)-- and/or
--C(.dbd.S)--R, wherein R is hydrogen or a further substituent. It
is noted that the thiocarbonyl radical may be further substituted
with a variety of substituents to form different thiocarbonyl
groups including thioacids, thioamides, thioesters, and
thioketones.
[0152] "Treatment" or "treating" means any administration of a
compound of the present invention and includes:
[0153] (1) preventing the disease from occurring in an animal which
may be predisposed to the disease but does not yet experience or
display the pathology or symptomotology of the disease,
[0154] (2) inhibiting the disease in an animal that is experiencing
or displaying the pathology or symptomotology of the diseased
(i.e., arresting further development of the pathology and/or
symptomotology), or
[0155] (3) ameliorating the disease in an animal that is
experiencing or displaying the pathology or symptomotology of the
diseased (i.e., reversing the pathology and/or symptomotology).
[0156] It is noted in regard to all of the definitions provided
herein that the definitions should be interpreted as being open
ended in the sense that further substituents beyond those specified
may be included. Hence, a C.sub.1 alkyl indicates that there is one
carbon atom but does not indicate what are the substituents on the
carbon atom. Hence, a (C.sub.1)alkyl comprises methyl (i.e.,
--CH.sub.3) as well as --CRR'R'' where R, R', and R'' may each
independently be hydrogen or a further substituent where the atom
attached to the carbon is a heteroatom or cyano. Hence, CF.sub.3,
CH.sub.2OH and CH.sub.2CN, for example, are all (C.sub.1)alkyls.
Similarly, terms such as alkylamino and the like comprise
dialkylamino and the like.
[0157] A compound having a formula that is represented with a
dashed bond is intended to include the formulae optionally having
zero, one or more double bonds, as exemplified and shown below:
##STR00003##
[0158] In addition, atoms making up the compounds of the present
invention are intended to include all isotopic forms of such atoms.
Isotopes, as used herein, include those atoms having the same
atomic number but different mass numbers. By way of general example
and without limitation, isotopes of hydrogen include tritium and
deuterium, and isotopes of carbon include .sup.13C and
.sup.14C.
DETAILED DESCRIPTION OF THE INVENTION
[0159] The present invention relates to compounds that may be used
to inhibit HSP90. The present invention also relates to
pharmaceutical compositions, kits and articles of manufacture
comprising such compounds. In addition, the present invention
relates to methods and intermediates useful for making the
compounds. Further, the present invention relates to methods of
using said compounds. It is noted that the compounds of the present
invention may also possess activity for other members of the same
protein family and thus may be used to address disease states
associated with these other family members.
[0160] It is noted that the compounds of the present invention may
also possess inhibitory activity for other HSP family members and
thus may be used to address disease states associated with these
other family members.
Compound of the Invention
[0161] In one of its aspects, the present invention relates to
compounds that are useful as HSP90 inhibitors. In one embodiment,
HSP90 inhibitors of the present invention is of a formula selected
from the group consisting of:
##STR00004##
or a tautomer, stereoisomer, or pharmaceutically acceptable salt
thereof, wherein
[0162] X is O, NR.sub.8 or CR.sub.9R.sub.9';
[0163] R.sub.1 is selected from the group consisting of hydrogen,
carbonyl, hydroxycarbonyl, oxycarbonyl, aminocarbonyl, sulfonyl,
sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, alkoxy(C.sub.1-10)alkyl,
amino(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, carbonylamino(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, hydroxycarbonyl(C.sub.1-10)alkyl,
aminocarbonyl(C.sub.1-10)alkyl, aminosulfonyl(C.sub.1-10)alkyl,
sulfonylamino(C.sub.1-10)alkyl,
(C.sub.1-6)alkylsulfonylamino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted;
[0164] R.sub.2 is selected from the group consisting of hydrogen,
halo, cyano, thio, hydroxy, carbonyloxy, (C.sub.1-10)alkoxy,
(C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy, carbonyl,
oxycarbonyl, aminocarbonyl, amino, (C.sub.1-10)alkylamino,
sulfonamido, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0165] R.sub.3 is selected from the group consisting of hydrogen,
halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy,
(C.sub.1-10)alkoxy, (C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy,
carbonyl, oxycarbonyl, aminocarbonyl, amino,
(C.sub.1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, (C.sub.1-10)alkenyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted with 1-3 substituents, and the substituents on adjacent
atoms may be taken together to form a substituted or unsubstituted
ring;
[0166] R.sub.4 is selected from the group consisting of hydrogen,
carbonyl, oxycarbonyl, amino, (C.sub.1-10)alkylamino, sulfonamido,
sulfonyl, sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.9-12)bicycloalkyl,
hetero(C.sub.3-12)bicycloalkyl, (C.sub.4-12)aryl,
hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl, and
hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0167] R.sub.5 and R.sub.5' are each independently selected from
the group consisting of hydrogen, cyano, carbonyl, oxycarbonyl,
aminocarbonyl, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0168] R.sub.6 and R.sub.6' are each independently selected from
the group consisting of hydrogen, halogen, cyano,
(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted, provided that R.sub.6' is absent when A is
CR.sub.5R.sub.5;
[0169] R.sub.7 is selected from the group consisting of hydrogen,
cyano, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.9-12)bicycloalkyl,
hetero(C.sub.3-12)bicycloalkyl, (C.sub.4-12)aryl,
hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl and
hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0170] R.sub.8 is selected from the group consisting of hydrogen,
(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0171] R.sub.9 and R.sub.9' are each independently selected from
the group consisting of hydrogen, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted; and
[0172] provided that for Formula II, when X is O, R.sub.1 is a
(C.sub.1-6)alkyl substituted with at least two hydroxyl group.
[0173] In another embodiment, the compounds of the invention
consisting the formula:
##STR00005##
or a tautomer, stereoisomer, or pharmaceutically acceptable salt
thereof, wherein
[0174] X is O, NR.sub.8 or CR.sub.9R.sub.9';
[0175] R.sub.1 is selected from the group consisting of hydrogen,
carbonyl, hydroxycarbonyl, oxycarbonyl, aminocarbonyl, sulfonyl,
sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, alkoxy(C.sub.1-10)alkyl,
amino(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, carbonylamino(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, hydroxycarbonyl(C.sub.1-10)alkyl,
aminocarbonyl(C.sub.1-10)alkyl, aminosulfonyl(C.sub.1-10)alkyl,
sulfonylamino(C.sub.1-10)alkyl,
(C.sub.1-6)alkylsulfonylamino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted;
[0176] R.sub.2 is selected from the group consisting of hydrogen,
halo, cyano, thio, hydroxy, carbonyloxy, (C.sub.1-10)alkoxy,
(C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy, carbonyl,
oxycarbonyl, aminocarbonyl, amino, (C.sub.1-10)alkylamino,
sulfonamido, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0177] R.sub.3 is selected from the group consisting of hydrogen,
halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy,
(C.sub.1-10)alkoxy, (C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy,
carbonyl, oxycarbonyl, aminocarbonyl, amino,
(C.sub.1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, (C.sub.1-10)alkenyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted with 1-3 substituents, and the substituents on adjacent
atoms may be taken together to form a substituted or unsubstituted
ring;
[0178] R.sub.5 and R.sub.5' are each independently selected from
the group consisting of hydrogen, cyano, carbonyl, oxycarbonyl,
aminocarbonyl, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0179] R.sub.6 and R.sub.6' are each independently selected from
the group consisting of hydrogen, halogen, cyano,
(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted, provided that R.sub.6' is absent when A is
CR.sub.5R.sub.5;
[0180] R.sub.7 is selected from the group consisting of hydrogen,
cyano, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.9-12)bicycloalkyl,
hetero(C.sub.3-12)bicycloalkyl, (C.sub.4-12)aryl,
hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl and
hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0181] R.sub.8 is selected from the group consisting of hydrogen,
(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted; and
[0182] R.sub.9 and R.sub.9' are each independently selected from
the group consisting of hydrogen, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted.
[0183] In another embodiment, the compounds of the invention
consist of the formula
##STR00006##
or a tautomer, stereoisomer, or pharmaceutically acceptable salt
thereof, wherein
[0184] X is O, NR.sub.8 or CR.sub.9R.sub.9';
[0185] R.sub.1 is selected from the group consisting of hydrogen,
carbonyl, hydroxycarbonyl, oxycarbonyl, aminocarbonyl, sulfonyl,
sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, alkoxy(C.sub.1-10)alkyl,
amino(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, carbonylamino(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, hydroxycarbonyl(C.sub.1-10)alkyl,
aminocarbonyl(C.sub.1-10)alkyl, aminosulfonyl(C.sub.1-10)alkyl,
sulfonylamino(C.sub.1-10)alkyl,
(C.sub.1-6)alkylsulfonylamino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted;
[0186] R.sub.2 is selected from the group consisting of hydrogen,
halo, cyano, thio, hydroxy, carbonyloxy, (C.sub.1-10)alkoxy,
(C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy, carbonyl,
oxycarbonyl, aminocarbonyl, amino, (C.sub.1-10)alkylamino,
sulfonamido, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0187] R.sub.3 is selected from the group consisting of hydrogen,
halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy,
(C.sub.1-10)alkoxy, (C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy,
carbonyl, oxycarbonyl, aminocarbonyl, amino,
(C.sub.1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, (C.sub.1-10)alkenyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted with 1-3 substituents, and the substituents on adjacent
atoms may be taken together to form a substituted or unsubstituted
ring;
[0188] R.sub.5 and R.sub.5' are each independently selected from
the group consisting of hydrogen, cyano, carbonyl, oxycarbonyl,
aminocarbonyl, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0189] R.sub.6 and R.sub.6' are each independently selected from
the group consisting of hydrogen, halogen, cyano,
(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted, provided that R.sub.6' is absent when A is
CR.sub.5R.sub.5;
[0190] R.sub.8 is selected from the group consisting of hydrogen,
(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0191] R.sub.9 and R.sub.9' are each independently selected from
the group consisting of hydrogen, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted; and
[0192] provided that when X is O, R.sub.1 is (C.sub.1-6)alkyl,
substituted with at least two hydroxyl groups.
[0193] In one embodiment, the compounds of the invention having the
formula:
##STR00007##
or a tautomer, stereoisomer, or pharmaceutically acceptable salt
thereof, wherein
[0194] X is O, NR.sub.8 or CR.sub.9R.sub.9';
[0195] R.sub.1 is selected from the group consisting of hydrogen,
carbonyl, hydroxycarbonyl, oxycarbonyl, aminocarbonyl, sulfonyl,
sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, alkoxy(C.sub.1-10)alkyl,
amino(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, carbonylamino(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, hydroxycarbonyl(C.sub.1-10)alkyl,
aminocarbonyl(C.sub.1-10)alkyl, aminosulfonyl(C.sub.1-10)alkyl,
sulfonylamino(C.sub.1-10)alkyl,
(C.sub.1-6)alkylsulfonylamino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted;
[0196] R.sub.2 is selected from the group consisting of hydrogen,
halo, cyano, thio, hydroxy, carbonyloxy, (C.sub.1-10)alkoxy,
(C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy, carbonyl,
oxycarbonyl, aminocarbonyl, amino, (C.sub.1-10)alkylamino,
sulfonamido, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0197] R.sub.3 is selected from the group consisting of hydrogen,
halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy,
(C.sub.1-10)alkoxy, (C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy,
carbonyl, oxycarbonyl, aminocarbonyl, amino,
(C.sub.1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, (C.sub.1-10)alkenyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted with 1-3 substituents, and the substituents on adjacent
atoms may be taken together to form a substituted or unsubstituted
ring;
[0198] R.sub.4 is selected from the group consisting of hydrogen,
carbonyl, oxycarbonyl, amino, (C.sub.1-10)alkylamino, sulfonamido,
sulfonyl, sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.9-12)bicycloalkyl,
hetero(C.sub.3-12)bicycloalkyl, (C.sub.4-12)aryl,
hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl, and
hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0199] R.sub.6 and R.sub.6' are each independently selected from
the group consisting of hydrogen, halogen, cyano,
(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted, provided that R.sub.6' is absent when A is
CR.sub.5R.sub.5;
[0200] R.sub.7 is selected from the group consisting of hydrogen,
cyano, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.9-12)bicycloalkyl,
hetero(C.sub.3-12)bicycloalkyl, (C.sub.4-12)aryl,
hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl and
hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0201] R.sub.8 is selected from the group consisting of hydrogen,
(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0202] R.sub.9 and R.sub.9' are each independently selected from
the group consisting of hydrogen, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted.
[0203] In another embodiment, the compounds of the invention
consisting of the formula:
##STR00008##
or a tautomer, stereoisomer, or pharmaceutically acceptable salt
thereof, wherein
[0204] X is O, NR.sub.8 or CR.sub.9R.sub.9';
[0205] R.sub.1 is selected from the group consisting of hydrogen,
carbonyl, hydroxycarbonyl, oxycarbonyl, aminocarbonyl, sulfonyl,
sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, alkoxy(C.sub.1-10)alkyl,
amino(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, carbonylamino(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, hydroxycarbonyl(C.sub.1-10)alkyl,
aminocarbonyl(C.sub.1-10)alkyl, aminosulfonyl(C.sub.1-10)alkyl,
sulfonylamino(C.sub.1-10)alkyl,
(C.sub.1-6)alkylsulfonylamino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted;
[0206] R.sub.2 is selected from the group consisting of hydrogen,
halo, cyano, thio, hydroxy, carbonyloxy, (C.sub.1-10)alkoxy,
(C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy, carbonyl,
oxycarbonyl, aminocarbonyl, amino, (C.sub.1-10)alkylamino,
sulfonamido, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0207] R.sub.3 is selected from the group consisting of hydrogen,
halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy,
(C.sub.1-10)alkoxy, (C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy,
carbonyl, oxycarbonyl, aminocarbonyl, amino,
(C.sub.1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, (C.sub.1-10)alkenyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted with 1-3 substituents, and the substituents on adjacent
atoms may be taken together to form a substituted or unsubstituted
ring;
[0208] R.sub.4 is selected from the group consisting of hydrogen,
carbonyl, oxycarbonyl, amino, (C.sub.1-10)alkylamino, sulfonamido,
sulfonyl, sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.9-12)bicycloalkyl,
hetero(C.sub.3-12)bicycloalkyl, (C.sub.4-12)aryl,
hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl, and
hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0209] R.sub.6 and R.sub.6' are each independently selected from
the group consisting of hydrogen, halogen, cyano,
(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted, provided that R.sub.6' is absent when A is
CR.sub.5R.sub.5;
[0210] R.sub.8 is selected from the group consisting of hydrogen,
(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted; and
[0211] R.sub.9 and R.sub.9' are each independently selected from
the group consisting of hydrogen, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted.
[0212] In another embodiment, the compounds of the invention
consisting of the formula:
##STR00009##
or a tautomer, stereoisomer, or pharmaceutically acceptable salt
thereof, wherein
[0213] X is O, NR.sub.8 or CR.sub.9R.sub.9';
[0214] R.sub.1 is selected from the group consisting of hydrogen,
carbonyl, hydroxycarbonyl, oxycarbonyl, aminocarbonyl, sulfonyl,
sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, alkoxy(C.sub.1-10)alkyl,
amino(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, carbonylamino(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, hydroxycarbonyl(C.sub.1-10)alkyl,
aminocarbonyl(C.sub.1-10)alkyl, aminosulfonyl(C.sub.1-10)alkyl,
sulfonylamino(C.sub.1-10)alkyl,
(C.sub.1-6)alkylsulfonylamino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted;
[0215] R.sub.2 is selected from the group consisting of hydrogen,
halo, cyano, thio, hydroxy, carbonyloxy, (C.sub.1-10)alkoxy,
(C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy, carbonyl,
oxycarbonyl, aminocarbonyl, amino, (C.sub.1-10)alkylamino,
sulfonamido, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0216] R.sub.3 is selected from the group consisting of hydrogen,
halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy,
(C.sub.1-10)alkoxy, (C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy,
carbonyl, oxycarbonyl, aminocarbonyl, amino,
(C.sub.1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, (C.sub.1-10)alkenyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted with 1-3 substituents, and the substituents on adjacent
atoms may be taken together to form a substituted or unsubstituted
ring;
[0217] R.sub.4 is selected from the group consisting of hydrogen,
carbonyl, oxycarbonyl, amino, (C.sub.1-10)alkylamino, sulfonamido,
sulfonyl, sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.9-12)bicycloalkyl,
hetero(C.sub.3-12)bicycloalkyl, (C.sub.4-12)aryl,
hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl, and
hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted;
[0218] R.sub.6 and R.sub.6' are each independently selected from
the group consisting of hydrogen, halogen, cyano,
(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted, provided that R.sub.6' is absent when A is
CR.sub.5R.sub.5;
[0219] R.sub.8 is selected from the group consisting of hydrogen,
(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted; and
[0220] R.sub.9 and R.sub.9' are each independently selected from
the group consisting of hydrogen, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted.
[0221] X
[0222] In one variation of the above embodiments of the compounds
of the invention, X is O.
[0223] In another variation, X is NR.sub.8, where R.sub.8 is
selected from the group consisting of hydrogen, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.9-12)bicycloalkyl,
hetero(C.sub.3-12)bicycloalkyl, (C.sub.4-12)aryl,
hetero(C.sub.1-10)aryl, each substituted or unsubstituted.
[0224] In yet another variation, X is NR.sub.8 where R.sub.8 is
selected from the group consisting of hydrogen, hydroxylalkyl,
alkyl, aminoalkyl, and alkoxyalkyl.
[0225] In still another variation, X is NR.sub.8 where R.sub.8 is
selected from the group consisting of hydrogen, hydroxyl,
(C.sub.1-3)alkyl, and hydroxy(C.sub.1-3)alkyl.
[0226] In still another variation, X is NH.
[0227] In still another variation, X is CR.sub.9R.sub.9' where
R.sub.9 and R.sub.9' are each individually selected from the group
consisting of hydrogen, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
aza(C.sub.1-10)alkyl, (C.sub.1-10)oxaalkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.4-12)aryl, and hetero(C.sub.1-10)aryl, each substituted or
unsubstituted.
[0228] In still another variation, X is CR.sub.9R.sub.9' where
R.sub.9 and R.sub.9' are each independently selected from the group
consisting of hydrogen, hydroxyl, halo, (C.sub.1-3)alkyl,
hydroxy(C.sub.1-3)alkyl, (C.sub.1-3)alkoxy, amino, aryl and
heteroaryl.
[0229] In still another variation, X is CR.sub.9R.sub.9' where one
of R.sub.9 and R.sub.9' is independently hydrogen.
[0230] In still another variation, X is CH.sub.2.
[0231] R.sub.1
[0232] In one variation of the above embodiments and variations of
the compounds of the invention, R.sub.1 is selected from the group
consisting of hydrogen, carbonyl, hydroxycarbonyl, oxycarbonyl,
aminocarbonyl, sulfonyl, sulfinyl, (C.sub.1-6)alkyl,
halo(C.sub.1-6)alkyl, hetero(C.sub.1-6)alkyl,
hydroxy(C.sub.1-6)alkyl, alkoxy(C.sub.1-6)alkyl,
amino(C.sub.1-6)alkyl, imino(C.sub.1-6)alkyl,
carbonyl(C.sub.1-6)alkyl, sulfonyl(C.sub.1-6)alkyl,
sulfinyl(C.sub.1-6)alkyl, carbonylamino(C.sub.1-6)alkyl,
thiocarbonyl(C.sub.1-6)alkyl, hydroxycarbonyl(C.sub.1-6)alkyl,
aminocarbonyl(C.sub.1-6)alkyl, aminosulfonyl(C.sub.1-6)alkyl,
sulfonylamino(C.sub.1-6)alkyl,
(C.sub.1-6)alkylsulfonylamino(C.sub.1-6)alkyl,
(C.sub.3-6)cycloalkyl(C.sub.1-6)alkyl,
hetero(C.sub.3-5)cycloalkyl(C.sub.1-6)alkyl,
(C.sub.4-6)aryl(C.sub.1-6)alkyl, and
hetero(C.sub.1-5)aryl(C.sub.1-6)alkyl, each unsubstituted or
substituted.
[0233] In another variation, R.sub.1 is selected from the group
consisting of hydrogen, hydroxycarbonyl, oxycarbonyl,
aminocarbonyl, (C.sub.1-6)alkyl, halo(C.sub.1-6)alkyl,
hetero(C.sub.1-6)alkyl, hydroxy(C.sub.1-6)alkyl,
alkoxy(C.sub.1-6)alkyl, amino(C.sub.1-6)alkyl,
imino(C.sub.1-6)alkyl, carbonyl(C.sub.1-6)alkyl,
carbonylamino(C.sub.1-6)alkyl, thiocarbonyl(C.sub.1-6)alkyl,
hydroxycarbonyl(C.sub.1-6)alkyl, aminocarbonyl(C.sub.1-6)alkyl,
(C.sub.1-6)alkylamino(C.sub.1-6)alkyl,
(C.sub.3-6)cycloalkyl(C.sub.1-6)alkyl,
hetero(C.sub.3-5)cycloalkyl(C.sub.1-6)alkyl,
(C.sub.4-6)aryl(C.sub.1-6)alkyl, and
hetero(C.sub.1-5)aryl(C.sub.1-6)alkyl, each unsubstituted or
substituted.
[0234] In another variation, R.sub.1 is selected from the group
consisting of hydrogen, (C.sub.1-6)alkyl, halo(C.sub.1-6)alkyl,
hetero(C.sub.1-6)alkyl, hydroxy(C.sub.1-6)alkyl,
alkoxy(C.sub.1-6)alkyl, amino(C.sub.1-6)alkyl,
carbonylamino(C.sub.1-6)alkyl, hydroxycarbonyl(C.sub.1-6)alkyl,
aminocarbonyl(C.sub.1-6)alkyl,
(C.sub.1-6)alkylamino(C.sub.1-6)alkyl,
(C.sub.3-6)cycloalkyl(C.sub.1-6)alkyl,
hetero(C.sub.3-5)cycloalkyl(C.sub.1-6)alkyl,
(C.sub.4-6)aryl(C.sub.1-6)alkyl, and
hetero(C.sub.1-5)aryl(C.sub.1-6)alkyl, each unsubstituted or
substituted.
[0235] In one particular variation of the above embodiments and
variations of the compounds of the invention, R.sub.1 is
-L-R.sub.45, where
[0236] L is absent or is a linker of one to five atoms, wherein the
atoms in L are each independently selected from the group
consisting of N, O, and S, and are independently unsubstituted or
substituted with 1-2 substituents selected from the group
consisting of nitro, cyano, thio, oxy, hydroxy, carbonyloxy,
(C.sub.1-10)alkoxy, (C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy,
oxo, carbonyl, oxycarbonyl, aminocarbonyl, amino,
alkylcarbonylamino, (C.sub.1-10)alkylamino, sulfonylamino,
aminosulfonyl, sulfonyl, sulfinyl, imino, (C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-6)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, heteroaryl(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl, aryl and
heteroaryl, each unsubstituted or further substituted; or any two
substituents on adjacent atoms of L are taken to form a 3, 4 and 5
membered ring, each unsubstituted or substituted; and
[0237] R.sub.45 is independently selected from the group consisting
of hydrogen, hydroxyl, halo, (C.sub.1-3)alkyl,
hydroxy(C.sub.1-3)alkyl, (C.sub.1-3)alkoxy, amino, carbonylamino,
aminocarbonyl, carbonyl, hydroxycarbonyl, aryl, heteroaryl,
cycloalkyl, and heterocycloalkyl, each unsubstituted or further
substituted.
[0238] In some variations L is absent.
[0239] In some variations of the above particular variation, L is
an alkyl or heteroalkyl of one to five atoms where each atom is
independently selected from the group consisting of N and O, and
each atoms is independently unsubstituted or substituted with 1-2
substituents selected from the group consisting of hydroxy, oxo,
carbonyloxy, (C.sub.1-6)alkoxy, (C.sub.4-6)aryloxy,
hetero(C.sub.1-5)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl,
amino, alkylcarbonylamino, (C.sub.1-10)alkylamino, imino,
(C.sub.1-6)alkyl, hetero(C.sub.1-6)alkyl, hydroxy(C.sub.1-6)alkyl,
carbonyl(C.sub.1-6)alkyl, thiocarbonyl(C.sub.1-6)alkyl,
sulfonyl(C.sub.1-6)alkyl, (C.sub.3-6)cycloalkyl(C.sub.1-6)alkyl,
hetero(C.sub.3-6)cycloalkyl(C.sub.1-6)alkyl, aryl(C.sub.1-6)alkyl,
heteroaryl(C.sub.1-6)alkyl, (C.sub.3-6)cycloalkyl,
hetero(C.sub.3-6)cycloalkyl, aryl and heteroaryl, each
unsubstituted or further substituted.
[0240] In other variation, L is (--CR.sub.46R.sub.47--).sub.n,
where n is 1, 2, 3, 4, or 5. In yet other variations, L is
(--CR.sub.46R.sub.47--).sub.5. In still other variations, L is
(--CR.sub.46R.sub.47--).sub.4. In still other variations, L is
(--CR.sub.46R.sub.47--).sub.3. In still other variations, L is
(--CR.sub.46R.sub.47--).sub.2. In still other variations, L is
--(CR.sub.46R.sub.47)--.
[0241] In the above variations where L is
(--CR.sub.46R.sub.47--).sub.n, R.sub.6 and R.sub.47 are each
independently selected from the group consisting of hydrogen,
hydroxy, oxo, carbonyloxy, (C.sub.1-6)alkoxy, (C.sub.4-6)aryloxy,
hetero(C.sub.1-5)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl,
amino, alkylcarbonylamino, (C.sub.1-10)alkylamino, imino,
(C.sub.1-6)alkyl, hetero(C.sub.1-6)alkyl, hydroxy(C.sub.1-6)alkyl,
carbonyl(C.sub.1-6)alkyl, thiocarbonyl(C.sub.1-6)alkyl,
sulfonyl(C.sub.1-6)alkyl, (C.sub.3-6)cycloalkyl(C.sub.1-6)alkyl,
hetero(C.sub.3-6)cycloalkyl(C.sub.1-6)alkyl, aryl(C.sub.1-6)alkyl,
heteroaryl(C.sub.1-6)alkyl, (C.sub.3-6)cycloalkyl,
hetero(C.sub.3-6)cycloalkyl, aryl and heteroaryl, each
unsubstituted or further substituted.
[0242] In other variations, R.sub.46 and R.sub.47 are each
independently selected from the group consisting of hydrogen,
hydroxyl, hydroxy(C.sub.1-6)alkyl, (C.sub.1-6)alkoxy, oxo, amino,
imino, (C.sub.1-6)alkyl, (C.sub.4-6)aryl(C.sub.1-6)alkyl,
hetero(C.sub.1-5)aryl(C.sub.1-6)alkyl,
(C.sub.3-6)cycloalkyl(C.sub.1-6)alkyl,
hetero(C.sub.1-5)cycloalkyl(C.sub.1-6)alkyl, (C.sub.4-6)aryl,
hetero(C.sub.1-5)aryl, (C.sub.3-6)cycloalkyl, and
hetero(C.sub.1-5)cycloalkyl, each unsubstituted or substituted. In
other variations, R.sub.46 and R.sub.47 are each independently
selected from the group consisting of hydrogen, hydroxyl, oxo,
(C.sub.1-6)alkyl, hydroxy(C.sub.1-6)alkyl, (C.sub.1-6)alkoxy, amino
and aminocarbonyl, each substituted or unsubstituted. In other
variations, R.sub.46 and R.sub.47 are both hydrogen.
[0243] In one variation of the above embodiment and variations,
R.sub.1 is selected from the group consisting of hydrogen, and
##STR00010## ##STR00011## ##STR00012##
[0244] In another variation, R.sub.1 is selected from the group
consisting of hydrogen,
##STR00013## ##STR00014## ##STR00015##
[0245] In still another variation, R.sub.1 is selected from the
group consisting of hydrogen,
##STR00016## ##STR00017##
[0246] In still another variation, R.sub.1 is selected from the
group consisting of hydrogen,
##STR00018##
[0247] In still another variation, R.sub.1 is selected from the
group consisting of hydrogen,
##STR00019##
[0248] In still other variations, R.sub.1 is selected from the
group consisting of hydrogen,
##STR00020##
In yet other variations, R.sub.1 is
##STR00021##
In yet other variations, R.sub.1 is
##STR00022##
In yet other variations, R.sub.1 is
##STR00023##
In yet other variations, R.sub.1 is
##STR00024##
In still further variations, R.sub.1 is
##STR00025##
In yet further variations, R.sub.1 is
##STR00026##
In yet further variations, R.sub.1 is
##STR00027##
In still yet further variations, R.sub.1 is hydrogen
[0249] X--R.sub.1
[0250] In one variation of the above embodiments and variations of
the compounds of the invention, --X--R.sub.1 is selected from the
group consisting of
##STR00028## ##STR00029##
[0251] In another variation, --X--R.sub.1 is selected from the
group consisting of
##STR00030## ##STR00031##
[0252] In another variation, --X--R.sub.1 is selected from the
group consisting of
##STR00032##
[0253] In another variation, --X--R.sub.1 is selected from the
group consisting of hydroxyl, methoxy,
##STR00033##
[0254] In still other variations, --X--R.sub.1 is --OH. In still
other variations, --X--R.sub.1 is --OCH.sub.3. In still other
variations, --X--R.sub.1 is
##STR00034##
In still other variations, --X--R.sub.1 is
##STR00035##
In still further variations, --X--R.sub.1 is
##STR00036##
In still further variations, --X--R.sub.1 is
##STR00037##
In other variations, --X--R.sub.1 is
##STR00038##
In yet other further variations, --X--R.sub.1 is
##STR00039##
In other further variations, --X--R.sub.1 is
##STR00040##
In yet other further variations, --X--R.sub.1 is
##STR00041##
[0255] R.sub.2
[0256] In another variation of the embodiments and variations of
the compounds of the invention, R.sub.2 is selected from the group
consisting of hydrogen, halo, hydroxy, (C.sub.1-10)alkoxy,
(C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy, amino,
(C.sub.1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted.
[0257] In another variation, R.sub.2 is selected from the group
consisting of hydrogen, of hydrogen, hydroxyl, halo, cyano, thiol,
(C.sub.1-6)alkoxy, (C.sub.1-6)alkylthiol, (C.sub.1-6)alkyl,
hetero(C.sub.1-6)alkyl, aryl(C.sub.1-6)alkyl,
heteroaryl(C.sub.1-6)alkyl, (C.sub.1-5)cycloalkyl(C.sub.1-6)alkyl,
hetero(C.sub.1-5)cycloalkyl(C.sub.1-6)alkyl, (C.sub.4-6) aryl,
(C.sub.1-5) heteroaryl, (C.sub.1-6)cycloalkyl, and
hetero(C.sub.1-5)cycloalkyl, each unsubstituted and
substituted.
[0258] In yet another variation, R.sub.2 is selected from the group
consisting of hydrogen, hydroxyl, halo, cyano, thiol,
(C.sub.1-6)alkoxy, (C.sub.1-6)alkylthiol, (C.sub.1-6)alkyl,
hetero(C.sub.1-6)alkyl, aryl(C.sub.1-6)alkyl,
heteroaryl(C.sub.1-6)alkyl, (C.sub.1-5)cycloalkyl(C.sub.1-6)alkyl,
hetero(C.sub.1-5)cycloalkyl(C.sub.1-6)alkyl, (C.sub.4-6) aryl,
(C.sub.1-5) heteroaryl, (C.sub.1-6)cycloalkyl, and
hetero(C.sub.1-5)cycloalkyl, each unsubstituted and
substituted.
[0259] In yet another variation, R.sub.2 is selected from the group
consisting of hydrogen, hydroxyl, methyl, ethyl, methoxymethyl,
trifluoromethyl, phenylethyl, and substituted benzyl where the
substituents are each independently selected from the group
consisting of methoxy, halo, nitro, amino, and acetamide.
[0260] In still another variation, R.sub.2 is selected from the
group consisting of hydrogen, (C.sub.1-6)alkyl or
halo(C.sub.1-6)alkyl, aza(C.sub.1-6)alkyl, (C.sub.1-6)oxaalkyl,
each unsubstituted or substituted.
[0261] In yet another variation, R.sub.2 is selected from the group
consisting of unsubstituted or substituted (C.sub.1-6)alkyl.
[0262] In yet another variation, R.sub.2 is hydrogen.
[0263] In yet another variation, R.sub.2 is methyl.
[0264] R.sub.4
[0265] In one variation of the above embodiments and variations of
the compounds of the invention, when present, R.sub.4 is selected
from the group consisting of hydrogen, (C.sub.1-6)alkyl,
(C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, hydroxy(C.sub.1-6)alkyl,
amino(C.sub.1-6)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.3-7)cycloalkyl,
(C.sub.5-7)cycloalkenyl, and hetero(C.sub.3-12)cycloalkyl, each
unsubstituted or substituted.
[0266] In another variation, when present, R.sub.4 is selected from
the group consisting of hydrogen, methyl, ethyl, allyl,
3-methylbutyl, isobutyl, 2-hydroxyethyl, 3-aminopropyl,
1-(4-methoxyphenyl)ethyl, (2-methyl-2-morpholin-4-yl)propyl,
pyridin-4-ylmethyl, tetrahydropyran-4-ylmethyl, benzyl,
2,4-dimethoxy-benzyl, 3-chloro-benzyl, 2-chloro-benzyl,
2-fluoro-benzyl, 4-fluoro-benzyl, 3-trifluoromethyl-benzyl,
pyrazin-2-yl, and --(CH.sub.2).sub.3NHC(O)O--C(CH.sub.3).sub.3.
[0267] In yet another variation, when present, R.sub.4 is selected
from the group consisting of hydrogen, unsubstituted
(C.sub.1-6)alkyl, and substituted (C.sub.1-6)alkyl.
[0268] In yet another variation, when present, R.sub.4 is selected
from the group consisting of methyl, ethyl, allyl, 3-methyl-butyl,
and isobutyl.
[0269] In still another variation, when present, R.sub.4 is
selected from the group consisting of hydrogen, benzyl,
1-(4-methoxyphenyl)ethyl, 1-methyl-(4-methoxyphenyl)methyl, methyl,
3-aminopropyl, and 2-methyl-2-morpholinopropyl.
[0270] In still another variation, when present, wherein R.sub.4 is
hydrogen.
[0271] R.sub.5 and R.sub.5'
[0272] In one variation of the embodiments and variations of the
compounds of the invention, when present, R.sub.5 and R.sub.5' are
each independently selected from the group consisting of hydrogen,
halo, cyano, carbonyl, aminocarbonyl, sulfonyl, (C.sub.1-10)alkyl,
halo(C.sub.10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, and hetero(C.sub.1-10)alkyl, each
substituted or unsubstituted.
[0273] In another variation, when present, R.sub.5 and R.sub.5' are
each independently selected from the group consisting of hydrogen,
halogen, (C.sub.1-6)alkyl, --OR.sub.42, --SR.sub.42,
--N(R.sub.42).sub.2, --OC(O)R.sub.42, --NR.sub.42C(O)R.sub.42, and
--N(R.sub.42)S(O).sub.2R.sub.42, where R.sub.42 is selected from
the group consisting of hydrogen, (C.sub.1-6)alkyl,
(C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, (C.sub.3-7)cycloalkyl,
(C.sub.5-7)cycloalkenyl, aryl, heteroaryl, and
(C.sub.3-7)heterocycloalkyl, each unsubstituted or substituted.
[0274] In another variation, when present, R.sub.5 and R.sub.5' are
each independently selected from the group consisting of hydrogen,
unsubstituted (C.sub.1-6)alkyl, and substituted
(C.sub.1-6)alkyl.
[0275] In still another variation, when present, R.sub.5 and
R.sub.5' is hydrogen.
[0276] In yet another variation, when present, both R.sub.5 and
R.sub.5' are hydrogen.
[0277] R.sub.6
[0278] In one variation of the embodiments and variations of the
compounds of the invention, when present, R.sub.6 and R.sub.6' are
each independently selected from the group consisting of hydrogen,
halogen, cyano, (C.sub.1-10)alkyl, and hetero(C.sub.1-10)alkyl,
each substituted or unsubstituted.
[0279] In another variation, when present, R.sub.6 and R.sub.6' are
each independently selected from the group consisting of hydrogen,
halogen, cyano, (C.sub.1-6)alkyl, --OR.sub.43, --SR.sub.43,
--N(R.sub.43).sub.2, --OC(O)R.sub.43, --NR.sub.43C(O)R.sub.43, and
--N(R.sub.43)S(O).sub.2R.sub.43, where R.sub.43 is selected from
the group consisting of hydrogen, halogen, cyano, nitro, amino,
(C.sub.1-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl,
(C.sub.3-7)cycloalkyl, (C.sub.5-7)cycloalkenyl, aryl, heteroaryl,
and (C.sub.3-7)heterocycloalkyl, each unsubstituted or
substituted.
[0280] In still another variation, when present, R.sub.6 and
R.sub.6' are each independently selected from the group consisting
of hydrogen, halogen, unsubstituted or substituted
(C.sub.1-6)alkyl.
[0281] In still another variation, when present, R.sub.6 and
R.sub.6' are both halogen.
[0282] In still another variation, when present, one of R.sub.6 and
R.sub.6' is halogen, and the other one of R.sub.6 and R.sub.6' is
hydrogen.
[0283] In one variation, the halogen of the R.sub.6 and R.sub.6'
definition is fluoro.
[0284] In yet still other variations, when present, R.sub.6 and
R.sub.6' are both hydrogen.
[0285] In yet still other variations, when present, R.sub.6 is
fluoro. In yet still other variations, when present, R.sub.6 is
cyano. In yet another variation, when present, R.sub.6 is
hydrogen.
[0286] R.sub.7
[0287] In one variation of the embodiments and variations of the
compounds of the invention, when present, R.sub.7 is selected from
the group consisting of hydrogen, cyano, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl, amino(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
(C.sub.1-10)alkoxy, and (C.sub.1-10)alkoxy(C.sub.1-10)alkyl, each
unsubstituted or substituted.
[0288] In another variation, when present, R.sub.7 is selected from
the group consisting of hydrogen, cyano, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl, aza(C.sub.1-10)alkyl,
and (C.sub.1-10)oxaalkyl, each substituted or unsubstituted.
[0289] In another variation, when present, R.sub.7 is selected from
the group consisting of hydrogen, cyano, alkoxy, hydroxylalkyl,
alkyl, aminoalkyl, and alkoxyalkyl.
[0290] In yet another variation, when present, R.sub.7 is
hydrogen.
[0291] R.sub.3
[0292] In one variation of the above embodiments and variations of
the compounds of the invention, R.sub.3 is selected from the group
consisting of hydrogen, (C.sub.1-6)alkyl, (C.sub.1-6)alkenyl,
(C.sub.3-15)cycloalkyl, hetero(C.sub.1-14)cycloalkyl cycloalkenyl,
(C.sub.4-15)aryl, and hetero(C.sub.1-14)aryl, each unsubstituted or
substituted with 1-4 substituents each of which is independently
selected from the group consisting of hydrogen, halo, cyano, thio,
oxy, hydroxy, carbonyloxy, (C.sub.1-10)alkoxy, (C.sub.4-12)aryloxy,
hetero(C.sub.1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl,
amino, (C.sub.1-10)alkylamino, sulfonylamino, aminosulfonyl,
sulfonyl, sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted with 1-3 substituents, or the substituents on adjacent
atom may be taken together to form a substituted or unsubstituted
ring.
[0293] In one variation, R.sub.3 is of the formula
##STR00042##
[0294] wherein
[0295] R.sub.10 and R.sub.11 are each independently selected from
the group consisting of hydrogen, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted, or R.sub.10 and R.sub.11 are taken together to form
Ring C which is selected from a group consisting of monocyclic,
bicyclic, saturated, unsaturated, aromatic, carbocyclyl and
heterocyclyl, each unsubstituted or substituted with 1-3
substituents independently selected from the group consisting of
hydroxy, nitro, halo, cyano, thio, oxy, carbonyloxy,
(C.sub.1-10)alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl,
aminocarbonyl, amino, (C.sub.1-10)alkylamino, sulfonylamino,
aminosulfonyl, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted; and
[0296] R.sub.12 is selected from a group consisting of
C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
hetero(C.sub.4-12)bicycloaryl, (C.sub.3-12)cycloalkyl, and
hetero(C.sub.2-11)cycloalkyl, each unsubstituted or substituted
with 1-3 substituents independently selected from the group
consisting of hydroxy, halo, nitro, cyano, thio, alkylthio,
carbonyloxy, (C.sub.1-10)alkoxy, (C.sub.1-10)haloalkoxy,
(C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy, carbonyl,
oxycarbonyl, aminocarbonyl, alkylaminocarbonyl, amino, amido,
(C.sub.1-10)alkylamino, sulfonylamino, aminosulfonyl, imino,
alkoxyalkyl, alkoxycarbonylalkyl, aryloxyalkyl, heteroarylalkyl,
sulfonyl, sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, unsubstituted or substituted; or
one of said 1-3 substituents on R.sub.12 and one of said 1-3
substituents on said Ring C are taken together to form a six or
seven membered, saturated, unsaturated, or aromatic ring that is
unsubstituted or substituted with 1-4 substituents.
[0297] In one variation, when present, R.sub.10 is selected from
the group consisting of hydrogen, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, and hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
each substituted or unsubstituted.
[0298] In another variation, when present, R.sub.10 is selected
from the group consisting of hydrogen, halo, unsubstituted or
substituted alkyl, and unsubstituted or substituted
heteroalkyl.
[0299] In still another variation, when present, R.sub.10 is
selected from the group consisting of hydrogen, halo, unsubstituted
or substituted alkyl.
[0300] In one variation, when present, R.sub.11 is selected from
the group consisting of hydrogen, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, and hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
each substituted or unsubstituted.
[0301] In another variation, when present, R.sub.11 is selected
from the group consisting of hydrogen, halo, alkyl, and
heteroalkyl.
[0302] In still another variation, when present, R.sub.11 is
methyl.
[0303] R.sub.10 and R.sub.11 are Taken Together to Form a Ring
[0304] In one specific variation of R.sub.3, where R.sub.10 and
R.sub.11 are taken together to form Ring C, R.sub.3 is of the
formula
##STR00043##
wherein Ring C is selected from the group consisting of
(C.sub.4-12)aryl, (C.sub.1-11)heteroaryl, (C.sub.3-12)cycloalkyl,
and hetero(C.sub.1-11)cycloalkyl, each of which is unsubstituted or
substituted said 1-3 substituents independently selected from the
group consisting of hydroxy, nitro, halo, cyano, thio, oxy,
carbonyloxy, (C.sub.1-10)alkoxy, aryloxy, heteroaryloxy, carbonyl,
oxycarbonyl, aminocarbonyl, amino, (C.sub.1-10)alkylamino,
sulfonylamino, aminosulfonyl, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted.
[0305] In another variation, Ring C is selected from the group
consisting of aryl, heterocyclyl, heteroaryl,
(C.sub.3-7)cycloalkyl, and (C.sub.5-7)cycloalkenyl, each of which
is substituted with 1-3 substituents. In some variations, the aryl,
heterocyclyl, heteroaryl, (C.sub.3-7)cycloalkyl, and
(C.sub.5-7)cycloalkenyl is selected from the group consisting of
pyrrolyl, phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl,
pyrazolyl, imidazolyl, triazolyl, indolyl, oxadiazole, thiadiazole,
furanyl, quinolinyl, isoquinolinyl, isoxazolyl, oxazolyl,
thiazolyl, morpholino, piperidinyl, pyrrolidinyl, thienyl,
cyclohexyl, cyclopentyl, cyclohexenyl, and cyclopentenyl, each
unsubstituted or substituted with 1-3 substituents selected from
the group consisting of halo, alkoxy, alkyl, amino, alkylamino,
haloalkyl, and haloalkoxy.
[0306] In another variation, Ring C is selected from the group
consisting of (C.sub.4-6)aryl or (C.sub.1-5)heteroaryl, each
unsubstituted or substituted with 1-3 substituents. In one
variation, the aryl or heteroaryl is selected from the group
consisting of phenyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl,
thiazolyl, and thienyl, each of which is unsubstituted or
substituted with 1-3 substituents.
[0307] In the above embodiments and variations, the 1-3
substituents on Ring C is, in some variations, independently
selected from the group consisting of hydroxy, nitro, halo, cyano,
thio, oxy, carbonyloxy, (C.sub.1-10)alkoxy, aryloxy, heteroaryloxy,
carbonyl, oxycarbonyl, aminocarbonyl, amino,
(C.sub.1-10)alkylamino, sulfonylamino, aminosulfonyl, sulfonyl,
sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted. In some other variations, the 1-3 substituents are
each independently selected from the group consisting of
substituted or unsubstituted aryl, substituted or unsubstituted
heteroaryl, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy. In some
other variations, at least one of the 1-3 substituents on Ring C is
selected from the group consisting of fluoro, methyl, and methoxy.
In other variations, the 1-3 substituents on Ring C are each
independently selected from the group consisting of halo. In other
variations, the substituents are fluoro. In still other variations,
the substituents are methyl. In yet still other variations, the
substituents are methoxy.
[0308] In one particular variation, R.sub.3 is of the formula:
##STR00044##
[0309] wherein
[0310] J.sub.10 is selected from the group consisting of O, S,
NR.sub.26, and CR.sub.27R.sub.27',
[0311] J.sub.11 is selected from the group consisting of O, S,
NR.sub.28, and CR.sub.29R.sub.29',
[0312] J.sub.12 is selected from the group consisting of O, S,
NR.sub.30, and CR.sub.31R.sub.31', [0313] where [0314] R.sub.26,
R.sub.28 and R.sub.30 are each independently selected from the
group consisting of hydrogen, (C.sub.1-10)alkylamino, sulfonamido,
sulfonyl, sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, aza(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.9-12)bicycloalkyl,
hetero(C.sub.3-12)bicycloalkyl, (C.sub.4-12)aryl,
hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl and
hetero(C.sub.4-12)bicycloaryl, each substituted or unsubstituted,
or R.sub.26, R.sub.28, and R.sub.30 are each independently absent
when the nitrogen atom to which it is bound forms parts of a double
bond, and [0315] R.sub.27, R.sub.27', R.sub.29, R.sub.29',
R.sub.31, and R.sub.31' are each independently selected from the
group consisting of hydrogen, halo, nitro, cyano, thio, oxy,
hydroxy, carbonyloxy, (C.sub.1-10)alkoxy, (C.sub.4-12)aryloxy,
hetero(C.sub.1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl,
amino, (C.sub.1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted, or R.sub.27', R.sub.29', R.sub.31' are each
independently absent when the carbon atom to which it is bound
forms parts of a double bond.
[0316] In one variation of the above variation of Ring C, R.sub.26,
R.sub.28 and R.sub.30, are each individually selected from the
group consisting of hydrogen, (C.sub.1-10)alkylamino, sulfonamido,
sulfonyl, sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, aza(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, and hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
each substituted or unsubstituted, or R.sub.26, R.sub.28, and
R.sub.30 are each independently absent when the nitrogen to which
it is bound forms parts of a double bond; and R.sub.27, R.sub.27',
R.sub.29, R.sub.29', R.sub.31, and R.sub.31' are each individually
selected from the group consisting of hydrogen, halo, nitro, cyano,
thio, oxy, hydroxy, carbonyloxy, (C.sub.1-10)alkoxy,
(C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy, carbonyl,
oxycarbonyl, aminocarbonyl, amino, (C.sub.1-10)alkylamino,
sulfonamido, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl, each
substituted or unsubstituted, or R.sub.27', R.sub.29', R.sub.31'
are each independently absent when the carbon atom to which it is
bound forms parts of a double bond.
[0317] In yet another variation of the above embodiment of Ring C,
R.sub.26, R.sub.28 and R.sub.30, are each individually selected
from the group consisting of hydrogen, (C.sub.1-10)alkylamino,
(C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, and aza(C.sub.1-10)alkyl, each
substituted or unsubstituted, or R.sub.26, R.sub.28, and R.sub.30
each is independently absent when the nitrogen atom to which it is
bound forms parts of a double bond; and R.sub.27, R.sub.27',
R.sub.29, R.sub.29', R.sub.31, and R.sub.31' are each individually
selected from the group consisting of hydrogen, halo, nitro, cyano,
oxy, hydroxy, carbonyloxy, (C.sub.1-10)alkoxy, carbonyl,
aminocarbonyl, amino, (C.sub.1-10)alkylamino,
hydroxy(C.sub.1-10)alkyl, aza(C.sub.1-10)alkyl, and
(C.sub.1-10)oxaalkyl, each substituted or unsubstituted, or
R.sub.27', R.sub.29', R.sub.31' are each independently absent when
the carbon atom to which it is bound forms parts of a double
bond.
[0318] In still another variation, R.sub.26, R.sub.28 and R.sub.30,
are each individually selected from the group consisting of
hydrogen, (C.sub.1-6)alkylamino, (C.sub.1-6)alkyl,
halo(C.sub.1-6)alkyl, hydroxy(C.sub.1-6)alkyl,
carbonyl(C.sub.1-6)alkyl, aza(C.sub.1-6)alkyl, each substituted or
unsubstituted, or R.sub.26, R.sub.28, and R.sub.30 each is
independently absent when the nitrogen atom to which it is bound
forms part of a double bond; and R.sub.27, R.sub.27', R.sub.29,
R.sub.29', R.sub.31, and R.sub.31' are each individually selected
from the group consisting of hydrogen, halo, nitro, cyano, oxy,
hydroxy, carbonyloxy, (C.sub.1-6)alkoxy, carbonyl, aminocarbonyl,
amino, (C.sub.1-10)alkylamino, hydroxy(C.sub.1-10)alkyl,
aza(C.sub.1-6)alkyl, (C.sub.1-6)oxaalkyl, each substituted or
unsubstituted, or R.sub.27', R.sub.29', R.sub.31' are each
independently absent when the carbon atom to which it is bound
forms part of a double bond.
[0319] In another particular variation, R.sub.3 is of the
formula:
##STR00045##
[0320] where
[0321] J.sub.13 is selected from the group consisting of O, S,
NR.sub.32, and CR.sub.33R.sub.33',
[0322] J.sub.14 is selected from the group consisting of O, S,
NR.sub.34, and CR.sub.35R.sub.35',
[0323] J.sub.15 is selected from the group consisting of O, S,
NR.sub.36, and CR.sub.37R.sub.37',
[0324] J.sub.16 is selected from the group consisting of O, S,
NR.sub.38, and CR.sub.39R.sub.39', [0325] where [0326] R.sub.32,
R.sub.34, R.sub.36, and R.sub.38 are each independently selected
from the group consisting of hydrogen, oxy, hydroxy,
(C.sub.1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
aza(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.9-12)bicycloalkyl,
hetero(C.sub.3-12)bicycloalkyl, (C.sub.4-12)aryl,
hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl, and
hetero(C.sub.4-12)bicycloaryl, each substituted or unsubstituted,
or R.sub.32, R.sub.34, R.sub.36, and R.sub.38 are each
independently absent when the nitrogen atom to which it is bound
forms parts of a double bond, and
[0327] R.sub.33, R.sub.33', R.sub.35, R.sub.35', R.sub.37,
R.sub.37', R.sub.38, and R.sub.38' are each independently selected
from the group consisting of hydrogen, halo, nitro, cyano, thio,
oxy, hydroxy, carbonyloxy, (C.sub.1-10)alkoxy, (C.sub.4-12)aryloxy,
hetero(C.sub.1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl,
amino, (C.sub.1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl,
(C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted, or R.sub.33', R.sub.35', R.sub.37', and R.sub.39'
are each independently absent when the carbon atom to which it is
bound forms parts of a double bond, and [0328] R.sub.12 is as
previously defined.
[0329] In one variation of the above embodiment of Ring C,
R.sub.32, R.sub.34, R.sub.36, and R.sub.38 are each independently
selected from the group consisting of hydrogen, oxy, hydroxy,
(C.sub.1-10)alkylamino, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, aza(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl, each
substituted or unsubstituted, or R.sub.32, R.sub.34, R.sub.36, and
R.sub.38 are each independently absent when the nitrogen atom to
which it is bound forms parts of a double bond, and R.sub.33,
R.sub.33', R.sub.35, R.sub.35', R.sub.37, R.sub.37', R.sub.39, and
R.sub.39' are each independently selected from the group consisting
of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy,
(C.sub.1-10)alkoxy, (C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy,
oxycarbonyl, aminocarbonyl, amino, (C.sub.1-10)alkylamino,
(C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl, each
substituted or unsubstituted, or R.sub.33', R.sub.35', R.sub.37',
and R.sub.39' are each independently absent when the carbon atom to
which it is bound forms parts of a double bond.
[0330] In still another variation, R.sub.32, R.sub.34, R.sub.36,
and R.sub.38 are each independently selected from the group
consisting of hydrogen, oxy, hydroxy, (C.sub.1-10)alkylamino,
(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl, aza(C.sub.1-10)alkyl,
each substituted or unsubstituted, or R.sub.32, R.sub.34, R.sub.36,
and R.sub.38 are each independently absent when the nitrogen atom
to which it is bound forms parts of a double bond, and R.sub.33,
R.sub.33', R.sub.35, R.sub.35', R.sub.37, R.sub.37', R.sub.39, and
R.sub.39' are each independently selected from the group consisting
of hydrogen, halo, nitro, cyano, oxy, hydroxy, carbonyloxy,
(C.sub.1-10)alkoxy, aminocarbonyl, amino, (C.sub.1-10)alkylamino,
(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, aza(C.sub.1-10)alkyl,
(C.sub.1-10)Oxaalkyl, each substituted or unsubstituted, or
R.sub.33', R.sub.35', R.sub.37', and R.sub.39' are each
independently absent when the carbon atom to which it is bound
forms parts of a double bond.
[0331] In still another variation, R.sub.3 is selected from the
group consisting of
##STR00046##
[0332] where
[0333] R.sub.29 and R.sub.31 are each independently selected from
the group consisting of hydrogen, halo, cyano, hydroxy,
carbonyloxy, (C.sub.1-10)alkoxy, (C.sub.4-12)aryloxy,
hetero(C.sub.1-10)aryloxy, aminocarbonyl, amino,
(C.sub.1-10)alkylamino, sulfonamido, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, each substituted or unsubstituted;
[0334] R.sub.33, R.sub.35, R.sub.37, and R.sub.39 are each
independently selected from the group consisting of hydrogen, halo,
(C.sub.1-10)alkoxy, (C.sub.1-10)alkyl; and
[0335] R.sub.34 and R.sub.36 are each independently selected from
selected from the group consisting of alkyl, aza(C.sub.1-10)alkyl,
and hydroxyl(C.sub.1-10)alkyl.
[0336] In still another variation, wherein R.sub.3 is of the
formula
##STR00047##
[0337] where
[0338] R.sub.29 and R.sub.31 are each independently selected from
the group consisting of hydrogen, halogen, cyano, nitro,
(C.sub.1-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, amino or
substituted amino, aryl, heteroaryl, (C.sub.3-7)cycloalkyl,
(C.sub.5-7)cycloalkenyl, (C.sub.3-7)heterocycloalkyl, --OR.sub.40,
--SR.sub.40, --C(O)R.sub.40, --C(O)OR.sub.40,
--C(O)N(R.sub.40).sub.2, --S(O)R.sub.40, --S(O).sub.2R.sub.40,
--S(O).sub.2N(R.sub.40).sub.2, --OC(O)R.sub.40,
--NR.sub.40C(O)R.sub.40, and --N(R.sub.40)S(O).sub.2R.sub.40;
[0339] where [0340] R.sub.40 is selected from the group consisting
of methyl, ethyl, isopropyl, cyclopentyl, cyclohexyl, unsubstituted
or substituted phenyl, unsubstituted or substituted thiazolyl,
unsubstituted or substituted pyridyl, unsubstituted or substituted
pyrazinyl, and unsubstituted or substituted pyrimindinyl,
2-aminoethyl, 2-piperidinylethyl, 2-piperazinylethyl,
2-morpholinylethyl, and 2-(N-methylpiperazinyl)ethyl.
[0341] In one variation of the immediately above variation,
R.sub.40 is selected from the group consisting of methyl, ethyl,
isopropyl, cyclopentyl, and 2-aminoethyl. In another variation,
R.sub.40 is methyl. In another variation, R.sub.40 is ethyl. In
another variation, R.sub.40 is isopropyl. In another variation,
R.sub.40 is cyclopentyl. In another variation, R.sub.40 is
2-aminoethyl.
[0342] In still another variation, R.sub.3 is of the formula
##STR00048##
[0343] where
[0344] R.sub.33, R.sub.35, R.sub.37, and R.sub.39 are each
independently selected from the group consisting of hydrogen,
alkyl, alkoxy, halo, unsubstituted or substituted aryl, and
substituted heteroaryl.
[0345] In still another variation, R.sub.3 is selected is selected
from the group consisting of
##STR00049##
[0346] R.sub.12
[0347] Of the above embodiments and variations of the present
invention, in some variations, R.sub.12 is selected from the group
consisting of (C.sub.4-12)aryl, hetero(C.sub.1-10)aryl,
(C.sub.9-12)bicycloaryl, hetero(C.sub.4-12)bicycloaryl,
(C.sub.3-12)cycloalkyl, and hetero(C.sub.2-11)cycloalkyl, each
unsubstituted or substituted with 1-3 substituents. In other
variations R.sub.12 is selected from the group consisting of
furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl,
pyrazolyl, triazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl,
phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl,
indolyl, isoindolyl, indolizinyl, benzimidazolyl, purinyl,
naphthalenyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl,
quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, pyridone,
and pyrimidone, each of which is unsubstituted or substituted with
1-3 substituents.
[0348] In some variations of the above embodiments and variations,
the 1-3 substituents of R.sub.12 are each independently selected
from the group consisting of halo, nitro, cyano, thio, oxy, oxo,
hydroxy, carbonyloxy, (C.sub.1-10)alkoxy, (C.sub.4-12)aryloxy,
hetero(C.sub.1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl,
amino, amido, (C.sub.1-10)alkylamino, sulfonamido, imino, sulfonyl,
sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or further
substituted.
[0349] In other variations, the 1-3 substituents on R.sub.12 are
each independently selected from the group consisting of halo,
cyano, oxy, oxo, (C.sub.1-6)alkoxy, (C.sub.4-12)aryloxy,
hetero(C.sub.1-10)aryloxy, carbonyl, amino, amido, sulfonyl,
(C.sub.1-6)alkyl, sulfonyl(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.4-12)aryl, and
hetero(C.sub.1-10)aryl, each unsubstituted or substituted.
[0350] In still other variations, the 1-3 substituents on R.sub.12
are each independently selected from the group consisting of halo,
cyano, (C.sub.1-6)alkyl, (C.sub.1-6)alkoxy, amino, acetamido,
carbonyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each
unsubstituted or substituted. In still other variations, the 1-3
substituents on R.sub.12 are each independently selected from the
group consisting of fluoro, difluoro, chloro, bromo, cyano, amino,
methylamino, ethylamino dimethylamino, hydroxyethylamino, methyl,
ethyl, ethynyl, trifluoromethyl, aminomethyl, methoxy, ethoxy,
dimethoxy, 2,2,2-trifluoroethoxy, trifluoromethoxy, phenoxy,
acetamido, ethoxyacetamido, acetyl, substituted methoxycarbonyl,
ethoxyaminocarbonyl, methanesulfonylamino,
4-trifluoromethoxyphenoxymethyl, 3-trifluoromethoxyphenoxymethyl,
and isothiazolidine 1,1 dioxide. In still other variations, the 1-3
substituents on R.sub.12 are each independently selected from the
group consisting of fluoro, chloro, methoxy, ethoxy, and amino. In
still another variation, the 1-3 substituents on R.sub.12 are each
independently selected from the group consisting of fluoro,
chloromethoxy, ethoxy, and amino.
[0351] In still another variation, R.sub.12 is selected from the
group consisting of (2-hydroxy-ethylamino)-pyrazin-2-yl,
1H-pyrazol-4-yl, 1-methyl-1H-pyrazol-4-yl,
1-methyl-1H-pyrazol-4-yl, 2-(5-methyl-pyridin-2-yl)-phenyl,
2,3-difluoro-phenyl, 2,3-dimethoxy-phenyl, 2,4-difluoro-phenyl,
2,4-dimethoxy-phenyl, 2,4-dimethoxy-pyrimidin-5-yl,
2,5-difluoro-phenyl, 2,6-difluoro-phenyl,
2,6-dimethyl-pyridin-3-yl, 2-acetamidophenyl,
2-aminocarbonylphenyl, 2-amino-pyrimidin-5-yl,
2-chloro-4-methoxy-pyrimidin-5-yl, 2-chloro-5-fluoro-pyridin-3-yl,
2-chloro-phenyl, 2-chloro-pyridin-3-yl, 2-chloro-pyridin-4-yl,
2-difluoro-3-methoxyphenyl, 2-ethyl-phenyl, 2-ethoxy-thiazol-4-yl,
2-fluoro-3-methoxy-phenyl, 2-fluoro-3-methylphenyl,
2-fluoro-4-methyl-phenyl, 2-fluoro-5-methoxy-phenyl,
2-fluoro-5-methylphenyl, 2-fluorophenyl, 2-fluoro-pyridin-3-yl,
2-hydroxymethyl-3-methoxyphenyl, 2-hydroxymethylphenyl,
2-isoquinolin-4-yl, 2-methoxy-5-trifluoromethyl-phenyl,
2-methoxy-phenyl, 2-methoxy-pyridin-3-yl, 2-methoxy-pyrimidin-4-yl,
2-methoxy-thiazol-4-yl, 2-methyl-phenyl, 2-methyl-pyridin-3-yl,
2-oxo-1,2-dihydro-pyridin-3-yl, 2-phenoxyphenyl, 2-pyridin-3-yl,
2-pyrimidin-5-yl, 2-trifluoromethoxyphenyl,
2-trifluoromethoxy-phenyl, 3,4-dimethoxy-phenyl,
3,5-dimethyl-isoxazol-4-yl, 3,6-dimethyl-pyrazin-2-yl,
3-acetamidophenyl, 3-aminocarbonylphenyl, 3-bromo-phenyl,
3-chloro-pyrazin-2-yl, 3-cyanophenyl, 3-dimethylaminophenyl,
3-ethoxy-phenyl, 3-ethyl-4-methyl-phenyl, 3-ethynyl-phenyl,
3-fluoro-6-methoxy-pyridin-2-yl, 3-fluorophenyl,
3-fluoro-pyrazin-2-yl, 3-methanesulfonamidophenyl,
3-methoxycarbonylphenyl, 3-methoxyphenyl, 3-methoxy-pyrazin-2-yl,
3-methyl-3H-imidazo[4,5-b]pyrazin-5-yl, 3-methylphenyl,
3-methyl-pyridin-2-yl, 3-trifluoromethoxyphenyl,
3-trifluoromethylphenyl, 4,5-dimethoxy-pyrimidin-2-yl,
4-amino-5-fluoro-pyrimidin-2-yl, 4-chloro-2,5-dimethoxy-phenyl,
4-chloro-2-fluoro-phenyl, 4-chloro-2-methoxy-5-methyl-phenyl,
4-chloro-pyridin-3-yl, 4-difluoro-2-methyl-phenyl,
4-ethoxy-5-fluoro-pyrimidin-2-yl, 4-ethoxy-pyrimidin-2-yl,
4-ethoxy-pyrimidin-5-yl, 4-ethyl-1H-pyrazol-3-yl,
4-fluoro-2-methoxy-phenyl, 4-fluoro-2-methyl-phenyl,
4-fluorophenyl, 4-methoxy-5-methyl-pyrimidin-2-yl,
4-methoxy-pyridin-3-yl, 4-methoxy-pyrimidin-2-yl,
4-methoxy-pyrimidin-5-yl, 4-methyl-phenyl, 4-methyl-pyridin-2-yl,
4-methyl-pyridin-3-yl, 4-pyrrolidin-1-yl-pyrimidin-2-yl,
5,6-dimethoxy-pyrazin-2-yl, 5-acetyl-thiophen-2-yl,
5-amino-6-ethoxy-pyrazin-2-yl,
5-amino-6-methoxy-3-methyl-pyrazin-2-yl,
5-amino-6-methoxy-pyridin-2-yl, 5-chloro-4-methoxy-pyrimidin-2-yl,
5-chloro-6-methoxy-pyrazin-2-yl,
5-dimethylamino-6-methoxy-pyrazin-2-yl, 5-fluoro-2-methoxyphenyl,
5-fluoro-4-methoxy-pyrimidin-2-yl, 5-fluoro-6-methoxy-pyrazin-2-yl,
5-fluoro-pyridin-2-yl, 5-methoxy-pyridin-3-yl,
5-methoxy-thiophen-2-yl, 5-trifluoromethyl-pyrimidin-2-yl,
6-acetyl-pyridin-2-yl, 6-chloro-pyrazin-2-yl,
6-ethoxy-pyrazin-2-yl, 6-ethoxy-pyridin-2-yl,
6-fluoro-pyridin-2-yl, 6-fluoro-pyridin-3-yl,
6-hydroxy-pyridin-2-yl, 6-methoxy-5-methylamino-pyrazin-2-yl,
6-methoxy-5-methyl-pyrazin-2-yl, 6-methoxy-pyrazin-2-yl,
6-methoxy-pyridin-2-yl, 6-methoxy-pyridin-3-yl,
6-methylamino-pyrazin-2-yl, 6-methyl-pyridin-2-yl,
5-amino-6-(2,2,2-trifluoroethoxy)pyrazin-2-yl, and
6-trifluoromethyl-pyridin-2-yl.
[0352] In other variations of the above embodiments and variations
of the invention, R.sub.12, when present, is a five membered aryl
or heteroaryl of the formula
##STR00050##
[0353] wherein
[0354] J.sub.0 is selected from the group consisting of N and
C;
[0355] J.sub.1 is selected from the group consisting of O, S, N,
NR.sub.13 and CR.sub.14;
[0356] J.sub.2 is selected from the group consisting of O, S, N,
NR.sub.15 and CR.sub.16;
[0357] J.sub.3 is selected from the group consisting of O, S, N,
NR.sub.17 and CR.sub.18;
[0358] J.sub.4 is selected from the group consisting of O, S, N,
NR.sub.19 and CR.sub.20; [0359] where [0360] R.sub.13, R.sub.15,
R.sub.17, and R.sub.19 are each individually selected from the
group consisting of hydrogen, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
aza(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.9-12)bicycloalkyl,
hetero(C.sub.3-12)bicycloalkyl, (C.sub.4-12)aryl,
hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl and
hetero(C.sub.4-12)bicycloaryl, each substituted or unsubstituted;
[0361] R.sub.14, R.sub.16, R.sub.18, and R.sub.20 are each
individually selected from the group consisting of hydrogen, halo,
nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C.sub.1-10)alkoxy,
(C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy, carbonyl,
oxycarbonyl, aminocarbonyl, amino, (C.sub.1-10)alkylamino,
sulfonamido, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted; and [0362] one of R.sub.13, R.sub.14, R.sub.19 and
R.sub.20 may be taken together with R.sub.11 to form a 6 or 7
membered, saturated, unsaturated or aromatic ring, each
unsubstituted or further substituted with 1-3 substitutents, and
one of R.sub.13, R.sub.14, R.sub.19 and R.sub.20 may be taken
together with a substituent on the ring formed by taking R.sub.10
and R.sub.11 together to form a 6 or 7 membered, saturated,
unsaturated or aromatic ring, each unsubstituted or further
substituted with 1-3 substituents.
[0363] In another variation, R.sub.12, when present, is a six
membered aryl or heteroaryl of the formula
##STR00051##
[0364] wherein
[0365] J.sub.0 is selected from the group consisting of N and
C;
[0366] J.sub.5 is selected from the group consisting of NR.sub.21',
CR.sub.21 and C(O);
[0367] J.sub.6 is selected from the group consisting of NR.sub.22',
CR.sub.22 and C(O);
[0368] J.sub.7 is selected from the group consisting of NR.sub.23',
CR.sub.23 and C(O);
[0369] J.sub.8 is selected from the group consisting of NR.sub.24',
CR.sub.24 and C(O);
[0370] J.sub.9 is selected from the group consisting of NR.sub.25',
CR.sub.25 and C(O); [0371] where [0372] R.sub.21, R.sub.21',
R.sub.22, R.sub.22', R.sub.23, R.sub.23', R.sub.24, R.sub.24',
R.sub.25 and R.sub.25' are each individually selected from the
group consisting of hydrogen, halo, nitro, cyano, thio, alkylthio,
hydroxy, oxy, (C.sub.1-10)alkoxy, (C.sub.1-10)haloalkoxy, aryloxy,
heteroaryloxy, carbonyloxy, carbonyl, alkoxycarbonyl,
alkoxyaminocarbonyl, alkylaminocarbonyl, amino,
(C.sub.1-10)alkylamino, hydroxy(C.sub.1-10)alkylamino,
(C.sub.1-10)alkylcarbonylamino, sulfonylamino, alkylsulfonylamino,
arylsulfonylamino, sulfonyl, aminosulfonyl, sulfinyl,
(C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
alkoxyalkyl, aryloxyalkyl, carbonyl(C.sub.1-10)alkyl,
alkoxycarbonylalkyl, aryloxycarbonylalkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
cycloalkylsulfonylalkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, alkoxycarbonylalkyl, aryloxyalkyl,
heteroaryloxyalkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted with 1-4 substituents, and R.sub.21', R.sub.22',
R.sub.23', R.sub.24', and R.sub.25' may be individually absent when
the nitrogen atom to which it is bonded forms part of a double
bond; and [0373] one of R.sub.21 and R.sub.25 may be taken together
with R.sub.11 to form a 6 or 7 membered, saturated, unsaturated or
aromatic ring, each unsubstituted or further substituted with 1-3
substituents; and one of R.sub.21 and R.sub.25 may be taken
together with a substituent on the ring formed by taking R.sub.10
and R.sub.11 together to form a 6 or 7 membered, saturated,
unsaturated or aromatic ring, each unsubstituted or further
substituted with 1-3 substituents.
[0374] In one variation of the immediately above embodiments and
variations, where R.sub.12, when present, is a six membered aryl or
heteroaryl of the formula
##STR00052##
J.sub.0 is selected from the group consisting of N and C; J.sub.5
is N or CR.sub.21 where R.sub.21 is hydrogen or fluoro; J.sub.6 is
N or CR.sub.22 where R.sub.22 is selected from the group consisting
of hydrogen, hydroxy, fluoro, methyl, ethyl, methoxy, and ethoxy;
J.sub.7 is N or CR.sub.23 where R.sub.23 is hydrogen or fluoro;
J.sub.8 is N or CR.sub.24 where R.sub.24 is hydrogen or fluoro; and
J.sub.9 is N or CR.sub.25 where R.sub.25 is hydrogen or fluoro. In
another variation, J.sub.0 is selected from the group consisting of
N and C; J.sub.5 is N; J.sub.6 is N or C(OCH.sub.3); J.sub.7 is CH;
J.sub.8 is CH; and J.sub.9 is N or CH.
[0375] In yet another variation, R.sub.12 is selected from the
group consisting of:
##STR00053## ##STR00054## ##STR00055##
[0376] In yet other variations, R.sub.12 is selected from the group
consisting of:
##STR00056##
[0377] In still other variations, R.sub.12 is of the formula
##STR00057##
[0378] In another variation, when present, R.sub.3 is selected from
the group consisting of:
##STR00058## ##STR00059## ##STR00060##
[0379] In still another variation, when present, R.sub.3 is
selected from the group consisting of:
##STR00061## ##STR00062## ##STR00063## ##STR00064##
[0380] In another variation, R.sub.3, when present, is selected
from the group consisting of:
##STR00065##
[0381] In another variation, R.sub.3, when present, is selected
from the group consisting of:
##STR00066## ##STR00067## ##STR00068## ##STR00069##
##STR00070##
[0382] In still another variation, R.sub.3, when present, is
selected from the group consisting of:
##STR00071## ##STR00072##
[0383] In another variation, R.sub.3, when present, is selected
from the group consisting of:
##STR00073##
[0384] In still another variation, R.sub.3, when present, is
selected from the group consisting of:
##STR00074##
[0385] In still another variation, R.sub.3, when present, is
selected from the group consisting of:
##STR00075##
[0386] where
[0387] R.sub.24 is selected from the group consisting of methoxy
and ethoxy;
[0388] R.sub.37 is selected from the group consisting of halo,
alkoxy and alkyl, each unsubstituted or substituted; and
[0389] R.sub.41 is selected from the group consisting of hydrogen,
(C.sub.1-6)oxaalkyl and (C.sub.1-6)alkyl.
[0390] In still another variation, R.sub.3, when present, is
selected from the group consisting of
##STR00076##
[0391] In yet still another variation, R.sub.3, when present,
is
##STR00077##
[0392] Particular examples of compounds according to the present
invention include, but are not limited to: [0393]
(E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-methyl oxime; [0394]
(R,E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-di-
hydroquinazolin-5(6H)-one O-methyl oxime [0395]
(S,E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-di-
hydroquinazolin-5(6H)-one O-methyl oxime [0396]
(E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-allyl oxime; [0397]
(E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-tert-butyl oxime; [0398]
(E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-isobutyl oxime; [0399]
(E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-benzyl oxime; [0400]
(E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-phenyl oxime; [0401]
(E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-4-nitrobenzyl oxime; [0402]
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-2-methoxyethyl oxime; [0403]
(R,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-2-methoxyethyl oxime [0404]
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-2-methoxyethyl oxime [0405]
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O--(R)-2,3-dihydroxypropyl oxime; [0406]
(R,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O--(R)-2,3-dihydroxypropyl oxime; [0407]
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O--(R)-2,3-dihydroxypropyl oxime; [0408]
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-2-tert-butoxyethyl oxime; [0409]
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-3-methoxypropyl oxime; [0410]
(E)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydroquinazolin-5(6H)-ylideneaminooxy)acetic acid; [0411]
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O--(S)-2,3-dihydroxypropyl oxime; [0412]
(R,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O--(R)-2,3-dihydroxypropyl oxime; [0413]
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O--(R)-2,3-dihydroxypropyl oxime; [0414]
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-2-aminoethyl oxime; [0415]
(R,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-2-aminoethyl oxime; [0416]
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-2-aminoethyl oxime; [0417]
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-pyridin-3-ylmethyl oxime; [0418]
(Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-pyridin-3-ylmethyl oxime; [0419]
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-3-hydroxy-2-(hydroxymethyl)propyl oxime;
[0420]
(R,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-3-hydroxy-2-(hydroxymethyl)propyl
oxime; [0421]
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydroquinazolin-5(6H)-one
O-3-hydroxy-2-(hydroxymethyl)propyl oxime; [0422]
(E)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydroquinazolin-5(6H)-ylidene)hydrazinecarboximidamide; [0423]
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O--(S)-3,4-dihydroxybutyl oxime; [0424]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl oxime; [0425]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(R)-2,3-dihydroxypropyl
oxime; [0426]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(S)-2,3-dihydroxypropyl oxime; [0427]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3-hydroxy-2-(hydroxymethyl)propyl oxime; [0428]
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl oxime; [0429]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl
oxime; [0430]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(R)-3,4-dihydroxybutyl oxime; [0431]
(S)-4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)amino)butane-1,2-diol-
; [0432]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-meth-
yl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--((R)-1,4-dioxan-2-yl)methyl oxime; [0433]
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-morpholin-2-ylmethyl
oxime; [0434]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(R)-morpholin-2-ylmethyl oxime; [0435]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-morpholin-2-ylmethyl
oxime; [0436]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2R,3S,4R)-3,4,5-trihydroxytetrahydrofuran-2-yl)methyl oxime;
[0437]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2R,3S,4R,5R)-3,4-dihydroxy-5-methoxytetrahydrofuran-2-yl)methyl
oxime; [0438]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((3aR,4R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-
-4-yl)methyl oxime; [0439]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2R,3S,4R,5S)-3,4-dihydroxy-5-methoxytetrahydrofuran-2-yl)methyl
oxime; [0440]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((3aR,4R,6S,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-
-4-yl)methyl oxime; [0441]
(R,Z)-2-amino-7-(3'-(cyclopropylsulfanyl)-5-fluorobiphenyl-2-yl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(S)-2,3-dihydroxypropyl oxime; [0442]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2R,3S,4R)-3,4,5-trihydroxytetrahydrofuran-2-yl)methyl oxime;
[0443]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2R,3S,4S)-3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime;
[0444]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2S,4R)-4-hydroxypyrrolidin-2-yl)methyl oxime; [0445]
(3R,5S)-1-acetyl-5-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-y-
l)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminoox-
y)methyl)pyrrolidin-3-yl acetate, [0446] (2S,4R)-methyl
4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)pyrrolidine-2-ca-
rboxylate; [0447]
(2S,4R)-4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)--
4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)pyrrolid-
ine-2-carboxylic acid; [0448]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3R,5S)-5-(hydroxymethyl)pyrrolidin-3-yl oxime; [0449]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2R,3R,4S)-3,4-dihydroxypyrrolidine-2-yl)methyl oxime; [0450]
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3R,4S)-3,4-dihydroxycyclopentyl oxime; [0451]
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((3R,4S)-3,4-dihydroxycyclopentyl)methyl oxime; [0452]
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3,4-dihydroxy-4-methylpentyl oxime; [0453]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one oxime; [0454]
(R)-4-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-m-
ethyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)methyl)oxaz-
olidin-2-one; [0455]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O-2-morpholinoethyl oxime;
[0456]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(tetrahydro-2H-pyran-4-yl)methyl oxime; [0457]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((1s,4S)-4-hydroxycyclohexyl)methyl oxime; [0458]
(S)-4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-hydroxybu-
tanamide; [0459]
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-2-(morpholin-2-yl)ethyl
oxime; [0460]
(S)-4-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phen-
yl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)meth-
yl)-3-benzyloxazolidin-2-one; [0461]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(R)-2-amino-3-hydroxypropyl oxime; [0462]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(1-methyl-1H-imidazol-4-yl)methyl oxime; [0463]
(R)-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-5-imino-4-methyl-5,6,7,8-
-tetrahydropyrido[4,3-d]pyrimidin-2-amine; [0464]
(R,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazine-2-yl)-4-fluorophenyl)-4-met-
hyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(S)-3,4-dihydroxybutyl oxime; [0465]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyrazine-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl
oxime; [0466]
(R,Z)-2-amino-7-(4-fluoro-2-(2-methoxythiazol-4-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(S)-3,4-dihydroxybutyl oxime; [0467]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-4,5-dihydroxypentyl
oxime; [0468]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(S)-3-amino-2-hydroxypropyl oxime; [0469]
(S)-5-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-m-
ethyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)methyl)oxaz-
olidin-2-one; [0470]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O-3-hydroxypropyl oxime;
[0471]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O-4-hydroxybutyl oxime;
[0472]
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-3-hydroxy-2-methoxypropyl
oxime; [0473]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(R)-4,5-dihydroxypentyl oxime; [0474]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-(2-hydroxyethyl)--
N-methylacetamide; [0475]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N,N-dimethylacetami-
de; [0476]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl-
)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((S-
)-3-hydroxypyrrolidin-1-yl)ethanone; [0477]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((R)-3-fluoro-
pyrrolidin-1-yl)ethanone; [0478]
(S)-4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-hydroxybu-
tanoic acid; [0479]
3-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)dihydrofuran-2(3-
H) one; [0480]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxybutana-
mide; [0481]
(S,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(R)-3,4-dihydroxybutyl
oxime; [0482]
(S,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(R)-3,4-dihydroxybutyl oxime; [0483]
2-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido-
[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-N,N-dimethylbutanamide;
[0484]
2-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydr-
opyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-N,N-dimethylbuta-
namide; [0485]
(S)-2-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropy-
rido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-N,N-dimethylbutanam-
ide; [0486]
(R)-2-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropy-
rido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-N,N-dimethylbutanam-
ide; [0487]
(R)-2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-N-
,N-dimethylbutanamide; [0488]
(S)-2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-N-
,N-dimethylbutanamide; [0489]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-1-mor-
pholinobutan-1-one;
[0490]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-
-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-methox-
y-N,N-dimethylbutanamide; [0491]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-N--((S)-2,3-dih-
ydroxypropyl)-N-methylacetamide; [0492]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-(2-hydroxyethyl)--
N-methylacetamide; [0493]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N,N-bis(2-hydroxyet-
hyl)acetamide; [0494]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-N,N-bis(2-hydro-
xypropyl)acetamide; [0495]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(azetidin-1-yl)et-
hanone; [0496]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(pyrrolidin-1-yl)-
ethanone; [0497]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((S)-2-(hydro-
xymethyl)pyrrolidin-1-yl)ethanone; [0498]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(4-hydroxypiperid-
in-1-yl)ethanone; [0499]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-methyl-N-((6-meth-
ylpyridin-2-yl)methyl)acetamide; [0500]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N,N-bis(2-methoxyet-
hyl)acetamide; [0501]
(R,Z)-N-(2-amino-2-oxoethyl)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
-yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminoo-
xy)-N-methylacetamide; [0502]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((R)-2-(hydro-
xymethyl)pyrrolidin-1-yl)ethanone; [0503]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-(2-methoxyethyl)--
N-methylacetamide; [0504]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((R)-3-hydrox-
ypyrrolidin-1-yl)ethanone; [0505]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((R)-3-hydrox-
ypiperidin-1-yl)ethanone; [0506]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((S)-3-hydrox-
ypyrrolidin-1-yl)ethanone; [0507]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((S)-3-hydrox-
ypiperidin-1-yl)ethanone; [0508]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(3-hydroxyazetidi-
n-1-yl)ethanone; [0509]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(3,3-difluoropyrr-
olidin-1-yl)ethanone; [0510]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((R)-3-fluoro-
pyrrolidin-1-yl)ethanone; [0511]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((S)-3-fluoro-
pyrrolidin-1-yl)ethanone; [0512]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(4-methoxypiperid-
in-1-yl)ethanone [0513]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(3,3-difluoroazet-
idin-1-yl)ethanone; [0514]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-(3-(methoxyme-
thyl)piperidin-1-yl)ethanone; [0515]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-methyl-N-(2-(meth-
ylamino)-2-oxoethyl)acetamide; [0516]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-(isoxazol-3-ylmet-
hyl)-N-methylacetamide; [0517]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-methyl-N-(thiazol-
-4-ylmethyl)acetamide; [0518]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(pyrazin-2-yl)eth-
anone; [0519]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-(3-(dimethyla-
mino)piperidin-1-yl)ethanone; [0520]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-(2-methyltetr-
ahydro-1H-pyrrolo[3,4-c]pyridin-5(6H,7H,7aH)-yl)ethanone; [0521]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-methyl-N-((5-meth-
yl-1H-pyrazol-3-yl)methyl)acetamide; [0522]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(2-methyl-6,7-dih-
ydro-3H-imidazo[4,5-c]pyridin-5(4H)-yl)ethanone; [0523]
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-(3-(hydroxyme-
thyl)pyrrolidin-1-yl)ethanone; [0524]
2-(2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-met-
hyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)acetyl)hexahy-
dropyrrolo[1,2-a]pyrazin-6(7H)-one; [0525]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(3-methoxyazetidi-
n-1-yl)ethanone; [0526]
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-(4,4-difluoropipe-
ridin-1-yl)ethanone; [0527]
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyrazine-2-yl)phenyl)-4-methyl-7,8-
-dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-3,4-dihydroxybutyl
oxime; [0528]
(7R,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazine-2-yl)-4-fluoropheny-
l)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3,4-dihydroxybutyl oxime; [0529]
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyrazine-2-yl)phenyl)-4-methyl-7,8-
-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxy-5-methoxytetrahydrofuran-2-yl)methyl oxime; [0530]
(7R,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazine-2-yl)-4-fluorophenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxy-5-methoxytetrahydrofuran-2-yl)methyl oxime; [0531]
5-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyrazine-2-yl)phenyl)-4-meth-
yl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)methyl)-3,4-di-
hydroxydihydrofuran-2(3H)-one; [0532]
5-(((Z)-((R)-2-amino-7-(2-(5-amino-6-methoxypyrazine-2-yl)-4-fluorophenyl-
)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)methyl-
)-3,4-dihydroxydihydrofuran-2(3H)-one; [0533]
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyrazine-2-yl)phenyl)-4-methyl-7,8-
-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime; [0534]
(7R,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazine-2-yl)-4-fluorophenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime; [0535]
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyrazine-2-yl)phenyl)-4-methyl-7,8-
-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxypyrrolidine-2-yl)methyl oxime; [0536]
(7R,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazine-2-yl)-4-fluorophenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxypyrrolidine-2-yl)methyl oxime; [0537]
(7S,Z)-2-amino-8,8-difluoro-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)--
4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3,4-dihydroxybutyl oxime; [0538]
(7S,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazine-2-yl)-4-fluorophenyl)-8,8--
difluoro-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3,4-dihydroxybutyl oxime; [0539]
(7S,Z)-2-amino-8,8-difluoro-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)--
4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime; [0540]
(7S,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazine-2-yl)-4-fluorophenyl)-8,8--
difluoro-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime; [0541]
(7S,Z)-2-amino-8,8-difluoro-7-(4-fluoro-2-(6-methoxypyridin-2-y)phenyl)-4-
-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxypyrrolidine-2-yl)methyl oxime; [0542]
(7S,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazine-2-yl)-4-fluorophenyl)-8,8--
difluoro-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxypyrrolidine-2-yl)methyl oxime; [0543]
(7S,Z)-2-amino-8-fluoro-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3,4-dihydroxybutyl oxime; [0544]
(7S,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazine-2-yl)-4-fluorophenyl)-8-fl-
uoro-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3,4-dihydroxybutyl oxime; [0545]
(7S,Z)-2-amino-8-fluoro-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime; [0546]
(7S,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazine-2-yl)-4-fluorophenyl)-8-fl-
uoro-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime; [0547]
(7S,Z)-2-amino-8-fluoro-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxypyrrolidine-2-yl)methyl oxime; [0548]
(7S,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazine-2-yl)-4-fluorophenyl)-8-fl-
uoro-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3,4-dihydroxypyrrolidine-2-yl)methyl oxime; [0549]
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-3-amino-4-hydroxybutyl
oxime; [0550]
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-meth-
yl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-4-amino-3-hydroxybutyl oxime; [0551]
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-2-amino-3-hydroxypropyl
oxime; and [0552]
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-3-amino-2-hydroxypropyl
oxime.
[0553] In another of its aspects, the present invention relates to
process of making compounds that are useful as HSP90
inhibitors.
[0554] In one embodiment, the process comprising:
[0555] reacting a compound having the formula
##STR00078##
with a compound having the formula H.sub.2N--O--R.sub.1 under
conditions that form a intermediate having the formula
##STR00079##
[0556] reacting the intermediate with a compound having the
formula
##STR00080##
under conditions that form product having the formula
##STR00081##
[0557] wherein
[0558] R.sub.1 is selected from the group consisting of hydrogen,
carbonyl, hydroxycarbonyl, oxycarbonyl, aminocarbonyl, sulfonyl,
sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, alkoxy(C.sub.1-10)alkyl,
amino(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, carbonylamino(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, hydroxycarbonyl(C.sub.1-10)alkyl,
aminocarbonyl(C.sub.1-10)alkyl, aminosulfonyl(C.sub.1-10)alkyl,
sulfonylamino(C.sub.1-10)alkyl,
(C.sub.1-6)alkylsulfonylamino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted; and
[0559] R.sub.2 is selected from the group consisting of hydrogen,
halo, cyano, thio, hydroxy, carbonyloxy, (C.sub.1-10)alkoxy,
(C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy, carbonyl,
oxycarbonyl, aminocarbonyl, amino, (C.sub.1-10)alkylamino,
sulfonamido, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted.
[0560] In another embodiment of the process of making the compounds
of the invention comprises
[0561] reacting a compound having the formula
##STR00082##
with a compound having the formula
##STR00083##
under conditions that form an intermediate having the formula
##STR00084##
and
[0562] reacting the intermediate with a compound having the formula
H.sub.2N--O--R.sub.1 under conditions that form a product having
the formula
##STR00085##
[0563] wherein
[0564] R.sub.1 is selected from the group consisting of hydrogen,
carbonyl, hydroxycarbonyl, oxycarbonyl, aminocarbonyl, sulfonyl,
sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, alkoxy(C.sub.1-10)alkyl,
amino(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, carbonylamino(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, hydroxycarbonyl(C.sub.1-10)alkyl,
aminocarbonyl(C.sub.1-10)alkyl, aminosulfonyl(C.sub.1-10)alkyl,
sulfonylamino(C.sub.1-10)alkyl,
(C.sub.1-6)alkylsulfonylamino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each unsubstituted or
substituted; and
[0565] R.sub.2 is selected from the group consisting of hydrogen,
halo, cyano, thio, hydroxy, carbonyloxy, (C.sub.1-10)alkoxy,
(C.sub.4-12)aryloxy, hetero(C.sub.1-10)aryloxy, carbonyl,
oxycarbonyl, aminocarbonyl, amino, (C.sub.1-10)alkylamino,
sulfonamido, sulfonyl, sulfinyl, (C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
hetero(C.sub.1-10)alkyl, imino(C.sub.1-10)alkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl, each substituted or
unsubstituted.
[0566] In yet another embodiment of the process of making the
compounds of the invention comprising:
reacting a compound having the formula
##STR00086##
with Starting Material I having the formula
##STR00087##
under conditions that form Intermediate F having the formula
##STR00088##
[0567] wherein
[0568] PG is a protecting group selected from the group consisting
of ((C.sub.1-6).sub.3alkyl)silyl,
(((C.sub.1-6)alkyl).sub.3-k)phenyl.sub.k)silyl where k is 0-3,
benzyl, and tetrahydropyranyl; and
[0569] R.sub.2 is selected from the group consisting of hydrogen,
(C.sub.1-6)alkyl, halo(C.sub.1-6)alkyl, aza(C.sub.1-6)alkyl,
(C.sub.1-6)oxaalkyl, each unsubstituted or substituted.
[0570] In the above embodiment of the process, preparation of the
compounds of the invention may be achieved via Method A
comprising:
[0571] coupling Starting Material II having the formula
##STR00089##
to said Intermediate F which form Intermediate G having the
formula
##STR00090##
[0572] coupling Starting Material III having the formula
##STR00091##
to said Intermediate G under conditions that form Intermediate H
having the formula
##STR00092##
[0573] deprotecting said Intermediate H under conditions that form
Product having the formula
##STR00093##
[0574] wherein
[0575] R.sub.1.sup.p is a protected form of R.sub.1;
[0576] R.sub.1 is selected from the group consisting of hydrogen,
carbonyl, (C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, and hetero(C.sub.1-10)aryl, each unsubstituted or
substituted with 1-3 substituents each of which is independently
selected from the group consisting of hydroxyl, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, amino, amino(C.sub.1-10)alkyl,
aminocarbonyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.4-12)aryl, and
hetero(C.sub.1-10)aryl, each is unsubstituted or further
substituted; and
[0577] R.sub.12 is selected from a group consisting of
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
hetero(C.sub.4-12)bicycloaryl, (C.sub.3-12)cycloalkyl, and
hetero(C.sub.2-11)cycloalkyl, each unsubstituted or substituted
with 1-3 substituents.
[0578] In the above embodiment of the process, preparation of the
compounds of the invention may be achieved via Method B
comprising:
[0579] deprotecting Intermediate F under conditions which form
Intermediate F' having the formula
##STR00094##
[0580] coupling Starting Material II having the formula
##STR00095##
to said Intermediate F' which form Intermediate G having the
formula
##STR00096##
[0581] coupling Starting Material III having the formula
##STR00097##
to said Intermediate G under conditions that form Intermediate H
having the formula
##STR00098##
[0582] deprotecting said Intermediate H under conditions that form
Product having the formula
##STR00099##
[0583] wherein
[0584] R.sub.1.sup.p is a protected form of R.sub.1;
[0585] R.sub.1 is selected from the group consisting of hydrogen,
carbonyl, (C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, and hetero(C.sub.1-10)aryl, each unsubstituted or
substituted with 1-3 substituents each of which is independently
selected from the group consisting of hydroxyl, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, amino, amino(C.sub.1-10)alkyl,
aminocarbonyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.4-12)aryl, and
hetero(C.sub.1-10)aryl, each is unsubstituted or further
substituted; and
[0586] R.sub.12 is selected from a group consisting of
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
hetero(C.sub.4-12)bicycloaryl, (C.sub.3-12)cycloalkyl, and
hetero(C.sub.2-11)cycloalkyl, each unsubstituted or substituted
with 1-3 substituents.
[0587] Another process which may be used to prepare the compounds
of the inventions comprising:
[0588] reacting a compound having the formula
##STR00100##
with Starting Material I having the formula
##STR00101##
under conditions that form Intermediate F having the formula
##STR00102##
[0589] deprotecting said Intermediate F under conditions which form
Intermediate F' having the formula
##STR00103##
[0590] coupling Starting Material III having the formula
##STR00104##
to Intermediate F' under conditions that form Intermediate J having
the formula
##STR00105##
[0591] deprotecting and then coupling Starting Material II having
the formula
##STR00106##
to Intermediate J under conditions which form Product having the
formula
##STR00107##
[0592] wherein
[0593] R.sub.1.sup.p is a protected form of R.sub.1;
[0594] R.sub.1 is selected from the group consisting of hydrogen,
carbonyl, (C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, and hetero(C.sub.1-10)aryl, each unsubstituted or
substituted with 1-3 substituents each of which is independently
selected from the group consisting of hydroxyl, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, amino, amino(C.sub.1-10)alkyl,
aminocarbonyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.4-12)aryl, and
hetero(C.sub.1-10)aryl, each is unsubstituted or further
substituted;
[0595] R.sub.2 is selected from the group consisting of hydrogen,
(C.sub.1-6)alkyl, halo(C.sub.1-6)alkyl, aza(C.sub.1-6)alkyl,
(C.sub.1-6)oxaalkyl, each unsubstituted or substituted; and
[0596] R.sub.12 is selected from a group consisting of
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl,
hetero(C.sub.4-12)bicycloaryl, (C.sub.3-12)cycloalkyl, and
hetero(C.sub.2-11)cycloalkyl, each unsubstituted or substituted
with 1-3 substituents.
[0597] In all the above embodiments of the processes, in some
variations, R.sub.1 is -L-R.sub.45,
[0598] where
[0599] L is (--CR.sub.46R.sub.47--).sub.n, where n is 1, 2, 3, 4,
or 5; where R.sub.46 and R.sub.47 are each independently selected
from the group consisting of hydrogen, hydroxyl,
hydroxy(C.sub.1-6)alkyl, (C.sub.1-6)alkoxy, oxo, amino, imino,
(C.sub.1-6)alkyl, (C.sub.4-6)aryl(C.sub.1-6)alkyl,
hetero(C.sub.1-5)aryl(C.sub.1-6)alkyl,
(C.sub.3-6)cycloalkyl(C.sub.1-6)alkyl,
hetero(C.sub.1-5)cycloalkyl(C.sub.1-6)alkyl, (C.sub.4-6)aryl,
hetero(C.sub.1-5)aryl, (C.sub.3-6)cycloalkyl, and
hetero(C.sub.1-5)cycloalkyl, each unsubstituted or substituted;
and
[0600] R.sub.45 is independently selected from the group consisting
of hydrogen, hydroxyl, halo, (C.sub.1-3)alkyl,
hydroxy(C.sub.1-3)alkyl, (C.sub.1-3)alkoxy, amino, carbonylamino,
aminocarbonyl, carbonyl, hydroxycarbonyl, aryl, heteroaryl,
cycloalkyl, and heterocycloalkyl, each unsubstituted or further
substituted.
[0601] In other variations, R.sub.1 is selected from the group
consisting of hydrogen,
##STR00108## ##STR00109## ##STR00110##
[0602] In other variations, R.sub.1 is selected from the group
consisting of: hydrogen,
##STR00111## ##STR00112## ##STR00113##
[0603] In still other variations, R.sub.1 is selected from the
group consisting of:
##STR00114## ##STR00115##
[0604] In still other variations, R.sub.1 is selected from the
group consisting of hydrogen,
##STR00116## ##STR00117##
[0605] In still other variations, R.sub.1 is selected from the
group consisting of hydrogen,
##STR00118##
[0606] In some variation of the process of the invention, R.sub.2
is selected from the group consisting of hydrogen,
(C.sub.1-6)alkyl, halo(C.sub.1-6)alkyl, aza(C.sub.1-6)alkyl,
(C.sub.1-6)oxaalkyl, each unsubstituted or substituted. In other
variations, R.sub.2 is selected from the group consisting of
unsubstituted or substituted (C.sub.1-6)alkyl. In still other
variations, R.sub.2 is methyl. In yet still other variations,
R.sub.2 is hydrogen.
[0607] In the above embodiments of the processes of the invention,
in some variations, R.sub.12 is selected from the group consisting
of
##STR00119## ##STR00120## ##STR00121##
[0608] In some other variations, R.sub.12 is selected from the
group consisting of
##STR00122##
[0609] In still other variations, R.sub.12 is of the formula
##STR00123##
[0610] Another aspect of the invention relates to compounds that
are useful for the preparation of the compounds of the
invention.
[0611] In one embodiment, intermediate compounds of the invention
consisting of the formula:
##STR00124##
[0612] wherein
[0613] R.sub.1 is selected from the group consisting of hydrogen,
carbonyl, (C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, and hetero(C.sub.1-10)aryl, each unsubstituted or
substituted with 1-3 substituents each of which is independently
selected from the group consisting of hydroxyl, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, amino, amino(C.sub.1-10)alkyl,
aminocarbonyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.4-12)aryl, and
hetero(C.sub.1-10)aryl, each is unsubstituted or further
substituted; and
[0614] X is a leaving group.
[0615] In yet another variation of the above embodiment of
intermediate compound, wherein the intermediate compound consisting
of the formula:
##STR00125##
[0616] wherein
[0617] R.sub.1 is selected from the group consisting of hydrogen,
carbonyl, (C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl,
halo(C.sub.1-10)alkyl, hydroxy(C.sub.1-10)alkyl,
carbonyl(C.sub.1-10)alkyl, thiocarbonyl(C.sub.1-10)alkyl,
sulfonyl(C.sub.1-10)alkyl, sulfinyl(C.sub.1-10)alkyl,
imino(C.sub.1-10)alkyl, (C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, and hetero(C.sub.1-10)aryl, each unsubstituted or
substituted with 1-3 substituents each of which is independently
selected from the group consisting of hydroxyl, (C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, amino, amino(C.sub.1-10)alkyl,
aminocarbonyl, (C.sub.3-12)cycloalkyl,
hetero(C.sub.3-12)cycloalkyl, (C.sub.4-12)aryl, and
hetero(C.sub.1-10)aryl, each is unsubstituted or further
substituted; and
[0618] X is a leaving group.
[0619] In some variations of the above embodiment and variations of
the intermediate compounds of the invention, R.sub.1 is selected
from the group consisting of hydrogen,
##STR00126## ##STR00127## ##STR00128## ##STR00129##
[0620] In some other variations, R.sub.1 is selected from the group
consisting of hydrogen,
##STR00130## ##STR00131## ##STR00132##
[0621] In still other variations, R.sub.1 is selected from the
group consisting of hydrogen,
##STR00133## ##STR00134## ##STR00135##
[0622] In still other variations, R.sub.1 is selected from the
group consisting of hydrogen,
##STR00136## ##STR00137##
[0623] In yet other variations, R.sub.1 is selected from the group
consisting of
##STR00138##
[0624] In yet still other variations, R.sub.1 is selected from the
group consisting of hydrogen,
##STR00139##
[0625] In yet still other variations, R.sub.1 is selected from the
group consisting of
##STR00140##
[0626] In yet still other variations, R.sub.1 is selected from the
group consisting of
##STR00141##
[0627] In yet still other variations, R.sub.1 is
##STR00142##
[0628] In yet still other variations, R.sub.1 is
##STR00143##
[0629] In yet still other variations, R.sub.1 is
##STR00144##
[0630] In yet still other variations, R.sub.1 is
##STR00145##
[0631] In some variations of the above embodiments and variations
of the compounds of the invention, R.sub.12 is a leaving group
selected from a group consisting of halo, and substituted and
unsubstituted alkylsulfonate. In some variations, R.sub.12 is
bromo. In other variations, R.sub.12 is chloro.
[0632] In still other variations, R.sub.12 is iodo. In still other
variations, R.sub.12 is trifluoromethanesulfonate.
[0633] In another embodiment, the intermediate compound of the
invention consisting of the formula:
##STR00146##
[0634] wherein
[0635] R.sub.a is selected from the group consisting of hydrogen,
(C.sub.1-6)alkyl, and a protecting group; and
[0636] R.sub.12 is selected from a group consisting of
(C.sub.4-12)aryl and hetero(C.sub.1-10)aryl, each unsubstituted or
substituted, with 1-3 substituents independently selected from the
group consisting of halo, nitro, cyano, thio, alkylthio,
(C.sub.1-10)alkoxy, (C.sub.1-10)haloalkoxy, hydroxy, aryloxy,
heteroaryloxy, carbonyloxy, carbonyl, alkylaminocarbonyl, amino,
(C.sub.1-10)alkylamino, sulfonylamino, sulfonyl, aminosulfonyl,
sulfinyl, (C.sub.1-10)alkyl, halo(C.sub.1-10)alkyl,
hydroxy(C.sub.1-10)alkyl, carbonyl(C.sub.1-10)alkyl,
thiocarbonyl(C.sub.1-10)alkyl, sulfonyl(C.sub.1-10)alkyl,
sulfinyl(C.sub.1-10)alkyl, hetero(C.sub.1-10)alkyl, alkoxyalkyl,
alkoxycarbonylalkyl, aryloxyalkyl, heteroaryloxyalkyl,
(C.sub.3-12)cycloalkyl(C.sub.1-5)alkyl,
hetero(C.sub.3-12)cycloalkyl(C.sub.1-10)alkyl,
aryl(C.sub.1-10)alkyl, hetero(C.sub.1-10)aryl(C.sub.1-5)alkyl,
(C.sub.9-12)bicycloaryl(C.sub.1-5)alkyl,
hetero(C.sub.8-12)bicycloaryl(C.sub.1-5)alkyl,
(C.sub.3-12)cycloalkyl, hetero(C.sub.3-12)cycloalkyl,
(C.sub.9-12)bicycloalkyl, hetero(C.sub.3-12)bicycloalkyl,
(C.sub.4-12)aryl, hetero(C.sub.1-10)aryl, (C.sub.9-12)bicycloaryl
and hetero(C.sub.4-12)bicycloaryl.
[0637] In another variation of the immediate above embodiment, the
intermediate compounds of the invention are of the formula:
##STR00147##
[0638] In some variations of the above embodiment and variations of
the compounds of the invention, R.sub.a is hydrogen. In other
variations, R.sub.a is methyl. In other variations, R.sub.a is a
protecting group selected from the group consisting of
((C.sub.1-6).sub.3alkyl)silyl,
(((C.sub.1-6)alkyl).sub.3-n)phenyl.sub.n)silyl where n is 0-3,
benzyl, and tetrahydropyranyl. In still other variations, R.sub.a
is selected from the group consisting trimethylsilyl,
triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl, and
tert-butyldiphenylsilyl. In still other variations, R.sub.a is
tert-butyldimethylsilyl. In still other variations, R.sub.a is
trimethylsilyl. In still other variation, R.sub.a is benzyl. In yet
still other variations, R.sub.a is tetrahydropyranyl.
[0639] In some variations of the above embodiment and variations of
the compounds of the invention, R.sub.12 is phenyl or
hetero(C.sub.1-5)aryl, each unsubstituted or substituted with said
1-3 substituents. In yet still other variations, R.sub.12 is
selected from the group consisting of halo,
##STR00148## ##STR00149## ##STR00150##
[0640] In still other variations, R.sub.12 is selected from the
group consisting of bromo,
##STR00151##
[0641] In still other variations, R.sub.12 is
##STR00152##
[0642] Particular examples of intermediate compounds according to
the present invention include, but are not limited to: [0643]
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one oxime; [0644]
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O-tert-butyldimethylsilyl oxime; [0645]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one oxime; [0646]
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl
oxime; [0647]
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrid-
o[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl oxime; [0648]
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O--((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl
oxime; [0649]
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrid-
o[4,3-d]pyrimidin-5(6H)-one O--(R)-2,3-dihydroxypropyl oxime;
[0650]
(R,Z)-2-(2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,-
3-d]pyrimidin-5(6H)-ylideneaminooxy)acetamide; [0651]
(R,Z)-2-(2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,-
3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-methylacetamide; and [0652]
(R,Z)-2-(2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,-
3-d]pyrimidin-5(6H)-ylideneaminooxy)-N,N-dimethylacetamide.
[0653] It is noted that the compounds of the present invention may
be in the form of a pharmaceutically acceptable salt,
biohydrolyzable ester, biohydrolyzable amide, biohydrolyzable
carbamate, solvate, hydrate or prodrug thereof. For example, the
compound optionally comprises a substituent that is convertible in
vivo to a different substituent such as hydrogen.
[0654] It is further noted that the compound may be present as a
mixture of stereoisomers, or the compound may present as a single
stereoisomer.
[0655] In another of its aspects, there is provided a
pharmaceutical composition comprising as an active ingredient a
compound according to any one of the above embodiments and
variations. In one particular variation, the composition is a solid
formulation adapted for oral administration. In another particular
variation, the composition is a liquid formulation adapted for oral
administration. In yet another particular variation, the
composition is a tablet. In still another particular variation, the
composition is a liquid formulation adapted for parenteral
administration.
[0656] The present invention also provides a pharmaceutical
composition comprising a compound according to any one of the above
embodiments and variations, wherein the composition is adapted for
administration by a route selected from the group consisting of
orally, parenterally, intraperitoneally, intravenously,
intraarterially, transdermally, sublingually, intramuscularly,
rectally, transbuccally, intranasally, liposomally, via inhalation,
vaginally, intraocularly, via local delivery (for example by
catheter or stent), subcutaneously, intraadiposally,
intraarticularly, and intrathecally.
[0657] In yet another of its aspects, there is provided a kit
comprising a compound of any one of the above embodiments and
variations; and instructions which comprise one or more forms of
information selected from the group consisting of indicating a
disease state for which the composition is to be administered,
storage information for the composition, dosing information and
instructions regarding how to administer the composition. In one
particular variation, the kit comprises the compound in a multiple
dose form.
[0658] In still another of its aspects, there is provided an
article of manufacture comprising a compound of any one of the
above embodiments and variations; and packaging materials. In one
variation, the packaging material comprises a container for housing
the compound. In one particular variation, the container comprises
a label indicating one or more members of the group consisting of a
disease state for which the compound is to be administered, storage
information, dosing information and/or instructions regarding how
to administer the compound. In another variation, the article of
manufacture comprises the compound in a multiple dose form.
[0659] In a further of its aspects, there is provided a therapeutic
method comprising administering a compound of any one of the above
embodiments and variations to a subject.
[0660] In another of its aspects, there is provided a method of
inhibiting HSP90 comprising contacting HSP90 with a compound of any
one of the above embodiments and variations.
[0661] In yet another of its aspects, there is provided a method of
inhibiting HSP90 comprising causing a compound of any one of the
above embodiments and variations to be present in a subject in
order to inhibit HSP90 in vivo.
[0662] In a further of its aspects, there is provided a method of
inhibiting HSP90 comprising administering a first compound to a
subject that is converted in vivo to a second compound wherein the
second compound inhibits HSP90 in vivo, the second compound being a
compound according to any one of the above embodiments and
variations.
[0663] In another of its aspects, there is provided a method of
treating a disease state for which HSP90 possesses activity that
contributes to the pathology and/or symptomology of the disease
state, the method comprising causing a compound of any one of the
above embodiments and variations to be present in a subject in a
therapeutically effective amount for the disease state.
[0664] In yet another of its aspects, there is provided a method of
treating a disease state for which HSP90 possesses activity that
contributes to the pathology and/or symptomology of the disease
state, the method comprising administering a compound of any one of
the above embodiments and variations to a subject, wherein the
compound is present in the subject in a therapeutically effective
amount for the disease state.
[0665] In a further of its aspects, there is provided a method of
treating a disease state for which HSP90 possesses activity that
contributes to the pathology and/or symptomology of the disease
state, the method comprising administering a first compound to a
subject that is converted in vivo to a second compound wherein the
second compound inhibits HSP90 in vivo, the second compound being a
compound according to any one of the above embodiments and
variations.
[0666] In one variation of each of the above methods, the disease
state is selected from the group consisting of cancer,
inflammation, inflammatory bowel disease, psoriasis, arthritis, and
transplant rejection.
[0667] In one variation of each of the above methods, the disease
state is cancer. The cancer is selected from the group consisting
of squamous cell carcinoma, astrocytoma, Kaposi's sarcoma,
glioblastoma, non small-cell lung cancer, bladder cancer, head and
neck cancer, melanoma, ovarian cancer, prostate cancer, breast
cancer, small-cell lung cancer, glioma, colorectal cancer,
genitourinary cancer, gastrointestinal cancer, renal cancer,
hematological cancers, non-Hodgkin's lymphoma, lymphoma, multiple
myeloma, leukemia (including acute myelogenous leukemia, chronic
myelogenous leukemia, chronic lymphocytic leukemia),
myelodysplastic syndrome, and mesothelioma.
[0668] In one variation of each of the above methods, the HSP90 is
an HSP90.alpha.. In another variation, the HSP90 is an
HSP90.beta..
Salts, Hydrates, and Prodrugs of HSP90 Inhibitors
[0669] It should be recognized that the compounds of the present
invention may be present and optionally administered in the form of
salts, hydrates and prodrugs that are converted in vivo into the
compounds of the present invention. For example, it is within the
scope of the present invention to convert the compounds of the
present invention into and use them in the form of their
pharmaceutically acceptable salts derived from various organic and
inorganic acids and bases in accordance with procedures well known
in the art.
[0670] When the compounds of the present invention possess a free
base form, the compounds can be prepared as a pharmaceutically
acceptable acid addition salt by reacting the free base form of the
compound with a pharmaceutically acceptable inorganic or organic
acid, e.g., hydrohalides such as hydrochloride, hydrobromide,
hydroiodide; other mineral acids and their corresponding salts such
as sulfate, nitrate, phosphate, etc.; and alkyl and
monoarylsulfonates such as ethanesulfonate, toluenesulfonate and
benzenesulfonate; and other organic acids and their corresponding
salts such as acetate, tartrate, maleate, succinate, citrate,
benzoate, salicylate and ascorbate. Further acid addition salts of
the present invention include, but are not limited to: adipate,
alginate, arginate, aspartate, bisulfate, bisulfite, bromide,
butyrate, camphorate, camphorsulfonate, caprylate, chloride,
chlorobenzoate, cyclopentanepropionate, digluconate,
dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, fumarate,
galacterate (from mucic acid), galacturonate, glucoheptonate,
gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate,
heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide,
hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate,
iso-butyrate, lactate, lactobionate, malate, malonate, mandelate,
metaphosphate, methanesulfonate, methylbenzoate,
monohydrogenphosphate, 2-naphthalenesulfonate, nicotinate, nitrate,
oxalate, oleate, pamoate, pectinate, persulfate, phenylacetate,
3-phenylpropionate, phosphate, phosphonate and phthalate. It should
be recognized that the free base forms will typically differ from
their respective salt forms somewhat in physical properties such as
solubility in polar solvents, but otherwise the salts are
equivalent to their respective free base forms for the purposes of
the present invention.
[0671] When the compounds of the present invention possess a free
acid form, a pharmaceutically acceptable base addition salt can be
prepared by reacting the free acid form of the compound with a
pharmaceutically acceptable inorganic or organic base. Examples of
such bases are alkali metal hydroxides including potassium, sodium
and lithium hydroxides; alkaline earth metal hydroxides such as
barium and calcium hydroxides; alkali metal alkoxides, e.g.,
potassium ethanolate and sodium propanoate; and various organic
bases such as ammonium hydroxide, piperidine, diethanolamine and
N-methylglutamine. Also included are the aluminum salts of the
compounds of the present invention. Further base salts of the
present invention include, but are not limited to: copper, ferric,
ferrous, lithium, magnesium, manganic, manganous, potassium, sodium
and zinc salts. Organic base salts include, but are not limited to,
salts of primary, secondary and tertiary amines, substituted amines
including naturally occurring substituted amines, cyclic amines and
basic ion exchange resins, e.g., arginine, betaine, caffeine,
chloroprocaine, choline, N,N'-dibenzylethylenediamine (benzathine),
dicyclohexylamine, diethanolamine, 2-diethylaminoethanol,
2-dimethylaminoethanol, ethanolamine, ethylenediamine,
N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine,
histidine, hydrabamine, iso-propylamine, lidocaine, lysine,
meglumine, N-methyl-D-glucamine, morpholine, piperazine,
piperidine, polyamine resins, procaine, purines, theobromine,
triethanolamine, triethylamine, trimethylamine, tripropylamine and
tris-(hydroxymethyl)-methylamine (tromethamine). It should be
recognized that the free acid forms will typically differ from
their respective salt forms somewhat in physical properties such as
solubility in polar solvents, but otherwise the salts are
equivalent to their respective free acid forms for the purposes of
the present invention.
[0672] Compounds of the present invention that comprise basic
nitrogen containing groups may be quaternized with such agents as
(C.sub.1-4)alkyl halides, e.g., methyl, ethyl, iso-propyl and
tert-butyl chlorides, bromides and iodides; di(C.sub.1-4)alkyl
sulfates, e.g., dimethyl, diethyl and diamyl sulfates;
(C.sub.10-18) alkyl halides, e.g., decyl, dodecyl, lauryl, myristyl
and stearyl chlorides, bromides and iodides; and aryl (C.sub.1-4)
alkyl halides, e.g., benzyl chloride and phenethyl bromide. Such
salts permit the preparation of both water-soluble and oil-soluble
compounds of the present invention.
[0673] N-oxides of compounds according to the present invention can
be prepared by methods known to those of ordinary skill in the art.
For example, N-oxides can be prepared by treating an unoxidized
form of the compound with an oxidizing agent (e.g.,
trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic
acid, meta-chloroperoxybenzoic acid, or the like) in a suitable
inert organic solvent (e.g., a halogenated hydrocarbon such as
dichloromethane) at approximately 0.degree. C. Alternatively, the
N-oxides of the compounds can be prepared from the N-oxide of an
appropriate starting material.
[0674] Prodrug derivatives of compounds according to the present
invention can be prepared by modifying substituents of compounds of
the present invention that are then converted in vivo to a
different substituent. It is noted that in many instances, the
prodrugs themselves also fall within the scope of the range of
compounds according to the present invention. For example, prodrugs
can be prepared by reacting a compound with a carbamoylating agent
(e.g., 1,1-acyloxyalkylcarbonochloridate, para-nitrophenyl
carbonate, or the like) or an acylating agent. Further examples of
methods of making prodrugs are described in Saulnier et al. (1994),
Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985.
[0675] Protected derivatives of compounds of the present invention
can also be made. Examples of techniques applicable to the creation
of protecting groups and their removal can be found in P. G. M.
Wuts and T. W. Greene in "Greene's Protective Groups in Organic
Synthesis" 4th edition, John Wiley and Sons, 2007.
[0676] Compounds of the present invention may also be conveniently
prepared, or formed during the process of the invention, as
solvates (e.g., hydrates). Hydrates of compounds of the present
invention may be conveniently prepared by recrystallization from an
aqueous/organic solvent mixture, using organic solvents such as
dioxin, tetrahydrofuran or methanol.
[0677] A "pharmaceutically acceptable salt", as used herein, is
intended to encompass any compound according to the present
invention that is utilized in the form of a salt thereof,
especially where the salt confers on the compound improved
pharmacokinetic properties as compared to the free form of compound
or a different salt form of the compound. The pharmaceutically
acceptable salt form may also initially confer desirable
pharmacokinetic properties on the compound that it did not
previously possess, and may even positively affect the
pharmacodynamics of the compound with respect to its therapeutic
activity in the body. An example of a pharmacokinetic property that
may be favorably affected is the manner in which the compound is
transported across cell membranes, which in turn may directly and
positively affect the absorption, distribution, biotransformation
and excretion of the compound. While the route of administration of
the pharmaceutical composition is important, and various
anatomical, physiological and pathological factors can critically
affect bioavailability, the solubility of the compound is usually
dependent upon the character of the particular salt form thereof,
which it utilized. One of skill in the art will appreciate that an
aqueous solution of the compound will provide the most rapid
absorption of the compound into the body of a subject being
treated, while lipid solutions and suspensions, as well as solid
dosage forms, will result in less rapid absorption of the
compound.
Uses of the Compounds of the Invention
[0678] One set of indications that HSP90 inhibitors of the present
invention may be used to treat are those involving undesirable or
uncontrolled cell proliferation. Such indications include benign
tumors, various types of cancers such as primary tumors and tumor
metastasis, restenosis (e.g. coronary, carotid, and cerebral
lesions), abnormal stimulation of endothelial cells
(atherosclerosis), insults to body tissue due to surgery, abnormal
wound healing, diseases that produce fibrosis of tissue, repetitive
motion disorders, disorders of tissues that are not highly
vascularized, proliferative responses associated with organ
transplants, neurodegenerative disorders including Parkinson's,
Alzheimer's, Huntington's and prion-related disease, inflammation
and inflammation related disorders such as pain, headaches, fever,
arthritis, asthma, bronchitis, tendonitis, eczema, inflammatory
bowel disease, and the like, and diseases dependent on angiogenesis
such as, cancer, arthritis, diabetic retinopathy, age associated
macular degeneration (AMD) and infectious diseases in particular
fungal infections, viral diseases including but not limited to
diseases caused by hepatitis B virus (HBV), hepatitis C virus (HCV)
and herpes simplex virus type-1 (HSV-1), cardiovascular and central
nervous system diseases.sup.3,4,5,6,7.
[0679] Generally, cells in benign tumors retain their
differentiated features and do not divide in a completely
uncontrolled manner. A benign tumor is usually localized and
non-metastatic. Specific types of benign tumors that can be treated
using HSP90 inhibitors of the present invention include
hemangiomas, hepatocellular adenoma, cavernous haemangioma, focal
nodular hyperplasia, acoustic neuromas, neurofibroma, bile duct
adenoma, bile duct cystanoma, fibroma, lipomas, leiomyomas,
mesotheliomas, teratomas, myxomas, nodular regenerative
hyperplasia, trachomas and pyogenic granulomas.
[0680] In the case of malignant tumors, cells become
undifferentiated, do not respond to the body's growth control
signals, and multiply in an uncontrolled manner. Malignant tumors
are invasive and capable of spreading to distant sites
(metastasizing). Malignant tumors are generally divided into two
categories: primary and secondary. Primary tumors arise directly
from the tissue in which they are found. Secondary tumors, or
metastases, are tumors that originated elsewhere in the body but
have now spread to distant organs. Common routes for metastasis are
direct growth into adjacent structures, spread through the vascular
or lymphatic systems, and tracking along tissue planes and body
spaces (peritoneal fluid, cerebrospinal fluid, etc.).
[0681] Specific types of cancers or malignant tumors, either
primary or secondary, that can be treated using the HSP90
inhibitors of the present invention include, but are not limited
to, leukemia, breast cancer, genitourinary cancer, skin cancer,
bone cancer, prostate cancer, liver cancer, lung cancer, brain
cancer, cancer of the larynx, gall bladder, pancreas, rectum,
parathyroid, thyroid, adrenal, neural tissue, bladder, head and
neck, colon, stomach, colorectal, bronchi, kidneys, basal cell
carcinoma, squamous cell carcinoma of both ulcerating and papillary
type, metastatic skin carcinoma, osteo sarcoma, Ewing's sarcoma,
veticulum cell sarcoma, myeloma, giant cell tumor, small-cell lung
tumor, non small-cell lung cancer, gallstones, islet cell tumor,
primary brain tumor, acute and chronic lymphocytic and granulocytic
tumors, hairy-cell tumor, adenoma, hyperplasia, medullary
carcinoma, pheochromocytoma, mucosal neurons, intestinal
ganglioneuromas, hyperplastic corneal nerve tumor, marfanoid
habitus tumor, Wilm's tumor, seminoma, ovarian tumor, leiomyomater
tumor, cervical dysplasia and in situ carcinoma, neuroblastoma,
retinoblastoma, soft tissue sarcoma, malignant carcinoid, topical
skin lesion, gastrointestinal cancer, hematological cancers,
myelodysplastic syndrome, mycosis fungoide, rhabdomyosarcoma,
astrocytoma, non-Hodgkin's lymphoma, Kaposi's sarcoma, osteogenic
and other sarcoma, malignant hypercalcemia, renal cell tumor,
polycythemia vera, adenocarcinoma, glioblastoma multiforma, glioma,
leukemia (including acute myelogenous leukemia, chronic myelogenous
leukemia, chronic lymphocytic leukemia), lymphomas, malignant
melanomas, epidermoid carcinomas, and other carcinomas and
sarcomas.
[0682] The HSP90 inhibitors of the present invention may also be
used to treat abnormal cell proliferation due to insults to body
tissue during surgery. These insults may arise as a result of a
variety of surgical procedures such as joint surgery, bowel
surgery, and cheloid scarring. Diseases that produce fibrotic
tissue include emphysema. Repetitive motion disorders that may be
treated using the present invention include carpal tunnel syndrome.
An example of a cell proliferative disorder that may be treated
using the invention is a bone tumor.
[0683] Proliferative responses associated with organ
transplantation that may be treated using HSP90 inhibitors of the
invention include proliferative responses contributing to potential
organ rejections or associated complications. Specifically, these
proliferative responses may occur during transplantation of the
heart, lung, liver, kidney, and other body organs or organ
systems.
[0684] Abnormal angiogenesis that may be may be treated using this
invention include those abnormal angiogenesis accompanying
rheumatoid arthritis, ischemic-reperfusion related brain edema and
injury, cortical ischemia, ovarian hyperplasia and
hypervascularity, (polycystic ovary syndrome), endometriosis,
psoriasis, diabetic retinopathy, and other ocular angiogenic
diseases such as retinopathy of prematurity (retrolental
fibroplastic), macular degeneration, corneal graft rejection,
neuroscular glaucoma and Oster Webber syndrome.
[0685] Examples of diseases associated with uncontrolled
angiogenesis that may be treated according to the present invention
include, but are not limited to retinal/choroidal
neovascularization and corneal neovascularization. Examples of
retinal/choroidal neovascularization include, but are not limited
to, Bests diseases, myopia, optic pits, Stargarts diseases, Pagets
disease, vein occlusion, artery occlusion, sickle cell anemia,
sarcoid, syphilis, pseudoxanthoma elasticum carotid abostructive
diseases, chronic uveitis/vitritis, mycobacterial infections,
Lyme's disease, systemic lupus erythematosis, retinopathy of
prematurity, Eales disease, diabetic retinopathy, macular
degeneration, Bechets diseases, infections causing a retinitis or
choroiditis, presumed ocular histoplasmosis, pars planitis, chronic
retinal detachment, hyperviscosity syndromes, toxoplasmosis, trauma
and post-laser complications, diseases associated with rubesis
(neovascularization of the angle) and diseases caused by the
abnormal proliferation of fibrovascular or fibrous tissue including
all forms of proliferative vitreoretinopathy. Examples of corneal
neovascularization include, but are not limited to, epidemic
keratoconjunctivitis, vitamin A deficiency, contact lens overwear,
atopic keratitis, superior limbic keratitis, pterygium keratitis
sicca, sjogrens, acne rosacea, phylectenulosis, diabetic
retinopathy, retinopathy of prematurity, corneal graft rejection,
Mooren ulcer, Terrien's marginal degeneration, marginal
keratolysis, polyarteritis, Wegener sarcoidosis, scleritis,
periphigoid radial keratotomy, neovascular glaucoma and retrolental
fibroplasia, syphilis, Mycobacteria infections, lipid degeneration,
chemical burns, bacterial ulcers, fungal ulcers, Herpes simplex
infections, Herpes zoster infections, protozoan infections and
Kaposi sarcoma.
[0686] Chronic inflammatory diseases associated with uncontrolled
angiogenesis may also be treated using HSP90 inhibitors of the
present invention. Chronic inflammation depends on continuous
formation of capillary sprouts to maintain an influx of
inflammatory cells. The influx and presence of the inflammatory
cells produce granulomas and thus maintains the chronic
inflammatory state. Inhibition of angiogenesis using an HSP90
inhibitor alone or in conjunction with other anti-inflammatory
agents may prevent the formation of the granulosmas and thus
alleviate the disease. Examples of chronic inflammatory diseases
include, but are not limited to, inflammatory bowel diseases such
as Crohn's disease and ulcerative colitis, psoriasis, sarcoidosis,
and rheumatoid arthritis.
[0687] Inflammatory bowel diseases such as Crohn's disease and
ulcerative colitis are characterized by chronic inflammation and
angiogenesis at various sites in the gastrointestinal tract. For
example, Crohn's disease occurs as a chronic transmural
inflammatory disease that most commonly affects the distal ileum
and colon but may also occur in any part of the gastrointestinal
tract from the mouth to the anus and perianal area. Patients with
Crohn's disease generally have chronic diarrhea associated with
abdominal pain, fever, anorexia, weight loss and abdominal
swelling. Ulcerative colitis is also a chronic, nonspecific,
inflammatory and ulcerative disease arising in the colonic mucosa
and is characterized by the presence of bloody diarrhea. These
inflammatory bowel diseases are generally caused by chronic
granulomatous inflammation throughout the gastrointestinal tract,
involving new capillary sprouts surrounded by a cylinder of
inflammatory cells. Inhibition of angiogenesis by these inhibitors
should inhibit the formation of the sprouts and prevent the
formation of granulomas. Inflammatory bowel diseases also exhibit
extra intestinal manifestations, such as skin lesions. Such lesions
are characterized by inflammation and angiogenesis and can occur at
many sites other the gastrointestinal tract. Inhibition of
angiogenesis by HSP90 inhibitors according to the present invention
can reduce the influx of inflammatory cells and prevent lesion
formation.
[0688] Sarcoidosis, another chronic inflammatory disease, is
characterized as a multisystem granulomatous disorder. The
granulomas of this disease can form anywhere in the body. Thus, the
symptoms depend on the site of the granulomas and whether the
disease is active. The granulomas are created by the angiogenic
capillary sprouts providing a constant supply of inflammatory
cells. By using HSP90 inhibitors according to the present invention
to inhibit angiogenesis, such granulomas formation can be
inhibited. Psoriasis, also a chronic and recurrent inflammatory
disease, is characterized by papules and plaques of various sizes.
Treatment using these inhibitors alone or in conjunction with other
anti-inflammatory agents should prevent the formation of new blood
vessels necessary to maintain the characteristic lesions and
provide the patient relief from the symptoms.
[0689] Rheumatoid arthritis (RA) is also a chronic inflammatory
disease characterized by non-specific inflammation of the
peripheral joints. It is believed that the blood vessels in the
synovial lining of the joints undergo angiogenesis. In addition to
forming new vascular networks, the endothelial cells release
factors and reactive oxygen species that lead to pannus growth and
cartilage destruction. The factors involved in angiogenesis may
actively contribute to, and help maintain, the chronically inflamed
state of rheumatoid arthritis. Treatment using HSP90 inhibitors
according to the present invention alone or in conjunction with
other anti-RA agents may prevent the formation of new blood vessels
necessary to maintain the chronic inflammation and provide the RA
patient relief from the symptoms.
Combination Therapy
[0690] A wide variety of therapeutic agents may have a therapeutic
additive or synergistic effect with HSP90 inhibitors according to
the present invention. Combination therapies that comprise one or
more compounds of the present invention with one or more other
therapeutic agents can be used, for example, to: 1) enhance the
therapeutic effect(s) of the one or more compounds of the present
invention and/or the one or more other therapeutic agents; 2)
reduce the side effects exhibited by the one or more compounds of
the present invention and/or the one or more other therapeutic
agents; and/or 3) reduce the effective dose of the one or more
compounds of the present invention and/or the one or more other
therapeutic agents. It is noted that combination therapy is
intended to cover when agents are administered before or after each
other (sequential therapy) as well as when the agents are
administered at the same time.
[0691] Examples of such therapeutic agents that may be used in
combination with HSP90 inhibitors include, but are not limited to,
anti-cell proliferation agents, anticancer agents, alkylating
agents, antibiotic agents, antimetabolic agents, hormonal agents,
plant-derived agents, and biologic agents.
[0692] Anti-cell proliferation agents are those which inhibit
undesirable and uncontrolled cell proliferation. Examples of
anti-cell proliferation agents that may be used in conjunction with
the HSP90 inhibitors of the present invention include, but are not
limited to, retinoid acid and derivatives thereof,
2-methoxyestradiol, ANGIOSTATIN.TM. protein, ENDOSTATIN.TM.
protein, suramin, squalamine, tissue inhibitor of
metalloproteinase-I, tissue inhibitor of metalloproteinase-2,
plasminogen activator inhibitor-1, plasminogen activator
inhibitor-2, cartilage-derived inhibitor, paclitaxel, platelet
factor 4, protamine sulphate (clupeine), sulphated chitin
derivatives (prepared from queen crab shells), sulphated
polysaccharide peptidoglycan complex (sp-pg), staurosporine,
modulators of matrix metabolism, including for example, proline
analogs ((1-azetidine-2-carboxylic acid (LACA), cishydroxyproline,
d,l-3,4-dehydroproline, thiaproline, beta-aminopropionitrile
fumarate, 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone, methotrexate,
mitoxantrone, heparin, interferons, 2 macroglobulin-serum, chimp-3,
chymostatin, beta.-cyclodextrin tetradecasulfate, eponemycin;
fumagillin, gold sodium thiomalate, d-penicillamine (CDPT),
beta-1-anticollagenase-serum, alpha-2-antiplasmin, bisantrene,
lobenzarit disodium, n-(2-carboxyphenyl-4-chloroanthronilic acid
disodium or "CCA", thalidomide, angiostatic steroid,
carboxynaminolmidazole, metalloproteinase inhibitors such as BB94.
Other anti-angiogenesis agents that may be used include antibodies,
preferably monoclonal antibodies against these angiogenic growth
factors: bFGF, aFGF, FGF-5, VEGF isoforms, VEGF-C, HGF/SF and
Ang-1/Ang-2. Ferrara N. and Alitalo, K. "Clinical application of
angiogenic growth factors and their inhibitors" (1999) Nature
Medicine 5:1359-1364.
[0693] Alkylating agents are polyfunctional compounds that have the
ability to substitute alkyl groups for hydrogen ions. Examples of
alkylating agents include, but are not limited to,
bischloroethylamines (nitrogen mustards, e.g. chlorambucil,
cyclophosphamide, ifosfamide, mechlorethamine, melphalan, uracil
mustard), aziridines (e.g. thiotepa), alkyl alkone sulfonates (e.g.
busulfan), nitrosoureas (e.g. carmustine, lomustine, streptozocin),
nonclassic alkylating agents (altretamine, dacarbazine, and
procarbazine), platinum compounds (carboplatin and cisplatin).
These compounds react with phosphate, amino, hydroxyl, sulfhydryl,
carboxyl, and imidazole groups. Under physiological conditions,
these drugs ionize and produce positively charged ion that attach
to susceptible nucleic acids and proteins, leading to cell cycle
arrest and/or cell death. Combination therapy including an HSP90
inhibitor and an alkylating agent may have therapeutic synergistic
effects on cancer and reduce sides affects associated with these
chemotherapeutic agents.
[0694] Antibiotic agents are a group of drugs that produced in a
manner similar to antibiotics as a modification of natural
products. Examples of antibiotic agents include, but are not
limited to, anthracyclines (e.g. doxorubicin, daunorubicin,
epirubicin, idarubicin and anthracenedione), mitomycin C,
bleomycin, dactinomycin, plicatomycin. These antibiotic agents
interfere with cell growth by targeting different cellular
components. For example, anthracyclines are generally believed to
interfere with the action of DNA topoisomerase II in the regions of
transcriptionally active DNA, which leads to DNA strand scissions.
Bleomycin is generally believed to chelate iron and forms an
activated complex, which then binds to bases of DNA, causing strand
scissions and cell death. Combination therapy including an HSP90
Inhibitor and an antibiotic agent may have therapeutic synergistic
effects on cancer and reduce sides affects associated with these
chemotherapeutic agents.
[0695] Antimetabolic agents are a group of drugs that interfere
with metabolic processes vital to the physiology and proliferation
of cancer cells. Actively proliferating cancer cells require
continuous synthesis of large quantities of nucleic acids,
proteins, lipids, and other vital cellular constituents. Many of
the antimetabolites inhibit the synthesis of purine or pyrimidine
nucleosides or inhibit the enzymes of DNA replication. Some
antimetabolites also interfere with the synthesis of
ribonucleosides and RNA and/or amino acid metabolism and protein
synthesis as well. By interfering with the synthesis of vital
cellular constituents, antimetabolites can delay or arrest the
growth of cancer cells. Examples of antimetabolic agents include,
but are not limited to, fluorouracil (5-FU), floxuridine (5-FUdR),
methotrexate, leucovorin, hydroxyurea, thioguanine (6-TG),
mercaptopurine (6-MP), cytarabine, pentostatin, fludarabine
phosphate, cladribine (2-CDA), asparaginase, and gemcitabine.
Combination therapy including an HSP90 inhibitor and an
antimetabolic agent may have therapeutic synergistic effects on
cancer and reduce sides affects associated with these
chemotherapeutic agents.
[0696] Hormonal agents are a group of drug that regulate the growth
and development of their target organs. Most of the hormonal agents
are sex steroids and their derivatives and analogs thereof, such as
estrogens, androgens, and progestins. These hormonal agents may
serve as antagonists of receptors for the sex steroids to down
regulate receptor expression and transcription of vital genes.
Examples of such hormonal agents are synthetic estrogens (e.g.
diethylstilbestrol), antiestrogens (e.g. tamoxifen, toremifene,
fluoxymesterol and raloxifene), antiandrogens (bicalutamide,
nilutamide, and flutamide), aromatase inhibitors (e.g.,
aminoglutethimide, anastrozole and tetrazole), ketoconazole,
goserelin acetate, leuprolide, megestrol acetate and mifepristone.
Combination therapy including an HSP90 inhibitor and a hormonal
agent may have therapeutic synergistic effects on cancer and reduce
sides affects associated with these chemotherapeutic agents.
[0697] Plant-derived agents are a group of drugs that are derived
from plants or modified based on the molecular structure of the
agents. Examples of plant-derived agents include, but are not
limited to, vinca alkaloids (e.g., vincristine, vinblastine,
vindesine, vinzolidine and vinorelbine), podophyllotoxins (e.g.,
etoposide (VP-16) and teniposide (VM-26)), and taxanes (e.g.,
paclitaxel and docetaxel). These plant-derived agents generally act
as antimitotic agents that bind to tubulin and inhibit mitosis.
Podophyllotoxins such as etoposide are believed to interfere with
DNA synthesis by interacting with topoisomerase II, leading to DNA
strand scission. Combination therapy including an HSP90 inhibitor
and a plant-derived agent may have therapeutic synergistic effects
on cancer and reduce sides affects associated with these
chemotherapeutic agents.
[0698] Biologic agents are a group of biomolecules that elicit
cancer/tumor regression when used alone or in combination with
chemotherapy and/or radiotherapy. Examples of biologic agents
include, but are not limited to, immuno-modulating proteins such as
cytokines, monoclonal antibodies against tumor antigens, tumor
suppressor genes, and cancer vaccines. Combination therapy
including an HSP90 inhibitor and a biologic agent may have
therapeutic synergistic effects on cancer, enhance the patient's
immune responses to tumorigenic signals, and reduce potential sides
affects associated with this chemotherapeutic agent.
[0699] Cytokines possess profound immunomodulatory activity. Some
cytokines such as interleukin-2 (IL-2, aldesleukin) and interferon
have demonstrated antitumor activity and have been approved for the
treatment of patients with metastatic renal cell carcinoma and
metastatic malignant melanoma. IL-2 is a T-cell growth factor that
is central to T-cell-mediated immune responses. The selective
antitumor effects of IL-2 on some patients are believed to be the
result of a cell-mediated immune response that discriminate between
self and nonself. Examples of interleukins that may be used in
conjunction with HSP90 inhibitors include, but are not limited to,
interleukin 2 (IL-2), and interleukin 4 (IL-4), interleukin 12
(IL-12).
[0700] Interferon include more than 23 related subtypes with
overlapping activities, all of the IFN subtypes within the scope of
the present invention. IFN has demonstrated activity against many
solid and hematologic malignancies, the later appearing to be
particularly sensitive.
[0701] Other cytokines that may be used in conjunction with an
HSP90 inhibitor include those cytokines that exert profound effects
on hematopoiesis and immune functions. Examples of such cytokines
include, but are not limited to erythropoietin, granulocyte-CSF
(filgrastin), and granulocyte, macrophage-CSF (sargramostim). These
cytokines may be used in conjunction with an HSP90 inhibitor to
reduce chemotherapy-induced myelopoietic toxicity.
[0702] Other immuno-modulating agents other than cytokines may also
be used in conjunction with an HSP90 inhibitor to inhibit abnormal
cell growth. Examples of such immuno-modulating agents include, but
are not limited to bacillus Calmette-Guerin, levamisole, and
ocreotide, a long-acting octapeptide that mimics the effects of the
naturally occurring hormone somatostatin.
[0703] Monoclonal antibodies against tumor antigens are antibodies
elicited against antigens expressed by tumors, preferably
tumor-specific antigens. For example, monoclonal antibody
HERCEPTIN.RTM. (Trastruzumab) is raised against human epidermal
growth factor receptor2 (HER2) that is overexpressed in some breast
tumors including metastatic breast cancer. Overexpression of HER2
protein is associated with more aggressive disease and poorer
prognosis in the clinic. HERCEPTIN.RTM. is used as a single agent
for the treatment of patients with metastatic breast cancer whose
tumors over express the HER2 protein. Combination therapy including
HSP90 inhibitor and HERCEPTIN.RTM. may have therapeutic synergistic
effects on tumors, especially on metastatic cancers.
[0704] Another example of monoclonal antibodies against tumor
antigens is RITUXAN.RTM. (Rituximab) that is raised against CD20 on
lymphoma cells and selectively deplete normal and malignant
CD20.sup.+ pre-B and mature B cells. RITUXAN.RTM. is used as single
agent for the treatment of patients with relapsed or refractory
low-grade or follicular, CD20.sup.+, B cell non-Hodgkin's lymphoma.
Combination therapy including an HSP90 inhibitor and RITUXAN.RTM.
may have therapeutic synergistic effects not only on lymphoma, but
also on other forms or types of malignant tumors.
[0705] Tumor suppressor genes are genes that function to inhibit
the cell growth and division cycles, thus preventing the
development of neoplasia. Mutations in tumor suppressor genes cause
the cell to ignore one or more of the components of the network of
inhibitory signals, overcoming the cell cycle check points and
resulting in a higher rate of controlled cell growth--cancer.
Examples of the tumor suppressor genes include, but are not limited
to, DPC-4, NF-1, NF-2, RB, p53, WT1, BRCA1 and BRCA2. DPC-4 is
involved in pancreatic cancer and participates in a cytoplasmic
pathway that inhibits cell division. NF-1 codes for a protein that
inhibits Ras, a cytoplasmic inhibitory protein. NF-1 is involved in
neurofibroma and pheochromocytomas of the nervous system and
myeloid leukemia. NF-2 encodes a nuclear protein that is involved
in meningioma, schwanoma, and ependymoma of the nervous system. RB
codes for the pRB protein, a nuclear protein that is a major
inhibitor of cell cycle. RB is involved in retinoblastoma as well
as bone, bladder, small cell lung and breast cancer. P53 codes for
p53 protein that regulates cell division and can induce apoptosis.
Mutation and/or inaction of p53 are found in wide ranges of
cancers. WT1 is involved in Wilms tumor of the kidneys. BRCA1 is
involved in breast and ovarian cancer, and BRCA2 is involved in
breast cancer. The tumor suppressor gene can be transferred into
the tumor cells where it exerts its tumor suppressing functions.
Combination therapy including an HSP90 inhibitor and a tumor
suppressor may have therapeutic synergistic effects on patients
suffering from various forms of cancers.
[0706] Cancer vaccines are a group of agents that induce the body's
specific immune response to tumors. Most of cancer vaccines under
research and development and clinical trials are tumor-associated
antigens (TAAs). TAA are structures (i.e. proteins, enzymes or
carbohydrates) which are present on tumor cells and relatively
absent or diminished on normal cells. By virtue of being fairly
unique to the tumor cell, TAAs provide targets for the immune
system to recognize and cause their destruction. Example of TAAs
include, but are not limited to gangliosides (GM2), prostate
specific antigen (PSA), .alpha.-fetoprotein (AFP), carcinoembryonic
antigen (CEA) (produced by colon cancers and other adenocarcinomas,
e.g. breast, lung, gastric, and pancreas cancers), melanoma
associated antigens (MART-1, gp100, MAGE 1,3 tyrosinase),
papillomavirus E6 and E7 fragments, whole cells or portions/lysates
of antologous tumor cells and allogeneic tumor cells.
[0707] An adjuvant may be used to augment the immune response to
TAAs. Examples of adjuvants include, but are not limited to,
bacillus Calmette-Guerin (BCG), endotoxin lipopolysaccharides,
keyhole limpet hemocyanin (GKLH), interleukin-2 (IL-2),
granulocyte-macrophage colony-stimulating factor (GM-CSF) and
cytoxin, a chemotherapeutic agent which is believe to reduce
tumor-induced suppression when given in low doses.
Compositions Comprising HSP90 Inhibitors
[0708] A wide variety of compositions and administration methods
may be used in conjunction with the compounds of the present
invention. Such compositions may include, in addition to the
compounds of the present invention, conventional pharmaceutical
excipients, and other conventional, pharmaceutically inactive
agents. Additionally, the compositions may include active agents in
addition to the compounds of the present invention. These
additional active agents may include additional compounds according
to the invention, and/or one or more other pharmaceutically active
agents.
[0709] The compositions may be in gaseous, liquid, semi-liquid or
solid form, formulated in a manner suitable for the route of
administration to be used. For oral administration, capsules and
tablets are typically used. For parenteral administration,
reconstitution of a lyophilized powder, prepared as described
herein, is typically used.
[0710] Compositions comprising compounds of the present invention
may be administered or coadministered orally, parenterally,
intraperitoneally, intravenously, intraarterially, transdermally,
sublingually, intramuscularly, rectally, transbuccally,
intranasally, liposomally, via inhalation, vaginally,
intraocularly, via local delivery (for example by catheter or
stent), subcutaneously, intraadiposally, intraarticularly, or
intrathecally. The compounds and/or compositions according to the
invention may also be administered or coadministered in slow
release dosage forms.
[0711] The HSP90 inhibitors and compositions comprising them may be
administered or coadministered in any conventional dosage form.
Co-administration in the context of this invention is intended to
mean the administration of more than one therapeutic agent, one of
which includes a HSP90 inhibitor, in the course of a coordinated
treatment to achieve an improved clinical outcome. Such
co-administration may also be coextensive, that is, occurring
during overlapping periods of time.
[0712] Solutions or suspensions used for parenteral, intradermal,
subcutaneous, or topical application may optionally include one or
more of the following components: a sterile diluent, such as water
for injection, saline solution, fixed oil, polyethylene glycol,
glycerin, propylene glycol or other synthetic solvent;
antimicrobial agents, such as benzyl alcohol and methyl parabens;
antioxidants, such as ascorbic acid and sodium bisulfite; chelating
agents, such as ethylenediaminetetraacetic acid (EDTA); buffers,
such as acetates, citrates and phosphates; agents for the
adjustment of tonicity such as sodium chloride or dextrose, and
agents for adjusting the acidity or alkalinity of the composition,
such as alkaline or acidifying agents or buffers like carbonates,
bicarbonates, phosphates, hydrochloric acid, and organic acids like
acetic and citric acid. Parenteral preparations may optionally be
enclosed in ampules, disposable syringes or single or multiple dose
vials made of glass, plastic or other suitable material.
[0713] When compounds according to the present invention exhibit
insufficient solubility, methods for solubilizing the compounds may
be used. Such methods are known to those of skill in this art, and
include, but are not limited to, using cosolvents, such as
dimethylsulfoxide (DMSO), using surfactants, such as TWEEN, or
dissolution in aqueous sodium bicarbonate. Derivatives of the
compounds, such as prodrugs of the compounds may also be used in
formulating effective pharmaceutical compositions.
[0714] Upon mixing or adding compounds according to the present
invention to a composition, a solution, suspension, emulsion or the
like may be formed. The form of the resulting composition will
depend upon a number of factors, including the intended mode of
administration, and the solubility of the compound in the selected
carrier or vehicle. The effective concentration needed to
ameliorate the disease being treated may be empirically
determined.
[0715] Compositions according to the present invention are
optionally provided for administration to humans and animals in
unit dosage forms, such as tablets, capsules, pills, powders, dry
powders for inhalers, granules, sterile parenteral solutions or
suspensions, and oral solutions or suspensions, and oil-water
emulsions containing suitable quantities of the compounds,
particularly the pharmaceutically acceptable salts, preferably the
sodium salts, thereof. The pharmaceutically therapeutically active
compounds and derivatives thereof are typically formulated and
administered in unit-dosage forms or multiple-dosage forms.
Unit-dose forms, as used herein, refers to physically discrete
units suitable for human and animal subjects and packaged
individually as is known in the art. Each unit-dose contains a
predetermined quantity of the therapeutically active compound
sufficient to produce the desired therapeutic effect, in
association with the required pharmaceutical carrier, vehicle or
diluent. Examples of unit-dose forms include ampoules and syringes
individually packaged tablet or capsule. Unit-dose forms may be
administered in fractions or multiples thereof. A multiple-dose
form is a plurality of identical unit-dosage forms packaged in a
single container to be administered in segregated unit-dose form.
Examples of multiple-dose forms include vials, bottles of tablets
or capsules or bottles of pint or gallons. Hence, multiple dose
form is a multiple of unit-doses that are not segregated in
packaging.
[0716] In addition to one or more compounds according to the
present invention, the composition may comprise: a diluent such as
lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose; a
lubricant, such as magnesium stearate, calcium stearate and talc;
and a binder such as starch, natural gums, such as gum
acaciagelatin, glucose, molasses, polyvinylpyrrolidine, celluloses
and derivatives thereof, povidone, crospovidones and other such
binders known to those of skill in the art. Liquid pharmaceutically
administrable compositions can, for example, be prepared by
dissolving, dispersing, or otherwise mixing an active compound as
defined above and optional pharmaceutical adjuvants in a carrier,
such as, for example, water, saline, aqueous dextrose, glycerol,
glycols, ethanol, and the like, to form a solution or suspension.
If desired, the pharmaceutical composition to be administered may
also contain minor amounts of auxiliary substances such as wetting
agents, emulsifying agents, or solubilizing agents, pH buffering
agents and the like, for example, acetate, sodium citrate,
cyclodextrine derivatives, sorbitan monolaurate, triethanolamine
sodium acetate, triethanolamine oleate, and other such agents.
Actual methods of preparing such dosage forms are known in the art,
or will be apparent, to those skilled in this art; for example, see
Remington: The Science and Practices of Pharmacy, Lippincott
Williams, and Wilkins Publisher, 21.sup.st edition, 2005. The
composition or formulation to be administered will, in any event,
contain a sufficient quantity of an inhibitor of the present
invention to reduce HSP90 activity in vivo, thereby treating the
disease state of the subject.
[0717] Dosage forms or compositions may optionally comprise one or
more compounds according to the present invention in the range of
0.005% to 100% (weight/weight) with the balance comprising
additional substances such as those described herein. For oral
administration, a pharmaceutically acceptable composition may
optionally comprise any one or more commonly employed excipients,
such as, for example pharmaceutical grades of mannitol, lactose,
starch, magnesium stearate, talcum, cellulose derivatives, sodium
croscarmellose, glucose, sucrose, magnesium carbonate, sodium
saccharin, talcum. Such compositions include solutions,
suspensions, tablets, capsules, powders, dry powders for inhalers
and sustained release formulations, such as, but not limited to,
implants and microencapsulated delivery systems, and biodegradable,
biocompatible polymers, such as collagen, ethylene vinyl acetate,
polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid
and others. Methods for preparing these formulations are known to
those skilled in the art. The compositions may optionally contain
0.01%-100% (weight/weight) of one or more HSP90 inhibitors,
optionally 0.1-95%, and optionally 1-95%.
[0718] Salts, preferably sodium salts, of the inhibitors may be
prepared with carriers that protect the compound against rapid
elimination from the body, such as time release formulations or
coatings. The formulations may further include other active
compounds to obtain desired combinations of properties.
A. Formulations for Oral Administration
[0719] Oral pharmaceutical dosage forms may be as a solid, gel or
liquid. Examples of solid dosage forms include, but are not limited
to tablets, capsules, granules, and bulk powders. More specific
examples of oral tablets include compressed, chewable lozenges and
tablets that may be enteric-coated, sugar-coated or film-coated.
Examples of capsules include hard or soft gelatin capsules.
Granules and powders may be provided in non-effervescent or
effervescent forms. Each may be combined with other ingredients
known to those skilled in the art.
[0720] In certain embodiments, compounds according to the present
invention are provided as solid dosage forms, preferably capsules
or tablets. The tablets, pills, capsules, troches and the like may
optionally contain one or more of the following ingredients, or
compounds of a similar nature: a binder; a diluent; a
disintegrating agent; a lubricant; a glidant; a sweetening agent;
and a flavoring agent.
[0721] Examples of binders that may be used include, but are not
limited to, microcrystalline cellulose, gum tragacanth, glucose
solution, acacia mucilage, gelatin solution, sucrose, and starch
paste.
[0722] Examples of lubricants that may be used include, but are not
limited to, talc, starch, magnesium or calcium stearate, lycopodium
and stearic acid.
[0723] Examples of diluents that may be used include, but are not
limited to, lactose, sucrose, starch, kaolin, salt, mannitol, and
dicalcium phosphate.
[0724] Examples of glidants that may be used include, but are not
limited to, colloidal silicon dioxide.
[0725] Examples of disintegrating agents that may be used include,
but are not limited to, croscarmellose sodium, sodium starch
glycolate, alginic acid, corn starch, potato starch, bentonite,
methylcellulose, agar and carboxymethylcellulose.
[0726] Examples of coloring agents that may be used include, but
are not limited to, any of the approved certified water-soluble FD
and C dyes, mixtures thereof; and water insoluble FD and C dyes
suspended on alumina hydrate.
[0727] Examples of sweetening agents that may be used include, but
are not limited to, sucrose, lactose, mannitol and artificial
sweetening agents such as sodium cyclamate and saccharin, and any
number of spray-dried flavors.
[0728] Examples of flavoring agents that may be used include, but
are not limited to, natural flavors extracted from plants such as
fruits and synthetic blends of compounds that produce a pleasant
sensation, such as, but not limited to peppermint and methyl
salicylate.
[0729] Examples of wetting agents that may be used include, but are
not limited to, propylene glycol monostearate, sorbitan monooleate,
diethylene glycol monolaurate, and polyoxyethylene lauryl
ether.
[0730] Examples of anti-emetic coatings that may be used include,
but are not limited to, fatty acids, fats, waxes, shellac,
ammoniated shellac and cellulose acetate phthalates.
[0731] Examples of film coatings that may be used include, but are
not limited to, hydroxyethylcellulose, sodium
carboxymethylcellulose, polyethylene glycol 4000 and cellulose
acetate phthalate.
[0732] If oral administration is desired, the salt of the compound
may optionally be provided in a composition that protects it from
the acidic environment of the stomach. For example, the composition
can be formulated in an enteric coating that maintains its
integrity in the stomach and releases the active compound in the
intestine. The composition may also be formulated in combination
with an antacid or other such ingredient.
[0733] When the dosage unit form is a capsule, it may optionally
additionally comprise a liquid carrier such as a fatty oil. In
addition, dosage unit forms may optionally additionally comprise
various other materials that modify the physical form of the dosage
unit, for example, coatings of sugar and other enteric agents.
[0734] Compounds according to the present invention may also be
administered as a component of an elixir, suspension, syrup, wafer,
sprinkle, chewing gum or the like. A syrup may optionally comprise,
in addition to the active compounds, sucrose as a sweetening agent
and certain preservatives, dyes and colorings and flavors.
[0735] The compounds of the present invention may also be mixed
with other active materials that do not impair the desired action,
or with materials that supplement the desired action, such as
antacids, H2 blockers, and diuretics. For example, if a compound is
used for treating asthma or hypertension, it may be used with other
bronchodilators and antihypertensive agents, respectively.
[0736] Examples of pharmaceutically acceptable carriers that may be
included in tablets comprising compounds of the present invention
include, but are not limited to binders, lubricants, diluents,
disintegrating agents, coloring agents, flavoring agents, and
wetting agents. Enteric-coated tablets, because of the
enteric-coating, resist the action of stomach acid and dissolve or
disintegrate in the neutral or alkaline intestines. Sugar-coated
tablets may be compressed tablets to which different layers of
pharmaceutically acceptable substances are applied. Film-coated
tablets may be compressed tablets that have been coated with
polymers or other suitable coating. Multiple compressed tablets may
be compressed tablets made by more than one compression cycle
utilizing the pharmaceutically acceptable substances previously
mentioned. Coloring agents may also be used in tablets. Flavoring
and sweetening agents may be used in tablets, and are especially
useful in the formation of chewable tablets and lozenges.
[0737] Examples of liquid oral dosage forms that may be used
include, but are not limited to, aqueous solutions, emulsions,
suspensions, solutions and/or suspensions reconstituted from
non-effervescent granules and effervescent preparations
reconstituted from effervescent granules.
[0738] Examples of aqueous solutions that may be used include, but
are not limited to, elixirs and syrups. As used herein, elixirs
refer to clear, sweetened, hydroalcoholic preparations. Examples of
pharmaceutically acceptable carriers that may be used in elixirs
include, but are not limited to solvents. Particular examples of
solvents that may be used include glycerin, sorbitol, ethyl alcohol
and syrup. As used herein, syrups refer to concentrated aqueous
solutions of a sugar, for example, sucrose. Syrups may optionally
further comprise a preservative.
[0739] Emulsions refer to two-phase systems in which one liquid is
dispersed in the form of small globules throughout another liquid.
Emulsions may optionally be oil-in-water or water-in-oil emulsions.
Examples of pharmaceutically acceptable carriers that may be used
in emulsions include, but are not limited to non-aqueous liquids,
emulsifying agents and preservatives.
[0740] Examples of pharmaceutically acceptable substances that may
be used in non-effervescent granules, to be reconstituted into a
liquid oral dosage form, include diluents, sweeteners and wetting
agents.
[0741] Examples of pharmaceutically acceptable substances that may
be used in effervescent granules, to be reconstituted into a liquid
oral dosage form, include organic acids and a source of carbon
dioxide.
[0742] Coloring and flavoring agents may optionally be used in all
of the above dosage forms.
[0743] Particular examples of preservatives that may be used
include glycerin, methyl and propylparaben, benzoic add, sodium
benzoate and alcohol.
[0744] Particular examples of non-aqueous liquids that may be used
in emulsions include mineral oil and cottonseed oil.
[0745] Particular examples of emulsifying agents that may be used
include gelatin, acacia, tragacanth, bentonite, and surfactants
such as polyoxyethylene sorbitan monooleate.
[0746] Particular examples of suspending agents that may be used
include sodium carboxymethylcellulose, pectin, tragacanth, Veegum
and acacia. Diluents include lactose and sucrose. Sweetening agents
include sucrose, syrups, glycerin and artificial sweetening agents
such as sodium cyclamate and saccharin.
[0747] Particular examples of wetting agents that may be used
include propylene glycol monostearate, sorbitan monooleate,
diethylene glycol monolaurate, and polyoxyethylene lauryl
ether.
[0748] Particular examples of organic acids that may be used
include citric and tartaric acid.
[0749] Sources of carbon dioxide that may be used in effervescent
compositions include sodium bicarbonate and sodium carbonate.
Coloring agents include any of the approved certified water soluble
FD and C dyes, and mixtures thereof.
[0750] Particular examples of flavoring agents that may be used
include natural flavors extracted from plants such fruits, and
synthetic blends of compounds that produce a pleasant taste
sensation.
[0751] For a solid dosage form, the solution or suspension, in for
example propylene carbonate, vegetable oils or triglycerides, is
preferably encapsulated in a gelatin capsule. Such solutions, and
the preparation and encapsulation thereof, are disclosed in U.S.
Pat. Nos. 4,328,245; 4,409,239; and 4,410,545. For a liquid dosage
form, the solution, e.g., for example, in a polyethylene glycol,
may be diluted with a sufficient quantity of a pharmaceutically
acceptable liquid carrier, e.g., water, to be easily measured for
administration.
[0752] Alternatively, liquid or semi-solid oral formulations may be
prepared by dissolving or dispersing the active compound or salt in
vegetable oils, glycols, triglycerides, propylene glycol esters
(e.g., propylene carbonate) and other such carriers, and
encapsulating these solutions or suspensions in hard or soft
gelatin capsule shells. Other useful formulations include those set
forth in U.S. Pat. Nos. Re 28,819 and 4,358,603.
B. Injectables, Solutions, and Emulsions
[0753] The present invention is also directed to compositions
designed to administer the compounds of the present invention by
parenteral administration, generally characterized by subcutaneous,
intramuscular or intravenous injection. Injectables may be prepared
in any conventional form, for example as liquid solutions or
suspensions, solid forms suitable for solution or suspension in
liquid prior to injection, or as emulsions.
[0754] Examples of excipients that may be used in conjunction with
injectables according to the present invention include, but are not
limited to water, saline, dextrose, glycerol or ethanol. The
injectable compositions may also optionally comprise minor amounts
of non-toxic auxiliary substances such as wetting or emulsifying
agents, pH buffering agents, stabilizers, solubility enhancers, and
other such agents, such as for example, sodium acetate, sorbitan
monolaurate, triethanolamine oleate and cyclodextrins. Implantation
of a slow-release or sustained-release system, such that a constant
level of dosage is maintained (see, e.g., U.S. Pat. No. 3,710,795)
is also contemplated herein. The percentage of active compound
contained in such parenteral compositions is highly dependent on
the specific nature thereof, as well as the activity of the
compound and the needs of the subject.
[0755] Parenteral administration of the formulations includes
intravenous, subcutaneous and intramuscular administrations.
Preparations for parenteral administration include sterile
solutions ready for injection, sterile dry soluble products, such
as the lyophilized powders described herein, ready to be combined
with a solvent just prior to use, including hypodermic tablets,
sterile suspensions ready for injection, sterile dry insoluble
products ready to be combined with a vehicle just prior to use and
sterile emulsions. The solutions may be either aqueous or
nonaqueous.
[0756] When administered intravenously, examples of suitable
carriers include, but are not limited to physiological saline or
phosphate buffered saline (PBS), and solutions containing
thickening and solubilizing agents, such as glucose, polyethylene
glycol, and polypropylene glycol and mixtures thereof.
[0757] Examples of pharmaceutically acceptable carriers that may
optionally be used in parenteral preparations include, but are not
limited to aqueous vehicles, nonaqueous vehicles, antimicrobial
agents, isotonic agents, buffers, antioxidants, local anesthetics,
suspending and dispersing agents, emulsifying agents, sequestering
or chelating agents and other pharmaceutically acceptable
substances.
[0758] Examples of aqueous vehicles that may optionally be used
include Sodium Chloride Injection, Ringers Injection, Isotonic
Dextrose Injection, Sterile Water Injection, Dextrose and Lactated
Ringers Injection.
[0759] Examples of nonaqueous parenteral vehicles that may
optionally be used include fixed oils of vegetable origin,
cottonseed oil, corn oil, sesame oil and peanut oil.
[0760] Antimicrobial agents in bacteriostatic or fungistatic
concentrations may be added to parenteral preparations,
particularly when the preparations are packaged in multiple-dose
containers and thus designed to be stored and multiple aliquots to
be removed. Examples of antimicrobial agents that may be used
include phenols or cresols, mercurials, benzyl alcohol,
chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters,
thimerosal, benzalkonium chloride and benzethonium chloride.
[0761] Examples of isotonic agents that may be used include sodium
chloride and dextrose. Examples of buffers that may be used include
phosphate and citrate. Examples of antioxidants that may be used
include sodium bisulfate. Examples of local anesthetics that may be
used include procaine hydrochloride. Examples of suspending and
dispersing agents that may be used include sodium
carboxymethylcellulose, hydroxypropyl methylcellulose and
polyvinylpyrrolidone. Examples of emulsifying agents that may be
used include Polysorbate 80 (TWEEN 80). A sequestering or chelating
agent of metal ions includes EDTA.
[0762] Pharmaceutical carriers may also optionally include ethyl
alcohol, polyethylene glycol and propylene glycol for water
miscible vehicles and sodium hydroxide, hydrochloric acid, citric
acid or lactic acid for pH adjustment.
[0763] The concentration of an inhibitor in the parenteral
formulation may be adjusted so that an injection administers a
pharmaceutically effective amount sufficient to produce the desired
pharmacological effect. The exact concentration of an inhibitor
and/or dosage to be used will ultimately depend on the age, weight
and condition of the patient or animal as is known in the art.
[0764] Unit-dose parenteral preparations may be packaged in an
ampoule, a vial or a syringe with a needle. All preparations for
parenteral administration should be sterile, as is known and
practiced in the art.
[0765] Injectables may be designed for local and systemic
administration. Typically a therapeutically effective dosage is
formulated to contain a concentration of at least about 0.1% w/w up
to about 90% w/w or more, preferably more than 1% w/w of the HSP90
inhibitor to the treated tissue(s). The inhibitor may be
administered at once, or may be divided into a number of smaller
doses to be administered at intervals of time. It is understood
that the precise dosage and duration of treatment will be a
function of the location of where the composition is parenterally
administered, the carrier and other variables that may be
determined empirically using known testing protocols or by
extrapolation from in vivo or in vitro test data. It is to be noted
that concentrations and dosage values may also vary with the age of
the individual treated. It is to be further understood that for any
particular subject, specific dosage regimens may need to be
adjusted over time according to the individual need and the
professional judgment of the person administering or supervising
the administration of the formulations. Hence, the concentration
ranges set forth herein are intended to be exemplary and are not
intended to limit the scope or practice of the claimed
formulations.
[0766] The HSP90 inhibitor may optionally be suspended in
micronized or other suitable form or may be derivatized to produce
a more soluble active product or to produce a prodrug. The form of
the resulting mixture depends upon a number of factors, including
the intended mode of administration and the solubility of the
compound in the selected carrier or vehicle. The effective
concentration is sufficient for ameliorating the symptoms of the
disease state and may be empirically determined.
C. Lyophilized Powders
[0767] The compounds of the present invention may also be prepared
as lyophilized powders, which can be reconstituted for
administration as solutions, emulsions and other mixtures. The
lyophilized powders may also be formulated as solids or gels.
[0768] Sterile, lyophilized powder may be prepared by dissolving
the compound in a sodium phosphate buffer solution containing
dextrose or other suitable excipient. Subsequent sterile filtration
of the solution followed by lyophilization under standard
conditions known to those of skill in the art provides the desired
formulation. Briefly, the lyophilized powder may optionally be
prepared by dissolving dextrose, sorbitol, fructose, corn syrup,
xylitol, glycerin, glucose, sucrose or other suitable agent, about
1-20%, preferably about 5 to 15%, in a suitable buffer, such as
citrate, sodium or potassium phosphate or other such buffer known
to those of skill in the art at, typically, about neutral pH. Then,
a HSP90 inhibitor is added to the resulting mixture, preferably
above room temperature, more preferably at about 30-35.degree. C.,
and stirred until it dissolves. The resulting mixture is diluted by
adding more buffer to a desired concentration. The resulting
mixture is sterile filtered or treated to remove particulates and
to insure sterility, and apportioned into vials for lyophilization.
Each vial may contain a single dosage or multiple dosages of the
inhibitor.
D. Formulation for Topical Administration
[0769] The compounds of the present invention may also be
administered as topical mixtures. Topical mixtures may be used for
local and systemic administration. The resulting mixture may be a
solution, suspension, emulsions or the like and are formulated as
creams, gels, ointments, emulsions, solutions, elixirs, lotions,
suspensions, tinctures, pastes, foams, aerosols, irrigations,
sprays, suppositories, bandages, dermal patches or any other
formulations suitable for topical administration.
[0770] The HSP90 inhibitors may be formulated as aerosols for
topical application, such as by inhalation (see, U.S. Pat. Nos.
4,044,126, 4,414,209, and 4,364,923, which describe aerosols for
delivery of a steroid useful for treatment of inflammatory
diseases, particularly asthma). These formulations for
administration to the respiratory tract can be in the form of an
aerosol or solution for a nebulizer, or as a microfine powder for
insufflation, alone or in combination with an inert carrier such as
lactose. In such a case, the particles of the formulation will
typically have diameters of less than 50 microns, preferably less
than 10 microns.
[0771] The inhibitors may also be formulated for local or topical
application, such as for topical application to the skin and mucous
membranes, such as in the eye, in the form of gels, creams, and
lotions and for application to the eye or for intracisternal or
intraspinal application. Topical administration is contemplated for
transdermal delivery and also for administration to the eyes or
mucosa, or for inhalation therapies. Nasal solutions of the HSP90
inhibitor alone or in combination with other pharmaceutically
acceptable excipients can also be administered.
E. Formulations for Other Routes of Administration
[0772] Depending upon the disease state being treated, other routes
of administration, such as topical application, transdermal
patches, and rectal administration, may also be used. For example,
pharmaceutical dosage forms for rectal administration are rectal
suppositories, capsules and tablets for systemic effect. Rectal
suppositories are used herein mean solid bodies for insertion into
the rectum that melt or soften at body temperature releasing one or
more pharmacologically or therapeutically active ingredients.
Pharmaceutically acceptable substances utilized in rectal
suppositories are bases or vehicles and agents to raise the melting
point. Examples of bases include cocoa butter (theobroma oil),
glycerin-gelatin, carbowax, (polyoxyethylene glycol) and
appropriate mixtures of mono-, di- and triglycerides of fatty
acids. Combinations of the various bases may be used. Agents to
raise the melting point of suppositories include spermaceti and
wax. Rectal suppositories may be prepared either by the compressed
method or by molding. The typical weight of a rectal suppository is
about 2 to 3 gm. Tablets and capsules for rectal administration may
be manufactured using the same pharmaceutically acceptable
substance and by the same methods as for formulations for oral
administration.
F. EXAMPLES OF FORMULATIONS
[0773] The following are particular examples of oral, intravenous
and tablet formulations that may optionally be used with compounds
of the present invention. It is noted that these formulations may
be varied depending on the particular compound being used and the
indication for which the formulation is going to be used.
TABLE-US-00001 ORAL FORMULATION Compound of the Present Invention
10-100 mg Citric Acid Monohydrate 105 mg Sodium Hydroxide 18 mg
Flavoring Water q.s. to 100 mL INTRAVENOUS FORMULATION Compound of
the Present Invention 0.1-10 mg Dextrose Monohydrate q.s. to make
isotonic Citric Acid Monohydrate 1.05 mg Sodium Hydroxide 0.18 mg
Water for Injection q.s. to 1.0 mL TABLET FORMULATION Compound of
the Present Invention 1% Microcrystalline Cellulose 73% Stearic
Acid 25% Colloidal Silica 1%.
Dosage, Host and Safety
[0774] The compounds of the present invention are stable and can be
used safely. In particular, the compounds of the present invention
are useful as HSP90 inhibitors for a variety of subjects (e.g.,
humans, non-human mammals and non-mammals).
[0775] The optimal dose may vary depending upon such conditions as,
for example, the type of subject, the body weight of the subject,
on the severity of the condition, the route of administration, and
specific properties of the particular compound being used.
Generally, acceptable and effective daily doses are amounts
sufficient to effectively slow or eliminate the condition being
treated. Typically, the daily dose for oral administration to an
adult (body weight of about 60 kg) is about 1 to 1000 mg, about 3
to 300 mg, or about 10 to 200 mg. It will be appreciated that the
daily dose can be given in a single administration or in multiple
(e.g., 2 or 3) portions a day.
Kits and Articles of Manufacture Comprising HSP90 Inhibitors
[0776] The invention is also directed to kits and other articles of
manufacture for treating diseases associated with HSP90. It is
noted that diseases are intended to cover all conditions for which
the HSP90 possess activity that contributes to the pathology and/or
symptomology of the condition.
[0777] In one embodiment, a kit is provided that comprises a
composition comprising at least one inhibitor of the present
invention in combination with instructions. The instructions may
indicate the disease state for which the composition is to be
administered, storage information, dosing information and/or
instructions regarding how to administer the composition. The kit
may also comprise packaging materials. The packaging material may
comprise a container for housing the composition. The kit may also
optionally comprise additional components, such as syringes for
administration of the composition. The kit may comprise the
composition in single or multiple dose forms.
[0778] In another embodiment, an article of manufacture is provided
that comprises a composition comprising at least one inhibitor of
the present invention in combination with packaging materials. The
packaging material may comprise a container for housing the
composition. The container may optionally comprise a label
indicating the disease state for which the composition is to be
administered, storage information, dosing information and/or
instructions regarding how to administer the composition. The kit
may also optionally comprise additional components, such as
syringes for administration of the composition. The kit may
comprise the composition in single or multiple dose forms.
[0779] It is noted that the packaging material used in kits and
articles of manufacture according to the present invention may form
a plurality of divided containers such as a divided bottle or a
divided foil packet. The container can be in any conventional shape
or form as known in the art which is made of a pharmaceutically
acceptable material, for example a paper or cardboard box, a glass
or plastic bottle or jar, a re-sealable bag (for example, to hold a
"refill" of tablets for placement into a different container), or a
blister pack with individual doses for pressing out of the pack
according to a therapeutic schedule. The container that is employed
will depend on the exact dosage form involved, for example a
conventional cardboard box would not generally be used to hold a
liquid suspension. It is feasible that more than one container can
be used together in a single package to market a single dosage
form. For example, tablets may be contained in a bottle that is in
turn contained within a box. Typically the kit includes directions
for the administration of the separate components. The kit form is
particularly advantageous when the separate components are
preferably administered in different dosage forms (e.g., oral,
topical, transdermal and parenteral), are administered at different
dosage intervals, or when titration of the individual components of
the combination is desired by the prescribing physician.
[0780] One particular example of a kit according to the present
invention is a so-called blister pack. Blister packs are well known
in the packaging industry and are being widely used for the
packaging of pharmaceutical unit dosage forms (tablets, capsules,
and the like). Blister packs generally consist of a sheet of
relatively stiff material covered with a foil of a preferably
transparent plastic material. During the packaging process recesses
are formed in the plastic foil. The recesses have the size and
shape of individual tablets or capsules to be packed or may have
the size and shape to accommodate multiple tablets and/or capsules
to be packed. Next, the tablets or capsules are placed in the
recesses accordingly and the sheet of relatively stiff material is
sealed against the plastic foil at the face of the foil which is
opposite from the direction in which the recesses were formed. As a
result, the tablets or capsules are individually sealed or
collectively sealed, as desired, in the recesses between the
plastic foil and the sheet. Preferably the strength of the sheet is
such that the tablets or capsules can be removed from the blister
pack by manually applying pressure on the recesses whereby an
opening is formed in the sheet at the place of the recess. The
tablet or capsule can then be removed via said opening.
[0781] Another specific embodiment of a kit is a dispenser designed
to dispense the daily doses one at a time in the order of their
intended use. Preferably, the dispenser is equipped with a
memory-aid, so as to further facilitate compliance with the
regimen. An example of such a memory-aid is a mechanical counter
that indicates the number of daily doses that has been dispensed.
Another example of such a memory-aid is a battery-powered
micro-chip memory coupled with a liquid crystal readout, or audible
reminder signal which, for example, reads out the date that the
last daily dose has been taken and/or reminds one when the next
dose is to be taken.
Preparation of HSP90 Inhibitors
[0782] Various methods may be developed for synthesizing compounds
according to the present invention. Representative methods for
synthesizing these compounds are provided in the Examples. It is
noted, however, that the compounds of the present invention may
also be synthesized by other synthetic routes that others may
devise.
[0783] Synthetic Schemes for Compounds of the Present Invention
[0784] Compounds according to the present invention may be
synthesized according to the reaction schemes shown below. Other
reaction schemes could be readily devised by those skilled in the
art. It should also be appreciated that a variety of different
solvents, temperatures and other reaction conditions can be varied
to optimize the yields of the reactions.
[0785] In the reactions described hereinafter it may be necessary
to protect reactive functional groups, for example hydroxy, amino,
imino, thio or carboxy groups, where these are desired in the final
product, to avoid their unwanted participation in the reactions.
Conventional protecting groups may be used in accordance with
standard practice, for examples see P. G. M. Wuts and T. W. Greene
in "Greene's Protective Groups in Organic Synthesis" 4th edition,
John Wiley and Sons, 2007.
##STR00153## ##STR00154##
[0786] Reaction of aldehyde 1A with acetone derivative 1B gives
enone 1C (Step 1). Treatment of enone 1C with malonate derivative
1D followed by saponification and decarboxylation gives vinylogous
acid 1E (Step 2). C-acylation with acid chloride 1F gives trione 1G
(Step 3). Treatment of 1G with guanidine in the presence of
pyrrolidine gives dihydroquinazolinone 1H (Step 4). Suzuki coupling
with boronic ester 1I (Step 5) gives compound 1J. Reaction with
alkoxyamine 1K in refluxing pyridine (Step 6), and, if necessary,
deprotection (Step 7), gives oxime ether 1L. Chiral separation via
SFC gives both enantiomers, 1M and 1N.
##STR00155## ##STR00156##
[0787] The reaction of aldehyde 2A with chiral sulfinamide 2B in
the presence of titanium tetraethoxide gives imine 2C (Step 1).
Treatment of the sulfinamide with the Reformatsky reagent of 2D
exclusively gives chiral sulfinamide 2E (Step 2) which is followed
by acid-catalyzed deprotection to give chiral beta-amino acid 2F
(Step 3). Reaction of the amine with functionalized diketene 2G
gives amide 2H (Step 4) which is followed by treatment with
methoxide to form Dieckmann condensation product 2I (Step 5).
Reaction of the vinylogous acid 2I with acetylguanidine gives
condensation product 2J (Step 6). Conversion of lactam 2J to the
thiolactam 2K is effected with a thiolating reagent such as Davy's
or Lawesson's reagent (Step 7). Conversion of thiolactam 2K to the
amidine 2M is achieved by treatment with substituted alkoxyamine 2L
(Step 8). Lastly, Suzuki coupling with boronic ester 2N (Step 9)
and, if necessary, deprotection (Step 10), gives final product
2O.
##STR00157## ##STR00158##
[0788] Reaction of aldehyde 3A with acetone derivative 3B gives
enone 3C (Step 1). Treatment of enone 3C with malonate derivative
3D followed by saponification and decarboxylation gives vinylogous
acid 3E (Step 2). C-acylation with acid chloride 3F gives trione 3G
(Step 3). Acetylation of the vinylogous acid gives 3H (Step 4),
which is in turn subjected to malononitrile under basic conditions
to give 3I (Step 5). Treatment of bisnitrile 3I with ammonia gives
aminopyridine 3J (Step 6). Suzuki coupling with boronic ester 3K
(Step 7) gives compound 3L. Reaction with alkoxyamine 3M in
refluxing pyridine (Step 8), and, if necessary, deprotection (Step
9), gives oxime ether 3N. Chiral separation via SFC gives both
enantiomers, 3O and 3P.
[0789] Furthermore, 3L may be manipulated with the following series
of transformations to access various R.sub.7 moieties.
Aminopyridine 3L is protected as its acetyl derivative 3Q (Step
10).
[0790] Treatment of nitrile 3Q with HCl gives acid 3R (Step 11).
Curtius rearrangement induced by diphenylphosphoryl azide (Step 12)
gives aniline 3S. Finally aniline 3S can be converted to phenol 3T
via Sandmeyer chemistry. Any of the intermediates 3Q, 3R,3S, and 3T
may be functionalized as in Steps 8 and 9 to give the corresponding
oxime ethers, followed by chiral separation via SFC.
##STR00159## ##STR00160##
[0791] The reaction of aldehyde 4A with chiral sulfonamide 4B in
the presence of titanium tetraethoxide gives imine 4C (Step 1).
Treatment of the sulfinamide with the Reformatsky reagent 4D
exclusively gives enantiopure sulfonamide 4E (Step 2) which is
followed by acid-catalyzed deprotection to give beta-amino acid 4F
(Step 3). Reaction of the amine with functionalized diketene 4G
gives amide 4H (Step 4) which is followed by treatment with
methoxide to give Dieckmann condensation product 4I (Step 5). After
oxidation, reaction of the bisnitrile 4I with ammonia gives
condensation product 4J (Step 6). Conversion of lactam 4J to the
thiolactam 4K is effected with a thiolating reagent such as Davy's
or Lawesson's reagent (Step 7). Conversion of thiolactam 4K to the
amidine 4M is achieved by treatment with substituted alkoxyamine 4L
(Step 8). Lastly, Suzuki coupling with boronic ester 4N (Step 9)
and, if necessary, deprotection (Step 10), gives final product
40.
##STR00161##
[0792] The reaction of thiolactam 2K with protected hydroxylamine
5A (e.g., TBS protected) in the presence of mercuric acetate yields
amidine 5B, which is followed by acid catalyzed deprotection to
give hydroxyl derivative 5C. Alkylation with the appropriate
haloalkyl 5D in base, e.g., Cs.sub.2CO.sub.3, yields oxime ether
5E, followed by a coupling reaction such as Suzuki coupling with
boronic acid 5C, and if necessary deprotection gives product
5F.
##STR00162##
[0793] The reaction of thiolactam 2K with protected hydroxylamine
6A (e.g., TBS protected) in the presence of a strong thiophile
(e.g., mercuric acetate) yields amidine 6B. Arylation reaction (e.g
Suzuki coupling) with boronic ester 6C and deprotection to give
hydroxyl derivative 6D. Alkylation with the appropriate haloalkyl
6E in base, e.g., Cs.sub.2CO.sub.3, gives product 6F.
[0794] In each of the above reaction procedures or schemes, the
various substituents may be selected from among the various
substituents otherwise taught herein.
[0795] General Procedures
[0796] It will be readily recognized that certain compounds
according to the present invention have atoms with linkages to
other atoms that confer a particular stereochemistry to the
compound (e.g., chiral centers). It is recognized that synthesis of
compounds according to the present invention may result in the
creation of mixtures of different stereoisomers (i.e., enantiomers
and diastereomers). Unless a particular stereochemistry is
specified, recitation of a compound is intended to encompass all of
the different possible stereoisomers.
[0797] Compounds according to the present invention can also be
prepared as their individual stereoisomers by reacting a racemic
mixture of the compound with an optically active resolving agent to
form a pair of diastereoisomeric compounds, separating the
diastereomers and recovering the optically pure enantiomer. While
resolution of enantiomers can be carried out using covalent
diastereomeric derivatives of compounds, dissociable complexes are
preferred (e.g., crystalline diastereoisomeric salts).
[0798] Compounds according to the present invention can also be
prepared as a pharmaceutically acceptable acid addition salt by
reacting the free base form of the compound with a pharmaceutically
acceptable inorganic or organic acid. Alternatively, a
pharmaceutically acceptable base addition salt of a compound can be
prepared by reacting the free acid form of the compound with a
pharmaceutically acceptable inorganic or organic base. Inorganic
and organic acids and bases suitable for the preparation of the
pharmaceutically acceptable salts of compounds are set forth in the
definitions section of this Application. Alternatively, the salt
forms of the compounds can be prepared using salts of the starting
materials or intermediates.
[0799] The free acid or free base forms of the compounds can be
prepared from the corresponding base addition salt or acid addition
salt form. For example, a compound in an acid addition salt form
can be converted to the corresponding free base by treating with a
suitable base (e.g., ammonium hydroxide solution, sodium hydroxide,
and the like). A compound in a base addition salt form can be
converted to the corresponding free acid by treating with a
suitable acid (e.g., hydrochloric acid, etc).
[0800] The N-oxides of compounds according to the present invention
can be prepared by methods known to those of ordinary skill in the
art. For example, N-oxides can be prepared by treating an
unoxidized form of the compound with an oxidizing agent (e.g.,
trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic
acid, meta-chloroperoxybenzoic acid, or the like) in a suitable
inert organic solvent (e.g., a halogenated hydrocarbon such as
dichloromethane) at approximately 0.degree. C. Alternatively, the
N-oxides of the compounds can be prepared from the N-oxide of an
appropriate starting material.
[0801] Compounds in an unoxidized form can be prepared from
N-oxides of compounds by treating with a reducing agent (e.g.,
sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride,
sodium borohydride, phosphorus trichloride, tribromide, or the
like) in an suitable inert organic solvent (e.g., acetonitrile,
ethanol, aqueous dioxane, or the like) at 0 to 80.degree. C.
[0802] Prodrug derivatives of the compounds can be prepared by
methods known to those of ordinary skill in the art (e.g., for
further details see Saulnier et al. (1994), Bioorganic and
Medicinal Chemistry Letters, Vol. 4, p. 1985). For example,
appropriate prodrugs can be prepared by reacting a non-derivatized
compound with a suitable carbamoylating agent (e.g.,
1,1-acyloxyalkylcarbonochloridate, para-nitrophenyl carbonate, or
the like).
[0803] Protected derivatives of the compounds can be made by
methods known to those of ordinary skill in the art. A detailed
description of the techniques applicable to the creation of
protecting groups and their removal can be found in P. G. M. Wuts
and T. W. Greene, "Greene's Protecting Groups in Organic
Synthesis", 4.sup.th edition, John Wiley & Sons, Inc. 2007.
[0804] Compounds according to the present invention may be
conveniently prepared, or formed during the process of the
invention, as solvates (e.g., hydrates). Hydrates of compounds of
the present invention may be conveniently prepared by
recrystallization from an aqueous/organic solvent mixture, using
organic solvents such as dioxin, tetrahydrofuran or methanol.
[0805] The present invention also provides
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl
oxime benzoate Form A. The formation of
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl
oxime benzoate Form A is generally carried out by crystallization
from a solvent. In practice suitable solvents include chloroform,
toluene, acetonitrile, and acetone. Anti-solvents, that is, a
solvent or solvents in which the compound is less soluble than in
the selected solvent can also be used. The volume of solvent is not
critical but should be kept to a minimal amount as a matter of
convenience. Optionally, the crystallization may be seeded with
Form A. Such processes generally require 2 hours to seven days. It
is understood that the terms "crystallize," "crystallizing,` and
"crystallization" to complete dissolution followed by precipitation
and slurry processes that do not involve complete dissolution.
[0806]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(S)-3,4-dihydroxybutyl oxime benzoate Form A can be
characterized by X-ray diffraction. A powder X-ray diffractogram of
Form A obtained by standard powder X-ray diffraction technique is
provided in FIG. 2. Standard powder diffractometers are generally
equipped with a copper source, primary beam monochromator, and
position sensitive detector. The incident beam is typically
collimated using a divergence slit to around 1.degree.. The source
generally operated at 40 kV and 30 mA. X-ray powder diffraction
data may be collected from 3 degrees to 120 degrees two theta using
a step width of 0.02 to 0.04 degrees two theta. The diffractometer
can be calibrated with a silicon standard or other suitable
standard materials. Many modern diffractometers are also equipped
with a goniometer head that can be motorized to permit spinning of
the sample during data acquisition. It is recognized that the
relative intensity of X-ray diffraction peaks can be dependent on
preferred orientation and other factors. Therefore, a sample of
Form A may require processing to mitigate such factors, such as
grinding the sample in an agate mortar and pestle or other
measures. It is understood that differences in relative intensity
of the diffraction peaks does not preclude an acquired pattern from
being consistent with
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl
benzoate Form A. Further it is also understood that only a subset
of the peaks shown in FIG. 2, in some instances as few as one peak,
are required to identify
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-met-
hyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(S)-3,4-dihydroxybutyl benzoate Form A.
[0807] Form A can also be characterized by thermal analysis,
typically differential scanning calorimetry (DSC) and
thermogravimetry. FIG. 3 shows DSC and thermogravimetry thermograms
of Form A. The DSC thermogram shows a single endothermic event at
128.degree. C. which was consistent with a melt.
[0808] As used herein the symbols and conventions used in these
processes, schemes and examples are consistent with those used in
the contemporary scientific literature, for example, the Journal of
the American Chemical Society or the Journal of Biological
Chemistry. Standard single-letter or three-letter abbreviations are
generally used to designate amino acid residues, which are assumed
to be in the L-configuration unless otherwise noted. Unless
otherwise noted, all starting materials were obtained from
commercial suppliers and used without further purification.
Specifically, the following abbreviations may be used in the
examples and throughout the specification:
TABLE-US-00002 .mu.L (microliters) Ac (acetyl) atm (atmosphere) ATP
(Adenosine Triphosphatase) BOC (tert-butyloxycarbonyl) BOP
(bis(2-oxo-3-oxazolidinyl)phosphinic chloride) BSA (Bovine Serum
Albumin) CBZ (benzyloxycarbonyl) CDI (1,1-carbonyldiimidazole) DCC
(dicyclohexylcarbodiimide) DCE (dichloroethane) DCM
(dichloromethane) DMAP (4-dimethylaminopyridine) DME
(1,2-dimethoxyethane) DMF (N,N-dimethylformamide) DMPU
(N,N'-dimethylpropyleneurea) DMSO (dimethylsulfoxide) EDCI
(ethylcarbodiimide hydrochloride) EDTA (Ethylenediaminetetraacetic
acid) Et (ethyl) Et.sub.2O (diethyl ether) EtOAc (ethyl acetate)
FMOC (9-fluorenylmethoxycarbonyl) g (grams) h (hours) HOAc or AcOH
(acetic acid) HOBT (1-hydroxybenzotriazole) HOSu
(N-hydroxysuccinimide) HPLC (high pressure liquid chromatography)
Hz (Hertz) i.v. (intravenous) IBCF (isobutyl chloroformate) i-PrOH
(isopropanol) L (liters) M (molar) mCPBA (meta-chloroperbenzoic
acid) Me (methyl) MeOH (methanol) mg (milligrams) MHz (megahertz)
min (minutes) mL (milliliters) mM (millimolar) mmol (millimoles)
mol (moles) MOPS (Morpholinepropanesulfonic acid) mp (melting
point) NaOAc (sodium acetate) OMe (methoxy) psi (pounds per square
inch) RP (reverse phase) r.t. (ambient temperature) SPA
(Scintillation Proximity Assay) TBAF (tetra-n-butylammonium
fluoride) TBS (t-butyldimethylsilyl) tBu (tert-butyl) TEA
(triethylamine) TFA (trifluoroacetic acid) TFAA (trifluoroacetic
anhydride) THF (tetrahydrofuran) TIPS (triisopropylsilyl) TLC (thin
layer chromatography) TMS (trimethylsilyl) TMSE
(2-(trimethylsilyl)ethyl) Tr (retention time) Brij35
(polyoxyethyleneglycol dodecyl ether)
[0809] All references to ether or Et.sub.2O are to diethyl ether;
and brine refers to a saturated aqueous solution of NaCl. Unless
otherwise indicated, all temperatures are expressed in .degree. C.
(degrees Centigrade). All reactions are conducted under an inert
atmosphere at r.t. unless otherwise noted.
[0810] .sup.1H NMR spectra were recorded on a Bruker Avance 400.
Chemical shifts are expressed in parts per million (ppm). Coupling
constants are in units of Hertz (Hz). Splitting patterns describe
apparent multiplicities and are designated as s (singlet), d
(doublet), t (triplet), q (quartet), m (multiplet), br (broad).
[0811] Low-resolution mass spectra (MS) and compound purity data
were acquired on a Waters ZQ LC/MS single quadrupole system
equipped with electrospray ionization (ESI) source, UV detector
(220 and 254 nm), and evaporative light scattering detector (ELSD).
Thin-layer chromatography was performed on 0.25 mm E. Merck silica
gel plates (60F-254), visualized with UV light, 5% ethanolic
phosphomolybdic acid, Ninhydrin or p-anisaldehyde solution. Flash
column chromatography was performed on silica gel (230-400 mesh,
Merck).
[0812] The starting materials and reagents used in preparing these
compounds are either available from commercial suppliers such as
the Aldrich Chemical Company (Milwaukee, Wis.), Bachem (Torrance,
Calif.), Sigma (St. Louis, Mo.), or may be prepared by methods well
known to a person of ordinary skill in the art, following
procedures described in such standard references as Fieser and
Fieser's Reagents for Organic Synthesis, vols. 1-23, John Wiley and
Sons, New York, N.Y., 2006; Rodd's Chemistry of Carbon Compounds,
vols. 1-5 and supps., Elsevier Science Publishers, 1998; Organic
Reactions, vols. 1-68, John Wiley and Sons, New York, N.Y., 2007;
March J.: Advanced Organic Chemistry, 5th ed., 2001, John Wiley and
Sons, New York, N.Y.; and Larock: Comprehensive Organic
Transformations, 2.sup.nd edition, John Wiley and Sons, New York,
1999. The entire disclosures of all documents cited throughout this
application are incorporated herein by reference.
[0813] Various methods for separating mixtures of different
stereoisomers are known in the art. For example, a racemic mixture
of a compound may be reacted with an optically active resolving
agent to form a pair of diastereoisomeric compounds. The
diastereomers may then be separated in order to recover the
optically pure enantiomers. Dissociable complexes may also be used
to resolve enantiomers (e.g., crystalline diastereoisomeric salts).
Diastereomers typically have sufficiently distinct physical
properties (e.g., melting points, boiling points, solubilities,
reactivity, etc.) and can be readily separated by taking advantage
of these dissimilarities. For example, diastereomers can typically
be separated by chromatography or by separation/resolution
techniques based upon differences in solubility. A more detailed
description of techniques that can be used to resolve stereoisomers
of compounds from their racemic mixture can be found in Jean
Jacques, Andre Collet, and Samuel H. Wilen, Enantiomers, Racemates
and Resolutions, John Wiley & Sons, Inc. (1981).
[0814] Diastereomers have distinct physical properties (e.g.,
melting points, boiling points, solubilities, reactivity, etc.) and
can be readily separated by taking advantage of these
dissimilarities. The diastereomers can be separated by
chromatography or, preferably, by separation/resolution techniques
based upon differences in solubility. The optically pure enantiomer
is then recovered, along with the resolving agent, by any practical
means that would not result in racemization. A more detailed
description of the techniques applicable to the resolution of
stereoisomers of compounds from their racemic mixture can be found
in Jean Jacques, Andre Collet, and Samuel H. Wilen, Enantiomers,
Racemates and Resolutions, John Wiley & Sons, Inc. (1981).
[0815] Chiral components can be separated and purified using any of
a variety of techniques known to those skilled in the art. For
example, chiral components can be purified using supercritical
fluid chromatography (SFC). In one particular variation, chiral
analytical SFC/MS analyses are conducted using a Berger analytical
SFC system (AutoChem, Newark, Del.) which consists of a Berger SFC
dual pump fluid control module with a Berger FCM 1100/1200
supercritical fluid pump and FCM 1200 modifier fluid pump, a Berger
TCM 2000 oven, and an Alcott 718 autosampler. The integrated system
can be controlled by BI-SFC Chemstation software version 3.4.
Detection can be accomplished with a Waters ZQ 2000 detector
operated in positive mode with an ESI interface and a scan range
from 200-800 Da with 0.5 second per scan. Chromatographic
separations can be performed on a ChiralPak AD-H, ChiralPak AS-H,
ChiralCel OD-H, or ChiralCel OJ-H column (5.mu.4.6.times.250 mm;
Chiral Technologies, Inc. West Chester, Pa.) with 10 to 40%
methanol as the modifier and with or without ammonium acetate (10
mM). Any of a variety of flow rates can be utilized including, for
example, 1.5 or 3.5 mL/min with an inlet pressure set at 100 bar.
Additionally, a variety of sample injection conditions can be used
including, for example, sample injections of either 5 or 10 .mu.L
in methanol at 0.1 mg/mL in concentration.
[0816] In another variation, preparative chiral separations are
performed using a Berger MultiGram II SFC purification system. For
example, samples can be loaded onto a ChiralPak AD column
(21.times.250 mm, 10.mu.). In particular variations, the flow rate
for separation can be 70 mL/min, the injection volume up to 2 mL,
and the inlet pressure set at 130 bar. Stacked injections can be
applied to increase the efficiency.
[0817] Descriptions of the syntheses of particular compounds
according to the present invention based on the above reaction
schemes and variations thereof are set forth in the Example
section.
Assaying the Biological Activity of the Compounds of the
Invention
[0818] The inhibitory effect of the compound of the invention on
HSP90 may be evaluated by a variety of binding assays and
functional assays. It is well known that binding to the N-terminal
ATP-binding domain of HSP90 inhibits ATP binding and ATP-dependent
chaperone activities, Roe et al. J. Med. Chem. 1999 42, 260-266. A
variety of in vitro and in vivo binding assays are available in the
literature for assessing the affinity of the compounds of the
invention on HSP90; e.g., Chiosis et al. Chemistry & Biology
2001 8: 289-299, Carreras et al. Anal Biochem 2003 317(1): 40-6;
Kim et al. J Biomol Screen 20049(5): 375-81; and Zhou et al. Anal
Biochem 2004 331(2): 349-57.
[0819] Example A-1 below provides an in vitro competition
fluorescence polarization assay in which a test compound competes
with a fluorescent probe for binding to the binding domain of human
recombinant HSP90. The reaction can be followed kinetically using
fluorescence (excitation .lamda.=485 nm; emission .lamda.=538 nm).
The binding affinity of the test compound to HSP90 is determined by
the changes in the polarized fluorescence; the intensity of the
polarized fluorescence is proportional to the fraction of bound
probe. A novel small molecule fluorescence probe,
(S,E)-5-(2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-
-methyl-7,8-dihydroquinazolin-5(6H)-ylideneaminooxy)ethylcarbamoyl)-2-(6-h-
ydroxy-3-oxo-3H-xanthene-9-yl)benzoic acid (TSD-FP probe) was
specifically developed for the assay. Inhibition constants
(IC.sub.50) may be calculated by non-linear curve fitting of the
compound concentrations and fluorescence intensities to the
standard IC.sub.50 equation. As reference, the IC.sub.50 values by
this assay for the two known HSP90 inhibitors geldanamycin (GM) and
17-allylamino, 17-demethoxygeldanamycin (17-AAG) after one hour
incubation with the enzyme and the TSD-FP probe were 90 nM and 400
nM, respectively. Using the procedure described in Example A-1,
some of the exemplified compounds were shown to have HSP90 binding
affinity at an IC.sub.50 of less than 10 .mu.M, some others less
than about 1 .mu.M, and most others of the compounds have an
IC.sub.50 value of less than about 0.1 .mu.M. The IC.sub.50 values
of the exemplified compounds of the present invention are given in
Table 1.
[0820] The inhibitory effect of the compounds of the invention
against HSP90 in live cells may be evaluated by measuring cell
viability. Example A-2 described a cell viability assay where
exponentially growing tumor cells were exposed to a range of drug
concentrations. After the drug treatment, the viability of the
cells was measured by the conversion of tetrazolium salts MTS
(3-[4,5,dimethylthiazol-2-yl]-5-[3-carboxymethoxy-phenyl]-2-[4-sulfopheny-
l]-2H-tetrazolium, inner salt), (Promega, Madison, Wis.) by
metabolically active cells. Further, the selected cancer cell panel
includes BT-474, HT-29, K-562, and MKN-45 cells each of which
represents a different cancer type and a well understood route of
oncogenic transformation.
[0821] Downstream effects of HSP90 inhibition can be evaluated
based on the induction of HSP70 and on the function and stability
of various steroid receptors and signaling proteins including,
e.g., HER2/ERBB2. HSP70 induction is a hallmark of HSP90
inhibition. HSP70 as an ATP dependent heat shock protein itself
will be transcriptionally up-regulated in response to misfolded,
denatured or aggregated proteins. As HSP90 function becomes
compromised, HSP70 is induced in direct response to HSP90 client
protein changes within the cell. Guo et al. Cancer Res 2005 65(22)
10536. Example A-3 provides a method to quantify HSP70 induction by
monitoring the non-infrared luminescence of P-galactosidase, and
determine the EC.sub.50 values of the test compounds for
HSP70.beta./.beta.-galactosidase induction.
[0822] The depletion of HER-2/ERBB2 oncoprotein is also a hallmark
of HSP90 inhibition. Sain et al. Mol Cancer Ther 2006 5(5) 1197;
Sharp et al. Mol Cancer Ther 2007 6(4) 1198. HER-2 uses HSP90 for
maturation; perturbations in HSP90 function lead to misfolded
proteins that ultimately will be sent for ubiquitination and
proteasomal degradation. Compounds of the present invention induce
degradation of these molecules, which can be measured using well
known antibody techniques such as immunoblotting,
radioimmunoassays, Western blotting, immunoprecipitation,
enzyme-linked immunosorbant assays (ELISA), and derivative
techniques that make use of antibodies directed against HER2.
Example A-4 provides a Western blotting procedure for the
determination of the EC.sub.50 value of the test compounds for
depletion of HER2/ERBB2.
[0823] It will be apparent to those skilled in the art that various
modifications and variations can be made in the compounds,
compositions, kits, and methods of the present invention without
departing from the spirit or scope of the invention. Thus, it is
intended that the present invention cover the modifications and
variations of this invention provided they come within the scope of
the appended claims and their equivalents.
Example
Example 1
General Procedure for the Preparation of Oxime Ethers and
Analogs
##STR00163## ##STR00164##
[0824] A. (E)-4-(2-Bromo-4-fluorophenyl)but-3-en-2-one (1B)
[0825] To a 500 mL recovery flask was added
2-bromo-4-fluorobenzaldehyde (1A, 10.0 g, 49.3 mmol, 1.0 eq.) and
acetone (22.9 g, 394 mmol, 8.0 eq.). The mixture was cooled to
0.degree. C. in an ice bath. H.sub.2O (200 mL) was added and the
mixture became a thick suspension. Solid NaOH (2.16 g, 54.2 mmol,
1.1 eq.) was added and the reaction was gradually warmed to room
temperature and stirred overnight. The reaction was acidified with
1N HCl and extracted with EtOAc (3.times.100 mL). The organic
phases were combined and washed with saturated aqueous NaCl. The
organic phase was dried over anhydrous Na.sub.2SO.sub.4, filtered,
and concentrated to give a dark yellow oil that was carried on to
the next step without further purification (11.9 g, 99%). ESI-MS:
m/z 243.2 (M+H).sup.+.
B. 5-(2-Bromo-4-fluorophenyl)-3-hydroxycyclohex-2-enone (1D)
[0826] To a 500 mL recovery flask was added
(E)-4-(2-bromo-4-fluorophenyl)but-3-en-2-one (1B, 11.9 g, 49.0
mmol, 1.0 eq.) and MeOH (200 mL). Dimethyl malonate (1C, 6.47 g,
49.0 mmol, 1.0 eq.) was added, followed by NaOMe (30% wt in MeOH,
9.6 mL, 51.4 mmol, 1.05 eq.). The reaction mixture was refluxed
overnight upon which it was concentrated to a brownish-red solid.
The residue was taken up in 1N NaOH (150 mL) and refluxed for 1 h,
during which the reaction color proceeded from cloudy-brown, to
clear brown, to clear solution with brown precipitate. Concentrated
HCl was carefully added until the mixture was acidic by pH paper.
The reaction mixture was diluted with EtOAc (200 mL) and washed
with saturated aqueous NaCl. The aqueous phase was extracted with
EtOAc (1.times.75 mL). The organic phase was dried over anhydrous
Na.sub.2SO.sub.4, filtered, and concentrated to give a foamy orange
solid that was carried on to the next step without further
purification (14.3 g, 100%). ESI-MS: m/z 285.2 (M+H).sup.+.
C.
5-(2-Bromo-4-fluorophenyl)-2-(1-hydroxyethylidene)cyclohexane-1,3-dione
(1E)
[0827] To a 500 mL recovery flask was added
5-(2-bromo-4-fluorophenyl)-3-hydroxycyclohex-2-enone (1D) (14.3 g,
50.1 mmol, 1.0 eq.), CH.sub.2Cl.sub.2 (200 mL), acetic anhydride
(6.65 g, 65.2 mmol, 1.3 eq.), Et.sub.3N (15.22 g, 150 mmol, 3.0
eq.), and DMAP (catalytic amount). The reaction mixture was stirred
overnight at room temperature. Monitoring by LC/MS judged the
reaction to be complete. The reaction mixture was concentrated and
purified via column chromatography (gradient 70%
CH.sub.2Cl.sub.2/Hex to 100% CH.sub.2Cl.sub.2) to yield the product
as light yellow foam which later became an oil (3.55 g, 22%). The
crude material was used in the next step without further
purification. ESI-MS: m/z 327.2 (M+H).sup.+.
D.
2-Amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-
-one (1F)
[0828] To a 150 mL pressure vessel was added
5-(2-bromo-4-fluorophenyl)-2-(1-hydroxyethylidene)cyclohexane-1,3-dione
(1E, 1.12 g, 3.42 mmol, 1.0 eq.), EtOH (30 mL), guanidine
hydrochloride (818 mg, 8.56 mmol, 2.5 eq.), and dimethylamine (2.0
M in THF, 10 mL, 20.5 mmol, 6.0 eq.). The vessel was sealed and
heated for 72 hours at 100.degree. C. LC/MS determined the reaction
to be complete. The reaction was cooled and concentrated to give a
pasty gray solid. EtOH (.about.10 mL) was added to the residue and
sonicated to give a suspension. The solid was collected by
filtration and rinsed with cold EtOH to give a light-yellow solid
(288 mg, 24%). ESI-MS: m/z 350.2 (M+H).sup.+.
E.
2-Amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihydr-
oquinazolin-5(6H)-one (1H)
[0829] To a 10 mL recovery flask was added
2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-o-
ne (33 mg, 0.0942 mmol, 1.0 eq.), 2-fluoropyridine-3-boronic acid
(27 mg, 0.188 mmol, 2.0 eq.), DME (2 mL), potassium carbonate (2.0M
aq., 94 .mu.L, 0.188 mmol, 2.0 eq.), and palladium tetrakis
triphenylphosphine (5 mg, 0.00471 mmol, 0.05 eq.). The reaction was
refluxed overnight whereupon LC/MS analysis judged the reaction to
be complete. The reaction mixture was filtered through Celite and
concentrated to a residue. The residue was purified via
preparatory-HPLC to give the product white solid (30 mg, 96%).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.67 (dd, J=3.54,
1.77 Hz, 1H) 2.89 (br. s., 1H) 3.06 (t, J=12.51 Hz, 2H) 3.18 (br.
s., 1H) 7.18 (dd, J=9.60, 2.78 Hz, 1H) 7.31-7.53 (m, 4H) 7.72 (dd,
J=8.84, 5.81 Hz, 1H) 7.98 (ddd, J=9.79, 7.52, 1.89 Hz, 1H) 8.28 (d,
J=4.80 Hz, 1H). ESI-MS: m/z 367.3 (M+H).sup.+. ESI-MS: m/z 367.3
(M+H).sup.+.
F. Formation of Oxime Ethers
[0830] Oxime ethers may be formed by either Method A or Method B
below.
[0831] Method A, basic conditions: A solution of
2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihydroq-
uinazolin-5(6H)-one (1H, 0.27 mmol, 1.0 eq.) and the corresponding
hydroxylamine 1I (0.54 mmol, 2.0 eq.) in dry pyridine (2 mL) were
stirred overnight at 75.degree. C. The mixture was poured into ice
water and the resulting precipitate was collected by filtration.
The crude solid was recrystallized in hot ethanol to yield pure
product 1J as a white solid in 90% yield.
[0832] Method B, acidic conditions: A solution of
2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihydroq-
uinazolin-5(6H)-one (1H, 0.27 mmol, 1.0 eq.) in EtOH (3 mL) was
stirred under nitrogen. The corresponding hydroxylamine 1I (0.35
mmol, 1.3 eq.) and aqueous HCl (5M, 0.48 mmol, 1.8 eq.) were added
and the reaction was heated to reflux for 4 h. The reaction mixture
was cooled to room temperature and concentrated. The resulting
residue was collected and recrystallized in hot ethanol to obtain
pure product 1J as a white or off-white powder in about 90%
yield.
Example 2
Preparation of Hydroxylamine Reagents
A. Synthesis of O-(2-methoxyethyl)hydroxylamine (2B)
##STR00165##
[0834] Step 1: 2-methoxyethanol (2.00 g, 26.3 mmol),
N-hydroxyphthalimide (4.72 g, 28.9 mmol, 1.1 eq., and
triphenylphosphine (7.58 g, 28.9 mmol, 1.1 eq.) were dissolved in
85 mL of dry THF and then the mixture was cooled in an ice bath.
Diisopropyl azodicarboxylate (6.91 g, 34.2 mmol, 1.3 eq.) was
dissolved in 15 mL of dry THF and was added slowly to the above
mixture. The reaction was stirred in the ice bath for 10 minutes
and then the ice bath was removed. The reaction then was allowed to
stir at room temperature under N.sub.2 overnight. The reaction was
done by LC/MS and was concentrated to an oil. It was then purified
by flash column chromatography using hexane/ethyl acetate 70/30 to
give 2-(2-methoxyethoxy)isoindoline-1,3-dione (2A, 5.19 g, 89.2%
yield). ESI-MS: m/z 222.3 (M+H).sup.+.
[0835] Step 2: 2-(2-methoxyethoxy) isoindoline-1,3-dione (5.18 g,
23.4 mmol) was dissolved in 50 mL of ethanol and hydrazine hydrate
(22.7 mL, 468 mmol). The solution was heated for 2 hours in a
80.degree. C. oil bath. The reaction was then cooled to room
temperature and a solid precipitated out. This solid was then
filtered and the filtrate was concentrated and purified on flash
column chromatography using chloroform/methanol 98/2 to give
O-(2-methoxyethyl) hydroxylamine (2B, 0.866 g, 36.2% yield).
.sup.1H NMR (400 MHz, MeOD) .delta. ppm 3.36 (s, 3H) 3.52-3.59 (m,
2H) 3.73-3.85 (m, 2H).
B. Synthesis of O-(3-methoxypropyl)hydroxylamine(2D)
##STR00166##
[0837] 2-(3-Methoxypropoxy)isoindoline-1,3-dione (2C) was prepared
from 3-methoxypropan-1-ol and N-hydroxyphthalimide by a procedure
analogous to Example 2A, Step 1 (3.71 g, 94.9% yield). ESI-MS: m/z
236.3 (M+H).sup.+.
[0838] 2C was deprotected as described in Example 2A, Step 2 to
yield O-(3-methoxypropyl)hydroxylamine (2D, 0.633 g, 38.1% yield).
.sup.1H NMR (400 MHz, MeOD) .delta. ppm 1.81 (t, J=6.32 Hz, 2H)
3.31 (s, 3H) 3.45 (t, J=6.32 Hz, 2H) 3.70 (t, J=6.32 Hz, 2H).
ESI-MS: m/z 106.4 (M+H).sup.+.
C. Synthesis of tert-butyl 2-(aminooxy)ethylcarbamate (2F)
##STR00167##
[0840] tert-Butyl 2-(1,3-dioxoisoindolin-2-yloxy)ethylcarbamate 2E
was prepared with quantitative yield from tert-butyl
2-hydroxyethylcarbamate and N-hydroxyphthalimide by a procedure
analogous to Example 2A, Step 1. ESI-MS: m/z 329.3
(M+Na).sup.+.
[0841] 2E was deprotected as previously described in 2A, Step 2 to
give tert-butyl 2-(aminooxy)ethylcarbamate (2F, 1.26 g, 58% yield).
.sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 1.45 (s, 9H) 3.37
(q, J=5.31 Hz, 2H) 3.62-3.85 (m, 2H) 4.90 (br. s., 1H) 5.47 (br.
s., 2H).
D. Synthesis of O-(pyridine-3-ylmethyl)hydroxylamine (2H)
##STR00168##
[0843] Phthalimide-protected intermediate 2G was prepared from
pyridin-3-ylmethanol and N-hydroxyphthalimide by a procedure
analogous to Example 2A, Step 1 (3.22 g, 81.3% yield). ESI-MS: m/z
255.2 (M+H).sup.+.
[0844] 2G was deprotected as previously described in Example 2A,
Step 2 to give O-(pyridine-3-ylmethyl)hydroxylamine (2H, 0.734 g,
69.2% yield). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 4.71
(s, 2H) 7.44 (dd, J=7.83, 5.05 Hz, 1H) 7.85 (d, J=7.83 Hz, 1H) 8.47
(dd, J=5.05, 1.26 Hz, 1H) 8.53 (d, J=2.27 Hz, 1H). ESI-MS: m/z
125.3 (M+H).sup.+.
2E. Synthesis of (R)--O-((1,4-dioxan-2-yl)methyl)hydroxylamine
(2M)
##STR00169##
[0846] Step 1: 2-chloroethanol (34.8 g, 43.2 mmol) and boron
trifluoride diethyl etherate (0.136 mL, 1.08 mmol) were dissolved
in 20 mL of THF and cooled in an ice bath. (R)-(-)-epichlorohydrin
(10.0 g, 10.8 mmol) in 10 mL of THF was added slowly through a
syringe. After the addition, the ice bath was removed and the
mixture was heated in a 45.degree. C. oil bath for 90 min at which
time the reaction was complete. The reaction was concentrated in
vacuo to give an oily crude product
(R)-1-chloro-3-(2-chloroethoxy)propan-2-ol (2I, 16.2 g, 86.6%
yield). .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 3.56-3.71
(m, 6H) 3.85-3.92 (m, 3H).
[0847] Step 2: 2I (16.2 g, 93.6 mmol) was dissolved in 45 mL of THF
and was cooled in an ice bath. Sodium hydroxide (9.36 g, 234 mmol)
in 20 mL of water was added dropwise and the reaction was stirred
in the ice bath for 15 min, and at room temperature for 6 h. The
reaction mixture was diluted with ethyl acetate and saturated
sodium chloride solution. The product was extracted into ethyl
acetate layer three times. The combined organic layers was then
washed with saturated sodium chloride solution, dried over sodium
sulfate and concentrated to a crude oily product,
(S)-2-((2-chloroethoxy)methyl)oxirane (2J, 11.1 g, 86.7% yield.
.sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 2.57-2.72 (m, 2H)
2.76-2.89 (m, 2H) 3.08-3.25 (m, 2H) 3.45 (dd, J=12.25, 5.68 Hz, 1H)
3.51-3.70 (m, 2H).
[0848] Step 3: 2J (11.1 g, 81.3 mmol) was dissolved in 50 mL of
THF. Sodium hydroxide (16.3 g, 406 mmol) in 50 mL of water was
added and the reaction was heated in a 90.degree. C. oil bath for
one day. Despite the TLC showing the reaction to be only half
completed the product was extracted from the aqueous layer with
ethyl acetate/THF, dichloromethane, n-butanol. The first two
extractions contained product and the starting material, which was
later purified by flash column (ethyl acetate/hexane 30/70). The
latter extractions contained pure (S)-(1,4-dioxan-2-yl)methanol
(2K, 1.98 g, 20.8% yield). .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta. ppm 3.47 (t, J=9.98 Hz, 1H) 3.51-3.67 (m, 3H) 3.67-3.87 (m,
5H).
[0849] Step 4: 2K (1.33 g, 11.2 mmol), N-hydroxyphthalimide (2.02
g, 12.4 mmol), triphenylphosphine (3.25 g, 12.4 mmol) were
dissolved in 30 mL of dry THF and the mixture was cooled in an ice
bath. Diisopropyl azodicarboxylate (2.51 g, 12.4 mmol) in 5 mL of
THF was added to the above mixture dropwise. After the addition was
complete, the ice bath was removed and the reaction was stirred at
room temp overnight. Next day, the reaction was done. It was
concentrated in vacuo to an oil and then purified on flash column
chromatography using ethyl acetate/hexane 20/80 to give
(R)-2-((1,4-dioxan-2-yl)methoxy)isoindoline-1,3-dione (2L).
[0850] .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 3.56 (t,
J=10.74 Hz, 1H) 3.60-3.85 (m, 4H) 3.92 (dd, J=11.75, 2.40 Hz, 1H)
4.05 (ddd, J=9.98, 3.03, 2.91 Hz, 1H) 4.11-4.19 (m, 1H) 4.20-4.29
(m, 1H) 7.71-7.80 (m, 2H) 7.81-7.91 (m, 2H).
[0851] Step 5: 2L (4.30 g, 12.4 mmol) was dissolved in 90 mL of
methanol/dichloromethane 1/9 ratio. Hydrazine hydrate (1.67 mL,
22.4 mmol) was added and the reaction was stirred at room
temperature for 2 h at which time the deprotection was done. The
precipitate byproduct was filtered, and the filtrate was
concentrated down to an oil and then purified by flash column
chromatography, using chloroform/methanol 99/1 ratio to yield
(R)--O-((1,4-dioxan-2-yl)methyl)hydroxylamine (2M, 0.915 g, 61.4%
yield over 2 steps). .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta.
ppm 3.41 (t, J=10.86 Hz, 1H) 3.57-3.71 (m, 4H) 3.71-3.82 (m, 3H)
3.83-3.92 (m, 1H) 5.55 (br. s., 2H).
F. Synthesis of (S)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethanamine
(2O)
##STR00170##
[0853] (S)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethanamine (20) was
prepared from (S)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethanol (2N)
using a literature procedure (Tetrahedron Lett, 2005, 46,
5475-5478).
G. Synthesis of
(R)--O-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)hydroxylamine
(2P)
##STR00171##
[0855] The title compound was prepared according to Bailey et al.,
J. Med. Chem., 1991, 34, 51-65.
2H. Synthesis of
(S)--O-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)hydroxylamine
(2Q)
##STR00172##
[0857] The title compound was prepared according to Bailey et al.,
J. Med. Chem., 1991, 34, 51-65.
2I. Synthesis of
O-((2,2-dimethyl-1,3-dioxan-5-yl)methyl)hydroxylamine (2R)
##STR00173##
[0859] The title compound was prepared according to Harnden et al,
J. Med. Chem., 1990, 33, 187-196.
J. Synthesis of tert-butyl
2-(aminooxymethyl)morpholine-4-carboxylate (2T)
##STR00174##
[0861] To a solution of tert-butyl
2-(hydroxymethyl)morpholine-4-carboxylate (5 g, 23 mmol) in
CH.sub.2Cl.sub.2 (250 mL) was added 2-hydroxyisoindolin-1,3-dione
(5.6 g, 34.5 mmol) and triphenylphosphine (15 g, 57.5 mmol). The
resultant mixture was cooled to 0.degree. C. and diisopropyl
azodicarboxylate (11.1 ml, 57.5 mmol) was slowly added dropwise
with an addition funnel under N.sub.2 atmosphere. The reaction
mixture was stirred at ambient temperature for 48 h. To the
reaction mixture H.sub.2O (300 mL) was added and extracted with
CH.sub.2Cl.sub.2. The organic layers were washed with brine. Dried
over anhydrous MgSO.sub.4, filtered and concentrated to provide
clear oil, which was purified by flash chromatography (50%
EtOAc-Hexane). The resultant clear oily compound 2S was dissolved
in CHCl.sub.3:CH.sub.3OH (50 ml). Hydrazine hydrate (25 mL, 0.25
mol) was added. The reaction mixture was stirred at ambient
temperature overnight. The resultant solid was filtered off and the
filtrate concentrated under reduced pressure to provide a clear
oil, which was purified by flash chromatography (10%
CH.sub.3OH--CH.sub.2Cl.sub.2) to afford 3 g (56%, over two steps)
of tert-butyl 2-(aminooxymethyl)morpholine-4-carboxylate (2T) as a
clear oil. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 1.47 (s,
9H) 3.46-3.62 (m, 2H) 3.61-3.79 (m, 4H) 3.79-4.04 (m, 3H). [M+H]
calc'd for C.sub.10H.sub.20N.sub.2O.sub.4, 233; found, 233.
K Synthesis of
(S)--O-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)hydroxylamine
(2W)
##STR00175##
[0863] To a solution of
(S)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethanol (14.2 mL, 0.1 mol) in
CH.sub.2Cl.sub.2 (250 mL) was added 2-hydroxyisoindolin-1,3-dione
(16.3 g, 0.1 mol) and triphenylphosphine (39.3 g, 0.15 mol). The
resultant mixture was cooled to 0.degree. C. and
diisopropylazodicarboxylate (29.5 ml, 0.15 mol) was slowly added
drop wise with an addition funnel under N.sub.2 atmosphere. The
reaction mixture was stirred at ambient temperature for 48 h. To
the reaction mixture, H.sub.2O (300 mL) was added and the mixture
extracted with CH.sub.2Cl.sub.2. The organic layers washed with
brine. Dried over anhydrous MgSO.sub.4, filtered and concentrated
to provide a yellow oil, which was purified by flash chromatography
(50% EtOAc-hexane) to yield 2U as a light yellow oil.
[0864] 2U was dissolved in CH.sub.2Cl.sub.2 (250 ml) and cooled to
0.degree. C. Hydrazine hydrate (25 mL, 0.25 mol) was added drop
wise through an addition funnel. The reaction mixture was stirred
at ambient temperature over night. The resultant solid was filtered
off and the filtrate concentrated under reduced pressure to provide
a yellow oil, which was purified by flash chromatography (70%
EtOAc-hexane) to afford 7.2 g (45%, over two steps) of
(S)--O-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)hydroxylamine (2W)
as a pale yellow oil. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta.
ppm 1.13 (s, 3H), 1.18 (s, 3H), 1.53-1.71 (m, 2H), 3.53 (q, J=6.48
Hz, 2H), 3.79-3.89 (m, 1H), 3.89-4.01 (m, 1H), 4.63-4.81 (m, 1H).
MS (ES) [M+H] calculated for C.sub.7H.sub.16NO.sub.3, 162.11; found
162.0.
2L Synthesis of
(R)--O-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)hydroxylamine
(2X)
##STR00176##
[0866] The title compound was prepared using the procedure
described for Example 2K by using
(R)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethanol (4.28 mL, 30 mmol),
CH.sub.2Cl.sub.2 (100 mL), 2-hydroxyisoindolin-1,3-dione (4.9 g, 30
mmol), triphenylphosphine (11.8 g, 45 mmol),
diisopropylazodicarboxylate (8.8 ml, 45 mmol) and hydrazine hydrate
(6.0 mL, 60 mmol) to afford 2.1 g (43%, over two steps) of
(R)--O-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)hydroxylamine
(2.times.) as a pale yellow oil. .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 1.13 (s, 3H), 1.18 (s, 3H), 1.53-1.71 (m,
2H), 3.53 (m, 2H), 3.79-3.89 (m, 1H), 3.89-4.01 (m, 1H), 4.63-4.81
(m, 1H). MS (ES) [M+H] calculated for C.sub.7H.sub.16NO.sub.3,
162.11; found 162.0.
2M. Synthesis of
O-(((3aR,4R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-
-yl)methyl)hydroxylamine (2Y)
##STR00177##
[0868] The title compound was prepared using the procedure
described for Example 2K by using
((3aR,4R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl-
)methanol (2.04 g, 10 mmol), CH.sub.2Cl.sub.2 (25 mL),
2-hydroxyisoindolin-1,3-dione (2.0 g, 12 mmol), triphenylphosphine
(4.0 g, 15 mmol), diisopropylazodicarboxylate (3.0 ml, 15 mmol) and
hydrazine hydrate (2.0 mL, 20 mmol) to afford 1.12 g of
O-(((3aR,4R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-
-yl)methyl)hydroxylamine (2Y) (50%, over two steps) as a pale
yellow oil. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 1.24
(s, 3H) 1.26 (s, 3H) 3.31 (s, 3H) 3.59-3.75 (m, 2H) 4.44 (t, J=7.20
Hz, 1H) 4.56 (d, J=5.81 Hz, 1H) 4.67 (d, J=6.06 Hz, 1H) 4.92-5.00
(m, 1H). MS (ES) [M+H] calculated for C.sub.9H.sub.18NO.sub.5,
220.11; found 220.10.
Example 3
Chiral Separation of Racemic Mixture of
2-Amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-o-
ne (1F.sup.a and 1F.sup.b)
##STR00178##
[0870] Dihydroquinazolinone 1F (Example 1) was separated into its
enantiomers by supercritical fluid chromatography (SFC) under the
following conditions: [0871] Column: ChiralPak IA, 250.times.10 mm,
5 .mu.m [0872] Mobile Phase: [0873] A: CO.sub.2 (1) [0874] B: MeOH
[0875] Gradient Condition: 20% MeOH [0876] Run Time: 12 min [0877]
Flow Rate: 20 mL/min [0878] Injection volume: 800 .mu.L
[0879] Total yield for the two enantiomers was 82% of the original
amount of the racemic mixture. The yield for
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydroquinazolin-5(6-
H)-one (1F.sup.a) was 45%. The yield for
(S)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydroquinazolin-5(6-
H)-one (1F.sup.b) was 37%.
Example 4
Chiral Separation of
2-Amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihydroq-
uinazolin-5(6H)-one (1H.sup.a and 1H.sup.b)
##STR00179##
[0881] Dihydroquinazolinone 1H (Example 1) was separated into its
enantiomers, 1H.sup.a and 1H.sup.b, by supercritical fluid
chromatography (SFC) under the following conditions: [0882] Column:
ChiralPak AD-H, 250.times.2 mm, 5 .mu.m [0883] Mobile Phase: [0884]
A: CO.sub.2 (1) [0885] B: MeOH [0886] Gradient condition: 30% MeOH
[0887] Run Time: 10 min [0888] Flow Rate: 50 mL/min [0889]
Injection volume: 1000 .mu.L
[0890] Total yield for the two enantiomers was 68% of the original
amount of the racemic mixture. The yield for
(R)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one (1H.sup.a) was 36%. The yield for
(S)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one (1H.sup.b) was 32%.
Example 5
Preparation of
(E)-2-Amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-methyl oxime (Compound 1)
##STR00180##
[0892] Compound 1 was prepared as a white or off-white powder (90%)
according to the procedure analogous to Example 1 using
O-methylhydroxylamine. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta.
ppm 2.58-2.68 (m, 5H), 2.78-2.88 (m, 3H), 5.02 (s, 2H), 6.92 (dd,
1H), 7.17 (td, 1H), 7.29 (m, 1H), 7.40 (dd, 1H), 7.67 (t, 1H), 8.25
(d, 1H). ESI-MS: m/z 396.1 (M+H).sup.+.
Example 6
Chiral Separation of R and S Enantiomers of
(E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-methyl oxime (Compound 2 and Compound
3)
##STR00181##
[0894] Racemic mixture of Compound 1 was separated into its R and S
enantiomers, Compound 2 and Compound 3, by SFC under the following
conditions: [0895] Column: ChiralPak IA, 250.times.21 mm, 5 .mu.m
[0896] Mobile Phase: [0897] A: CO.sub.2 (1) [0898] B: EtOH [0899]
Gradient condition: 40% EtOH [0900] Runtime: 8 min [0901] Flow
Rate: 50 mL/min [0902] Injection volume: 1000 .mu.L
[0903] Total yield for the two enantiomers was 45%. Yield for
(R,E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-di-
hydroquinazolin-5(6H)-one O-methyl oxime (1) was 23%. Yield for
(S,E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-di-
hydroquinazolin-5(6H)-one (2) was 22%.
Example 7
Preparation of
(E)-2-Amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-allyl oxime (Compound 4)
##STR00182##
[0905] Compound 4 was prepared as a white or off-white powder (90%)
according to the procedure described in Example 1 using
O-allylhydroxylamine. The R and S enantiomers of Compound 4 may be
obtained by SFC using a procedure analogous to Example 6. .sup.1H
NMR (300 MHz, CDCl.sub.3) .delta. ppm 2.58 (m, 5H), 2.82 (m, 3H),
4.60 (s, 2H), 4.97 (s, 2H), 5.19-5.23 (m, 2H), 5.99 (s, 1H), 6.92
(dd, 1H), 7.17 (td, 1H), 7.27 (m, 1H), 7.41 (dd, 1H), 7.69 (m, 1H),
8.23 (s, 1H). ESI-MS: m/z 422.1 (M+H).sup.+.
Example 8
Preparation of
(E)-2-Amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-tert-butyl oxime (Compound 5)
##STR00183##
[0907] Compound 5 was prepared as a white or off-white powder (90%)
according to a procedure described in Example 1 using
O-tert-butylhydroxylamine. The R and S enantiomers of Compound 5
may be obtained by SFC using a procedure analogous to Example 6.
.sup.1H NMR (300 MHz, CDCl.sub.3) .delta. ppm 1.29 (s, 9H), 2.61
(m, 4H), 2.82 (m, 3H), 4.96 (s, 2H), 6.94 (dd, 1H), 7.18 (td, 1H),
7.30 (m, 1H), 7.43 (dd, 1H), 7.70 (m, 1H), 8.25 (s, 1H). ESI-MS:
m/z 438.2 (M+H).sup.+.
Example 9
Preparation of
(E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-isobutyl oxime (Compound 6)
##STR00184##
[0909] Compound 6 was prepared as a white or off-white powder (90%)
according to the procedure described in Example 1 using
O-isobutylhydroxylamine. The R and S enantiomers of Compound 6 may
be obtained by SFC using a procedure analogous to Example 6.
.sup.1H NMR (300 MHz, CDCl.sub.3) .delta. ppm 0.88 (m, 6H), 1.67
(m, 1H), 2.29 (m, 5H), 2.59 (s, 3H), 3.86 (m, 2H), 5.03 (m, 2H),
6.93 (dd, 1H), 7.19 (td, 1H), 7.27 (m, 1H), 7.41 (dd, 1H), 7.70 (m,
1H), 8.24 (s, 1H). ESI-MS: m/z 438.2 (M+H).sup.+.
Example 10
Preparation of
(E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-benzyl oxime (Compound 7)
##STR00185##
[0911] Compound 7 was prepared as a white or off-white powder (90%)
according to the procedure described in Example 1 using
O-benzylhydroxylamine. The R and S enantiomers of Compound 7 may be
obtained by SFC using a procedure analogous to Example 6. .sup.1H
NMR (300 MHz, CDCl.sub.3) .delta. ppm 2.51 (s, 3H), 2.60-2.81 (m,
4H), 4.97 (m, 2H), 5.12 (m, 2H), 6.91 (dd, 1H), 7.16 (td, 1H),
7.26-7.39 (m, 7H), 7.65 (m, 1H), 8.25 (m, 1H). ESI-MS: m/z 472.1
(M+H).sup.+.
Example 11
Preparation of
(E)-2-amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-phenyl oxime (Compound 8)
##STR00186##
[0913] Compound 8 was prepared as a white or off-white powder (90%)
according to the procedure described in Example 1 using
O-phenylhydroxylamine. The R and S enantiomers of Compound 8 may be
obtained by SFC using a procedure analogous to Example 6. .sup.1H
NMR (300 MHz, CDCl.sub.3) .delta. ppm 2.65-3.07 (m, 7H), 6.04 (m,
2H), 6.96 (dd, 1H), 6.99 (t, 1H), 7.11-7.25 (m, 3H), 7.26-7.35 (m,
3H), 7.44 (dd, 1H), 7.72 (m, 1H), 8.25 (m, 1H). ESI-MS: m/z 458.1
(M+H).sup.+.
Example 12
Preparation of
(E)-2-Amino-7-(4-fluoro-2-(2-fluoropyridin-3-yl)phenyl)-4-methyl-7,8-dihy-
droquinazolin-5(6H)-one O-4-nitrobenzyl oxime (Compound 9)
##STR00187##
[0915] Compound 9 was prepared as a white or off-white powder (90%)
according to the procedure described in Example 1 using
0-4-nitrobenzylhydroxylamine. The R and S enantiomers of Compound 9
may be obtained by SFC using a procedure analogous to Example 6.
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 2.44 (s, 3H),
2.64-6.80 (m, 3H), 3.20 (m, 2H), 5.28 (s, 2H), 7.18 (dd, 1H), 7.38
(td, 1H), 7.45 (m, 1H), 7.60 (m, 2H), 7.72 (dd, 1H), 7.99 (m, 1H),
8.25 (m, 3H). ESI-MS: m/z 517.2 (M+H).sup.+.
Example 13
Preparation of
2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dihydro-
quinazolin-5(6H)-one (13A)
##STR00188##
[0917] To a 5 mL microwave vial was added
2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-o-
ne (1F (Example 1), 56 mg, 0.163 mmol, 1.0 eq.),
2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
(77 mg, 0.325 mmol, 2.0 eq.), Pd(dppf)Cl.sub.2 (11 mg, 0.013 mmol,
0.08 eq.), 2.0 M aqueous K.sub.2CO.sub.3 (162 .mu.L, 0.325 mmol,
2.0 eq.), and dimethylacetamide (2 mL). The vial was sealed and
heated in a microwave at 150.degree. C. for 10 min. LC/MS analysis
showed the reaction was completed. The reaction mixture was
filtered through Celite and purified via preparative-HPLC to give
the product 13A as a white solid (33 mg, 55%). .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 2.54 (s, 3H) 2.62 (ddd, J=15.73,
3.03, 2.72 Hz, 1H) 2.84-3.04 (m, 2H) 3.15-3.31 (m, 1H) 3.60-3.73
(m, 1H) 3.78 (s, 3H) 6.81 (d, J=8.34 Hz, 1H) 7.15 (d, J=7.07 Hz,
1H) 7.22 (dd, J=9.60, 2.78 Hz, 1H) 7.33 (td, J=8.59, 2.78 Hz, 1H)
7.55 (br. s., 2H) 7.71 (dd, J=8.84, 5.81 Hz, 1H) 7.81 (dd, J=8.34,
7.33 Hz, 1H). ESI-MS: m/z 379.3 (M+H).sup.+.
Example 14
Chiral Separation of R and S Enantiomers of
2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dihydro-
quinazolin-5(6H)-one (13A.sup.a and 13A.sup.b)
##STR00189##
[0919] Racemic mixture of Compound 13A was separated into its R and
S enantiomers, Compound 13A.sup.a and Compound 13A.sup.b, by SFC
under the following conditions: [0920] Column: ChiralPak AD-H,
150.times.2.1 mm, 5 .mu.m [0921] Mobile Phase: [0922] A: CO.sub.2
(1) [0923] B: MeOH [0924] Gradient condition: 30% MeOH [0925] Run
Time: 10 min [0926] Flow Rate: 50 mL/min [0927] Injection volume:
1000 .mu.L
[0928] Total yield for the two enantiomers was 20%. Yield for
(R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one (13A.sup.a) was 10%. Yield for
(S)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one (13A.sup.b) was 10%.
Example 15
Preparation of
(E)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-2-methoxyethyl oxime (Compound 10)
##STR00190##
[0930]
2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one (13A (Example 13), 0.126 g, 0.33 mmol)
and O-(2-methoxyethyl) hydroxylamine (0.121 g, 1.33 mmol) were
dissolved in 2.2 mL of acetic acid/ethyl acetate 20/80 mol/mol
ratio with a small amount of p-toluenesulfonic acid monohydrate
(0.0127 g, 0.0666 mmol). The reaction was heated in a 80-85.degree.
C. oil bath overnight. The product was purified by preparatory
LC/MS (35-50% CH.sub.3CN in H.sub.2O to give
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-2-methoxyethyl oxime (10) as a TFA salt
(0.067 g, 45% yield). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 2.58 (s, 3H) 2.60-2.69 (m, 1H) 2.73-2.83 (m, 1H) 3.17-3.22 (m,
1H) 3.23 (s, 3H) 3.36 (dd, J=13.89, 2.02 Hz, 2H) 3.55 (t, J=4.67
Hz, 2H) 3.74 (s, 3H) 4.17 (q, J=4.29 Hz, 2H) 6.79 (d, J=8.34 Hz,
1H) 7.15 (d, J=7.33 Hz, 1H) 7.22 (dd, J=9.73, 2.65 Hz, 1H) 7.32
(td, J=8.53, 2.65 Hz, 1H) 7.69 (dd, J=8.59, 5.81 Hz, 1H) 7.78 (t,
J=7.83 Hz, 1H). ESI-MS: m/z 452.2 (M+H).sup.+.
Example 16
Chiral Separation of R and S Enantiomers of
(E)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-2-methoxyethyl oxime (Compound 11 and
Compound 12)
##STR00191##
[0932] Racemic mixture of Compound 10 was separated into its R and
S enantiomers, Compound 11 and Compound 12, by SFC under the
following conditions: [0933] Column: ChiralPak AD-H, 250.times.21.2
mm, 5 .mu.m [0934] Mobile Phase: [0935] A: CO.sub.2 (1) [0936] B:
EtOH [0937] Gradient condition: 30% B [0938] Run Time: 15 min
[0939] Flow Rate: 50 mL/min [0940] Injection volume: 1000 .mu.L
[0941] Total yield for the two enantiomers was 68.1%. The yield for
(R,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-2-methoxyethyl oxime (11) was 33.6%.
The yield for
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydroquinazolin-5(6H)-one O-2-methoxyethyl oxime (12)
was 34.5%.
Example 17
Preparation of
(E)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O--(R)-2,3-dihydroxypropyl oxime (Compound
13)
##STR00192##
[0943]
2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one (13A (Example 13), 0.097 g, 0.256 mmol)
and R--O-(2,2-dimethyl-1,3-dioxolan-4-yl-methyl)-hydroxylamine
(0.113 g, 0.769 mmol) were dissolved in 2.0 mL of dry pyridine. The
reaction was heated in a 70-80.degree. C. oil bath overnight. The
reaction was poured into an ice cold water beaker and the product
precipitated out. It was then filtered and rinsed with H.sub.2O to
yield
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one
O--((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl oxime (17A) which was
taken onto the next step without further purification. ESI-MS:m/z
508.4 (M+H).sup.+.
[0944] 17A was deprotected with 80% acetic acid in water for 40
min, and the product was then purified by preparatory LC/MS (30-45%
CH.sub.3CN in H.sub.2O to give
(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O--(R)-2,3-dihydroxypropyl oxime (13) as a
TFA salt (0.108 g, 89.7% yield). .sup.1H NMR (400 MHz, MeOD)
.delta. ppm 2.69-2.81 (m, 4H) 3.07 (br. s., 1H) 3.15-3.25 (m, 2H)
3.36-3.63 (m, 3H) 3.81-3.86 (s, 3H) 3.87-3.97 (m, 1H) 4.21 (m, 2H)
4.38 (m, 1H) 4.42-4.54 (m, 1H) 6.75 (d, J=8.34 Hz, 1H) 7.06 (d,
J=7.07 Hz, 1H) 7.09-7.17 (m, 1H) 7.17-7.27 (m, 1H) 7.57 (d, J=2.27
Hz, 1H) 7.73 (t, J=7.96 Hz, 1H). ESI-MS: m/z 468.4 (M+H).sup.+.
Example 18
Chiral Separation of R and S Enantiomers of
(E)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O--(R)-2,3-dihydroxypropyl oxime (Compound
14 and Compound 15)
##STR00193##
[0946] Racemic mixture of Compound 13 was separated into its R and
S enantiomers, Compound 14 and Compound 15 by SFC under the
following conditions: [0947] Column: ChiralPak AD-H, 250.times.21.2
mm, 5 .mu.m [0948] Mobile Phase: [0949] A: CO.sub.2 (1) [0950] B:
EtOH [0951] Gradient condition: 20% B [0952] Run Time: 25 min
[0953] Flow Rate: 20 mL/min [0954] Injection volume: 1000 .mu.L
[0955] Total yield for the two enantiomers was 16.2%. Yield for
(R,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O--(R)-2,3-dihydroxypropyl oxime (14)
was 9.0%. Yield for
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydroquinazolin-5(6H)-one O--(R)-2,3-dihydroxypropyl
oxime (15) was 7.2%.
Example 19
Preparation of
(E)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-2-tert-butoxyethyl oxime (Compound
16)
##STR00194##
[0957] Compound 16 was prepared according to a procedure analogous
to that described in Example 15 using
O-(2-tert-butoxyethyl)hydroxylamine. The crude product was purified
by preparatory LC/MS (45-55% CH.sub.3CN in H.sub.2O) to give
Compound 16 as a TFA salt (0.0417 g, 51% yield). The R and S
enantiomers of Compound 16 may be obtained by SFC using a procedure
analogous to Example 16. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.07 (s, 9H) 2.58 (s, 3H) 2.60-2.69 (m, 1H) 2.73-2.87
(m, 1H) 3.20 (dd, J=16.04, 12.25 Hz, 1H) 3.28-3.44 (m, 2H) 3.52 (t,
J=5.31 Hz, 2H) 3.75 (s, 3H) 4.02-4.17 (m, 2H) 6.79 (d, J=8.08 Hz,
1H) 7.14 (d, J=7.33 Hz, 1H) 7.22 (dd, J=9.73, 2.91 Hz, 1H) 7.32
(td, J=8.53, 2.91 Hz, 1H) 7.68 (dd, J=8.59, 5.81 Hz, 1H) 7.74-7.83
(m, 1H). ESI-MS:m/z 494.3 (M+H).sup.+.
Example 20
Preparation of
(E)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-3-methoxypropyl oxime (Compound 17)
##STR00195##
[0959] Compound 17 was prepared according to a procedure analogous
to that described in Example 15 except
O-(3-methoxy-propyl)hydroxylamine was used. The crude product was
purified by preparatory LC/MS (50-65% CH.sub.3CN in H.sub.2O to
give Compound 17 as a TFA salt (0.0428 g, 55.4% yield). The R and S
enantiomers of Compound 17 may be obtained by SFC using a procedure
analogous to Example 16. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.83 (t, J=6.57 Hz, 2H) 2.51 (s, 3H) 2.55-2.66 (m, 1H)
2.67-2.79 (m, 1H) 3.07-3.18 (m, 1H) 3.20 (s, 3H) 3.25-3.32 (m, 2H)
3.35 (t, J=6.32 Hz, 2H) 3.74 (s, 3H) 4.08 (td, J=6.44, 1.77 Hz, 2H)
6.79 (d, J=8.08 Hz, 1H) 7.14 (d, J=7.33 Hz, 1H) 7.21 (dd, J=9.60,
2.78 Hz, 1H) 7.31 (td, J=8.65, 2.91 Hz, 1H) 7.68 (dd, J=8.84, 5.81
Hz, 1H) 7.74-7.84 (m, 1H). ESI-MS: m/z 466.4 (M+H).sup.+.
Example 21
Preparation of
(E)-2-(2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydroquinazolin-5(6H)-ylideneaminooxy)acetic acid (Compound
18)
##STR00196##
[0961] Compound 18 was prepared using an analogous procedure
described for Example 15 except that 2-(aminooxy)acetic acid was
used. The crude product was purified by preparatory LC/MS (40-60%
CH.sub.3CN in H.sub.2O to give Compound 18 as a TFA salt (0.0413 g,
70% yield). The R and S enantiomers of Compound 18 may be obtained
by SFC using a procedure analogous to Example 16. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 2.42 (s, 3H) 2.66-2.79 (m, 3H)
3.08-3.12 (m, 2H) 3.75 (s, 3H) 4.56 (d, J=1.77 Hz, 2H) 6.79 (d,
J=8.08 Hz, 1H) 7.14 (d, J=7.07 Hz, 1H) 7.21 (dd, J=9.73, 2.91 Hz,
1H) 7.26-7.36 (m, 1H) 7.66-7.73 (m, 1H) 7.74-7.83 (m, 1H). ESI-MS:
m/z 452.3 (M+H).sup.+.
Example 22
Preparation of
(E)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O--(S)-2,3-dihydroxypropyl oxime (Compound
19)
##STR00197##
[0963] Compound 19 was prepared using an analogous procedure
described for Example 17 except that
S--O-(2,2-dimethyl-1,3-dioxolan-4-yl-methyl)-hydroxylamine was
used. The crude product was purified by preparatory LC/MS (30-40%
CH.sub.3CN in H.sub.2O to give Compound 19 as a TFA salt (0.0818 g,
70.5% yield). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.52
(s, 3H) 2.62 (dd, J=17.94, 14.15 Hz, 1H) 2.75 (d, J=1.01 Hz, 1H)
3.07-3.19 (m, 1H) 3.27-3.38 (m, 5H) 3.68-3.73 (m, 2H) 3.75 (s, 3H)
3.89-3.99 (m, 1H) 4.06 (ddd, J=10.86, 4.67, 3.16 Hz, 1H) 6.79 (d,
J=7.83 Hz, 1H) 7.14 (d, J=7.33 Hz, 1H) 7.21 (dd, J=9.60, 2.78 Hz,
1H) 7.32 (td, J=8.59, 2.78 Hz, 1H) 7.69 (dd, J=8.72, 5.94 Hz, 1H)
7.75-7.82 (m, 1H). ESI-MS: m/z 468.4 (M+H).sup.+.
Example 23
Chiral Separation of R and S Enantiomers of
(E)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O--(R)-2,3-dihydroxypropyl oxime (Compound
20 and Compound 21)
##STR00198##
[0965] Racemic mixture of Compound 19 was separated into its R and
S enantiomers, Compound 20 and Compound 21 by SFC under the
following conditions: [0966] Column: ChiralPak AD-H, 250.times.10
mm, 5 .mu.m [0967] Mobile Phase: [0968] A: CO.sub.2 (1) [0969] B:
MeOH [0970] Gradient condition: 25% B [0971] Run Time: 15 min
[0972] Flow Rate: 20 mL/min [0973] Injection volume: 1000 .mu.L
[0974] Total yield for the two enantiomers was 34.7%. Yield for
(R,E)-(E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7-
,8-dihydroquinazolin-5(6H)-one O--(R)-2,3-dihydroxypropyl oxime
(20) was 14.1%. Yield for
(S,E)-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydroquinazolin-5(6H)-one O--(R)-2,3-dihydroxypropyl oxime (21)
was 20.6%.
Example 24
Preparation of
(E)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-2-aminoethyl oxime (Compound 22)
##STR00199##
[0976] Compound 22 was prepared using an analogous procedure
described for Example 15 except that tert-butyl
2-(aminooxy)ethylcarbamate was used. The final Boc-deprotection was
effected by treatment of 24A (0.180 g, 0.019 mmol) with 20%
TFA/CH.sub.2Cl.sub.2 for 10 min. The reaction was completed as
judged by LC/MS. The reaction was concentrated in vacuo and the
residue was purified by preparatory LC/MS (25-35% CH.sub.3CN in
H.sub.2O) to give product 22 as a TFA salt (0.0625 g, 75.3% yield).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.52 (s, 3H)
2.62-2.74 (m, 1H) 2.76-2.90 (m, 1H) 2.99-3.18 (m, 3H) 3.32 (d,
J=12.38 Hz, 2H) 3.75 (s, 3H) 4.20 (t, J=5.05 Hz, 2H) 6.80 (d,
J=8.08 Hz, 1H) 7.14 (d, J=7.33 Hz, 1H) 7.23 (dd, J=9.73, 2.91 Hz,
1H) 7.33 (td, J=8.53, 2.91 Hz, 1H) 7.69 (dd, J=8.84, 5.81 Hz, 1H)
7.74-7.86 (m, 1H). ESI-MS: m/z 437.4 (M+H).sup.+.
Example 25
Chiral Separation of R and S Enantiomers of
(E)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-2-aminoethyl oxime (Compound 23 and
Compound 24)
##STR00200##
[0978] Racemic mixture of Compound 22 was separated into its R and
S enantiomers, Compound 23 and Compound 24, by SFC under the
following conditions: [0979] Column: ChiralPak AD-H, 250.times.10
mm, 5 .mu.m [0980] Mobile Phase: [0981] A: CO.sub.2 (1) [0982] B:
MeOH+10 mM NH.sub.4OAc [0983] Gradient condition: 30% B [0984] Run
Time: 8 min [0985] Flow Rate: 20 mL/min [0986] Injection volume: 75
.mu.L
[0987] Total yield for the two enantiomers was 23%. Yield for
(R,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-2-aminoethyl oxime (23) was 9.2%.
Yield for
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-2-aminoethyl oxime (24) was 13.9%.
Example 26
Preparation of (E) and (Z) Isomers of
2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dihydro-
quinazolin-5(6H)-one O-pyridin-3-ylmethyl oxime (Compound 25 and
Compound 26)
##STR00201##
[0989] The racemic mixture which contained Compounds 25 and 26 was
prepared by a procedure analogous to that described in Example 15
except that O-(pyridin-3-ylmethyl)hydroxylamine was used. The crude
product was purified by preparatory LC/MS (25-40% CH.sub.3CN in
H.sub.2O to give products as TFA salt. The E and Z isomers were
separated by preparatory LC/MS (25%-40% CH.sub.3CN in H.sub.2O)
with a total yield of 71.6%.
[0990] Yield for (E)
2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dihydro-
quinazolin-5(6H)-one O-pyridin-3-ylmethyl oxime (25) was 0.0398 g,
50.2%. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.37 (s, 3H)
2.58-2.83 (m, 2H) 3.12 (dd, J=16.04, 12.25 Hz, 1H) 3.32 (dd,
J=13.26, 3.92 Hz, 2H) 3.67 (s, 3H) 5.20 (d, J=3.03 Hz, 2H) 6.78 (d,
J=8.34 Hz, 1H) 7.14 (d, J=7.33 Hz, 1H) 7.21 (dd, J=9.60, 2.78 Hz,
1H) 7.31 (td, J=8.53, 2.91 Hz, 1H) 7.63-7.73 (m, 2H) 7.78 (t,
J=7.83 Hz, 1H) 8.11 (d, J=7.58 Hz, 1H) 8.68 (br. s., 1H) 8.74 (s,
1H). ESI-MS: m/z 485.4 (M+H).sup.+.
[0991] Yield for (Z)
2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dihydro-
quinazolin-5(6H)-one O-pyridin-3-ylmethyl oxime (26) was 0.017 g,
21.4%. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.12 (s, 3H)
2.63-2.71 (m, 1H) 2.72-3.00 (m, 4H) 3.80 (s, 3H) 5.11 (s, 2H) 6.83
(d, J=8.34 Hz, 1H) 7.12 (d, J=7.33 Hz, 1H) 7.18 (dd, J=9.73, 2.91
Hz, 1H) 7.26 (td, J=8.53, 2.91 Hz, 1H) 7.57 (ddd, J=13.71, 8.40,
5.43 Hz, 2H) 7.73-7.88 (m, 1H) 7.96 (d, J=7.33 Hz, 1H) 8.64 (s, 1H)
8.79 (br. s., 1H). ESI-MS: m/z 485.4 (M+H).sup.+.
Example 27
Preparation of
(E)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydroquinazolin-5(6H)-one O-3-hydroxy-2-(hydroxymethyl)propyl oxime
(Compound 27) and Chiral Separation of Enantiomers
##STR00202##
[0993] Compound 27 was prepared by a procedure analogous to that
described in Example 17 except that
O-((2,2-dimethyl-1,3-dioxan-5-yl)methyl)hydroxylamine was used. The
crude product was purified by preparatory LC/MS (35-40% CH.sub.3CN
in H.sub.2O to give Compound 17 as a TFA salt (0.109 g, 42.9%
yield). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.89 (m,
1H) 2.47 (s, 3H) 2.54 (m, 1H) 2.67 (br. s., 2H) 3.07 (d, J=15.66
Hz, 1H) 3.25 (m, 1H) 3.41 (q, J=5.31 Hz, 4H) 3.75 (s, 3H) 4.03 (d,
J=8.00 Hz, 2H) 4.39 (q, J=4.97 Hz, 2H) 6.79 (d, J=8.34 Hz, 1H) 7.13
(d, J=7.33 Hz, 1H) 7.20 (dd, J=9.60, 2.53 Hz, 1H) 7.25-7.35 (m, 1H)
7.68 (dd, J=8.59, 5.81 Hz, 1H) 7.74-7.83 (m, 1H). ESI-MS: m/z 482.4
(M+H).sup.+.
[0994] The R and S enantiomers of Compound 27 was separated by SFC
under the following conditions: [0995] Column: ChiralPak AD,
250.times.10 mm, 5 .mu.m [0996] Mobile Phase: [0997] A: CO.sub.2
(1) [0998] B: IPOH [0999] Gradient condition: 40% B [1000] Run
Time: 12 min [1001] Flow Rate: 15 mL/min [1002] Injection volume:
500 .mu.L
[1003] Total yield for the two enantiomers was 50.3%. Yield for
(R,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-3-hydroxy-2-(hydroxymethyl)propyl
oxime (28) was 27.9%. Yield for
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O-3-hydroxy-2-(hydroxymethyl)propyl
oxime (29) was 22.4%.
Example 28
Preparation of
(E)-2-(2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydroquinazolin-5(6H)-ylidene)hydrazinecarboximidamide (Compound
30)
##STR00203##
[1005] The ketone 13A ((Example 13) 0.100 g), aminoguanidine
hydrochloride (0.0876 g, 3 eq.) and 5N HCl (5 eq.) were dissolved
in ethanol and was heated in a 90.degree. C. oil bath for 2 hours.
The crude product was then purified by preparatory LC/MS (40-45%
CH.sub.3CN in H.sub.2O to give
(E)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydroquinazolin-5(6H)-ylidene)hydrazinecarboximidamide (30) as a
TFA salt (0.0617 g, 53.6% yield). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 2.64 (s, 3H) 2.70-2.82 (m, 2H) 3.15-3.33
(m, 2H) 3.48 (br. s., 1H) 3.73 (s, 3H) 6.80 (d, J=8.34 Hz, 1H) 7.17
(d, J=7.33 Hz, 1H) 7.25 (dd, J=9.73, 2.65 Hz, 1H) 7.33-7.40 (m, 1H)
7.74-7.86 (m, 2H) 10.74 (s, 1H). ESI-MS: m/z 435.4 (M+H).sup.+.
Example 29
Preparation of
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O--(S)-3,4-dihydroxybutyl oxime
(Compound 31)
##STR00204##
[1007] Compound 31 was prepared using an analogous procedure
described for Example 17 except that
(S)--O-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)hydroxylamine was
used. The crude product was purified by preparatory LC/MS
(CH.sub.3CN in H.sub.2O to give
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydroquinazolin-5(6H)-one O--(S)-3,4-dihydroxybutyl oxime as a TFA
salt (31, 4.5 mg, 7.1% yield). .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta. ppm 1.17-1.37 (m, 1H) 2.46-2.64 (m, 4H) 2.81-2.99 (m, 2H)
3.25-3.53 (m, 3H) 3.58-3.66 (m, 1H) 3.77-3.96 (m, 4H) 4.16-4.38 (m,
3H) 5.18 (br. s., 2H) 6.66-6.78 (m, 1H) 6.95 (dd, J=7.33, 4.29 Hz,
1H) 7.02-7.22 (m, 2H) 7.31-7.44 (m, 1H) 7.55-7.68 (m, 1H). [M+H]
calc'd for C.sub.25H.sub.28FN.sub.5O.sub.4, 482; found, 482.
Example 30
Preparation of
2-Amino-7-(3-(6-methoxypyridin-2-yl)thiophen-2-yl)-4-methyl-7,8-dihydroqu-
inazolin-5(6H)-one (30H)
##STR00205## ##STR00206##
[1008] A. Synthesis of
3-(6-methoxypyridin-2-yl)thiophene-2-carbaldehyde (30C)
[1009] To a 500 mL flask was added 2-formylthiophene-3-boronic acid
(30A, 5.00 g, 32.1 mmol, 1.0 eq.), 2-bromo-6-methoxypyridine (30B,
6.03 g, 32.1 mmol, 1.0 eq.), toluene (100 mL), EtOH (100 mL),
aqueous sodium carbonate (2N, 32 ml, 64 mmol, 2.0 eq.), and
Pd(dppf)Cl.sub.2 (1.17 g, 1.6 mmol, 0.05 eq.). The reaction was
stirred overnight at 90.degree. C. The reaction was cooled and
saturated aqueous NaCl (100 mL) was added and the mixture was
stirred for 20 min. The reaction mixture was extracted with EtOAc
(2.times.100 mL) and the resulting organic layers were combined and
passed through a Celite pad to remove residual Pd. The organic
phases were washed with a succession of H.sub.2O (100 mL) and
saturated aqueous NaCl (100 mL) and then dried over anhydrous
Na.sub.2SO.sub.4, filtered, and concentrated to give a bubbly brown
solid that was used in the next step without further purification
(6.2 g, 88%). ESI-MS: m/z 220.2 (M+H).sup.+.
B. Synthesis of
(E)-4-(3-(6-methoxypyridin-2-yl)thiophen-2-yl)but-3-en-2-one
(30D)
[1010] To a 500 mL recovery flask was added
3-(6-methoxypyridin-2-yl)thiophene-2-carbaldehyde (30C, 6.2 g, 28.3
mmol, 1.0 eq.), acetone (16.6 mL, 226 mmol, 8.0 eq.), and H.sub.2O
(130 mL). Upon cooling to 0.degree. C. in an ice bath, aqueous NaOH
(5N, 6.2 mL, 31.1 mmol, 1.1 eq.) was added. The reaction mixture
was stirred overnight while warming to room temperature. LC/MS
monitoring showed the reaction to be .about.60% complete, so
additional aqueous NaOH (5N, 1 mL, 5.0 mmol, 0.18 eq.) was added.
After stirring for an additional 6 h the reaction was complete by
LC/MS. The reaction mixture was neutralized with 3N aqueous HCl to
a pH .about.8. The mixture was extracted with EtOAc (3.times.100
mL). The organic phases were combined and washed with saturated
aqueous NaCl (100 mL). The combined aqueous phases were extracted
with EtOAc (100 mL). The organic phases were combined and dried
over anhydrous Na.sub.2SO.sub.4, filtered, and concentrated to give
a black solid. The residue was purified via flash chromatography
(60% CH.sub.2Cl.sub.2/Hex to 100% CH.sub.2Cl.sub.2) to give a
yellow solid 30D (4.8 g, 67%). .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 2.29 (s, 3H) 3.96 (s, 3H) 6.59 (d, J=15.92 Hz, 1H) 6.84
(d, J=8.34 Hz, 1H) 7.41 (d, J=7.58 Hz, 1H) 7.60 (d, J=5.31 Hz, 1H)
7.75-7.88 (m, 2H) 8.71 (d, J=15.92 Hz, 1H). ESI-MS: m/z 260.3
(M+H).sup.+.
C. Synthesis of
3-hydroxy-5-(3-(6-methoxypyridin-2-yl)thiophen-2-yl)cyclohex-2-enone
(30F)
[1011] To a 200 mL recovery flask was added
(E)-4-(3-(6-methoxypyridin-2-yl)thiophen-2-yl)but-3-en-2-one (30D,
4.81 g, 18.6 mmol, 1.0 eq.), MeOH (100 mL), and dimethylmalonate
(30E, 2.13 mL, 18.6 mmol, 1.0 eq.). NaOMe (30% wt in MeOH, 3.66 mL,
19.5 mmol, 1.05 eq.) was added and the reaction mixture was stirred
overnight at reflux. LC/MS analysis showed the desired intermediate
and the mixture was concentrated and then taken up in 1N aqueous
NaOH (100 mL) and refluxed for 1 h. The reaction was then cooled to
0.degree. C. in an ice bath and acidified with 1N HCl until acidic.
The reaction mixture was then stirred at 80.degree. C. for 1 h.
After cooling to room temperature, EtOAc (200 mL) was added and the
organic phase was washed with saturated aqueous NaCl (100 mL). The
combined aqueous phases were extracted with EtOAc (100 mL). The
combined organic phases were dried over anhydrous Na.sub.2SO.sub.4,
filtered, and concentrated to give a foamy brown solid 30F that was
taken on to the next step without further purification. (4.9 g,
88%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.67 (m, 3H)
3.79 (s, 3H) 4.54-4.70 (m, 1H) 5.30 (s, 1H) 6.73 (d, J=8.08 Hz, 1H)
7.31 (d, J=7.33 Hz, 1H) 7.39-7.54 (m, 2H) 7.76 (t, J=7.83 Hz, 1H).
ESI-MS: m/z 302.3 (M+H).sup.+.
D. Synthesis of
2-acetyl-3-hydroxy-5-(3-(6-methoxypyridin-2-yl)thiophen-2-yl)cyclohex-2-e-
none (30G)
[1012] To a 200 mL recovery flask was added
3-hydroxy-5-(3-(6-methoxypyridin-2-yl)thiophen-2-yl)cyclohex-2-enone
(30F, 4.9 g, 16.3 mmol, 1.0 eq.), CH.sub.2CT.sub.2 (100 mL), acetic
anhydride (2.15 g, 21.1 mmol, 1.3 eq.), Et.sub.3N (6.8 mL, 48.8
mmol, 3.0 eq.), and DMAP (catalytic). The reaction mixture was
stirred overnight at room temperature whereupon LC/MS showed two
signals corresponding to M+H=344. Additional acetic anhydride (0.5
mL, 5.3 mmol, 0.32 eq.) was added and the reaction mixture was
heated for 6 h at 40.degree. C. LC/MS analysis showed the reaction
to be complete whereupon the mixture was concentrated to a solid
and purified via flash chromatography (70% CH.sub.2Cl.sub.2/Hex to
100% CH.sub.2Cl.sub.2) to yield a dark orange solid 30G (1.72 g,
31%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.52-2.57 (m,
3H) 2.83 (m, 2H) 3.09 (m, 2H) 3.78 (s, 3H) 4.68 (m, 1H) 6.74 (d,
J=8.34 Hz, 1H) 7.32 (d, J=7.33 Hz, 1H) 7.41-7.47 (m, 1H) 7.51 (d,
J=5.31 Hz, 1H) 7.76 (t, J=7.96 Hz, 1H). ESI-MS: m/z 344.3
(M+H).sup.+.
E. Synthesis of
2-amino-7-(3-(6-methoxypyridin-2-yl)thiophen-2-yl)-4-methyl-7,8-dihydroqu-
inazolin-5(6H)-one (30H)
[1013] To a 150 mL pressure vessel was added
2-acetyl-3-hydroxy-5-(3-(6-methoxypyridin-2-yl)thiophen-2-yl)cyclohex-2-e-
none (30G, 1.72 g, 5.01 mmol, 1.0 eq.), EtOH (50 mL), pyrrolidine
(2.13 g, 30.1 mmol, 6.0 eq.), guanidine hydrochloride (1.44 g, 15
mmol, 3.0 eq.). The vessel was sealed and heated overnight at
100.degree. C. LC/MS analysis showed the reaction to be complete
whereupon the reaction mixture was concentrated and the residue was
taken up in 20% EtOAc/CH.sub.2Cl.sub.2. An insoluble solid proving
not to be product was filtered off. The remaining filtrate was
purified via column chromatography (20% EtOAc/CH.sub.2Cl.sub.2 to
70% EtOAc/CH.sub.2Cl.sub.2) to yield the product 30H as a light
gray solid (270 mg, 15%). .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 2.55 (s, 3H) 2.76-2.95 (m, 2H) 3.02-3.22 (m, 2H) 3.70
(s, 3H) 4.62-4.77 (m, 1H) 6.72 (d, J=8.34 Hz, 1H) 7.31 (d, J=7.58
Hz, 1H) 7.41-7.54 (m, 4H) 7.75 (t, J=7.83 Hz, 1H). ESI-MS: m/z
367.3 (M+H).sup.+.
Example 31
Preparation of
(R)-2-Amino-7-(2-bromo-4-fluoro-phenyl)-4-methyl-7,8-dihydro-6H-pyrido[4,-
3-d]pyrimidine-5-thione (31I) and
(R)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydropyrido[4,3-d]pyrimidin-5(6H)-one (31J)
##STR00207##
[1014] A. Synthesis of (S)-2-methyl-propane-2-sulfinic acid
1-(2-bromo-4-fluoro-phenyl)-methyl-(E)-ylideneamide (31C)
[1015] (S)-tert-Butanesulfinimide (31A, 9.9 g, 81.6 mmol),
2-bromo-4-fluoro-benzaldehyde (31B, 15.5 g, 76 mmol), and titanium
tetraethoxide (34 mL) were charged into a 500 mL round bottom flask
containing THF (dry, 50 mL). The reaction was allowed to stir at
ambient temperature for 2 h which was deemed complete by LCMS.
EtOAc (200 mL), brine (150 mL), and celite was added and stir for 1
h. The heterogeneous mixture was filtered through a pad of celite,
and washed with EtOAc. The organic layer was washed with brine and
dried (Na.sub.2SO.sub.4), then concentrated in vacuo to afford the
product 31C as viscous oil (23.3 g, 99% yield). 31C was used in the
next step without further purification.
B. Synthesis of (R)-3-amino-3-(2-bromo-4-fluoro-phenyl)-propionic
acid ethyl ester (31D)
[1016] A 500 mL 3-necked flask fitted with an overhead stirrer, a
150 mL addition funnel and a reflux condenser, was charged with THF
(dry, 150 mL), Zn (74.5 g, 1.14 mol, 10 .mu.m particle size) and
CuCl (11.3 g, 114 mmol) under N.sub.2 atmosphere. The heterogeneous
mixture was refluxed for 1 h while stirring vigorously. After
cooling to ambient temperature, ethyl bromoacetate (12.61 mL, 114
mmol) was added and the reaction was held at 50.degree. C. for 1 h
then cooled to 0.degree. C. 31C (23.3 g, 76 mmol) in THF (dry, 80
mL) was added via the addition funnel over 10 min. The reaction was
held at 0.degree. C. for 4 h then warmed to ambient temp and
stirred for 12 h. The heterogeneous mixture was filtered through a
pad of celite and washed with EtOAc. The organic layer was washed
with citric acid (IM), NaHCO.sub.3, brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo to give 24.3 g of light
yellow solid. The solid was then taken up in diethyl ether (200
mL), EtOH (5 mL), and HCl (38 mL, 4M in dioxane). After 30 min the
product 31D precipitated and was filtered, the solid washed with
excess diethyl ether dried under high vacuum to afford the P-amino
ester HCl salt in good yield (15.6 g, 47.7 mmol, 63%). The mother
liquor contained an additional 1.9 g (6.5 mmol, 8.5%) of freebase
after neutralization and column chromatography (1-5%, MeOH in DCM).
ESI-MS: m/z 290.01 (MH+).
C. Synthesis of
(R)-3-(2-bromo-4-fluoro-phenyl)-3-(3-oxo-butyrylamino)-propionic
acid ethyl ester (31F)
[1017] A 500 mL round-bottom flask charged with 31D (13.3 g, 41
mmol) in 200 mL of DCM and TEA (22.8 mL, 3 equiv.) was added
diketene (31E, 8.81 mL, 50% in DCM). The reaction was stirred at
ambient temperature until completion (2 h, determined by LCMS). The
reaction mixture was washed with 1 N NaHSO.sub.4, brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo to afford Compound 31F
as a yellow solid (15.3 g, 99%). ESI-MS: m/z 374.0 (MH.sup.+).
D. Synthesis of
(R,E)-6-(2-bromo-4-fluorophenyl)-3-(1-hydroxyethylidene)piperidine-2,4-di-
one (31G)
[1018] To a flask containing 30 mL dry MeOH was added sodium metal
(1.00 g, 43.5 mmol, 3.4 eq.). The mixture was stirred vigorously
until sodium is dissolved. To a pressure vessel containing 31F
(4.81 g, 12.9 mmol, 1.0 eq.) in MeOH (50 mL) was added the freshly
prepared NaOMe solution. The pressure vessel was sealed and heated
at 100.degree. C. overnight. LC/MS analysis showed the product as
the major signal. The reaction mixture was concentrated and then
diluted with methylene chloride (500 mL) and aqueous 1 N NH.sub.4Cl
(100 mL). The organic phase was further washed with aqueous 1 N
NH.sub.4Cl (100 mL) and saturated aqueous NaCl (100 mL). The
combined aqueous phases were extracted with methylene chloride
(2.times.75 mL). The combined organic phases were dried over
anhydrous Na.sub.2SO.sub.4, filtered, and concentrated to give a
dark yellow solid 31G which was deemed pure enough to take on to
the next reaction without further purification (2.05 g, 49%).
ESI-MS: m/z 328.2 (M+H)+
E. Synthesis of
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]p-
yrimidin-5(6H)-one (31H)
[1019] A microwave vial charged with acetylguanidine (800 mg, 7.9
mmol) was added pyrrolidine (3.25 mL, 39 mmol), 5 mL of EtOH and
31G (1.3 g, 3.9 mmol). The mixture was heated in a microwave at
160.degree. C. for 10 min. The reaction mixture was diluted with
EtOAc (50 mL) and washed with 1M NaHSO.sub.4 (40 mL.times.2),
brine, dried over Na.sub.2SO.sub.4, concentrated in vacuo. The
resulting solid was purified by column chromatography (2-5% MeOH in
DCM gradient) to give the product 31H as a light yellow crystalline
solid (989 mg, 72%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 2.61 (s, 3H) 2.83 (dd, J=16.29, 5.94 Hz, 1H) 3.22 (dd, J=16.42,
6.06 Hz, 1H) 4.84-5.06 (m, 1H) 7.11 (br. s., 2H) 7.19-7.40 (m, 2H)
7.61 (dd, J=8.59, 2.53 Hz, 1H) 7.98 (d, J=3.28 Hz, 4H). ESI-MS: m/z
351.0 (MH.sup.+).
F. Synthesis of
(R)-2-Amino-7-(2-bromo-4-fluoro-phenyl)-4-methyl-7,8-dihydro-6H-pyrido[4,-
3-d]pyrimidine-5-thione (31I)
[1020] A 4 mL vial charged with 31H and 2 mL of DME was added Davy
reagent (250 mg, 0.71 mmol). The mixture was heated to 100.degree.
C. for 20 min. The crude mixture was directly charged into a 12 g
silica column and eluted (2-4% MeOH in DCM) to give the thiolactam
31I in modest yield (134 mg, 52%). ESI-MS: m/z 367.0
(MH.sup.+).
G. Synthesis of
(R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dih-
ydropyrido[4,3-d]pyrimidin-5(6H)-one (31J)
[1021] To a 5 mL microwave vial was added 31H (700 mg, 1.99 mmol,
1.0 eq.),
2-(6-methoxypyridin-2-yl)-6-phenyl-1,3,6,2-dioxazaborocane (1.43 g,
4.78 mmol, 2.4 eq.), Pd(dppf)Cl.sub.2 (73 mg, 0.0997 mmol, 0.05
eq.), K.sub.2CO.sub.3 (826 mg, 5.98 mmol, 3.0 eq.), and
dimethylacetamide (10 mL). The vial was sealed and heated in a
microwave at 110.degree. C. for 30 min. LC/MS analysis showed the
reaction was complete. The reaction mixture was diluted with
methanol, filtered, and purified via preparative-HPLC to give the
product 31J as a white solid (618 mg, 81.7% yield). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 2.58 (s, 3H) 2.80-2.95 (m, 1H)
3.08-3.22 (m, 1H) 3.86 (s, 3H) 5.15 (br. s., 1H) 6.86 (d, J=7.58
Hz, 1H) 7.18 (d, J=6.82 Hz, 1H) 7.23-7.33 (m, 2H) 7.55 (dd, J=8.59,
5.81 Hz, 1H) 7.84 (dd, J=8.34, 7.33 Hz, 2H). ESI-MS: m/z 380.2
(M+H).sup.+.
Example 32
Preparation of
(R,Z)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl oxime (Compound 32)
and
(R,Z)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(R)-2,3-dihydroxypropyl
oxime (Compound 33)
##STR00208##
[1023] A 4 mL vial charged with
(R)-2-amino-7-(2-bromo-4-fluoro-phenyl)-4-methyl-7,8-dihydro-6H-pyrido[4,-
3-d]pyrimidine-5-thione (31I (Example 31), 107 mg, 0.28 mmol),
(R)--O-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)hydroxylamine (247
mg, 1.68 mmol), and dioxane (2 mL) was heated to 100.degree. C. for
12 h. The crude mixture was purified by preparative reverse phase
HPLC (10-70% H.sub.2O--AcCN, 0.035% TFA) to afford the product
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O--((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl
oxime (32A) in modest yield (40 mg, 30% yield). ESI-MS: m/z 480.1
(M+H).sup.+.
[1024] To a vial containing 32A (40 mg, 0.083 mmol),
2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
(58 mg, 0.25 mmol), Na.sub.2CO.sub.3 (0.5 mL, 1.0 mmol),
Pd(dppf).sub.2Cl.sub.2 (3.4 mg, 0.004 mmol) and DMA (0.5 mL) was
heated to 130.degree. C. for 20 min in the microwave. The resultant
crude mixture was diluted with EtOAc, and washed with H.sub.2O,
brine, dried over Na.sub.2SO.sub.4, and concentrated in vacuo to
yield
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl oxime (32) after
reverse-phase preparative HPLC (16 mg, 39% yield, 10-70%
H.sub.2O--AcCN, 0.035% TFA). .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta. ppm 1.35 (s, 3H) 1.41 (s, 3H) 2.85 (s, 3H) 3.15 (dd,
J=17.05, 10.48 Hz, 1H) 3.46 (dd, J=17.18, 3.79 Hz, 1H) 3.70-3.80
(m, 1H) 3.88 (s, 3H) 3.99-4.17 (m, 3H) 4.36-4.49 (m, 1H) 4.90 (dd,
J=10.36, 3.54 Hz, 1H) 4.30-5.10 (br, 2H) 5.80 (br, 1H) 6.76 (d,
J=8.34 Hz, 1H) 7.02 (d, J=7.33 Hz, 1H) 7.10-7.24 (m, 2H) 7.60 (dd,
J=8.59, 5.56 Hz, 1H) 7.68 (t, J=7.83 Hz, 1H). ESI-MS: m/z 509.4
(M+H).sup.+.
[1025] Compound 32 was taken up in AcOH--H.sub.2O (1 mL, 5:1) and
heated to 80.degree. C. for 30 min; the excess AcOH was removed
under vacuum. The crude product was then purified by reverse phase
preparative HPLC to yield
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(R)-2,3-dihydroxypropyl oxime (33, 12 mg, 20-75% H.sub.2O--AcCN,
10 mM (NH.sub.4).sub.2CO.sub.2). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 2.48 (s, 3H) 2.81 (dd, J=16.17, 7.83 Hz,
1H) 3.04 (dd, J=16.17, 4.80 Hz, 1H) 3.28-3.41 (m, 2H) 3.66-3.76 (m,
1H) 3.78-3.84 (m, 1H) 3.9 (s, 3H) 3.89-3.97 (m, 1H) 4.51 (t, J=5.68
Hz, 1H) 4.64 (d, J=4.80 Hz, 1H) 4.94-5.05 (m, 1H) 6.48 (s, 1H) 6.79
(s, 2H) 6.85 (d, J=8.34 Hz, 1H) 7.18 (d, J=7.33 Hz, 1H) 7.23-7.35
(m, 2H) 7.53 (dd, J=8.59, 5.81 Hz, 1H) 7.84 (t, J=7.83 Hz, 1H).
ESI-MS: m/z 469.2 (M+H).sup.+.
Example 33
Preparation of
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-2,3-dihydroxypropyl
oxime (Compound 34)
##STR00209##
[1027] The title compound was prepared by the procedure of Example
32 except that
(S)--O-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)hydroxylamine was
used. .sup.1H NMR (400 MHz, CHLOROFORM-c) ppm 2.63 (s, 3H)
2.97-3.14 (m, 1H) 3.16-3.28 (m, 1H) 3.55-3.68 (m, 1H) 3.68-3.76 (m,
3H) 3.90 (s, 3H) 3.97-4.20 (m, 3H) 4.90 (dd, J=10.23, 3.92 Hz, 1H)
5.26 (br. s., 2H) 5.83 (s, 1H) 6.74 (d, J=8.34 Hz, 1H) 7.00 (d,
J=7.07 Hz, 1H) 7.07-7.22 (m, 2H) 7.52-7.76 (m, 2H). ESI-MS: m/z
469.2 (M+H.sup.+).
Example 34
Synthesis of
(R,Z)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3-hydroxy-2-(hydroxymethyl)propyl oxime (Compound 35)
##STR00210##
[1029] The title compound 35 was prepared by a procedure analogous
to that disclosed in Example 32 except
O-((2,2-dimethyl-1,3-dioxan-5-yl)methyl)hydroxylamine was used. The
crude product was purified by reverse phase HPLC (5 mg, 20-75%
H.sub.2O--AcCN, 10 mM (NH.sub.4).sub.2CO.sub.2) to afford
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3-hydroxy-2-(hydroxymethyl)propyl oxime (33, 5 mg, 2.9% yield).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.88-2.05 (m, 1H)
2.53 (s, 3H) 2.81 (dd, J=16.17, 7.33 Hz, 1H) 3.03 (dd, J=16.04,
4.93 Hz, 1H) 3.42-3.50 (m, 4H) 3.86 (s, 3H) 3.93 (dd, J=6.32, 2.53
Hz, 2H) 4.29-4.39 (m, 2H) 5.00-5.10 (m, 1H) 6.31 (s, 1H) 6.76 (s,
2H) 6.85 (d, J=8.34 Hz, 1H) 7.19 (d, J=7.33 Hz, 1H) 7.21-7.32 (m,
2H) 7.49 (dd, J=8.59, 5.81 Hz, 1H) 7.84 (t, J=7.83 Hz, 1H). ESI-MS:
m/z 483.3 (M+H.sup.+).
Example 35
Synthesis of
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl oxime (Compound 36)
and
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl
oxime (Compound 37)
##STR00211##
[1031] A mixture of
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]p-
yrimidine-5(6H)-thione (31I, 100 mg, 0.3 mmol),
(S)--O-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)hydroxylamine (194
mg, 1.2 mmol), Hg(OAc).sub.2 (192 mg, 0.6 mmol) and anhydrous
toluene (2 mL) was heated at 100.degree. C. for 1 h. LCMS shows
completion of the reaction. The mixture was cooled, filtered
through celite and washed with ethyl acetate. Filtrate concentrated
and the resulting oily residue was purified by preparative LCMS to
afford
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl
oxime (35A, 87 mg, 65%) as a pale yellow solid. .sup.1H NMR (400
MHz, CHLOROFORM-d) .delta. 1.35 (s, 3H) 1.40 (s, 3H) 2.01 (qd,
J=6.32, 3.03 Hz, 2H) 2.76 (s, 3H) 2.95 (dd, J=16.42, 8.84 Hz, 1H)
3.18 (dd, J=17.18, 5.05 Hz, 1H) 3.56-3.62 (m, 1H) 4.09 (dd, J=7.96,
5.94 Hz, 1H) 4.16-4.28 (m, 2H) 4.98 (ddd, J=8.78, 4.61, 1.52 Hz,
1H) 7.07 (td, J=8.21, 2.53 Hz, 1H) 7.34 (dd, J=8.08, 2.53 Hz, 1H)
7.68 (dd, J=12.00, 6.95 Hz, 1H). MS (ES) [M+H] calculated for
C.sub.21H.sub.26BrFN.sub.5O.sub.3, 494.11; found 494.00.
[1032] A mixture of the above compounds (83.0 mg, 0.17 mmol),
2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
(80.0 mg, 0.34 mmol), Pd(dppf).sub.2Cl.sub.2 (14 mg, 0.017 mmol),
2N Na.sub.2CO.sub.3 (0.42 mL, 0.85 mmol) in DMA (2 mL) was degassed
with N.sub.2 and heated at 80.degree. C. for 2.5 h. LCMS shows 1:1
mixture of starting material and product. The reaction mixture was
cooled, filtered through celite and washed with 1:1
MeOH--CH.sub.2Cl.sub.2. The filtrate was concentrated and the
residue was dissolved in 4:1 mixture of AcOH--H.sub.2O and heated
at 80.degree. C. for 30 minutes. Solvent removed under reduced
pressure and the residue was purified by preparative HPLC (basic
mode) to afford Compounds 36 and 37.
[1033] Compound 36:
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl oxime (36, 8.0 mg).
.sup.1H NMR (400 MHz, METHANOL-d.sub.4) d 1.68-1.80 (dddd, J=14.31,
8.75, 5.65, 5.65 Hz, 1H), 2.02 (dddd, J=14.24, 7.74, 6.44, 3.92 Hz,
1H), 2.85 (s, 3H), 3.18 (dd, J=16.93, 6.57 Hz, 1H), 3.37 (dd,
J=16.80, 5.43 Hz, 1H), 3.43-3.55 (m, 2H), 3.72-3.82 (m, 1H),
4.18-4.31 (m, 2H), 5.14 (t, J=5.94 Hz, 1H), 7.15 (td, J=8.40, 2.65
Hz, 1H), 7.39 (dd, J=8.84, 5.81 Hz, 1H), 7.46 (dd, J=8.34, 2.78 Hz,
1H). MS (ES) [M+H] calculated for
C.sub.18H.sub.22BrFN.sub.5O.sub.3, 454.29; found 454.20).
[1034] Compound 37:
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl
oxime (37, 8.0 mg). .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta.
1.53-1.58 (m, 1H) 1.69-1.73 (m, 1H) 2.46 (s, 3H) 2.79-2.87 (m, 1H)
2.93-2.98 (m, 1H) 3.22-3.28 (m, 1H) 3.35-3.38 (m, 1H) 3.54-3.60 (m,
1H) 3.70 (s, 3H) 3.94-4.00 (m, 2H) 4.69 (ddd, J=10.23, 3.03, 2.91
Hz, 1H) 6.55 (dd, J=8.34, 2.53 Hz, 1H) 6.84 (dd, J=7.33, 2.53 Hz,
1H) 6.94-7.00 (m, 2H) 7.43-7.52 (m, 2H). MS (ES) [M+H] calculated
for C.sub.24H.sub.28FN.sub.6O.sub.4, 483.50; found 483.30.
Example 36
Synthesis of
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl
oxime (Compound 37)
##STR00212##
[1036] Compound 37 was synthesized using an analogous procedure
described for Example 39 except that
(S)--O-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)hydroxylamine was
used. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. 1.43-1.55 (m, 1H)
1.66 (m, 1H) 2.55 (s, 3H) 2.83-2.95 (m, 2H) 3.11-3.44 (m, 1H)
3.17-3.24 (m, 1H) 3.27-3.33 (m, 1H) 3.48-3.56 (m, 1H) 3.65 (s, 3H)
3.89-4.01 (m, 2H) 4.68 (ddd, J=10.23, 3.03, 2.91 Hz, 1H) 6.53 (dd,
J=8.34, 2.53 Hz, 1H) 6.81 (dd, J=7.33, 2.53 Hz, 1H) 6.90 (dt,
J=9.28, 2.68 Hz, 1H) 6.96 (td, J=8.40, 2.65 Hz, 1H) 7.38-7.43 (m,
1H) 7.44-7.51 (m, 1H). MS (ES) [M+H].sup.+ calculated for
C.sub.24H.sub.28FN.sub.6O.sub.4, 483.21; found 483.00.
Example 37
(R,Z)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-di-
hydropyrido[4,3-d]pyrimidin-5(6H)-one O--(R)-3,4-dihydroxybutyl
oxime (Compound 38)
##STR00213##
[1038] Compound 38 was synthesized using an analogous procedure
described for Example 39 except that
(R)--O-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)hydroxylamine was
used. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 1.74-1.93 (m,
1H) 2.13-2.16 (m, 1H) 2.66 (s, 3H) 3.00-3.11 (m, 1H) 3.14-3.24 (m,
1H) 3.32 (d, J=3.03 Hz, 1H) 3.50 (ddd, J=11.18, 7.01, 4.55 Hz, 1H)
3.65 (ddd, J=10.74, 6.95, 3.54 Hz, 1H) 3.90 (s, 3H) 4.13-4.28 (m,
2H) 4.88 (dd, J=10.61, 4.04 Hz, 1H) 5.11 (s, 2H, OH) 5.72 (s, 1H,
NH) 6.74 (d, J=8.84 Hz, 1H) 7.00 (d, J=7.83 Hz, 1H) 7.10-7.22 (m,
2H) 7.61-7.70 (m, 2H). MS (ES) [M+H] calculated for
C.sub.24H.sub.28FN.sub.6O.sub.4, 483.21; found 483.30.
Example 38
(S)-4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-met-
hyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)amino)butane-1,2-diol
(Compound 39)
##STR00214##
[1040] Compound 39 was synthesized using an analogous procedure
described for Example 39 except that
(S)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethanamine (2O, Example 2-F)
was used. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 1.55-1.68
(m, 2H) 2.57 (s, 3H) 2.66-2.78 (m, 2H) 3.16 (dd, J=16.17, 3.54 Hz,
1H) 3.25 (ddd, J=14.08, 4.29, 4.11 Hz, 1H) 3.41-3.49 (m, 1H)
3.52-3.59 (m, 1H) 3.65-3.78 (m, 1H) 3.88 (s, 3H) 4.83 (dd, J=12.63,
3.03 Hz, 1H) 5.30 (br. s., 2H, OH) 6.70 (d, J=8.34 Hz, 1H) 7.01 (d,
J=7.33 Hz, 1H) 7.10 (dd, J=9.47, 2.65 Hz, 1H) 7.17 (td, J=8.27,
2.65 Hz, 1H) 7.62 (t, J=7.83 Hz, 1H) 7.80 (dd, J=8.59, 5.81 Hz,
1H). MS (ES) [M+H] calculated for C.sub.24H.sub.28FN.sub.6O.sub.3,
467.21; found 467.30.
Example 39
Synthesis of
(R,Z)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--((R)-1,4-dioxan-2-yl)methyl oxime (Compound 40)
##STR00215##
[1042] Thiolactam (31I (Example 31), 0.087 g, 0.0272 mmol),
(R)--O-((1,4-dioxan-2-yl)methyl)hydroxylamine (2M (Example 2-E),
0.145 g, 1.09 mmol), and mercury (II) acetate (0.173 g, 0.045 mmol)
were dissolved in 3.5 mL of dry toluene and heated in 100.degree.
C. oil bath for 1 h. The reaction was done as judged by LC/MS. The
crude mixture was filtered through Celite, rinsed with methanol and
then concentrated and purified on preparatory LC/MS (25-55%
CH.sub.3CN in H.sub.2O) to afford
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O--((R)-1,4-dioxan-2-yl)methyl oxime (39A,
0.0405 g, 36.7% yield). .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta.
ppm 2.90 (s, 3H) 3.04 (dd, J=17.05, 8.97 Hz, 2H) 3.28 (dd, J=17.56,
4.17 Hz, 1H) 3.43 (dd, J=11.62, 9.85 Hz, 1H) 3.58-3.68 (m, 1H)
3.70-3.76 (m, 2H) 3.77-3.88 (m, 2H) 3.93-4.00 (m, 1H) 4.01-4.08 (m,
1H) 4.09-4.18 (m, 1H) 5.01 (d, J=5.05 Hz, 1H) 5.78 (s, 1H) 7.11
(td, J=8.21, 2.53 Hz, 1H) 7.37 (dd, J=7.96, 2.65 Hz, 1H) 7.41 (dd,
J=8.84, 5.81 Hz, 1H). ESI-MS: m/z 468.1 (M+H).sup.+.
[1043] 39A was reacted with
2-(6-methoxypyridin-2-yl)-6-phenyl-1,3,6,2-dioxazaborocane (39B)
according to a procedure analogous to Example 31, the step of 31H
to 31J, to afford
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--((R)-1,4-dioxan-2-yl)methyl oxime (40, 37.3% yield). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 2.55 (s, 3H) 2.85 (dd, J=16.17,
7.07 Hz, 1H) 3.10 (dd, J=16.29, 5.18 Hz, 1H) 3.24-3.35 (m, 1H) 3.45
(dd, J=10.99, 2.65 Hz, 1H) 3.50-3.59 (m, 1H) 3.59-3.74 (m, 2H)
3.76-3.84 (m, 3H) 3.86 (s, 3H) 3.89-3.96 (m, 1H) 5.10 (m, 1H) 6.54
(br. s., 1H) 6.85 (d, J=8.34 Hz, 1H) 7.19 (d, J=7.07 Hz, 1H)
7.23-7.31 (m, 2H) 7.45 (dd, J=8.46, 5.94 Hz, 1H) 7.78-7.92 (m, 1H).
ESI-MS:m/z 495.3 (M+H).sup.+.
Example 40
Preparation of
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-morpholin-2-ylmethyl
oxime and isomers (Compounds 41-43)
##STR00216## ##STR00217##
[1045] 40A was prepared by a procedure analogous to that disclosed
in Example 39 except tert-butyl
2-(aminooxymethyl)morpholine-4-carboxylate was used. The final
Boc-deprotection was effected by treatment of 40A (6 mg, 0.01 mmol)
with 4N HCl in dioxane (0.7 mL). The reaction was dried in vacuo to
afford
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-morpholin-2-ylmethyl
oxime as a tan oil (41, quantitative yield). .sup.1H NMR (400 MHz,
MeOD) .delta. ppm 2.84 (s, 3H) 3.00-3.10 (m, 1H) 3.11-3.21 (m, 1H)
3.34-3.50 (m, 2H) 3.53-3.77 (m, 2H) 3.81-3.92 (m, 1H) 4.06 (s, 3H)
4.09-4.13 (m, 2H) 4.13-4.21 (m, 2H) 4.95-4.99 (m, 1H) 7.11-7.18 (m,
1H) 7.23-7.29 (m, 1H) 7.29-7.38 (m, 2H) 7.67-7.76 (m, 1H) 8.04-8.12
(m, 1H). [M+H].sup.+ calc'd for C.sub.25H.sub.28FN.sub.7O.sub.3,
494; found, 494. SFC separation of 41 yields the two
enantiomers.
[1046]
(R,Z)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(R)-morpholin-2-ylmethyl oxime (42). .sup.1H NMR (400 MHz, MeOD)
.delta. ppm 2.82 (s, 3H) 2.95-3.28 (m, 4H) 3.33-3.45 (m, 2H) 3.83
(td, J=12.57, 2.40 Hz, 1H) 3.92 (s, 3H) 4.02-4.21 (m, 4H) 5.07 (dd,
J=8.84, 4.29 Hz, 1H) 6.81 (d, J=8.34 Hz, 1H) 7.13 (d, J=7.33 Hz,
1H) 7.17-7.29 (m, 2H) 7.63 (dd, J=8.59, 5.56 Hz, 1H) 7.78 (t,
J=7.83 Hz, 1H). [M+H] calc'd for C.sub.25H.sub.28FN.sub.7O.sub.3,
494; found, 494.
[1047]
(R,Z)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(S)-morpholin-2-ylmethyl oxime (43). .sup.1H NMR (400 MHz, MeOD)
.delta. ppm 2.82 (s, 3H) 2.95-3.28 (m, 4H) 3.33-3.45 (m, 2H) 3.83
(td, J=12.57, 2.40 Hz, 1H) 3.92 (s, 3H) 4.02-4.21 (m, 4H) 5.07 (dd,
J=8.84, 4.29 Hz, 1H) 6.81 (d, J=8.34 Hz, 1H) 7.13 (d, J=7.33 Hz,
1H) 7.17-7.29 (m, 2H) 7.63 (dd, J=8.59, 5.56 Hz, 1H) 7.78 (t,
J=7.83 Hz, 1H). [M+H] calc'd for C.sub.25H.sub.28FN.sub.7O.sub.3,
494; found, 494.
Example 41
Synthesis of
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2R,3S,4R)-3,4,5-trihydroxytetrahydrofuran-2-yl)methyl oxime
(44) and its analog (Compound 44) and stereoisomers (Compounds 45,
46, 47, and 48)
##STR00218## ##STR00219##
[1049] Reaction of 31I and
O-(((3aR,4R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-
-yl)methyl)hydroxylamine (2Y) according to a procedure analogous to
Example 39 yielded a racemic mixture of
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one
O-((3aR,4R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4--
yl)methyl oxime. Prep LC/MS (40-85% NH.sub.4OAc--H.sub.2O--AcCN)
separation yielded the diastereomers 41A and 41B.
[1050] The diastereomers, 41A and 41B, were each separately coupled
to
2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
according also according to the procedure described in Example 39.
Deprotection and prep LC/MS (40-85% NH.sub.4OAc--H.sub.2O--AcCN)
separation of each of the reaction mixtures yielded a hydroxyl
analog and two stereoisomers.
[1051]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2R,3S,4R)-3,4,5-trihydroxytetrahydrofuran-2-yl)methyl oxime
(44). .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 2.35 (s, 3H)
2.67-2.72 (m, 1H) 2.78-2.90 (m, 1H) 3.29 (dt, J=11.94, 2.87 Hz, 1H)
3.39-3.48 (m, 1H) 3.59 (s, 3H) 3.65-3.77 (m, 1H) 3.82-3.90 (m, 1H)
3.91-4.01 (m, 1H) 4.57-4.69 (m, 1H) 4.83-4.97 (m, 1H) 6.37-6.50 (m,
1H) 6.75 (d, J=7.33 Hz, 1H) 6.79-6.91 (m, 2H) 7.32-7.44 (m, 2H). MS
(ES) [M+H] calculated for C.sub.25H.sub.28FN.sub.6O.sub.6, 527.20;
found 527.20.
[1052]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-((2R,3S,4R,
SR)-3,4-dihydroxy-5-methoxytetrahydrofuran-2-yl)methyl oxime (45).
.sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 2.44 (s, 3H)
2.72-2.84 (m, 1H) 2.88-2.97 (m, 1H) 3.05 (s, 3H) 3.68 (s, 3H) 3.70
(d, J=2.27 Hz, 1H) 3.81-3.94 (m, 2H) 3.95-4.03 (m, 2H) 4.56 (s, 1H)
4.69 (dd, J=9.98, 3.16 Hz, 1H) 6.53 (d, J=8.34 Hz, 1H) 6.82 (d,
J=7.33 Hz, 1H) 6.88-7.00 (m, 2H) 7.39-7.52 (m, 2H). MS (ES) [M+H]
calculated for C.sub.26H.sub.30FN.sub.6O.sub.6, 541.21; found
541.20.
[1053]
(R,Z)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((3aR,4R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-
-4-yl)methyl oxime (46). .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta. ppm 1.10 (s, 3H) 1.27 (s, 3H) 2.46 (s, 3H) 2.79-2.88 (m,
1H) 2.92-3.01 (m, 1H) 3.08 (s, 3H) 3.69 (s, 3H) 3.78-3.91 (m, 2H)
4.32 (t, J=6.44 Hz, 1H) 4.37 (d, J=5.81 Hz, 1H) 4.57 (d, J=6.06 Hz,
1H) 4.72 (dd, J=10.74, 3.66 Hz, 1H) 4.75 (s, 1H) 6.56 (d, J=9.85
Hz, 1H) 6.84 (d, J=6.32 Hz, 1H) 6.90-7.04 (m, 2H) 7.44-7.54 (m,
2H). MS (ES) [M+H] calculated for C.sub.29H.sub.34FN.sub.6O.sub.6,
581.24; found 581.30.
[1054]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-((2R,3S,4R,
SS)-3,4-dihydroxy-5-methoxytetrahydrofuran-2-yl)methyl oxime (47).
.sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 2.51 (s, 3H)
2.81-2.91 (m, 1H) 2.96-3.04 (m, 1H) 3.12 (s, 3H) 3.74 (s, 3H) 3.77
(d, J=4.80 Hz, 1H) 3.92-4.00 (m, 2H) 4.01-4.07 (m, 2H) 4.63 (s, 1H)
4.74 (dd, J=10.36, 4.04 Hz, 1H) 6.59 (d, J=8.08 Hz, 1H) 6.88 (d,
J=7.07 Hz, 1H) 6.94-7.07 (m, 2H) 7.52 (t, J=7.83 Hz, 2H). MS (ES)
[M+H] calculated for C.sub.26H.sub.30FN.sub.6O.sub.6, 541.21; found
541.20.
[1055]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((3aR,4R,6S,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-
-4-yl)methyl oxime (48) .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta.
ppm 1.04 (s, 3H) 1.20 (s, 3H) 2.40 (s, 3H) 2.72-2.81 (m, 1H)
2.86-2.94 (m, 1H) 3.02 (s, 3H) 3.63 (s, 3H) 3.64-3.79 (m, 3H) 4.26
(t, J=6.69 Hz, 1H) 4.51 (d, J=4.55 Hz, 1H) 4.62-4.70 (m, 2H) 6.50
(d, J=8.59 Hz, 1H) 6.79 (d, J=7.33 Hz, 1H) 6.85-6.95 (m, 2H)
7.39-7.47 (m, 2H). MS (ES) [M+H] calculated for
C.sub.29H.sub.34FN.sub.6O.sub.6, 581.24; found 581.30.
Example 42
General Procedure for Suzuki Coupling
##STR00220##
[1057] Into a 5 mL microwave vial was charged
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]p-
yrimidin-5(6H)-one (31H (Example 31), 100 mg, 0.28 mmol, 1 eq),
boronic acid 42A (4 eq), and Pd(dppf)Cl.sub.2 CH.sub.2Cl.sub.2 (93
mg, 0.11 mmol, 0.4 eq). The compounds were dissolved in a mixture
of DMA (3 mL) and 2M K.sub.2CO.sub.3 (1 mL, 8 eq) and the vial was
sealed. The reaction mixture was heated to 120.degree. C. for 10
min in a microwave reactor. After cooling to RT, the reaction
mixture was diluted with DCM and washed with H.sub.2O (.times.3)
and saturated brine, then dried over anhydrous sodium sulfate,
filtered, and evaporated under reduced pressure to give crude
product. The crude material was purified via preparative HPLC to
yield the pure TFA salt of the product 42B as an off-white
solid.
Example 43
Preparation of
(R)-2-amino-7-(5-fluoro-3'-((4-(trifluoromethoxy)phenoxy)methyl)biphenyl--
2-yl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
(43A)
##STR00221##
[1059] Compound 43A was prepared by the method outlined in Example
42 using 3-((4-(trifluoromethoxy)phenoxy)methyl)phenylboronic acid.
.sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 2.79 (s, 3H)
2.86-2.93 (m, 1H) 3.08 (dd, J=16.80, 11.75 Hz, 1H) 4.83 (dd,
J=11.49, 4.42 Hz, 1H) 5.07 (s, 2H) 6.91-6.97 (m, 3H) 6.98-7.05 (m,
2H) 7.17-7.24 (m, 2H) 7.45-7.48 (m, 1H) 7.51-7.62 (m, 2H) 7.66-7.75
(m, 1H). ESI-MS: m/z 539 (MH.sup.+).
Example 44
Preparation of
(R)-2-amino-7-(5-fluoro-2'-((3-(1,1-dioxidoisothiazolidin-2-yl)methyl)bip-
henyl-2-yl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
(41A)
##STR00222##
[1061] The title compound 44A was prepared by the method outlined
in Example 42 using 3-(1,1-dioxidoisothiazolidin-2-yl)phenylboronic
acid. .sup.1H NMR (400 MHz, MeOD) .delta. ppm 2.50 (quin, J=6.88
Hz, 2H) 2.80 (s, 3H) 3.00 (dd, J=17.05, 4.17 Hz, 1H) 3.23-3.29 (m,
1H) 3.43 (t, J=7.45 Hz, 2H) 3.80 (t, J=6.44 Hz, 2H) 4.90-4.93 (m,
1H) 7.06 (dd, J=9.22, 2.40 Hz, 1H) 7.12 (d, J=7.58 Hz, 1H)
7.19-7.28 (m, 3H) 7.45 (t, J=7.83 Hz, 1H) 7.69 (dd, J=8.84, 5.56
Hz, 1H). ESI-MS: m/z 468 (MH.sup.+).
Example 45
(R,Z)-2-Amino-7-(3'-(cyclopropylsulfonyl)-5-fluorobiphenyl-2-yl)-4-methyl--
7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(S)-2,3-dihydroxypropyl oxime (Compound 49)
##STR00223##
[1063] Compound 45A was synthesized according to the procedure of
Example 39 using
(S)--O-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)hydroxylamine.
3-(cyclopropylsulfonyl)phenylboronic acid was then coupled to 45A
according to the Suzuki coupling reaction of Example 42 yielding
the title compound 49. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta.
ppm 0.76-0.88 (m, 1H) 0.99-1.11 (m, 1H) 2.29-2.38 (m, 1H) 2.45 (s,
3H) 2.60 (dd, J=16.55, 3.66 Hz, 1H) 2.81 (dd, J=16.42, 10.86 Hz,
1H) 3.28-3.43 (m, 1H) 3.70-3.76 (m, 1H) 3.77-3.85 (m, 1H) 3.85-3.92
(m, 1H) 4.21 (dd, J=10.86, 3.28 Hz, 1H) 6.78 (dd, J=9.09, 2.53 Hz,
1H) 6.98 (td, J=8.27, 2.40 Hz, 1H) 7.37-7.48 (m, 3H) 7.62 (s, 1H)
7.68 (dt, 1H). MS (ES) [M+H] calculated for
C.sub.26H.sub.29FN.sub.5O.sub.5S, 542.18; found 542.20.
Example 46
(S)-4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-met-
hyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-methoxybut-
anoic acid (Compound 50)
##STR00224##
[1064] A. Synthesis of (S)-methyl
4-(aminooxy)-2-methoxybutanoate
[1065] To a suspension of NaH (60% in mineral oil, 552 mg, 12.0
mmol) in THF (5 mL) was added a solution of
(S)-3-hydroxydihydrofuran-2(3H)-one (46a, 1.02 g, 10.0 mmol) in THF
(5 mL) slowly drop wise at 0.degree. C. under N.sub.2 atmosphere.
The reaction mixture was stirred for 30 minutes and
dimethylsulphate (1.4 mL, 15.0 mmol) was added. The reaction
mixture was stirred at r.t. overnight and the TLC shows completion
of the reaction. Cold water (25 mL) was added to the reaction
mixture and extracted with ethyl acetate. Organic layer washed with
brine, dried over anhydrous Na.sub.2SO.sub.4 and filtered.
Concentrated to provide (S)-3-hydroxydihydrofuran-2(3H)-one (46a)
as yellow oil, which was dissolved in MeOH. Catalytic amount of
K.sub.2CO.sub.3 (50 mg) was added at 0.degree. C. and the reaction
mixture stirred for 1 h. TLC shows completion of the reaction. Cold
water (25 mL) was added to the reaction mixture and extracted with
ethyl acetate. Organic layer washed with brine, dried over
anhydrous Na.sub.2SO.sub.4 and filtered. Concentrated to provide
(S)-methyl 4-hydroxy-2-methoxybutanoate (46b, 1.5 g, 99%) as yellow
oil. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 2.07-2.28 (m,
1H) 2.36-2.58 (m, 1H) 3.36 (s, 3H) 3.49 (s, 3H) 3.85-4.07 (m, 1H)
4.29-4.42 (m, 2H).
[1066] To a solution of (S)-methyl 4-hydroxy-2-methoxybutanoate
(46b, 1.48 g, 10.0 mmol) in CH.sub.2CT.sub.2 (25.0 mL) was added
2-hydroxyisoindolin-1,3-dione (1.63 g, 10.0 mmol) and
triphenylphosphine (3.93 g, 15.0 mmol). The resultant mixture was
cooled to 0.degree. C. and diisopropylazodicarboxylate (2.95 ml,
15.0 mmol) was slowly added drop wise under N.sub.2 atmosphere. The
reaction mixture was stirred at ambient temperature for 48 h. To
the reaction mixture, H.sub.2O (100 mL) was added and extracted
with CH.sub.2Cl.sub.2. The organic layers washed with brine. Dried
over anhydrous Na.sub.2SO.sub.4, filtered and concentrated to
provide yellow oil, which was purified by flash chromatography (50%
EtOAc-hexane) to afford (S)-methyl
4-(1,3-dioxoisoindolin-2-yloxy)-2-methoxybutanoate (46c, 1.25 g,
42%) as light yellow oil. .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta. ppm 1.98-2.10 (m, 1H) 2.23-2.37 (m, 1H) 3.51 (s, 3H) 3.79
(s, 3H) 4.24 (dd, J=9.47, 3.66 Hz, 1H) 4.31-4.40 (m, 2H) 7.74-7.82
(m, 2H) 7.81-7.90 (m, 2H).
[1067] To a solution of (S)-methyl
4-(1,3-dioxoisoindolin-2-yloxy)-2-methoxybutanoate (1.2 g, 4.0
mmol) in CH.sub.2Cl.sub.2 (5.0 ml) was added hydrazine hydrate
(0.98 mL, 10.0 mmol) was added drop wise at 0.degree. C. The
reaction mixture was stirred at ambient temperature over night. The
resultant solid was filtered off and the filtrate concentrated
under reduced pressure to provide a yellow oil, which was purified
by flash chromatography (70% EtOAc-hexane) to afford (S)-methyl
4-(aminooxy)-2-methoxybutanoate (46c, 0.552 g, 84%) as a pale
yellow oil. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm
1.75-2.23 (m, 2H) 3.40 (s, 3H) 3.46 (s, 3H) 3.65-3.86 (m, 2H) 4.96
(dt, J=12.57, 6.22 Hz, 1H).
B. Preparation of Compound 50
[1068] A mixture of
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]p-
yrimidine-5(6H)-thione (31I, 146 mg, 0.4 mmol), (S)-methyl
4-(aminooxy)-2-methoxybutanoate (46c, 260 mg, 1.6 mmol),
Hg(OAc).sub.2 (257 mg, 0.8 mmol) and toluene (2 mL) was heated at
100.degree. C. for 2 h. Cooled to rt, filtered through celite and
purified to afford (S)-methyl
4-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido-
[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-methoxybutanoate (23 mg,
12%) as off white solid. MS (ES) [M+H] calculated for
C.sub.20H.sub.24BrFN.sub.5O.sub.4, 496.09; found 496.20.
[1069] A mixture of the resultant compound (23 mg, 0.05 mmol),
2-(6-methoxypyridin-2-yl)-6-phenyl-1,3,6,2-dioxazaborocane (74.5
mg, 0.25 mmol), Pd(dppf).sub.2Cl.sub.2 (4.0 mg, 0.005 mmol), 2N aq
Na.sub.2CO.sub.3 (0.25 mL, 0.5 mmol) and DMA (2 mL) was degassed
with N.sub.2 and heated at 85.degree. C. for 4 h. During the
reaction, the methyl ester saponified in situ. Cooled to rt,
filtered trough celite and purified to afford
(S)-4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-methoxybu-
tanoic acid (4.6 mg, 20%) as off white solid. .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 1.91-2.03 (m, 1H) 2.10-2.24 (m, 1H) 2.74
(s, 3H) 2.84-2.98 (m, 1H) 3.00-3.10 (m, 1H) 3.31 (br. s., 3H)
3.75-3.79 (m, 1H) 3.81 (s, 3H) 4.02-4.16 (m, 2H) 4.82 (ddd,
J=10.23, 2.91, 2.78 Hz, 1H) 6.69 (dd, J=8.34, 2.02 Hz, 1H) 6.95
(dd, J=7.20, 1.89 Hz, 1H) 7.06 (ddd, J=9.16, 2.46, 2.27 Hz, 1H)
7.09-7.16 (m, 1H) 7.60 (dddd, J=15.73, 8.15, 7.96, 2.27 Hz, 2H). MS
(ES) [M+H] calculated for C.sub.25H.sub.28FN.sub.6O.sub.5, 511.20;
found 511.40.
Example 47
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-di-
hydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2R,3S,4S)-3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime
(Compound 51)
##STR00225##
[1071] To a solution of
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2R,3S,4R)-3,4-dihydroxy-5-methoxytetrahydrofuran-2-yl)methyl
oxime (10.5 mg, 0.02 mmol) in CH.sub.2Cl.sub.2 (1 mL) was added
Et.sub.3SiH (16 .mu.L, 0.05 mmol) and BF.sub.3.Et.sub.2O (8.0
.mu.L, 0.05 mmol) at 0.degree. C. under N.sub.2 atmosphere. The
reaction mixture was stirred overnight at r.t. and poured on
crushed ice. The resultant slurry was extracted with
CH.sub.2Cl.sub.2 and washed with brine. Work-up and purification by
Preparative LCMS afforded the title compound (3.0 mg, 30%) as light
brown solid. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 2.50
(s, 3H) 2.77 (dd, J=16.04, 6.95 Hz, 1H) 3.00 (dd, J=16.04, 5.18 Hz,
1H) 3.15-3.26 (m, 2H) 3.35-3.42 (m, 2H) 3.83 (s, 3H) 3.85-3.94 (m,
2H) 4.38-4.41 (m, 1H) 4.93-5.13 (m, 1H) 6.82 (d, J=9.09 Hz, 1H)
7.16 (d, J=7.07 Hz, 1H) 7.21-7.30 (m, 2H) 7.45 (dd, J=8.46, 5.94
Hz, 1H) 7.86 (dd, J=8.34, 7.33 Hz, 1H). MS (ES) [M+H] calculated
for C.sub.25H.sub.28FN.sub.6O.sub.5, 511.51; found 511.20.
Example 48
(2S,4R)-tert-butyl
2-(aminooxymethyl)-4-(tert-butyldimethylsilyloxy)pyrrolidine-1-carboxylat-
e
##STR00226##
[1073] To a solution of (2S,4R)-tert-butyl
4-(tert-butyldimethylsilyloxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate
(2.0 g, 6.0 mmol) in CH.sub.2CT.sub.2 (15.0 mL) was added
2-hydroxyisoindolin-1,3-dione (978 mg, 6.0 mmol) and
triphenylphosphine (2.36 g, 9.0 mmol). The resultant mixture was
cooled to 0.degree. C. and diisopropylazodicarboxylate (1.78 ml,
9.0 mmol) was slowly added drop wise under N.sub.2 atmosphere. The
reaction mixture was stirred at ambient temperature for 48 h. To
the reaction mixture, H.sub.2O (100 mL) was added and extracted
with CH.sub.2Cl.sub.2. The organic layers washed with brine. Dried
over anhydrous Na.sub.2SO.sub.4, filtered and concentrated to
provide yellow oil, which was purified by flash chromatography (50%
EtOAc-hexane) to yield (2S,4R)-tert-butyl
4-(tert-butyldimethylsilyloxy)-2-((1,3-dioxoisoindolin-2-yloxy)methyl)pyr-
rolidine-1-carboxylate as light yellow oil.
[1074] The resultant oily compound was dissolved in
CH.sub.2Cl.sub.2 (250 ml) and cooled to 0.degree. C. Hydrazine
hydrate (1.2 mL, 12.0 mmol) was added dropwise. The reaction
mixture was stirred at ambient temperature over night. The
resultant solid was filtered off and the filtrate concentrated
under reduced pressure to provide a yellow oil, which was purified
by flash chromatography (70% EtOAc-hexane) to afford 1.2 g (60%,
over two steps) of (2S,4R)-tert-butyl
2-(aminooxymethyl)-4-(tert-butyldimethylsilyloxy)pyrrolidine-1-carboxylat-
e as a pale yellow oil. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta.
ppm 0.24 (s, 3H) 0.26 (s, 3H) 0.87 (s, 9H) 1.26 (s, 9H) 1.67-1.76
(m, 1H) 1.81-1.94 (m, 1H) 3.18 (dd, J=12.25, 4.93 Hz, 1H) 3.22-3.31
(m, 1H) 3.70-3.81 (m, 1H) 3.88-3.96 (m, 1H) 3.98-4.09 (m, 1H)
4.12-4.21 (m, 1H). MS (ES) [M+H] calculated for
C.sub.16H.sub.35N.sub.2O.sub.4Si, 347.23; found 347.22.
Example 49
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-di-
hydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2S,4R)-4-hydroxypyrrolidin-2-yl)methyl oxime (Compound 52)
##STR00227##
[1076] A mixture of
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]p-
yrimidine-5(6H)-thione (183 mg, 0.5 mmol), (2S,4R)-tert-butyl
2-(aminooxymethyl)-4-(tert-butyldimethylsilyloxy)pyrrolidine-1-carboxylat-
e (692 mg, 2.0 mmol), Hg(OAc).sub.2 (320 mg, 1.0 mmol) and toluene
(2 mL) was heated at 100.degree. C. for 2 h.
Cooled to r.t., filtered through celite and purified to afford
(2S,4R)-tert-butyl
2-(((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrid-
o[4,3-d]pyrimidin-5-(6H)-ylidene)aminooxy)methyl)-4-(tert-butyldimethylsil-
yloxy)pyrrolidine-1-carboxylate (200 mg, 50%) as off white solid.
MS (ES) [M+H] calculated for C.sub.30H.sub.45BrFN.sub.6O.sub.4Si,
679.24; found 679.20.
[1077] A mixture of the resultant compound (200 mg, 0.3 mmol),
2-(6-methoxypyridin-2-yl)-6-phenyl-1,3,6,2-dioxazaborocane (447 mg,
1.5 mmol), Pd(dppf).sub.2Cl.sub.2 (25 mg, 0.03 mmol), 2N aq
Na.sub.2CO.sub.3 (1.5 mL, 3.0 mmol) and DMA (2 mL) was degassed
with N.sub.2 and heated at 85.degree. C. for 4 h. Cooled to rt,
filtered trough celite and purified to afford (2S,4R)-tert-butyl
2-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)methyl)-4-hydro-
xypyrrolidine-1-carboxylate (94 mg, 53%) as a viscous oil. MS (ES)
[M+H] calculated for C.sub.30H.sub.37FN.sub.7O.sub.5, 594.28; found
594.30.
The resultant oily compound was dissolved in dioxane (1.0 ml) and
cooled to 0.degree. C. 4N HCl in dioxane (0.1 mL, 0.375 mmol) was
added and the reaction mixture was stirred at ambient temperature
for 2 h. The resultant solid was filtered off and dried to afford
Compound 52 as an HCl salt (56 mg, 76%) as white solid. .sup.1H NMR
(400 MHz, CHLOROFORM-d) .delta. ppm 1.64 (ddd, J=13.64, 8.08, 5.56
Hz, 1H) 1.88 (dd, J=13.64, 7.07 Hz, 1H) 2.65 (s, 3H) 2.90 (d,
J=11.62 Hz, 1H) 3.00-3.09 (m, 2H) 3.13-3.27 (m, 1H) 3.68-3.82 (m,
1H) 3.84-3.94 (m, 4H) 3.95-4.02 (m, 1H) 4.40 (t, J=4.67 Hz, 1H)
4.87 (dd, J=10.48, 3.92 Hz, 1H) 5.18 (s, 2H) 5.72 (s, 1H) 6.73 (d,
J=8.34 Hz, 1H) 7.00 (d, J=7.07 Hz, 1H) 7.07-7.24 (m, 2H) 7.57-7.77
(m, 2H). MS (ES) [M+H] calculated for
C.sub.25H.sub.29FN.sub.7O.sub.3, 494.22; found 494.20.
Example 50
(3R,5S)-1-acetyl-5-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl-
)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy-
)methyl)pyrrolidin-3-yl acetate (Compound 53)
##STR00228##
[1079] To a solution of
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2S,4R)-4-hydroxypyrrolidin-2-yl)methyl oxime (20 mg, 0.05 mmol)
in CH.sub.2Cl.sub.2 (1 mL) containing catalytic amount of DMAP was
added Et.sub.3N (20.86 .mu.L, 0.15 mmol) and acetyl chloride (10.0
.mu.L, 0.1 mmol) at 0.degree. C. under N.sub.2 atmosphere. The
reaction mixture was stirred at r.t. for 2 h. Quenched with sat
NH.sub.4Cl solution and extracted with CH.sub.2Cl.sub.2. The
combined organic layers washed with brine, dried over anhydrous
Na.sub.2SO.sub.4. The resultant residue was purified by preparative
LCMS to afford the title compound (5 mg, 25%) as a white solid.
.sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 2.00 (s, 3H) 2.04
(s, 3H) 2.09-2.23 (m, 1H) 2.29-2.41 (m, 1H) 2.64 (s, 3H) 2.95-3.11
(m, 1H) 3.15-3.29 (m, 1H), 3.66 (dd, J=11.37, 5.56 Hz, 1H) 3.90 (s,
3H) 4.04 (dd, J=11.87, 5.31 Hz, 1H) 4.13-4.30 (m, 1H) 4.32-4.49 (m,
1H) 4.77-4.95 (m, 1H), 5.06-5.16 (m, 1H) 5.20-5.32 (m, 1H) 6.74 (d,
J=8.34 Hz, 1H) 7.01 (d, J=8.34 Hz, 1H) 7.10-7.22 (m, 2H) 7.57-7.74
(m, 2H). MS (ES) [M+H] calculated for
C.sub.29H.sub.33FN.sub.7O.sub.5, 578.60; found 578.30.
Example 51
(2S,4R)-1-tert-butyl 2-methyl
4-(aminooxy)pyrrolidine-1,2-dicarboxylate
##STR00229##
[1081] To a solution of (2S,4R)-1-tert-butyl 2-methyl
4-hydroxypyrrolidine-1,2-dicarboxylate (4.9 g, 20.0 mmol) in
CH.sub.2Cl.sub.2 (50.0 mL) was added 2-hydroxyisoindolin-1,3-dione
(3.26 g, 20.0 mmol) and triphenylphosphine (7.86 g, 30.0 mmol). The
resultant mixture was cooled to 0.degree. C. and
diisopropylazodicarboxylate (5.90 ml, 30.0 mmol) was slowly added
drop wise under N.sub.2 atmosphere. The reaction mixture was
stirred at ambient temperature for 48 h. Work-up and purification
as described in Example 2A, Step 1 afforded (2S,4R)-1-tert-butyl
2-methyl
4-(1,3-dioxoisoindolin-2-yloxy)pyrrolidine-1,2-dicarboxylate as a
viscous oil. The resultant oily compound was dissolved in
CH.sub.2Cl.sub.2 (100 ml) and cooled to 0.degree. C. Hydrazine
hydrate (4.0 mL, 40.0 mmol) was added drop wise. The reaction
mixture was stirred at ambient temperature over night. Work-up and
purification as described in Example 2A, Step 2 afforded (2.8 g,
53%, over two steps) of (2S,4R)-1-tert-butyl 2-methyl
4-(aminooxy)pyrrolidine-1,2-dicarboxylate as a pale yellow oil.
.sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 1.42 (s, 9H)
2.13-2.29 (m, 1H) 2.34-2.48 (m, 1H) 3.48-3.68 (m, 2H) 3.72 (s, 3H)
4.23-4.30 (m, 1H) 4.30-4.49 (m, 1H). MS (ES) [M+H] calculated for
C.sub.11H.sub.21N.sub.2O.sub.5, 261.14; found 261.22.
Example 52
(2S,4R)-methyl
4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)pyrrolidine-2-ca-
rboxylate (Compound 54)
##STR00230##
[1083] A mixture of
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]p-
yrimidine-5(6H)-thione (150 mg, 0.4 mmol), (2S,4R)-1-tert-butyl
2-methyl 4-(aminooxy)pyrrolidine-1,2-dicarboxylate (416 mg, 1.6
mmol), Hg(OAc).sub.2 (256 mg, 0.8 mmol) and toluene (2 mL) was
heated at 100.degree. C. for 2 h. Cooled to rt, filtered through
celite and purified to afford (2S,4R)-1-tert-butyl 2-methyl
4-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido-
[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)pyrrolidine-1,2-dicarboxylate
(172 mg, 570%) as off white solid. MS (ES) [M+H] calculated for
C.sub.25H.sub.31BrFN.sub.6O.sub.5, 593.14; found 593.10.
[1084] A mixture of
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]p-
yrimidine-5(6H)-thione (150 mg, 0.4 mmol), (2S,4R)-1-tert-butyl
2-methyl 4-(aminooxy)pyrrolidine-1,2-dicarboxylate (416 mg, 1.6
mmol), Hg(OAc).sub.2 (256 mg, 0.8 mmol) and toluene (2 mL) was
heated at 100.degree. C. for 2 h. Cooled to rt, filtered through
celite and purified to afford (2S,4R)-1-tert-butyl 2-methyl
4-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido-
[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)pyrrolidine-1,2-dicarboxylate
(172 mg, 570%) as off white solid. MS (ES) [M+H] calculated for
C.sub.25H.sub.31BrFN.sub.6O.sub.5, 593.14; found 593.10.
[1085] The resultant oily compound was dissolved in dioxane (1.0
ml) and cooled to 0.degree. C. 4N HCl in dioxane (62.0 .mu.L, 0.25
mmol) was added and the reaction mixture was stirred at ambient
temperature for 2 h. The resultant solid was filtered off and dried
to afford Compound 54 as an HCl salt (45.0 mg, 82%) as white solid.
.sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 2.32-2.46 (m, 2H)
2.53 (s, 3H) 2.87 (dd, J=16.80, 10.74 Hz, 2H) 3.12 (d, J=4.04 Hz,
1H) 3.30 (dd, J=12.63, 3.54 Hz, 1H) 3.47 (s, 3H) 3.71 (s, 3H) 4.38
(dd, J=9.98, 2.65 Hz, 1H) 4.67 (t, J=3.79 Hz, 1H) 4.73 (dd,
J=10.23, 3.66 Hz, 1H) 6.60 (d, J=8.34 Hz, 1H) 6.87 (d, J=7.07 Hz,
1H) 6.97 (dd, J=9.22, 2.65 Hz, 1H) 7.03 (td, J=8.46, 2.02 Hz, 1H)
7.46 (dd, J=9.09, 4.80 Hz, 1H) 7.53 (t, J=7.71 Hz, 1H). MS (ES)
[M+H] calculated for C.sub.26H.sub.29FN.sub.7O.sub.4, 522.542;
found 522.24
Example 53
(2S,4R)-4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-
-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)pyrrolidi-
ne-2-carboxylic acid (Compound 55)
##STR00231##
[1087] The title compound was prepared analogous to the procedure
described for Example 52. .sup.1H NMR (400 MHz, MeOD) .delta. ppm
2.23-2.36 (m, 1H) 2.39-2.49 (m, 1H) 2.69 (s, 3H) 3.14-3.26 (m, 2H)
3.43-3.54 (m, 2H) 3.76 (s, 3H) 4.14-4.26 (m, 1H) 4.53 (dd, J=9.09,
3.79 Hz, 1H) 4.60 (d, J=2.27 Hz, 1H) 6.82-6.91 (m, 1H) 6.93-7.09
(m, 2H) 7.20-7.32 (m, 1H) 7.44 (dd, J=8.84, 5.31 Hz, 1H) 7.68-7.90
(m, 1H). MS (ES) [M+H] calculated for
C.sub.25H.sub.27FN.sub.7O.sub.4, 507.51; found 508.20.
Example 54
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-di-
hydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3R,5S)-5-(hydroxymethyl)pyrrolidin-3-yl oxime (Compound 56)
##STR00232##
[1089] To a solution of (2S,4R)-methyl
4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)
aminooxy)pyrrolidine-2-carboxylate (25.0 mg, 0.04 mmol) in dry
ether (1 mL) was added LiAlH.sub.4 (0.1 mL, 0.01 mmol, 1M solution
in ether) at 0.degree. C. under N.sub.2 atmosphere. Stirred for 1 h
and quenched with 1N NaOH (0.1 mL) solution. Anhydrous MgSO.sub.4
was added and filtered through celite. The filtrate was
concentrated under reduced pressure and purified by preparative
LCMS to afford the title compound (6.0 mg, 32%) as a white solid.
.sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 1.67-1.95 (m, 2H)
2.47 (s, 3H) 2.58 (d, J=3.03 Hz, 1H) 2.71 (d, J=3.28 Hz, 1H)
2.94-3.00 (m, 2H) 3.13-3.19 (m, 1H) 3.22-3.39 (m, 2H) 3.43 (dd,
J=11.12, 6.32 Hz, 1H) 3.58 (s, 3H) 4.65-4.73 (m, 1H) 6.47 (dd,
J=8.46, 2.91 Hz, 1H) 6.76 (dd, J=7.20, 2.65 Hz, 1H) 6.84 (ddd,
J=9.73, 2.78, 2.65 Hz, 1H) 6.87-6.93 (m, 1H) 7.29-7.36 (m, 1H) 7.41
(t, J=7.83 Hz, 1H). MS (ES) [M+H] calculated for
C.sub.25H.sub.29FN.sub.7O.sub.3, 494.53; found 494.20.
Example 55
(3aR,4R,6aS)-tert-butyl
4-(aminooxymethyl)-2,2-dimethyldihydro-3aH-[1,3]dioxolo[4,5-c]pyrrole-5(4-
H)-carboxylate
##STR00233##
[1091] To a solution of (S)-1-tert-butyl 2-methyl 1H-pyrrole-1,
2(2H, 5H)-dicarboxylate (1.0 g, 4.5 mmol) in dioxane --H.sub.2O
(4:1) was added NMO (580 mg, 4.95 mmol) and OsO.sub.4 114 mg, 0.45
mmol, 2.5 wt % in H.sub.2O) and the reaction mixture was stirred
for 24 h at r.t. Quenched with 10% aqueous Na.sub.2S.sub.2O.sub.3
solution and extracted with ethyl acetate. The combined organic
layers washed with brine and dried over anhydrous Na.sub.2SO.sub.4.
The resultant residue was dissolved in acetone (5 mL), added
catalytic amount of PPTS and dimethoxy propane (1.5 mL). The
reaction mixture was stirred over night at r.t. and diluted with
ethyl acetate, washed with saturated NaHCO.sub.3 and brine. Dried
over anhydrous Na.sub.2SO.sub.4 and concentrated under reduced
pressure. The residue was dissolved in ether (5.0 mL) and
LiAlH.sub.4 (3.0 mL, 3.0 mmol, 1M solution in ether) was added at
0.degree. C. under N.sub.2 atmosphere. Stirred for 1 h and quenched
with 1N NaOH (0.1 mL) solution. Anhydrous MgSO.sub.4 was added and
filtered through celite. The filtrate was concentrated under
reduced pressure and purified by flash chromatography (5%
MeOH--CH.sub.2Cl.sub.2) to afford (3aR,4R,6aS)-tert-butyl
4-(hydroxymethyl)-2,2-dimethyldihydro-3aH-[1,3]dioxolo[4,5-c]pyrrole-5(4H-
)-carboxylate (550 mg, 45%, over 3 steps). .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 1.32 (s, 6H) 1.47 (s, 9H) 3.33-3.38 (m,
1H) 3.50 (dd, J=13.14, 6.06 Hz, 2H) 4.54 (d, J=3.79 Hz, 1H)
4.59-4.61 (m, 1H) 4.66-4.73 (m, 2H).
[1092] The resultant oily compound (550 mg, 2.0 mmol) was subjected
to the Mitsunobu coupling followed by phthalimide deprotection
analogous to the procedure described in Example 2 afforded
(3aR,4R,6aS)-tert-butyl
4-(aminooxymethyl)-2,2-dimethyldihydro-3aH-[1,3]dioxolo[4,5-c]pyrrole-5(4-
H)-carboxylate (340 mg, 59%) as a viscous oil. .sup.1H NMR (400
MHz, CHLOROFORM-d) .delta. ppm 1.31 (s, 3H) 1.45 (s, 3H) 1.47 (s,
9H) 3.26-3.47 (m, 1H) 3.59-3.80 (m, 2H) 4.07-4.38 (m, 1H) 4.51-4.67
(m, 1H) 5.41-5.71 (m, 2H). MS (ES) [M+H] calculated for
C.sub.13H.sub.25N.sub.2O.sub.5, 289.17; found 289.20.
Example 56
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-di-
hydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((2R,3R,4S)-3,4-dihydroxypyrrolidine-2-yl)methyl oxime (Compound
57)
##STR00234##
[1094] The title compound was prepared according to the procedure
described for example # using
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]p-
yrimidine-5(6H)-thione (150 mg, 0.4 mmol) and
(3aR,4R,6aS)-tert-butyl
4-(aminooxymethyl)-2,2-dimethyldihydro-3aH-[1,3]dioxolo[4,5-c]pyrrole-5(4-
H)-carboxylate (340 mg, 1.2 mmol). Suzuki coupling followed by
deprotection afforded the title compound as a white solid. .sup.1H
NMR (400 MHz, CHLOROFORM-d) .delta. ppm 2.53 (s, 3H) 2.85-2.99 (m,
1H) 3.02-3.15 (m, 1H) 3.18-3.25 (m, 1H) 3.26-3.31 (m, 2H) 3.81 (s,
3H) 3.83-3.95 (m, 1H) 3.97-4.04 (m, 1H) 4.10 (brs, 1H) 4.20-4.29
(m, 1H) 4.37 (d, J=4.80 Hz, 1H) 4.60 (brs, 1H) 4.81 (dd, J=9.47,
3.41 Hz, 1H) 6.68 (d, J=8.34 Hz, 1H) 6.95 (d, J=7.07 Hz, 2H)
7.01-7.14 (m, 1H) 7.48-7.57 (m, 1H) 7.61 (t, J=7.71 Hz, 1H). MS
(ES) [M+H] calculated for C.sub.25H.sub.29FN.sub.7O.sub.4, 510.53;
found 510.40.
Example 57
(1R,2S)-4-(aminooxy)cyclopentane-1,2-diol
##STR00235##
[1096] To a solution of cyclopent-3-enol (840 mg, 10.0 mmol) in
CH.sub.2CT.sub.2 (25.0 mL) was added 2-hydroxyisoindolin-1,3-dione
(1.96 g, 12.0 mmol) and triphenylphosphine (3.93 g, 15.0 mmol). The
resultant mixture was cooled to 0.degree. C. and
diisopropylazodicarboxylate (2.95 ml, 15.0 mmol) was slowly added
drop wise under N.sub.2 atmosphere. The reaction mixture was
stirred at ambient temperature for 48 h. To the reaction mixture,
H.sub.2O (100 mL) was added and extracted with CH.sub.2Cl.sub.2.
The organic layers washed with brine. Dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to provide yellow oil,
which was purified by flash chromatography (50% EtOAc-hexane) to
yield 2-(cyclopent-3-enyloxy)isoindoline-1,3-dione (740 mg, 32%) as
light yellow oil. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm
2.57-2.87 (m, 4H) 5.12 (t, J=6.19 Hz, 1H) 5.75 (s, 2H) 7.74 (dd,
J=5.68, 3.16 Hz, 2H) 7.79-7.87 (m, 2H). MS (ES) [M+H] calculated
for C.sub.13H.sub.12NO.sub.3, 230.07; found 230.20.
[1097] To a solution of
2-(cyclopent-3-enyloxy)isoindoline-1,3-dione (736 mg, 3.2 mmol) in
dioxane --H.sub.2O (5.0 mL, 4:1) was added NMO (421 mg, 3.60 mmol)
and OsO.sub.4 (1.0 mL mg, 0.32 mmol, 2.5 wt % in H.sub.2O) and the
reaction mixture was stirred for 24 h at rt. Quenched with 10%
aqueous Na.sub.2S.sub.2O.sub.3 solution and extracted with ethyl
acetate. The combined organic layers washed with brine and dried
over anhydrous Na.sub.2SO.sub.4. Filtered and concentrated to
provide yellow oil, which was purified by flash chromatography (80%
EtOAc-hexane) to yield
2-((3R,4S)-3,4-dihydroxycyclopentyloxy)isoindoline-1,3-dione (650
mg, 77%) as light yellow oil. .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta. ppm 1.94-2.12 (m, 2H) 2.14-2.35 (m, 2H) 4.22-4.88 (m, 2H)
4.75-5.11 (m, 1H) 7.67-7.78 (m, 2H) 7.79-7.86 (m, 2H). MS (ES)
[M+H] calculated for C.sub.13H.sub.14NO.sub.5, 264.08; found
264.20.
[1098] The resultant oily compound (650 mg, 2.47 mmol) was
dissolved in CH.sub.2Cl.sub.2 (5 ml) and cooled to 0.degree. C.
Hydrazine hydrate (0.3 mL, 6.17 mmol) was added dropwise. The
reaction mixture was stirred at ambient temperature over night. The
resultant solid was filtered off and the filtrate concentrated
under reduced pressure to afford (248 mg, 71%) of
(1R,2S)-4-(aminooxy)cyclopentane-1,2-diol as a pale yellow oil.
.sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 1.67-1.87 (m, 4H)
3.86-3.96 (m, 2H) 4.00-4.21 (m, 1H). MS (ES) [M+H] calculated for
C.sub.6H.sub.12NO.sub.3, 134.07; found 134.21.
Example 58
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(3R,4S)-3,4-dihydroxycyclopentyl oxime (Compound 58)
##STR00236##
[1100] A mixture of
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]p-
yrimidine-5(6H)-thione (146 mg, 0.4 mmol),
(1R,2S)-4-(aminooxy)cyclopentane-1,2-diol (212 mg, 1.6 mmol),
Hg(OAc).sub.2 (256 mg, 0.8 mmol) and toluene (2 mL) was heated at
100.degree. C. for 2 h. Cooled to rt, filtered through celite and
purified to afford
(7R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3--
d]pyrimidin-5(6H)-one O-(3R,4S)-3,4-dihydroxycyclopentyl oxime (78
mg, 43%) as off white solid. MS (ES) [M+H] calculated for
C.sub.19H.sub.22BrFN.sub.5O.sub.3, 466.08; found 467.30.
[1101] A mixture of the resultant compound (75 mg, 0.16 mmol),
2-(6-methoxypyridin-2-yl)-6-phenyl-1,3,6,2-dioxazaborocane (238 mg,
0.8 mmol), Pd(dppf).sub.2Cl.sub.2 (13 mg, 0.016 mmol), 2N aq
Na.sub.2CO.sub.3 (0.4 mL, 0.8 mmol) and DMA (2 mL) was degassed
with N.sub.2 and heated at 85.degree. C. for 4 h. Cooled to r.t.,
filtered trough celite and purified to afford
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8--
dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-(3R,
4S)-3,4-dihydroxycyclopentyl oxime (8.4 mg, 12%) as white solid.
.sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 1.75-2.03 (m, 4H)
2.51 (s, 3H) 2.71-2.89 (m, 1H) 2.95-3.10 (m, 1H) 3.86 (s, 3H) 4.36
(d, J=3.28 Hz, 2H) 4.49-4.63 (m, 1H) 4.94 (m, 1H) 6.85 (d, J=7.83
Hz, 1H) 7.19 (d, J=7.33 Hz, 1H) 7.22-7.32 (m, 2H) 7.42-7.54 (m, 1H)
7.84 (t, J=7.58 Hz, 1H). MS (ES) [M+H] calculated for
C.sub.25H.sub.28FN.sub.6O.sub.4, 495.52; found 495.40.
Example 59
(1R,2S)-4-(aminooxymethyl)cyclopentane-1,2-diol
##STR00237##
[1103] The title compound was prepared analogous to the procedure
described in Example 57. .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta. ppm 1.21-1.38 (m, 2H) 1.50-1.64 (m, 2H) 1.69-1.84 (m, 1H)
3.86-3.96 (m, 2H) 4.11 (dd, J=7.33, 1.52 Hz, 2H). MS (ES) [M+H]
calculated for C.sub.6H.sub.14NO.sub.3, 148.09; found 148.07.
Example 60
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((3R,4S)-3,4-dihydroxycyclopentyl)methyl oxime (Compound 59)
##STR00238##
[1105] The title compound was prepared analogous to the procedure
described in Example 58. .sup.1H NMR (400 MHz, MeOD) .delta.
1.54-1.69 (m, 2H), 1.73-1.88 (m, 2H), 2.61 (s, 3H), 2.64-2.75 (m,
1H), 2.90-3.03 (m, 1H), 3.11 (dd, J=16.29, 4.42 Hz, 1H), 3.80-3.88
(m, 2H), 3.90 (s, 3H), 3.94-4.05 (m, 2H), 5.00 (dd, J=8.46, 4.42
Hz, 1H), 6.78 (d, J=8.34 Hz, 1H), 7.11 (d, J=7.33 Hz, 1H),
7.13-7.24 (m, 2H), 7.59 (dd, J=8.08, 5.81 Hz, 1H), 7.76 (t, J=7.83
Hz, 1H). MS (ES) [M+H] calc'd for C.sub.26H.sub.30FN.sub.6O.sub.4,
509.22; found, 509.20.
Example 61
5-(aminooxy)-2-methylpentane-2,3-diol
[1106] Route-A
##STR00239##
[1107] To a solution of 5-bromo-2-methylpent-2-ene (1.33 mL, 10.0
mmol) in CH.sub.3CN (25 mL) was added tert-butyl hydroxycarbamate
(2.0 g, 15.0 mmol) and DBU (4.5 mL, 30 mmol) at 0.degree. C. and
the reaction mixture stirred at r.t. for overnight. Quenched with
saturated NH.sub.4CT solution and extracted with brine. Combined
organic layers washed with brine and dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated to provide yellow oil,
which was purified by flash chromatography (50% EtOAc-hexane) to
yield tert-butyl 4-methylpent-3-enyloxycarbamate (750 mg, 70%) as a
viscous oil. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 1.40
(s, 9H) 1.54 (s., 3H) 1.61 (s., 3H) 2.21-2.31 (m, 2H) 3.70-3.78 (m,
2H) 5.02-5.10 (m, 1H). MS (ES) [M+H] calculated for
C.sub.11H.sub.22NO.sub.3, 216.15; found 216.10.
[1108] The resultant oily compound (750 mg, 3.5 mmol) was dissolved
in 4:1 dioxane-H.sub.2O, NMO (409 mg, 3.85 mmol) and OsO.sub.4 (0.2
mL, 0.35 mmol, 2.5 wt % in H.sub.2O) was added. The reaction
mixture was stirred for 24 h at rt. Work-up similar to the
procedure described in Example 58 afforded tert-butyl
3,4-dihydroxy-4-methylpentyloxycarbamate (510 mg, 58%) as a viscous
oil. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. 1.14 (s, 3H) 1.20
(s, 3H) 1.46 (s, 9H) 1.57-1.70 (m, 1H) 1.72-1.88 (m, 1H) 3.62-3.76
(m, 1H) 3.92-4.15 (m, 2H). MS (ES) [M+H] calculated for
C.sub.11H.sub.24NO.sub.5, 250.15; found 250.20.
[1109] The resultant oily compound (498 mg, 2.0 mmol) was dissolved
in dioxane (2.0 ml) and cooled to 0.degree. C. 4N HCl in dioxane
(1.25 mL, 5.0 mmol) was added and the reaction mixture was stirred
at ambient temperature for 2 h. The resultant solid was filtered
off and dried to afford the HCl salt of the title compound (260 mg,
70%) as white solid. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta.
1.16 (s, 3H) 1.19 (s, 3H) 1.63-1.71 (m, 1H) 1.98-2.06 (m, 1H) 3.45
(d, J=12.88 Hz, 1H) 4.14-4.33 (m, 2H). MS (ES) [M+H] calculated for
C.sub.6H.sub.16NO.sub.3, 150.11; found 150.10.
[1110] Route-B
##STR00240##
[1111] A mixture of 5-bromo-2-methylpent-2-ene (0.66 mL, 5.0 mmol)
in CH.sub.3CN (15 mL) was added 2-hydroxyisoindolin-1,3-dione (3.33
g, 6.0 mmol) and DBU (4.5 mL, 30 mmol) was heated at 100.degree. C.
for 4 h. Work-up analogous to the procedure described in Example 58
afforded 2-(4-methylpent-3-enyloxy)isoindoline-1,3-dione (1.14 g,
90%) as a viscous oil.
[1112] The resultant compound was subjected for dihydroxylation
followed by phthalimide deprotection analogous to the procedures
described earlier (Example 57) afforded the title compound.
Example 62
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-3,4-dihydroxy-4-methylpentyl oxime (Compound 60)
##STR00241##
[1114] The title compound was prepared analogous to the procedure
described in Example 58. .sup.1H NMR (400 MHz, MeOD) .delta. ppm
0.99 (d, J=5.31 Hz, 3H) 1.04 (d, J=5.31 Hz, 3H) 1.34-1.51 (m, 1H)
1.92-2.07 (m, 1H) 2.53 (d, J=1.77 Hz, 3H) 2.73-2.89 (m, 1H) 3.03
(dd, J=16.17, 5.05 Hz, 1H) 3.16-3.30 (m, 1H) 3.86 (d, J=3.03 Hz,
3H) 3.95-4.06 (m, 2H) 4.93-5.13 (m, 1H) 6.86 (d, J=8.34 Hz, 1H)
7.19 (d, J=7.33 Hz, 1H) 7.22-7.34 (m, 2H) 7.41-7.56 (m, 1H)
7.78-7.91 (m, 1H). MS (ES) [M+H] calc'd for
C.sub.26H.sub.32FN.sub.6O.sub.4, 511.56; found 511.40.
Example 63
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-di-
hydropyrido[4,3-d]pyrimidin-5(6H)-one oxime (Compound 61)
##STR00242##
[1116] A mixture of
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]p-
yrimidine-5(6H)-thione (366 mg, 1.0 mmol),
O-(tert-butyldimethylsilyl)hydroxylamine (588 mg, 4.0 mmol),
Hg(OAc).sub.2 (640 mg, 2.0 mmol) and toluene (5 mL) was heated at
100.degree. C. for 2 h. The mixture was cooled to r.t. and filtered
through celite. Filtrate concentrated and the resulting oily
residue was triturated with dry methanol to afford a pale yellow
solid. Filtered and dried to afford
((R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3--
d]pyrimidin-5(6H)-one O-tert-butyldimethylsilyloxime (384 mg, 80%)
as a pale yellow solid. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta.
ppm 0.22 (s, 3H), 0.23 (s, 3H) 0.97 (s, 9H) 2.70 (s, 3H) 2.91 (dd,
J=16.42, 8.08 Hz, 1H) 3.19 (ddd, J=16.36, 4.86, 1.26 Hz, 1H) 4.99
(ddd, J=7.77, 5.12, 2.02 Hz, 1H) 7.05 (td, J=8.27, 2.65 Hz, 1H)
7.33 (dd, J=8.08, 2.78 Hz, 1H) 7.39 (dd, J=8.72, 5.94 Hz, 1H). MS
(ES) [M+H] calculated for C.sub.20H.sub.28BrFN.sub.5OSi, 480.12;
found 480.30.
[1117] A mixture of the above compound (47.9 mg, 0.1 mmol),
2-(6-methoxypyridin-2-yl)-6-phenyl-1,3,6,2-dioxazaborocane (149 mg,
0.5 mmol), Pd(dppf).sub.2Cl.sub.2 (8.12 mg, 0.01 mmol), 2N
Na.sub.2CO.sub.3 (0.25 mL, 0.5 mmol) in DMA (3 mL) was degassed
with N.sub.2 and heated at 85.degree. C. overnight. LCMS shows
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O-tert-butyldimethylsilyl
oxime ([M+H] calculated for C.sub.26H.sub.34BrFN.sub.6O.sub.2Si,
509.24; found 509.40. The reaction mixture was diluted with ethyl
acetate and filtered through celite. The filtrate was concentrated
to afford brown oil which was purified by preparative LCMS to
afford
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one oxime (11.8 mg, 30%) as
white solid.
Example 64
(R)-4-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)methyl)oxazo-
lidin-2-one (Compound 62)
##STR00243## ##STR00244##
[1119] A solution of (R)-3-tert-butyl 4-methyl
2,2-dimethyloxazolidine-3,4-dicarboxylate (5 g, 19.3 mmol) in
anhydrous diethyl ether was chilled in an ice bath and 1 M
LiAlH.sub.4 in diethyl ether (38 mL, 38.6 mmol) was added dropwise
under an N.sub.2 atmosphere. The reaction was allowed to warm to
room temperature with stirring overnight. The reaction was quenched
by slowly adding saturated aqueous Na.sub.2SO.sub.4 (5 mL). The
slurry was filtered through a pad of Celite. The Celite pad was
rinsed with EtOAc and the solution was dried in vacuo to yield
(S)-tert-butyl
4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-carboxylate (2.77 g, 12
mmol) as a clear oil. [M+H] calc'd for C.sub.11H.sub.21NO.sub.4,
232; found, 232.
[1120] Standard Mitsunobu and hydrazine deprotection route to
alkoxyamine was used as described in Example 2. [M+H] calc'd for
C.sub.11H.sub.22N.sub.2O.sub.4, 247; found, 247.
[1121] Standard coupling to thiolactam scaffold via Hg(OAc).sub.2
was used as described in Example 39. [M+H] calc'd for
C.sub.25H.sub.32BrFN.sub.6O.sub.4, 580; found, 580.
[1122] To a solution of (R)-tert-butyl
4-(((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrid-
o[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)methyl)-2,2-dimethyloxazolidine-3-
-carboxylate in dioxane was added 4 N HCl in dioxane. The reaction
was allowed to stir under an N.sub.2 atmosphere at room temperature
for 90 min. The reaction was lyophilized to dryness to yield
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O--(R)-2-amino-3-hydroxypropyl oxime (65 mg,
0.13 mmol). [M+H] calc'd for C.sub.17H.sub.20BrFN.sub.6O.sub.2,
440; found, 440.
[1123] To a solution of
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O--(R)-2-amino-3-hydroxypropyl oxime (65 mg,
0.13 mmol) in anhydrous dichloromethane (3 mL) was added
triethylamine (400 .mu.L, 22 eq) and triphosgene (94 mg, 0.33
mmol). The reaction was stirred under an N.sub.2 atmosphere at room
temperature overnight. The reaction was washed with
H.sub.2O.times.1 and the organic phase dried over anhydrous
Na.sub.2SO.sub.4. The solvent was removed in vacuo and the residue
was purified via preparative HPLC eluting with TFA/ACN/H.sub.2O to
yield
(R)-4-(((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-
-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)methyl)oxazolidin-2--
one (12 mg, 0.026 mmol). [M+H] calc'd for
C.sub.18H.sub.18BrFN.sub.6O.sub.3, 466; found, 466.
[1124] Standard Suzuki conditions to attach pyridyl ring were used
as described in Example 39. .sup.1H NMR (400 MHz, MeOD) .delta.
2.76 (s, 3H), 3.03-3.19 (m, 1H), 3.33-3.53 (m, 1H), 3.91 (s, 3H),
3.97-4.08 (m, 1H), 4.07-4.24 (m, 2H), 4.29 (dd, J=8.72, 4.67 Hz,
1H), 4.42-4.55 (m, 1H), 5.05 (dd, J=8.97, 4.17 Hz, 1H), 6.79 (d,
J=8.34 Hz, 1H), 7.12 (d, J=7.33 Hz, 1H), 7.14-7.29 (m, 2H), 7.66
(dd, J=8.59, 5.56 Hz, 1H), 7.77 (t, J=7.83 Hz, 1H). [M+H] calc'd
for C.sub.24H.sub.24FN.sub.7O.sub.4, 494; found, 494.
Example 65
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-di-
hydropyrido[4,3-d]pyrimidin-5(6H)-one O-2-morpholinoethyl oxime
(Compound 63)
##STR00245##
[1126] To a solution of 2-morpholinoethanol (5 g, 38 mmol) in
CH.sub.2Cl.sub.2 (250 mL) was added 2-hydroxyisoindolin-1,3-dione
(9.3 g, 57 mmol) and triphenylphosphine (15 g, 57 mmol). The
resultant mixture was cooled to 0.degree. C. and diisopropyl
azodicarboxylate (11 ml, 57 mmol) was slowly added drop wise with
an addition funnel under N.sub.2 atmosphere. The reaction mixture
was stirred at ambient temperature for 48 h. The reaction mixture
was concentrated to provide clear oil, which was purified by flash
chromatography (50% EtOAc-Hexane). The resultant clear oily
compound was dissolved in CH.sub.2Cl.sub.2 (50 ml). Hydrazine
hydrate (5.8 mL, 76 mmol) was added. The reaction mixture was
stirred at ambient temperature for 8 h. The resultant solid was
filtered off and the filtrate concentrated under reduced pressure
to provide a clear oil of O-(2-morpholinoethyl)hydroxylamine (3.5
g, 24 mmol). [M+H] calc'd for C.sub.6H.sub.14N.sub.2O.sub.2, 147;
found, 147.
[1127] To a solution of O-(2-morpholinoethyl)hydroxylamine (600 mg,
4.1 mmol) in anhydrous toluene (6 mL) was added
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]p-
yrimidine-5(6H)-thione (0.150 g, 0.41 mmol) and mercuric acetate
(II) (262 mg, 0.82 mmol). The resultant mixture was heated to
100.degree. C. for 1 h. The reaction was allowed to cool to r.t.
and filtered through a pad of Celite, rinsing with EtOAc and
CH.sub.3OH. The filtrate was concentrated to provide a yellow-green
oil, which was purified by preparative HPLC eluting with
TFA/ACN/H.sub.2O. The fractions were concentrated to provide
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O-2-morpholinoethyl oxime (196 mg, 0.41 mmol).
[M+H] calc'd for C.sub.20H.sub.24BrFN.sub.6O.sub.2, 480; found,
480.
[1128] To a solution of
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O-2-morpholinoethyl oxime (100 mg, 0.21 mmol)
in DMA was added 6-methoxypyridine-2-boronic acid
N-phenyldiethanolamine ester (250 mg, 0.84 mmol),
Pd(dppf).sub.2Cl.sub.2 (17 mg, 0.02 mmol), and 2N Na.sub.2CO.sub.3
(522 .mu.L, 1.05 mmol). The resultant mixture was degassed with
N.sub.2 for 5 min then heated in a sealed tube at 85.degree. C. for
14 h. The reaction was allowed to cool to r.t. and filtered through
a pad of Celite topped with anhydrous Na.sub.2SO.sub.4, rinsing
with EtOAc and CH.sub.3OH. The filtrate was concentrated to provide
a brown residue which was purified by preparative HPLC eluting with
TFA/ACN/H.sub.2O. The solvent was removed on a rotary evaporator
and the sample was dried under high vacuum to yield
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O-2-morpholinoethyl oxime
(67.4 mg, 0.13 mmol). .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta.
2.81 (s, 3H), 2.95 (td, J=11.87, 3.79 Hz, 2H), 3.12 (dd, J=17.18,
9.60 Hz, 1H), 3.34-3.56 (m, 3H), 3.70 (dd, J=11.75, 3.41 Hz, 2H),
3.84-4.06 (m, 7H), 4.39 (t, J=4.80 Hz, 2H), 4.94 (dd, J=9.60, 4.04
Hz, 1H), 6.81 (d, J=8.34 Hz, 1H), 7.06 (d, J=7.07 Hz, 1H),
7.08-7.21 (m, 2H), 7.50 (dd, J=8.59, 5.31 Hz, 1H), 7.68-7.81 (m,
1H). [M+H] calc'd for C.sub.26H.sub.30FN7O.sub.3, 508; found,
508.
Example 66
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-di-
hydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(tetrahydro-2H-pyran-4-yl)methyl oxime (Compound 64)
##STR00246##
[1130] A solution of methyl tetrahydro-2H-pyran-4-carboxylate (5 g,
34.6 mmol) in anhydrous diethyl ether was chilled in an ice bath
and 1 M LiAlH.sub.4 in diethyl ether (52 mL, 51.9 mmol) was added
dropwise under an N.sub.2 atmosphere. The reaction was allowed to
warm to room temperature with stirring overnight. The reaction was
quenched by slowly adding 1 N aqueous NaOH (3 mL). The slurry was
filtered through a pad of Celite. The Celite pad was rinsed with
diethyl ether followed by methanol and the solution was dried in
vacuo to yield (tetrahydro-2H-pyran-4-yl)methanol (4 g, 34.6 mmol)
as a clear oil. [M+H] calc'd for C.sub.6H.sub.12O.sub.2, 117;
found, 117.
[1131] Standard Mitsunobu/hydrazine deprotection route to
alkoxyamine was used as described in Example 2, [M+H] calc'd for
C.sub.6H.sub.13NO.sub.2, 132; found, 132.
[1132] Standard coupling to thiolactam scaffold via Hg(OAc).sub.2
was used as described in Example 39. [M+H] calc'd for
C.sub.20H.sub.23BrFN.sub.5O.sub.2, 465; found, 465.
[1133] Standard Suzuki conditions to attach pyridyl ring were used
as described in Example 39. .sup.1H NMR (400 MHz, MeOD) .delta.
1.19-1.41 (m, 2H), 1.64 (d, J=12.88 Hz, 2H), 1.96-2.13 (m, 1H),
2.80 (s, 3H), 3.19 (dd, J=16.93, 8.59 Hz, 1H), 3.33-3.47 (m, 3H),
3.84-4.00 (m, 7H), 5.03-5.13 (m, 1H), 6.80 (d, J=8.34 Hz, 1H), 7.12
(d, J=7.07 Hz, 1H), 7.15-7.27 (m, 2H), 7.60 (dd, J=8.34, 5.56 Hz,
1H), 7.77 (t, J=7.83 Hz, 1H). [M+H] calc'd for
C.sub.26H.sub.29FN.sub.6O.sub.3, 493; found, 493.
Example 67
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-di-
hydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((1s,4S)-4-hydroxycyclohexyl)methyl oxime (Compound 65)
##STR00247##
[1135] To a solution of (1r,4r)-4-hydroxycyclohexanecarboxylic acid
(5 g, 34.7 mmol) in anhydrous DMF (35 mL) was added imidazole (4.72
g, 69.4 mmol) and TBDMS chloride (5.75 g, 38.2 mmol). The reaction
was allowed to stir under an N.sub.2 atmosphere at room temperature
overnight. The reaction was diluted with diethyl ether and washed
with 1 N aqueous HCl.times.2 then brine.times.1. The organic phase
was dried over anhydrous Na.sub.2SO.sub.4 and the solvent removed
in vacuo to yield
(1r,4r)-4-(tert-butyldimethylsilyloxy)cyclohexanecarboxylic acid
(8.9 g, 34.7 mmol) as a clear oil.
[1136] A solution of
(1r,4r)-4-(tert-butyldimethylsilyloxy)cyclohexanecarboxylic acid
(8.9 g, 34.7 mmol) in anhydrous dichloromethane (80 mL) was chilled
in a dry ice/acetone bath and a 20 wt % solution of DIBAL-H in
toluene (57 mL, 69.4 mmol) was added dropwise under an N.sub.2
atmosphere. The reaction was allowed to warm to -30.degree. C. with
stirring over 1 h. The cold reaction mixture was slowly poured into
chilled 1 N aqueous HCl (150 mL). The aqueous phase is washed with
DCM.times.2 and the combined organic phases were washed with
brine.times.1 and dried over anhydrous Na.sub.2SO.sub.4. The
solvent was removed in vacuo to yield
((1r,4r)-4-(tert-butyldimethylsilyloxy)cyclohexyl)methanol (4.5 g,
18.4 mmol).
[1137] To a solution of
((1r,4r)-4-(tert-butyldimethylsilyloxy)cyclohexyl)methanol (4.5 g,
18.4 mmol) in CH.sub.2Cl.sub.2 (150 mL) was added
2-hydroxyisoindolin-1,3-dione (4.5 g, 27.6 mmol) and
triphenylphosphine (7.25 g, 27.6 mmol). The resultant mixture was
cooled to 0.degree. C. and diisopropyl azodicarboxylate (5.35 ml,
27.6 mmol) was slowly added drop wise with an addition funnel under
N.sub.2 atmosphere. The reaction mixture was stirred at ambient
temperature for 48 h. The reaction mixture was concentrated to
provide clear oil, which was purified by flash chromatography (50%
EtOAc-Hexane). The resultant clear oily compound was dissolved in
CH.sub.2Cl.sub.2 (50 ml). Hydrazine hydrate (1.47 mL, 19.3 mmol)
was added. The reaction mixture was stirred at ambient temperature
for 8 h. The resultant solid was filtered off and the filtrate
concentrated under reduced pressure to provide a clear oil of
O-(((1r,4r)-4-(tert-butyldimethylsilyloxy)cyclohexyl)methyl)hydroxylamine
(2.5 g, 9.66 mmol). [M+H] calc'd for C.sub.13H.sub.29NO.sub.2Si,
260; found, 260.
[1138] To a solution of
O-(((1r,4r)-4-(tert-butyldimethylsilyloxy)cyclohexyl)methyl)hydroxylamine
(530 mg, 2.05 mmol) in anhydrous toluene (8 mL) was added
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]p-
yrimidine-5(6H)-thione (0.150 g, 0.41 mmol) and mercuric acetate
(262 mg, 0.82 mmol). The resultant mixture was heated to
100.degree. C. for 1 h. The reaction was allowed to cool to r.t.
and filtered through a pad of Celite, rinsing with EtOAc and
CH.sub.3OH. The filtrate was concentrated to provide a yellow-green
oil, which was purified by preparative HPLC eluting with
TFA/ACN/H.sub.2O. Upon drying down the preparative HPLC fractions
at 50.degree. C. on a rotary evaporator, the alcohol was formed
cleanly to provide
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O-((1s,4S)-4-hydroxycyclohexyl)methyl oxime
(63 mg, 0.13 mmol). [M+H] calc'd for
C.sub.21H.sub.25BrFN.sub.5O.sub.2, 479; found, 479.
[1139] To a solution of
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O-((1s,4S)-4-hydroxycyclohexyl)methyl oxime
(63 mg, 0.13 mmol) in DMA was added 6-methoxypyridine-2-boronic
acid N-phenyldiethanolamine ester (157 mg, 0.52 mmol),
Pd(dppf).sub.2Cl.sub.2 (10.6 mg, 0.013 mmol), and 2N
Na.sub.2CO.sub.3 (329 .mu.L, 0.65 mmol). The resultant mixture was
degassed with N.sub.2 for 5 min then heated in a sealed tube at
85.degree. C. for 14 h. The reaction was allowed to cool to r.t.
and filtered through a pad of Celite topped with anhydrous
Na.sub.2SO.sub.4, rinsing with EtOAc and CH.sub.3OH. The filtrate
was concentrated to provide a brown residue which was purified by
preparative HPLC eluting with TFA/ACN/H.sub.2O. The solvent was
removed on a rotary evaporator and the sample was dried under high
vacuum to yield
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-((1s,4S)-4-hydroxycyclohexyl)methyl oxime (10 mg, 0.02 mmol).
.sup.1H NMR (400 MHz, MeOD) .delta. 1.40-1.60 (m, 6H), 1.69 (dd,
J=8.08, 4.55 Hz, 2H), 1.77-1.92 (m, 1H), 2.73 (s, 3H), 3.05-3.18
(m, 1H), 3.21-3.28 (m, 1H), 3.83-3.96 (m, 6H), 5.09 (dd, J=8.34,
4.55 Hz, 1H), 6.80 (d, J=8.34 Hz, 1H), 7.12 (d, J=7.07 Hz, 1H),
7.15-7.25 (m, 2H), 7.58 (dd, J=8.34, 5.81 Hz, 1H), 7.71-7.82 (m,
1H). [M+H] calc'd for C.sub.27H.sub.31FN.sub.6O.sub.3, 507; found,
507.
Example 68
(S)-4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-met-
hyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-hydroxybut-
anamide (Compound 66)
##STR00248## ##STR00249##
[1141] To a solution of 3-hydroxydihydrofuran-2(3H)-one (5 g, 49
mmol) in anhydrous DMF (50 mL) was added imidazole (6.7 g, 98 mmol)
and TBDMS chloride (8.1 g, 54 mmol). The reaction was allowed to
stir under an N.sub.2 atmosphere at room temperature overnight. The
reaction was diluted with diethyl ether and washed with 1 N aqueous
HCl.times.2 then brine.times.1. The organic phase was dried over
Na.sub.2SO.sub.4 and the solvent removed in vacuo to yield
3-(tert-butyldimethylsilyloxy)dihydrofuran-2(3H)-one (11 g, 49
mmol) as a clear oil. [M+H] calc'd for C.sub.10H.sub.20O.sub.3Si,
217; found, 217.
[1142] To a solution of
3-(tert-butyldimethylsilyloxy)dihydrofuran-2(3H)-one (11 g, 49
mmol) in methanol was added 7 N ammonia in methanol (20 mL, 140
mmol). The reaction was stirred in a sealed tube for 2 days. The
solvent was removed in vacuo to yield
(S)-2-(tert-butyldimethylsilyloxy)-4-hydroxybutanamide (4.85 g,
20.8 mmol) as a white solid. [M+H] calc'd for
C.sub.10H.sub.23NO.sub.3Si, 234; found, 234.
[1143] To a solution of
(S)-2-(tert-butyldimethylsilyloxy)-4-hydroxybutanamide (4.85 g,
20.8 mmol) in CH.sub.2Cl.sub.2 (150 mL) was added
2-hydroxyisoindolin-1,3-dione (5.1 g, 31.2 mmol) and
triphenylphosphine (8.2 g, 31.2 mmol). The resultant mixture was
cooled to 0.degree. C. and diisopropyl azodicarboxylate (6.0 ml,
31.2 mmol) was slowly added dropwise with an addition funnel under
N.sub.2 atmosphere. The reaction mixture was stirred at ambient
temperature for 48 h. The reaction mixture was concentrated to
provide clear oil, which was purified by flash chromatography (60%
EtOAc-Hexane). The resultant pale yellow compound was dissolved in
CH.sub.2Cl.sub.2 (60 ml). Hydrazine hydrate (670 .mu.L, 8.8 mmol)
was added. The reaction mixture was stirred at ambient temperature
for 8 h. The resultant solid was filtered off and the filtrate
concentrated under reduced pressure to provide a clear yellow oil
of (S)-4-(aminooxy)-2-(tert-butyldimethylsilyloxy)butanamide (1.1
g, 4.4 mmol). [M+H] calc'd for C.sub.10H.sub.24N.sub.2O.sub.3Si,
249; found, 249.
[1144] To a solution of
(S)-4-(aminooxy)-2-(tert-butyldimethylsilyloxy)butanamide (1 g, 4.1
mmol) in anhydrous toluene (10 mL) was added
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]p-
yrimidine-5(6H)-thione (0.300 g, 0.82 mmol) and mercuric (II)
acetate (523 mg, 1.64 mmol). The resultant mixture was heated to
100.degree. C. for 2 h. The reaction was allowed to cool to r.t.
and filtered through a pad of Celite, rinsing with EtOAc and
CH.sub.3OH. The filtrate was concentrated to provide a yellow-green
oil, which was purified by preparative HPLC eluting with
TFA/ACN/H.sub.2O. Upon drying down the preparative HPLC fractions
at 50.degree. C. on a rotary evaporator, the alcohol was formed
cleanly to provide
(S)-4-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropy-
rido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-hydroxybutanamide
(51 mg, 0.11 mmol). [M+H] calc'd for
C.sub.18H.sub.20BrFN.sub.6O.sub.3, 477; found, 477.
[1145] To a solution of
(S)-4-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropy-
rido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-hydroxybutanamide
(51 mg, 0.11 mmol) in DMA was added 6-methoxypyridine-2-boronic
acid N-phenyldiethanolamine ester (130 mg, 0.44 mmol),
Pd(dppf).sub.2Cl.sub.2 (9 mg, 0.011 mmol), and 2N Na.sub.2CO.sub.3
(273 .mu.L, 0.55 mmol). The resultant mixture was degassed with
N.sub.2 for 5 min then heated in a sealed tube at 85.degree. C. for
14 h. The reaction was allowed to cool to r.t. and filtered through
a pad of Celite topped with anhydrous Na.sub.2SO.sub.4, rinsing
with EtOAc and CH.sub.3OH. The filtrate was concentrated to provide
a brown residue which was purified by preparative HPLC eluting with
TFA/ACN/H.sub.2O. The solvent was removed on a rotary evaporator
and the sample was dried under high vacuum to yield
(S)-4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-hydroxybu-
tanamide (12.6 mg, 0.025 mmol). .sup.1H NMR (400 MHz, MeOD) .delta.
1.76-1.93 (m, 1H), 2.16-2.35 (m, 1H), 2.80 (s, 3H), 3.18 (dd,
J=16.80, 9.22 Hz, 1H), 3.32-3.42 (m, 1H), 3.90 (s, 3H), 4.10 (dd,
J=8.72, 3.16 Hz, 1H), 4.13-4.31 (m, 2H), 5.07 (dd, J=9.09, 4.04 Hz,
1H), 6.79 (d, J=8.08 Hz, 1H), 7.12 (d, J=7.33 Hz, 1H), 7.15-7.28
(m, 2H), 7.66 (dd, J=8.59, 5.56 Hz, 1H), 7.71-7.83 (m, 1H). [M+H]
calc'd for C.sub.24H.sub.26FN.sub.7O.sub.4, 496; found, 496.
Example 69
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O-2-(morpholin-2-yl)ethyl
oxime (Compound 67)
##STR00250##
[1147] .sup.1H NMR (400 MHz, MeOD) .delta. 1.75-1.92 (m, 1H),
1.91-2.08 (m, 1H), 2.78 (s, 3H), 2.90 (t, J=11.87 Hz, 1H),
3.03-3.18 (m, 1H), 3.18-3.28 (m, 2H), 3.32-3.42 (m, 2H), 3.68-3.85
(m, 2H), 3.91 (s, 3H), 4.02 (d, J=12.88 Hz, 1H), 4.07-4.28 (m, 2H),
5.01-5.11 (m, 1H), 6.81 (d, J=8.34 Hz, 1H), 7.13 (d, J=7.07 Hz,
1H), 7.16-7.35 (m, 2H), 7.56-7.69 (m, 1H), 7.78 (t, J=7.83 Hz, 1H).
[M+H] calc'd for C.sub.26H.sub.30FN.sub.7O.sub.3, 508; found,
508.
Example 70
(S)-4-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)methyl)-3-be-
nzyloxazolidin-2-one (Compound 68)
##STR00251##
[1149] .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. 2.48-2.65 (m,
3H), 2.97-3.16 (m, 1H), 3.19-3.35 (m, 1H), 3.88 (s, 3H), 3.90-3.99
(m, 1H), 4.00-4.16 (m, 2H), 4.15-4.27 (m, 1H), 4.26-4.39 (m, 1H),
4.72-4.86 (m, 1H), 4.90 (dd, J=10.23, 3.41 Hz, 1H), 5.47-5.63 (m,
1H), 6.74 (d, J=8.34 Hz, 1H), 6.97-7.06 (m, 1H), 7.10-7.21 (m, 2H),
7.20-7.26 (m, 5H), 7.57-7.71 (m, 2H). [M+H] calc'd for
C.sub.31H.sub.30FN.sub.7O.sub.4, 584; found, 584.
Example 71
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-di-
hydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(R)-2-amino-3-hydroxypropyl oxime (Compound 69)
##STR00252##
[1151] .sup.1H NMR (400 MHz, MeOD) .delta. 2.81 (s, 3H), 2.90-3.00
(m, 1H), 3.02-3.16 (m, 1H), 3.69-3.78 (m, 1H), 3.82 (dd, J=11.37,
3.54 Hz, 2H), 3.91 (s, 3H), 4.13-4.34 (m, 2H), 5.03-5.10 (m, 1H),
6.72-6.92 (m, 1H), 7.13 (d, J=7.07 Hz, 1H), 7.16-7.34 (m, 2H),
7.63-7.75 (m, 1H), 7.79 (t, J=7.71 Hz, 1H). [M+H] calc'd for
C.sub.23H.sub.26FN.sub.7O.sub.3, 468; found, 468.
Example 72
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-di-
hydropyrido[4,3-d]pyrimidin-5(6H)-one
O-(1-methyl-1H-imidazol-4-yl)methyl oxime (Compound 70)
##STR00253##
[1153] .sup.1H NMR (400 MHz, MeOD) .delta. 2.71 (s, 3H), 3.18 (dd,
J=16.80, 9.22 Hz, 1H), 3.34-3.43 (m, 1H), 3.87 (s, 3H), 3.92 (s,
3H), 5.06-5.11 (m, 3H), 6.80 (d, J=8.34 Hz, 1H), 7.12 (d, J=7.33
Hz, 1H), 7.15-7.29 (m, 2H), 7.53-7.67 (m, 2H), 7.67-7.85 (m, 1H),
8.85 (br. s., 1H). [M+H] calc'd for
C.sub.25H.sub.25FN.sub.8O.sub.2, 489; found, 489.
Example 73
(R)-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-5-imino-4-methyl-5,6,7,8--
tetrahydropyrido[4,3-d]pyrimidin-2-amine (Compound 71)
##STR00254##
[1155] .sup.1H NMR (400 MHz, MeOD) .delta. 2.56-2.66 (m, 3H), 3.28
(d, J=7.83 Hz, 2H), 3.88 (s, 3H), 5.32 (t, J=7.83 Hz, 1H),
6.75-6.86 (m, 1H), 7.11-7.22 (m, 1H), 7.23-7.36 (m, 2H), 7.72 (t,
J=6.82 Hz, 1H), 7.74-7.84 (m, 1H). [M+H] calc'd for
C.sub.20H.sub.19FN.sub.6O, 379; found, 379.
Example 74
(R,Z)-2-amino-7-(2-(5-amino-6-methoxypyrazine-2-yl)-4-fluorophenyl)-4-meth-
yl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(S)-3,4-dihydroxybutyl oxime (Compound 72)
##STR00255##
[1157] .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 1.44-1.61 (m,
1H), 1.78-1.95 (m, 1H), 2.53 (s, 3H), 2.86 (dd, J=16.04, 7.45 Hz,
1H), 3.08 (dd, J=15.92, 4.80 Hz, 1H), 3.20-3.30 (m, 2H), 3.47-3.58
(m, 1H), 3.89 (s, 3H), 3.96-4.07 (m, 2H), 4.40-4.51 (m, 2H),
4.95-5.06 (m, 1H), 6.22 (d, J=1.52 Hz, 1H), 6.54 (s, 2H), 6.78 (s,
2H), 7.13-7.29 (m, 2H), 7.45 (dd, J=8.46, 5.94 Hz, 1H), 7.70 (s,
1H). [M+H] calc'd for C.sub.23H.sub.27FN.sub.8O.sub.4, 499; found,
499.
Example 75
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyrazine-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl
oxime (Compound 73)
##STR00256##
[1159] .sup.1H NMR (400 MHz, MeOD) .delta. 1.59-1.74 (m, 1H),
1.88-2.06 (m, 1H), 2.62 (s, 3H), 3.02 (dd, J=16.29, 9.22 Hz, 1H),
3.13-3.25 (m, 1H), 3.39-3.53 (m, 2H), 3.67-3.78 (m, 1H), 3.97 (s,
3H), 4.06-4.24 (m, 2H), 4.89-4.94 (m, 1H), 7.20-7.33 (m, 2H),
7.63-7.74 (m, 1H), 8.21 (s, 1H), 8.32 (s, 1H). [M+H] calc'd for
C.sub.23H.sub.26FN.sub.7O.sub.4, 484; found, 484.
Example 76
(R,Z)-2-amino-7-(4-fluoro-2-(2-methoxythiazol-4-yl)phenyl)-4-methyl-7,8-di-
hydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl
oxime (Compound 74)
##STR00257##
[1161] .sup.1H NMR (400 MHz, MeOD) .delta. 1.61-1.75 (m, 1H),
1.91-2.06 (m, 1H), 2.63 (s, 3H), 2.95 (dd, J=16.17, 8.08 Hz, 1H),
3.21 (dd, J=16.17, 4.80 Hz, 1H), 3.40-3.53 (m, 2H), 3.69-3.79 (m,
1H), 4.08 (s, 3H), 4.11-4.22 (m, 2H), 5.06 (dd, J=7.71, 4.93 Hz,
1H), 7.00 (s, 1H), 7.10 (td, J=8.46, 2.78 Hz, 1H), 7.22 (dd,
J=9.60, 2.78 Hz, 1H), 7.48 (dd, J=8.72, 5.68 Hz, 1H). [M+H] calc'd
for C.sub.22H.sub.25FN.sub.6O.sub.4S, 489; found, 489.
Example 77
Synthesis of
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-4,5-dihydroxypentyl
oxime (Compound 75)
##STR00258## ##STR00259##
[1163] Compound A was synthesized as previously reported (70.7%
yield) .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. 1.36 (s, 3H),
1.41 (s, 3H), 1.71-2.01 (m, 4H), 3.43-3.67 (m, 1H), 4.05-4.10 (m,
1H), 4.16-4.31 (m, 3H), 7.70-7.79 (m, 2H), 7.80-7.91 (m, 2H).
[1164] Compound B
((S)--O-(3-(2,2-dimethyl-1,3-dioxolan-4-yl)propyl)hydroxylamine)
was synthesized as previously reported on similar chemistry,
quantitative yield. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta.
1.36 (s, 3H), 1.41 (s, 3H), 1.57-1.76 (m, 4H), 3.50-3.55 (m, 1H),
3.69 (td, J=6.13, 2.65 Hz, 2H), 4.02-4.07 (m, 1H), 4.07-4.16 (m,
1H), 5.36 (s, 2H).
[1165] Compound C was also prepared as described before. ESI-MS:
m/z 508.2 (M+H).sup.+. Purification by prep TFA method deprotected
the acetonide group and gave compound D (55.1% yield). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 1.21-1.37 (m, 1H), 1.47-1.60 (m,
1H), 1.68 (ddd, J=13.01, 10.11, 5.94 Hz, 1H), 1.73-1.91 (m, 1H),
2.61 (s, 3H), 2.87 (dd, J=16.17, 4.29 Hz, 1H), 3.16-3.33 (m, 3H),
3.35-3.50 (m, 1H), 3.87-4.07 (m, 3H), 4.89-5.00 (m, 2H), 6.91 (br.
s., 1H), 7.14-7.26 (m, 3H), 7.58 (dd, J=8.46, 2.40 Hz, 1H).
[1166] Suzuki's coupling of compound D with the usual procedure
provided compound 75 (19.3% yield). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 1.16-1.33 (m, 2H), 1.48 (d, J=4.55 Hz, 1H),
1.62 (br. s., 1H), 1.76 (d, J=10.36 Hz, 1H), 2.52 (s, 3H), 2.80
(dd, J=16.04, 6.95 Hz, 1H), 2.97-3.07 (m, 1H), 3.18-3.29 (m, 2H),
3.41 (br. s., 2H), 3.86 (s, 3H), 3.87-3.98 (m, 2H), 4.40 (br. s.,
2H), 4.97-5.15 (m, 1H), 6.19-6.39 (m, 1H), 6.78 (s, 2H), 6.85 (d,
J=8.34 Hz, 1H), 7.19 (d, J=6.57 Hz, 1H), 7.21-7.30 (m, 2H), 7.47
(dd, J=8.46, 5.94 Hz, 1H), 7.84 (dd, J=8.34, 7.33 Hz, 1H).
Example 78
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-di-
hydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(S)-3-amino-2-hydroxypropyl oxime (Compound 76)
##STR00260## ##STR00261##
[1168] Compound F: .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. 1.26
(s, 9H), 1.28 (s, 6H), 3.65-3.74 (m, 2H), 3.89-3.93 (m, 1H), 4.12
(m, 1H), 4.28-4.41 (m, 1H), 5.58 (br. s., 2H).
[1169] Compound G was synthesized as described above. ESI-MS: m/z
579.1 (M+H).sup.+.
[1170] Purification of G by LC/MS gradient 35-60% ACN in H.sub.2O
with TFA system deprotected the acetonide group to give compound H
after evaporation step. ESI-MS: m/z 539.2 (M+H).sup.+, 20.8% yield
over 2 steps.
[1171] Suzuki's coupling of H produced compound I. ESI-MS: m/z
568.3 (M+H).sup.+, which was then deprotected with 20% TFA in
dichloromethane for 45 minutes to give product Compound 76.
[1172] Compound 76 was purified by basic mode, gradient 25-50% ACN
in H.sub.2O, 46.1% yield. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 2.52 (s, 3H), 2.69-2.86 (m, 2H), 3.05 (d, J=4.55 Hz, 2H),
3.85 (s, 3H), 3.88 (dd, J=5.81, 3.79 Hz, 2H), 3.98 (br. s., 2H),
5.02 (br. s., 1H), 5.05 (br.s., 2H), 6.59 (d, J=1.77 Hz, 1H), 6.86
(d, J=7.58 Hz, 1H), 7.18 (d, J=7.33 Hz, 1H), 7.28 (ddd, J=5.68,
2.78, 2.65 Hz, 2H), 7.52 (dd, J=8.59, 5.81 Hz, 1H), 7.75 (br. s.,
2H), 7.84 (dd, J=8.34, 7.33 Hz, 1H).
Example 79
(S)-5-(((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)methyl)oxazo-
lidin-2-one (Compound 77)
##STR00262## ##STR00263##
[1174] Compound H was deprotected with 20% TFA in dichloromethane
for 10 minutes to give compound K, ESI-MS: m/z 439.1
(M+H).sup.+.
[1175] Compound K was reacted with triphosgene, triethylamine in
dichloromethane as described previously to give compound L. It was
purified by preparative LC/MS, gradient 25-50% ACN in H.sub.2O,
10.6% yield, ESI-MS: m/z 439.2 (M+H).sup.+.
[1176] Suzuki's coupling of compound K with the normal procedure
provided compound 77, 32.7% yield. .sup.1H NMR (400 MHz, MeOD)
.delta. 2.92 (s, 3H), 3.35-3.40 (m, 1H), 3.44-3.52 (m, 1H),
3.55-3.59 (m, 1H), 3.63-3.66 (m, 1H), 3.91 (s, 3H), 4.20 (dd,
J=6.44, 4.67 Hz, 2H), 4.95 (m, 1H), 5.05 (m, 1H), 6.79 (d, J=8.34
Hz, 1H), 7.11 (d, J=6.57 Hz, 1H), 7.14-7.25 (m, 2H), 7.59 (m, 1H),
7.76 (dd, J=8.46, 7.20 Hz, 1H).
Example 80
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-di-
hydropyrido[4,3-d]pyrimidin-5(6H)-one O-3-hydroxypropyl oxime
(Compound 78)
##STR00264## ##STR00265##
[1178] Compound 3 as prepared by procedure described above, 78.7%
yield. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. 0.08 (s, 6H),
0.84-0.93 (m, 9H), 1.99 (s, 2H), 3.76-3.90 (m, 2H), 4.27-4.39 (m,
2H), 7.70-7.78 (m, 2H), 7.80-7.88 (m, 2H).
[1179] Compound 4 as prepared by procedure described above, 93.2%
yield. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. 0.05-0.09 (m,
6H), 0.84-0.95 (m, 9H), 1.73-1.86 (m, 2H), 3.69 (t, J=6.19 Hz, 2H),
3.75 (t, J=6.32 Hz, 2H), 5.34 (s, 2H).
[1180] Compound 6: ESI-MS: m/z 538.3 (M+H).sup.+. Purification was
done by preparative LC/MS, using gradient 50-85% ACN in H.sub.2O
with TFA system. After evaporation compound 7 was obtained, 42.5%
yield over 2 step, ESI-MS: m/z 424.2 (M+H).sup.+.
[1181] Compound 78, LC/MS purification using basic mode, gradient
40-60% ACN in H.sub.2O, 45.9% yield. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 1.77 (quin, J=6.44 Hz, 2H), 2.53 (s, 3H),
2.82 (dd, J=16.29, 7.20 Hz, 1H), 3.04 (dd, J=16.17, 5.05 Hz, 1H),
3.42-3.54 (m, 2H), 3.86 (s, 3H), 3.91-4.04 (m, 2H), 4.97-5.13 (m,
1H), 6.37 (br. s., 1H), 6.85 (d, J=7.58 Hz, 1H), 6.90 (br. S., 2H),
7.19 (d, J=6.82 Hz, 1H), 7.21-7.33 (m, 2H), 7.47 (dd, J=8.46, 5.94
Hz, 1H), 7.84 (dd, J=8.34, 7.33 Hz, 1H).
Example 81
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-di-
hydropyrido[4,3-d]pyrimidin-5(6H)-one O-4-hydroxybutyl oxime
(Compound 79)
##STR00266## ##STR00267##
[1183] Compound 81c as prepared by the procedure described above,
88.0% yield. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. 0.03-0.07
(m, 6H), 0.82-0.96 (m, 9H), 1.74 (d, J=8.84 Hz, 2H), 1.86 (d,
J=8.34 Hz, 2H), 3.69 (t, J=6.19 Hz, 2H), 4.24 (t, J=6.57 Hz, 2H),
7.75 (dd, J=5.56, 3.03 Hz, 2H), 7.80-7.87 (m, 2H).
[1184] Compound 81d as prepared by the procedure described above,
94.5% yield. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. 0.060 (s,
6H), 0.85-0.94 (m, 9H), 1.51-1.59 (m, 3H), 1.59-1.69 (m, 2H), 3.63
(t, J=6.32 Hz, 2H), 3.65-3.72 (m, 2H), 5.35 (s, 2H).
[1185] Compound 81f as prepared by the procedure described above.
ESI-MS: m/z 554.3 (M+H).sup.+. Purification by LC/MS using the TFA
system of gradient 60-90% ACN/H.sub.2O deprotected the TBDMS group
to give compound 15, 22.2% yield over 2 steps. ESI-MS: m/z 438.1
(M+H).sup.+.
[1186] Compound 79 as prepared by the procedure described above.
The product was purified by the basic mode, gradient 35-65%
ACN/H.sub.2O, 19.2% yield. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 1.37-1.56 (m, 2H), 1.56-1.74 (m, 2H), 2.53 (s, 3H), 2.81
(dd, J=16.04, 7.20 Hz, 1H), 3.03 (dd, J=16.17, 5.05 Hz, 1H), 3.40
(t, J=6.44 Hz, 2H), 3.92 (s, 3H), 3.88-3.98 (m, 2H), 5.05 (br. s.,
1H), 6.31 (br. s., 1H), 6.85 (d, J=8.34 Hz, 3H), 7.19 (d, J=6.57
Hz, 1H), 7.22-7.32 (m, 2H), 7.47 (dd, J=8.46, 5.94 Hz, 1H), 7.84
(dd, J=8.34, 7.33 Hz, 1H).
Example 82
(7R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O-3-hydroxy-2-methoxypropyl
oxime (Compound 80)
##STR00268## ##STR00269##
[1188] Compound N: ESI-MS: m/z 122.0 (M+H).sup.+. .sup.1H NMR (400
MHz, CHLOROFORM-d) .delta. 3.33 (s, 3H), 3.40-3.46 (m, 3H),
3.67-3.75 (m, 1H), 3.75-3.83 (m, 1H), 4.07 (m, 1H), 5.52 (br. s.,
2H).
[1189] Compound O: purified by preparative LC/MS, gradient 25-55%
ACN in H.sub.2O, 4.9% yield, ESI-MS: m/z 454.3 (M+H).sup.+.
[1190] Compound 80: purified by preparative LC/MS, basic mode,
gradient 30-70% ACN in H.sub.2O, 16.1% yield. .sup.1H NMR (400 MHz,
MeOD) .delta. 2.61 (s, 3H), 2.89-3.05 (m, 1H), 3.07-3.21 (m, 1H),
3.34 (d, J=2.02 Hz, 3H), 3.37-3.50 (m, 2H), 3.61-3.75 (m, 1H), 3.89
(s, 3H), 3.92-4.01 (m, 1H), 4.01-4.09 (m, 2H), 4.93-5.03 (m, 1H),
6.78 (d, J=8.34 Hz, 1H), 7.11 (d, J=7.07 Hz, 1H), 7.13-7.25 (m,
2H), 7.64 (dd, J=8.46, 5.68 Hz, 1H), 7.75 (t, J=7.83 Hz, 1H).
Example 83
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-di-
hydropyrido[4,3-d]pyrimidin-5(6H)-one O--(R)-4,5-dihydroxypentyl
oxime (Compound 81)
##STR00270## ##STR00271##
[1192] Compound 83b as prepared by a procedure described above.
.sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. 1.36 (s, 3H), 1.39-1.45
(s, 3H), 1.73-2.00 (m, 4H), 2.05 (s, 1H), 3.54-3.63 (m, 1H),
4.04-4.14 (m, 1H), 4.14-4.21 (m, 1H), 4.21-4.33 (m, 2H), 7.72-7.79
(m, 2H), 7.81-7.87 (m, 2H).
[1193] Compound 83c as prepared by a procedure described above,
88.2% yield over 2 steps.
[1194] .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. 1.36 (s, 3H),
1.41 (s, 3H), 1.59-1.78 (m, 4H), 3.50-3.55 (m, 1H), 3.69 (td,
J=6.25, 2.40 Hz, 2H), 4.01-4.07 (m, 1H), 4.11 (dd, J=7.07, 5.56 Hz,
1H), 5.36 (s, 2H).
[1195] Compound 83d: ESI-MS: m/z 508.3 (M+H).sup.+. LC/MS
purification using gradient 40-60% ACN in H.sub.2O (TFA method)
gave compound 5, ESI-MS: m/z 468.1 (M+H).sup.+, 24.1% yield over 2
steps.
[1196] Compound 81, purification was done by both the basic mode
and acidic mode, 21.6% yield, .sup.1H NMR (400 MHz, MeOD) .delta.
1.35-1.52 (m, 1H), 1.59 (dt, J=10.04, 4.07 Hz, 1H), 1.74 (ddd,
J=13.71, 10.04, 6.06 Hz, 1H), 1.82-2.08 (m, 1H), 3.14 (dd, J=16.67,
8.84 Hz, 1H), 3.28-3.35 (m, J=4.55 Hz, 1H), 3.38-3.49 (m, 2H),
3.54-3.68 (m, 1H), 3.84-3.97 (s, 3H), 4.06 (t, J=6.44 Hz, 2H), 5.08
(dd, J=8.84, 4.29 Hz, 1H), 6.79 (d, J=7.58 Hz, 1H), 7.12 (d, J=6.57
Hz, 1H), 7.15-7.24 (m, 2H), 7.62 (dd, J=8.59, 5.56 Hz, 1H), 7.76
(dd, J=8.34, 7.33 Hz, 1H).
Example 84
(S)-4-(2-iodoethyl)-2,2-dimethyl-1,3-dioxolane
##STR00272##
[1198] To a solution of
(S)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethanol (1.58 mL, 10.0 mmol)
in CH.sub.2Cl.sub.2 (25 mL) was added DMAP (120 mg, 1.0 mmol) and
triethylamine (2.08 mL, 15.0 mmol). The reaction mixture was cooled
to 0.degree. C. and methanesulfonyl chloride (12.0 mmol, 0.928 mL)
was added slowly dropwise under N.sub.2 atmosphere. The reaction
mixture was stirred for 2 h (monitored by TLC, 1:2 EtOAc-Hexanes).
Saturated NH.sub.4Cl solution (20 mL) was added and the mixture was
extracted with CH.sub.2Cl.sub.2. The combined organic layers were
washed with brine, dried over anhydrous Na.sub.2SO.sub.4, filtered
and concentrated to provide a yellow oil, which was dissolved in
dry acetone (25 ml), followed by addition of NaI (7.5 g, 50 mmol).
The reaction mixture was refluxed for 2 h (monitored by TLC, 1:4
EtOAc-Hexanes), cooled to room temperature and water (50 mL) was
added. Extraction with ethyl acetate, washing of the combined
organic layers with brine, drying over anhydrous Na.sub.2SO.sub.4,
filtration and concentration provided a yellow oil, which was
purified by flash chromatography (25% EtOAC-Hexane) to afford the
title compound, (S)-4-(2-iodoethyl)-2,2-dimethyl-1,3-dioxolane
(0.82 g, 32% over two steps) as a clear oil. .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 1.36 (s, 3H), 1.41 (s, 3H), 1.99-1.16 (m,
2H), 3.25 (dd, J=18.19, 8.84 Hz, 2H), 3.58 (t, J=7.20 Hz, 1H),
4.03-4.13 (m, 1H), 4.13-4.24 (m, 1H). MS (ES) [M+H] calculated for
C.sub.7H.sub.14IO.sub.2, 257.00; found 257.08.
Example 85
Alternative synthesis of
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl
oxime (Compound 37)
##STR00273## ##STR00274##
[1200] Compound 2K was prepared as previously described. A mixture
of
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]p-
yrimidine-5(6H)-thione (2K, 366 mg, 1.0 mmol),
O-(tert-butyldimethylsilyl)hydroxylamine (85a, 588 mg, 4.0 mmol),
Hg(OAc).sub.2 (640 mg, 2.0 mmol) and toluene (5 mL) was heated at
100.degree. C. for 2 h. The mixture was cooled to room temperature
and filtered through Celite. The filtrate was concentrated and the
resulting oily residue was triturated with dry methanol to afford,
after filtration and drying,
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O-tert-butyldimethylsilyloxime (384 mg, 80%)
as a pale yellow solid. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta.
ppm 0.22 (s, 3H), 0.23 (s, 3H) 0.97 (s, 9H) 2.70 (s, 3H) 2.91 (dd,
J=16.42, 8.08 Hz, 1H) 3.19 (ddd, J=16.36, 4.86, 1.26 Hz, 1H) 4.99
(ddd, J=7.77, 5.12, 2.02 Hz, 1H) 7.05 (td, J=8.27, 2.65 Hz, 1H)
7.33 (dd, J=8.08, 2.78 Hz, 1H) 7.39 (dd, J=8.72, 5.94 Hz, 1H). MS
(ES) [M+H] calculated for C.sub.20H.sub.28BrFN.sub.5OSi, 480.12;
found 480.30.
[1201] To a solution of
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O-tert-butyldimethylsilyloxime (85b, 384 mg,
0.8 mmol) in dioxane (2 mL) was added 1:9 TFA-H.sub.2O and the
reaction mixture stirred at room temperature for 2 h. The resulting
solid was filtered and washed with dioxane, then dried to afford
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one oxime (85c, 206 mg, 70%) as a pale yellow
solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.56 (s, 3H)
2.83 (dd, J=15.92, 4.55 Hz, 1H) 3.17 (dd, J=16.04, 5.94 Hz, 1H)
4.90 (q, J=4.97 Hz, 1H) 7.20 (d, J=1.52 Hz, 1H) 7.21-7.23 (m, 1H)
7.57 (ddd, J=8.34, 1.64, 1.39 Hz, 1H) 9.82 (s, 1H). MS (ES) [M+H]
calculated for C.sub.14H.sub.14BrFN.sub.5O, 366.03; found
366.20.
[1202] To a solution of
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one oxime (85c, 9.2 mg, 0.025 mmol) in dry DMF (1
mL) was added Cs.sub.2CO.sub.3 (12.2 mg, 0.0375 mmol) and the
reaction mixture stirred at ambient temperature for 30 minutes.
Then, (S)-4-(2-iodoethyl)-2,2-dimethyl-1,3-dioxolane (85d, 7.68 mg,
0.03 mmol) was added and the reaction mixture stirred overnight.
LCMS showed complete consumption of the starting material. The
reaction mixture was poured onto crushed ice and the resulting
solid was filtered and rinsed with cold water. Drying afforded
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl
oxime (7.8 mg, 63%) as a light brown solid. .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 1.35 (s, 3H) 1.41 (s, 3H) 2.02 (qd,
J=6.32, 3.03 Hz, 2H) 2.75 (s, 3H) 2.94 (dd, J=16.42, 8.84 Hz, 1H)
3.17 (dd, J=16.42, 4.55 Hz, 1H) 3.59 (dd, J=8.08, 7.07 Hz, 1H) 4.09
(dd, J=8.08, 6.06 Hz, 1H) 4.17-4.28 (m, 3H) 4.98 (ddd, J=8.72,
4.55, 1.64 Hz, 1H) 7.07 (td, J=8.27, 2.65 Hz, 1H) 7.34 (dd, J=8.08,
2.78 Hz, 1H) 7.43 (dd, J=8.72, 5.94 Hz, 1H). MS (ES) [M+H]
calculated for C.sub.21H.sub.27BrFN.sub.5O.sub.3, 495.11; found
495.30.
[1203] To a solution of
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl
oxime (85e, 1 g, 2 mmol) in 3N aq HCl (10 mL) and the reaction
mixture stirred at ambient temperature for 1 h. LCMS shows complete
consumption of the starting material. The resulting solid was
filtered, washed with cold 1N HCl, and dried to afford
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl oxime (deprotected
85e, 603 mg, 65%) as an off-white solid. MS (ES) [M+H] calculated
for C.sub.18H.sub.22BrFN.sub.5O.sub.3, 454.08; found 454.02.
[1204] A mixture of
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl oxime (deprotected
85e, 480 mg, 1.05 mmol),
2-(6-methoxypyridin-2-yl)-6-phenyl-1,3,6,2-dioxazaborocane (1.57 g,
5.25 mmol), Pd(dppf).sub.2Cl.sub.2 (0.086 g, 0.1 mmol), and 2N
Na.sub.2CO.sub.3 (2.64 mL, 5.25 mmol) in DMAc (5 mL) was degassed
with N.sub.2 and heated at 85.degree. C. overnight. The reaction
mixture was cooled to ambient temperature, diluted with ethyl
acetate and filtered through Celite. The filtrate was concentrated
to afford a brown oil, which was purified by preparative LCMS
(NH.sub.4HCO.sub.3/ACN/H.sub.2O) to afford
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(S)-3,4-dihydroxybutyl oxime (Compound 37, 375 mg, 73%) as a
light brown solid. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm
1.43-1.55 (m, 1H) 1.66 (m, 1H) 2.55 (s, 3H) 2.83-2.95 (m, 2H)
3.11-3.44 (m, 1H) 3.17-3.24 (m, 1H) 3.27-3.33 (m, 1H) 3.48-3.56 (m,
1H) 3.65 (s, 3H) 3.89-4.01 (m, 2H) 4.68 (ddd, J=10.23, 3.03, 2.91
Hz, 1H) 6.53 (dd, J=8.34, 2.53 Hz, 1H) 6.81 (dd, J=7.33, 2.53 Hz,
1H) 6.90 (dt, J=9.28, 2.68 Hz, 1H) 6.96 (td, J=8.40, 2.65 Hz, 1H)
7.38-7.43 (m, 1H) 7.44-7.51 (m, 1H). MS (ES) [M+H] calculated for
C.sub.24H.sub.28FN.sub.6O.sub.4, 483.21; found 483.00.
Example 86
Second alternative synthesis of
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl
oxime (Compound 37)
##STR00275## ##STR00276##
[1206] Compound 86b was prepared as described in Example 85 above.
Coupling of 86f to 86b was prepared by both Method A and Method
B.
[1207] Method A: A mixture of
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one O-tert-butyldimethylsilyloxime (86b, 47.9 mg,
0.1 mmol),
2-(6-methoxypyridin-2-yl)-6-phenyl-1,3,6,2-dioxazaborocane (86f,
149 mg, 0.5 mmol), Pd(dppf)Cl.sub.2 (8.12 mg, 0.01 mmol), and 2N
Na.sub.2CO.sub.3 (0.25 mL, 0.5 mmol) in DMA (3 mL) was degassed
with N.sub.2 and heated at 85.degree. C. overnight. LCMS showed
consumption of starting material and formation of
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O-tert-butyldimethylsilyl
oxime (86 g or 61). ([M+H] calculated for
C.sub.26H.sub.34BrFN.sub.6O.sub.2Si, 509.24; found 509.40).
[1208] The reaction mixture was diluted with ethyl acetate and
filtered through Celite. The filtrate was concentrated to afford a
brown oil, which was purified by preparative HPLC. During this
purification the tert-butyldimethylsilyl protecting group was
cleaved as well, thus affording
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one oxime (37, 11.8
mg, 30%) as a white solid. .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta. ppm 2.78 (s, 3H) 3.14-3.31 (m, 1H) 3.43-3.46 (m, 1H) 3.89
(s, 3H) 5.08 (d, J=7.58 Hz, 1H) 6.78 (d, J=8.34 Hz, 1H) 7.05 (d,
J=7.07 Hz, 2H) 7.18 (d, J=8.84, 2H) 7.70 (t, J=7.71, 1H). MS (ES)
[M+H] calculated for C.sub.20H.sub.20FN.sub.6O.sub.2, 395.16; found
395.20.
[1209] Method B:
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one oxime (Compound 86c) was prepared as described
in Example 85 above. A mixture of 86c (36.5 mg, 0.1 mmol and
2-(6-methoxypyridin-2-yl)-6-phenyl-1,3,6,2-dioxazaborocane (86f,
149 mg, 0.5 mmol), Pd(dppf).sub.2Cl.sub.2 (8.12 mg, 0.01 mmol), and
2N Na.sub.2CO.sub.3 (0.25 mL, 0.5 mmol) in DMA (3 mL) was degassed
with N.sub.2 and heated at 85.degree. C. overnight. The reaction
mixture was cooled to ambient temperature, diluted with ethyl
acetate and filtered through Celite. The filtrate was concentrated
to afford brown oil which was purified by preparative HPLC to
afford
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one oxime (86 g or 61), 13.2 mg,
33%) as white solid. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta.
ppm 2.78 (s, 3H) 3.14-3.31 (m, 1H) 3.43-3.46 (m, 1H) 3.89 (s, 3H)
5.08 (d, J=7.58 Hz, 1H) 6.78 (d, J=8.34 Hz, 1H) 7.05 (d, J=7.07 Hz,
2H) 7.18 (d, J=8.84, 2H) 7.70 (t, J=7.71, 1H). MS (ES) [M+H]
calculated for C.sub.20H.sub.20FN.sub.6O.sub.2, 395.16; found
395.20.
[1210] To a solution of
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one oxime (86 g or Compound 61,
10.0 mg, 0.025 mmol) in dry DMF (1 mL) was added Cs.sub.2CO.sub.3
(12.2 mg, 0.0375 mmol) and the reaction mixture stirred at ambient
temperature for 30 minutes. Then,
(S)-4-(2-iodoethyl)-2,2-dimethyl-1,3-dioxolane (86d, 7.68 mg, 0.03
mmol) was added and the reaction mixture stirred overnight. LCMS
showed complete consumption of starting material. The reaction
mixture was poured onto crushed ice and the resulting solid was
filtered, rinsed with cold water, and dried to afford
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one
O-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethyl oxime (86 h, 8.2 mg,
63%) as a light brown solid. .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta. ppm 1.33 (s, 3H) 1.39 (s, 3H) 1.91-2.01 (m, 4H) 2.72 (s,
3H) 3.07 (dd, J=16.55, 10.48 Hz, 1H) 3.26 (dd, J=17.05, 4.93 Hz,
1H) 3.55 (dd, J=7.96, 7.20 Hz, 1H) 3.90 (s, 3H) 4.05 (dd, J=7.96,
5.94 Hz, 1H) 4.10-4.21 (m, 3H) 4.89 (dd, J=10.61, 3.79 Hz, 1H) 6.74
(d, J=8.84 Hz, 1H) 7.01 (d, J=8.08 Hz, 1H) 7.11-7.22 (m, 2H)
7.61-7.69 (m, 2H)MS (ES) [M+H] calculated for
C.sub.27H.sub.32FN.sub.6O.sub.4, 523.24; found 523.50.
[1211] Deprotection of 86 h was achieved by treating with diluted
HCl as described in Example 85 to yield Compound 37.
Example 87
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-
-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-methylacetamide
(Compound 82)
##STR00277##
[1212] A. Synthesis of 2-(aminooxy)-N-methylacetamide (87c)
##STR00278##
[1214] A solution of 2-(tert-butoxycarbonylaminooxy)acetic acid
(87a, 1 g, 5.23 mmol) in anhydrous THF was chilled in an ice bath
and N-methylmorpholine (863 .mu.L, 7.85 mmol) and isobutyl
chloroformate (746 .mu.L, 5.75 mmol) were added sequentially. The
mixture was stirred under an N.sub.2 atmosphere for 20 min. A 33 wt
% solution of methanamine in ethanol (1.3 mL, 10.46 mmol) was added
to the reaction which was subsequently allowed to warm to room
temperature with stirring overnight. The THF was removed in vacuo
and the residue was partitioned between ethyl acetate and water.
The organic phase was washed with H.sub.2O.times.2 and dried over
anhydrous Na.sub.2SO.sub.4. The ethyl acetate was removed in vacuo
to yield tert-butyl 2-(methylamino)-2-oxoethoxycarbamate (87b, 775
mg, 3.80 mmol).
[1215] To a slurry of tert-butyl
2-(methylamino)-2-oxoethoxycarbamate (87c, 775 mg, 3.80 mmol) in
anhydrous dioxane was added 4N HCl in dioxane (3 mL, 12 mmol). The
reaction was allowed to stir at room temperature under an N.sub.2
atmosphere for 5 h. The reaction was freeze-dried and the residue
was taken up in 20% triethylamine in ethyl acetate to neutralize
the HCl salt. The slurry was stirred for 1 h and the solvents were
removed in vacuo to yield a mixture of
2-(aminooxy)-N-methylacetamide (87c) and triethylammonium chloride
salt.
B. Preparation of Compound 82
[1216] The titled compound 82 was prepared by a procedure analogous
to Example 68, coupling of 2-(aminooxy)-N-methylacetamide (87c) was
via Hg(OAc).sub.2. .sup.1H NMR (400 MHz, MeOD) .delta. 2.75 (s,
3H), 2.76 (s, 3H), 3.19 (dd, J=16.67, 9.35 Hz, 1H), 3.41 (dd,
J=16.80, 4.17 Hz, 1H), 3.91 (s, 3H), 4.47 (s, 2H), 5.06 (dd,
J=9.35, 4.04 Hz, 1H), 6.80 (d, J=8.34 Hz, 1H), 7.13 (d, J=7.33 Hz,
1H), 7.16-7.29 (m, 2H), 7.71 (dd, J=8.84, 5.56 Hz, 1H), 7.73-7.82
(m, 1H). [M+H] calc'd for C.sub.23H.sub.24FN.sub.7O.sub.3, 466;
found, 466.
Example 88
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-
-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N,N-dimethylacetamid-
e (Compound 83)
##STR00279##
[1218] The titled compound 83 was prepared by a procedure
analoguous to Example 87 except dimethylamine was used. .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. 2.74 (s, 3H), 2.93 (s, 3H),
3.04 (s, 3H), 3.10-3.24 (m, 1H), 3.35-3.45 (m, 1H), 3.91 (s, 3H),
4.69-4.81 (m, 2H), 5.06 (dd, J=9.35, 4.04 Hz, 1H), 6.79 (d, J=8.08
Hz, 1H), 7.13 (d, J=7.07 Hz, 1H), 7.16-7.29 (m, 2H), 7.70 (dd,
J=8.72, 5.68 Hz, 1H), 7.73-7.82 (m, 1H). [M+H] calc'd for
C.sub.24H.sub.26FN.sub.7O.sub.3, 480; found, 480.
Example 89
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-
-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)acetamide
(Compound 84)
##STR00280##
[1220] The titled compound 84 was prepared by a procedure
analoguous to Example 87 except dimethylamine was used. .sup.1H NMR
(400 MHz, MeOD) .delta. 2.73 (s, 3H), 3.09-3.23 (m, 1H), 3.34-3.43
(m, 1H), 3.91 (s, 3H), 4.46 (s, 2H), 5.01-5.12 (m, 1H), 6.80 (d,
J=8.34 Hz, 1H), 7.12 (d, J=7.07 Hz, 1H), 7.16-7.28 (m, 2H),
7.64-7.73 (m, 1H), 7.73-7.82 (m, 1H). [M+H] calc'd for
C.sub.22H.sub.22FN.sub.7O.sub.3, 452; found, 452.
Example 90
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl--
7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((R)-3-fluorop-
yrrolidin-1-yl)ethanone (Compound 85)
##STR00281##
[1222] To a solution of
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)acetic acid
(0.05 mmol, 22.6 mg) in DMF (0.5 mL) was added HBTU (0.075 mmol, 28
mg), Et.sub.3N (0.125 mmol, 17 .mu.L) and (R)-3-fluoropyrrolidin
(0.06 mmol, 7.5 mg). The reaction mixture was stirred over night at
r.t. and LCMS shows completion of the reaction. Purified by prep
LCMS to afford the title compound (Compound 85, 13.0 mg, 50%) as
light brown solid. .sup.1H NMR (400 MHz, methanol-d.sub.4) .delta.
ppm 2.05-2.40 (m, 2H) 2.72 (s, 3H) 3.06 (dd, J=16.93, 10.36 Hz, 1H)
3.27-3.38 (m, 1H) 3.39-3.62 (m, 4H) 3.63-3.78 (m, 2H) 3.82 (s, 3H)
4.47-4.67 (m, 2H) 4.87 (dd, J=10.36, 3.03 Hz, 1H) 5.11-5.36 (m, 1H)
6.69 (d, J=8.34 Hz, 1H) 6.97 (d, J=7.33 Hz, 1H) 7.06 (dd, J=9.35,
2.53 Hz, 1H) 7.13 (t, J=8.34 Hz, 1H) 7.50-7.70 (m, 2H). MS (ES)
[M+H] calculated for C.sub.26H.sub.28F.sub.2N.sub.7O.sub.3, 524.53;
found 524.50.
Example 91
(S)-4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-met-
hyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-hydroxybut-
anoic acid (Compound 86)
##STR00282## ##STR00283##
[1224] Step A.
[1225] To a solution of (S)-3-hydroxydihydrofuran-2(3H)-one (91a, 5
g, 49 mmol) in anhydrous DMF (40 mL) was added imidazole (6.7 g, 98
mmol) and TBDMS-chloride (8.1 g, 54 mmol) and the reaction is
stirred for 3 h. The reaction was diluted with diethyl ether and
washed with 1N HCl.times.3. The organic phase was dried over
anhydrous sodium sulfate and the solvent was removed in vacuo to
yield (S)-3-(tert-butyldimethylsilyloxy)dihydrofuran-2(3H)-one
(91b) as a clear oil (10.6 g, 49 mmol). .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. 0.15 (s, 3H), 0.18 (s, 3H), 0.86-0.99 (m,
9H), 2.23 (dq, J=12.63, 8.67 Hz, 1H), 2.46 (dddd, J=12.63, 7.58,
6.57, 3.28 Hz, 1H), 2.84-3.01 (m, 1H), 4.20 (td, J=9.16, 6.44 Hz,
1H), 4.33-4.47 (m, 2H).
[1226] Step B.
[1227] To a solution of
(S)-3-(tert-butyldimethylsilyloxy)dihydrofuran-2(3H)-one (91b, 6 g,
27.8 mmol) in methanol (40 mL) was added potassium carbonate (500
mg, 3.6 mmol). The reaction was refluxed overnight. The methanol
was removed in vacuo and the residue partitioned between ethyl
acetate and water. The organic phase was washed with
H.sub.2O.times.2 and dried over anhydrous sodium sulfate. The
solvent was removed in vacuo to yield (S)-methyl
2-(tert-butyldimethylsilyloxy)-4-hydroxybutanoate (91c, 3.9 g, 15.7
mmol) as a clear oil. [M+H] calc'd for C.sub.11H.sub.24O.sub.4Si,
249; found, 249.
[1228] Step C.
[1229] To a solution of (S)-methyl
2-(tert-butyldimethylsilyloxy)-4-hydroxybutanoate (91c, 3.9 g, 15.7
mmol) in anhydrous dichloromethane was added triethylamine, DMAP,
and mesyl chloride. The reaction was allowed to stir for 1.5 h. The
reaction was quenched with saturated aqueous NH.sub.4Cl. The
aqueous phase was extracted with dichlormethane and the combine
organic phases were washed with brine. The organic layer was dried
over anhydrous sodium sulfate and the solvent removed in vacuo to
yield (S)-methyl 2-(tert-butyldimethylsilyloxy)-4-mesylbutanoate
(91d, 4.9 g, 15 mmol) as a yellow oil. [M+H] calc'd for
C.sub.12H.sub.26O.sub.6SSi, 327; found, 327.
[1230] Step D.
[1231] To a solution of (S)-methyl
2-(tert-butyldimethylsilyloxy)-4-mesylbutanoate (91d, 4.9 g, 15
mmol) in anhydrous acetone was added sodium iodide (11.5 g, 75
mmol). The reaction was heated at reflux for 1.5 h. The reaction
was quenched with water and extracted into EtOAc.times.3. The
combined organic phases were washed with brine then dried over
anhydrous sodium sulfate. The solvent was removed in vacuo to yield
(S)-methyl 2-(tert-butyldimethylsilyloxy)-4-iodobutanoate (91e,
4.33 g, 12 mmol) as a yellow oil. .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. 0.07-0.13 (m, 6H), 0.82-0.99 (m, 9H),
2.09-2.32 (m, 2H), 3.17-3.36 (m, 2H), 3.74 (s, 3H), 4.29 (dd,
J=8.08, 4.04 Hz, 1H).
[1232] Step E.
[1233] To a solution of
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one oxime (91e, 150 mg, 0.41 mmol) in anhydrous
DMF (2 mL) was added cesium carbonate (200 mg, 0.62 mmol). The
reaction mixture was allowed to stir for 1 h, at which time
(S)-methyl 2-(tert-butyldimethylsilyloxy)-4-mesylbutanoate (91f,
220 mg, 0.62 mmol) was added. The reaction was allowed to stir
under a nitrogen atmosphere overnight. The reaction was poured onto
ice to crash out (S)-methyl
4-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido-
[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-(tert-butyldimethylsilyloxy)but-
anoate (91 g, 244 mg, 0.41 mmol) as a dark yellow precipitate.
[M+H] calc'd for C.sub.25H.sub.35BrFN.sub.5O.sub.4Si, 596; found,
596.
[1234] Step F.
[1235] To a solution of (S)-methyl
4-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido-
[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-(tert-butyldimethylsilyloxy)but-
anoate (91 g, 244 mg, 0.41 mmol) in DMA was added
6-methoxypyridine-2-boronic acid N-phenyldiethanolamine ester (488
mg, 1.64 mmol), Pd(dppf).sub.2Cl.sub.2 (66 mg, 0.08 mmol), and 2 N
Na.sub.2CO.sub.3 (2 mL, 4.1 mmol). The resultant mixture was
degassed with N.sub.2 for 5 min then heated in a sealed tube at
85.degree. C. for 14 h. The reaction was allowed to cool to r.t.
and filtered through a pad of Celite topped with anhydrous
Na.sub.2SO.sub.4, rinsing with EtOAc and CH.sub.3OH. The filtrate
was concentrated to provide a black residue which was purified by
preparative HPLC eluting with TFA/ACN/H.sub.2O. The fractions were
dried down in vacuo to yield (S)-methyl
4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-(tert-butyldi-
methylsilyloxy)butanoate. This material was directly taken up in
dioxane (700 .mu.L) and treated with 1:9 TFA:H.sub.2O (1 mL) for 3
h. The solvents were removed in vacuo to yield (S)-methyl
4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-hydroxybutano-
ate (91h, 15 mg, 0.03 mmol). [M+H] calc'd for
C.sub.25H.sub.27FN.sub.6O.sub.5, 511; found, 511.
[1236] Step G.
[1237] To a solution of (S)-methyl
4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-hydroxybutano-
ate (91h, 15 mg, 0.03 mmol) in dioxane (500 .mu.L) was added 1 N
LiOH (74 .mu.L, 0.08 mmol). The reaction was allowed to stir for 3
h, at which time it was diluted with 1:1 DMSO:MeOH and purified via
preparative HPLC eluting with TFA/ACN/H.sub.2O. The fractions were
dried down in vacuo to yield
(S)-4-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl-
)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-2-hyd-
roxybutanoic acid (Compound 86, 7.1 mg, 0.014 mmol) as a yellow
oil. .sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta. 1.86-2.08 (m,
1H), 2.18-2.35 (m, 1H), 2.70-2.87 (m, 3H), 3.18 (dd, J=16.80, 9.22
Hz, 1H), 3.31-3.44 (m, 1H), 3.84-3.97 (m, 3H), 4.10-4.32 (m, 3H),
5.08 (dd, J=9.09, 4.04 Hz, 1H), 6.79 (d, J=8.34 Hz, 1H), 7.12 (d,
J=7.33 Hz, 1H), 7.14-7.31 (m, 2H), 7.66 (dd, J=8.59, 5.56 Hz, 1H),
7.76 (t, J=7.83 Hz, 1H). [M+H] calc'd for
C.sub.24H.sub.25FN.sub.6O.sub.5, 497; found, 497.
Example 92
3-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl--
7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)dihydrofuran-2(3H-
) one (Compound 87)
##STR00284##
[1239] To a solution of
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d-
]pyrimidin-5(6H)-one oxime (0.3 mmol, 109 mg) in DMF (2.0 mL) was
added Cs.sub.2CO.sub.3 (0.45 mmol, 146 mg) and
3-bromodihydrofuran-2(3H)-one (0.36 mmol, 33.6 .mu.L). The reaction
mixture was stirred overnight at r.t. and LCMS shows completion of
the reaction. The reaction mixture was poured on crushed ice and
the resultant solid was filtered and dried to afford
3-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydr-
opyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)dihydrofuran-2(3H)-one
(105 mg, 78%) as off white solid. MS (ES). [M+H] calculated for
C.sub.18H.sub.18BrFN.sub.5O.sub.3, 450.05; found 450.30.
[1240] A mixture of the resultant compound (0.2 mmol, 92 mg),
2-(6-methoxypyridin-2-yl)-6-phenyl-1,3,6,2-dioxazaborocane (0.5
mmol, 150 mg), Pd(dppf).sub.2Cl.sub.2 (0.02 mmol, 16 mg), 2N aq
Na.sub.2CO.sub.3 (1.0 mmol, 0.5 mL) and DMA (2.0 mL) was degassed
with N.sub.2 and heated at 85.degree. C. for 4 h. Cooled to rt,
filtered trough celite and purified by prep LCMS to afford
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxybutano-
ic acid (29 mg, 29%) as brown solid. MS (ES) [M+H] calculated for
C.sub.24H.sub.26FN.sub.6O.sub.5, 497.19; found 497.00.
[1241] The resultant compound was dissolved in THF (1.0 ml) and
cooled to 0.degree. C. N-methyl morpholine (0.15 mmol, 16.5 .mu.L)
and isobutyl chloroformate (0.1 mmol, 15.5 .mu.L) was added and the
reaction mixture was stirred at ambient temperature for 2 h.
Purified by prep LCMS to afford the title compound
3-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)dihydrofuran-2(3-
H)one (5 mg, 21%) as white solid. .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. 2.52 (d, J=3.54 Hz, 1H) 2.66 (br. s., 3H)
2.95-3.11 (m, 1H) 3.27 (br. s., 2H) 3.79 (s, 3H) 4.19-4.29 (m, 1H)
4.34-4.45 (m, 1H) 4.73-4.91 (m, 2H) 6.67 (d, J=8.34 Hz, 1H) 6.94
(d, J=6.57 Hz, 1H) 7.00-7.15 (m, 2H) 7.49-7.66 (m, 2H). MS (ES)
[M+H] calculated for C.sub.24H.sub.24FN.sub.6O.sub.4, 479.47; found
479.40.
Example 93
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl--
7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxybutanam-
ide (Compound 88)
##STR00285##
[1243]
3-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4--
methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)dihydrofur-
an-2(3H)one (14.3 mg, 0.03 mmol) was dissolved in 7N NH.sub.3-MeOH
solution and stirred overnight in a sealed tube. The solvent was
removed and residue dried to afford the title compound
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxybutana-
mide (13.2 mg, 89%) as a white solid. .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 1.83-2.16 (m, 2H) 2.58 (d, J=6.06 Hz, 3H)
2.85-3.03 (m, 1H) 3.07-3.25 (m, 1H) 3.70 (q, J=7.24 Hz, 2H) 3.90
(d, J=11.37 Hz, 3H) 4.54 (td, J=7.83, 5.05 Hz, 1H) 4.97-5.17 (m,
1H) 6.69-6.85 (m, 1H) 7.11 (dd, J=7.71, 2.40 Hz, 1H) 7.14-7.26 (m,
2H) 7.57-7.72 (m, 1H) 7.76 (dd, J=15.03, 6.69 Hz, 1H). MS (ES)
[M+H] calculated for C.sub.24H.sub.27FN.sub.7O.sub.4, 496.50; found
496.40.
Example 94
2-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[-
4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-N,N-dimethylbutanamide
(Compound 89) and chiral separation
##STR00286##
[1245] To a solution of
3-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido-
[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)dihydrofuran-2(3H)-one (310
mg, 0.668 mg) in THF (2 mL) was added N,N-dimethylamine (2.0M
solution in MeOH, 0.86 mL, 1.72 mmol) and the reaction mixture was
stirred overnight at r.t. The solvent was removed and purified by
LCMS to afford the title compound
2-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihy-
dropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-N,N-dimethylbu-
tanamide (89, 80 mg, 24%) as white solid. .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 2.63 (d, J=2.78 Hz, 3H) 2.84-2.99 (m, 1H)
3.01 (d, J=3.28 Hz, 3H) 3.08-3.25 (m, 4H) 3.61-3.93 (m, 2H) 4.99
(dddd, J=15.03, 4.86, 2.59, 2.27 Hz, 1H) 5.09-5.23 (m, 3H) 5.91 (d,
J=9.09 Hz, 1H) 6.98-7.14 (m, 1H) 7.33 (ddd, J=7.89, 4.99, 2.53 Hz,
1H) 7.38-7.48 (m, 1H). MS (ES) [M+H] calculated for
C.sub.20H.sub.25BrFN.sub.6O.sub.3, 495.34; found 495.30.
[1246]
2-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydro-
pyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-N,N-dimethylbutan-
amide (89) was separated into its enantiomers by supercritical
fluid chromatography (SFC) under the following conditions.
[1247] Column: ChiralPak AS-H (250.times.21 mm, 5 Mm)
[1248] Mobile Phase: [1249] A: CO.sub.2 (1) [1250] B: i-PrOH
[1251] Gradient Condition: 25% i-PrOH
[1252] Run Time: 8 min
[1253] Flow Rate: 50 mL/min
[1254] Injection volume: 2000 .mu.L
Example 95
Synthesis of
(R)-2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-N-
,N-dimethylbutanamide (Compound 92)
##STR00287##
[1256] A mixture of
(R)-2-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropy-
rido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-N,N-dimethylbutanam-
ide (31 mg, 0.063 mmol),
2-(6-methoxypyridin-2-yl)-6-phenyl-1,3,6,2-dioxazaborocane (93 mg,
0.313 mmol), Pd(dppf).sub.2Cl.sub.2 (9.16 mg, 0.013 mmol), 2N aq
Na.sub.2CO.sub.3 (0.156 mL, 0.313 mmol) and DMA (2.0 mL) was
degassed with N.sub.2 and heated at 85.degree. C. for 4 h. Cooled
to r.t., filtered trough celite and purified by prep LCMS to afford
(R)-2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)
aminooxy)-4-hydroxy-N,N-dimethylbutanamide (92, 14.4 mg, 43.9%) as
off-white solid. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta.
2.08-2.16 (m, 2H) 2.60 (s, 3H) 2.98 (s, 3H) 3.02 (d, J=9.85 Hz, 1H)
3.10 (s, 3H) 3.16-3.33 (m, 1H) 3.62-3.81 (m, 2H) 3.89 (s, 3H) 4.94
(ddd, J=10.04, 3.98, 0.88 Hz, 1H) 5.03 (t, J=6.19 Hz, 1H) 5.27 (br.
s., 2H) 5.79 (s, 1H) 6.74 (dd, J=8.34, 0.76 Hz, 1H) 7.01 (dd,
J=7.33, 0.76 Hz, 1H) 7.07-7.23 (m, 2H) 7.65 (dd, J=8.34, 7.33 Hz,
2H). MS (ES) [M+H] calculated for C.sub.26H.sub.31FN.sub.7O.sub.4,
524.56; found 524.40.
Example 96
(S)-2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-met-
hyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-N,-
N-dimethylbutanamide (Compound 93)
##STR00288##
[1258] A mixture of
(S)-2-((Z)-((R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropy-
rido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-N,N-dimethylbutanam-
ide (26 mg, 0.052 mmol),
2-(6-methoxypyridin-2-yl)-6-phenyl-1,3,6,2-dioxazaborocane (78 mg,
0.262 mmol), Pd(dppf).sub.2Cl.sub.2 (7.68 mg, 0.01 mmol), 2N aq
Na.sub.2CO.sub.3 (0.131 mL, 0.262 mmol) and DMA (2.0 mL) was
degassed with N.sub.2 and heated at 85.degree. C. for 4 h. Cooled
to r.t., filtered trough celite and purified by prep LCMS to afford
(S)-2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-N-
,N-dimethylbutanamide (93, 10.3 mg, 37%) as off-white solid.
.sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. 2.04-2.15 (m, 2H) 2.60
(s, 3H) 2.97 (s, 3H) 3.01-3.07 (m, 1H) 3.13 (s, 3H) 3.30 (ddd,
J=16.42, 3.79, 1.52 Hz, 1H) 3.70-3.84 (m, 2H) 3.89 (s, 3H) 4.90
(dd, J=10.74, 3.66 Hz, 1H) 5.12 (t, J=6.32 Hz, 1H) 5.26 (br. s.,
1H) 5.78 (s, 1H) 6.74 (dd, J=8.34, 0.76 Hz, 1H) 7.02 (dd, J=7.20,
0.88 Hz, 1H) 7.11-7.21 (m, 2H) 7.65 (dd, J=8.34, 7.07 Hz, 2H). MS
(ES) [M+H] calculated for C.sub.26H.sub.31FN.sub.7O.sub.4, 524.56;
found 524.40.
Example 97
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl--
7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-1-morp-
holinobutan-1-one (Compound 94)
##STR00289##
[1260] To a solution of
3-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)dihydrofuran-2(3-
H) one (12.0 mg, 0.025 mmol) in THF (1.0 mL) was added morpholine
(5.52 .mu.L, 0.063 mmol) and the reaction mixture was stirred
overnight. Solvent was removed and purified by prep LCMS to afford
the title compound
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-
-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydr-
oxy-1-morpholinobutan-1-one (94, 5.7 mg, 40%) as white solid.
.sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta. 1.79-2.03 (m, 2H)
2.57 (d, J=7.07 Hz, 3H) 2.99 (ddd, J=16.86, 8.72, 8.53 Hz, 1H)
3.10-3.18 (m, 1H) 3.22-3.29 (m, 4H) 3.46-3.55 (m, 4H) 3.57-3.62 (m,
2H) 3.81 (d, J=5.81 Hz, 3H) 4.95 (ddd, J=19.45, 8.84, 4.80 Hz, 1H)
5.00-5.06 (m, 1H) 6.70 (dd, J=7.58, 6.06 Hz, 1H) 7.03 (d, J=6.57
Hz, 1H) 7.06-7.16 (m, 2H) 7.54 (ddd, J=19.20, 8.34, 5.81 Hz, 1H)
7.67 (td, J=7.83, 4.80 Hz, 1H). MS (ES) [M+H] calculated for
C.sub.28H.sub.33FN.sub.7O.sub.5, 566.59; found 566.50.
Example 98
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl--
7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-methoxy-N,N-di-
methylbutanamide (Compound 95)
##STR00290##
[1262] To a solution of
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-hydroxy-N,N-d-
imethylbutanamide (0.03 mmol, 16 mg) in THF (2 mL) was added 50%
NaH (0.034 mmol, 1.65 mg) at 0.degree. C. under N.sub.2 atmosphere.
The reaction mixture was stirred for 15 minutes and dimethyl
sulphate (4.08 .mu.L, 0.043 mmol) was added. The reaction mixture
was stirred at r.t. for 3 h. Quenched with MeOH (1 mL) and purified
by LCMS to afford the title compound
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-4-methoxy-N,N-d-
imethylbutanamide (95, 3.6 mg, 25%) as an off-white solid. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 1.81-2.06 (m, 2H) 2.47 (s, 3H)
2.70-2.80 (m, 1H) 2.83 (d, J=10.61 Hz, 3H) 3.05 (d, J=7.58 Hz, 3H)
3.07-3.17 (m, 1H) 3.20 (d, J=4.80 Hz, 3H) 3.31-3.39 (m, 2H)
3.40-3.49 (m, 2H) 3.87 (d, J=3.79 Hz, 3H) 4.80-4.93 (m, 1H)
5.06-5.22 (m, 1H) 6.83-6.90 (m, 1H) 7.20 (d, J=8.84 Hz, 1H)
7.23-7.32 (m, 2H) 7.44 (ddd, J=14.34, 8.91, 5.81 Hz, 1H) 7.85 (td,
J=7.83, 3.28 Hz, 1H). MS (ES) [M+H] calculated for
C.sub.27H.sub.33FN.sub.7O.sub.4, 538.58; found 538.40.
Example 99
Synthesis of
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-N--((S)-2,3-dih-
ydroxypropyl)-N-methylacetamide (Compound 96)
##STR00291##
[1264] .sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta. 2.57 (d,
J=5.31 Hz, 3H), 2.89-3.21 (m, 5H), 3.34-3.65 (m, 4H), 3.75-3.88 (m,
1H), 3.89 (s, 3H), 4.55-4.77 (m, 4H), 5.01 (dt, J=9.16, 4.64 Hz,
1H), 6.77 (d, J=8.34 Hz, 1H), 7.12 (d, J=7.33 Hz, 1H), 7.13-7.25
(m, 2H), 7.67 (dd, J=8.21, 5.68 Hz, 1H), 7.75 (t, J=7.83 Hz,
1H).
[1265] [M+H] calc'd for C.sub.26H.sub.30FN.sub.7O.sub.5, 540;
found, 540.
Example 100
Synthesis of
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-cyclopropylacetam-
ide (Compound 97)
##STR00292##
[1267] The titled compound 97 was prepared by a procedure
analoguous to Example 87 except cyclopropanamine was used .sup.1H
NMR (400 MHz, MeOD) .delta. 0.43-0.53 (m, 2H), 0.68-0.79 (m, 2H),
2.67 (dt, J=7.33, 3.41 Hz, 1H), 2.71 (s, 3H), 3.09-3.21 (m, 1H),
3.37-3.52 (m, 1H), 3.91 (s, 3H), 4.43 (s, 2H), 5.06 (dd, J=9.35,
4.29 Hz, 1H), 6.80 (d, J=8.34 Hz, 1H), 7.13 (d, J=7.07 Hz, 1H),
7.15-7.29 (m, 2H), 7.69 (dd, J=8.84, 5.56 Hz, 1H), 7.72-7.83 (m,
1H). [M+H] calc'd for C.sub.25H.sub.26FN.sub.7O.sub.3, 492; found,
492.
Example 101
Synthesis of
(R,Z)-4-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N,N-dimethylbutanam-
ide (Compound 98)
##STR00293##
[1269] A solution of
(R,Z)-4-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)butanoic acid
(110a, 26 mg, 0.054 mmol) in anhydrous THF was chilled in an ice
bath and N-methylmorpholine (9 .mu.L, 0.081 mmol) and isobutyl
chloroformate (7.7 .mu.L, 0.060 mmol) were added sequentially. The
mixture was stirred under an N.sub.2 atmosphere for 20 min. A 33 wt
% solution of dimethylamine in methanol (54 .mu.L, 0.11 mmol) was
added to the reaction which was subsequently allowed to warm to
room temperature with stirring overnight. The THF was removed in
vacuo and the residue was partitioned between ethyl acetate and
water. The organic phase was washed with H.sub.2O.times.2 and dried
over anhydrous Na.sub.2SO.sub.4. The ethyl acetate was removed in
vacuo and the residue was purified via preparative HPLC to yield
(R,Z)-4-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N,N-dimethylbutanam-
ide (98, 6.4 mg, 0.0126 mmol).
[1270] .sup.1H NMR (400 MHz, MeOD) .delta. 1.91-2.05 (m, 2H), 2.46
(t, J=7.33 Hz, 2H), 2.70 (s, 3H), 2.87 (s, 3H), 3.00 (s, 3H),
3.02-3.16 (m, 1H), 3.25 (dd, J=16.55, 4.67 Hz, 1H), 3.91 (s, 3H),
4.00-4.12 (m, 2H), 5.05 (dd, J=8.59, 4.55 Hz, 1H), 6.79 (d, J=8.34
Hz, 1H), 7.12 (d, J=7.33 Hz, 1H), 7.15-7.25 (m, 2H), 7.59 (dd,
J=8.46, 5.68 Hz, 1H), 7.71-7.82 (m, 1H). [M+H] calc'd for
C.sub.26H.sub.30FN.sub.7O.sub.3, 508; found, 508.
Example 102
Synthesis of
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N-(2-hydroxyethyl)--
N-methylacetamide (Compound 99)
##STR00294##
[1272] To a solution of
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)acetic acid
(102a, 43 mg, 0.095 mmol) in anhydrous DMF (1 mL) was added
2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (72 mg, 0.19 mmol), triethylamine (53 .mu.L,
0.39 mmol), and finally 2-(methylamino)ethanol (102b, 16 .mu.L,
0.19 mmol). The reaction was allowed to stir under a nitrogen
atmosphere overnight. The reaction mixture was diluted with 1:1
DMSO:MeOH and purified via preparative HPLC eluting with
NH.sub.4HCO.sub.3/ACN/H.sub.2O. The titled compound (Compound 99,
11 mg, 0.022 mmol) was crashed out from the HPLC fractions as a
white solid. .sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta. 2.57
(d, J=4.04 Hz, 3H), 2.86-3.21 (m, 5H), 3.44-3.55 (m, 2H), 3.66-3.73
(m, 2H), 3.89 (s, 3H), 4.69-4.82 (m, 2H), 5.01 (dt, J=9.09, 4.29
Hz, 1H), 6.77 (d, J=8.34 Hz, 1H), 7.12 (d, J=7.33 Hz, 1H),
7.14-7.24 (m, 2H), 7.60-7.70 (m, 1H), 7.70-7.80 (m, 1H). [M+H]
calc'd for C.sub.25H.sub.28FN.sub.7O.sub.4, 510; found, 510.
Example 103
Synthesis of
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylidene)aminooxy)-1-((S)-3-hydrox-
ypyrrolidin-1-yl)ethanone (Compound 100)
##STR00295##
[1274] The titled compound 100 was prepared by a procedure
analoguous to Example 102 except (S)-pyrrolidin-3-ol was used.
.sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta. 1.82-2.13 (m, 2H),
2.57 (d, J=3.03 Hz, 3H), 2.95 (ddd, J=16.23, 8.91, 3.92 Hz, 1H),
3.09-3.22 (m, 2H), 3.38-3.54 (m, 2H), 3.54-3.74 (m, 2H), 3.90 (s,
3H), 4.41 (d, J=9.35 Hz, 1H), 4.55-4.73 (m, 2H), 4.96-5.08 (m, 1H),
6.78 (d, J=8.34 Hz, 1H), 7.12 (d, J=7.07 Hz, 1H), 7.13-7.24 (m,
2H), 7.64 (dt, J=8.53, 5.84 Hz, 1H), 7.75 (t, J=7.83 Hz, 1H). [M+H]
calc'd for C.sub.26H.sub.28FN.sub.7O.sub.4, 522; found, 522.
Example 104
Synthesis of
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-N,N-diethylacetamid-
e (Compound 101)
##STR00296##
[1276] The titled compound 101 was prepared by a procedure
analoguous to Example 102. .sup.1H NMR (400 MHz, METHANOL-d.sub.4)
.delta. 1.12 (t, J=7.07 Hz, 3H), 1.15-1.26 (m, 3H), 2.71 (s, 3H),
3.17 (dd, J=16.80, 9.47 Hz, 1H), 3.32-3.46 (m, 5H), 3.89 (s, 3H),
4.65-4.81 (m, 2H), 5.05 (dd, J=9.47, 4.17 Hz, 1H), 6.79 (d, J=8.34
Hz, 1H), 7.13 (d, J=7.33 Hz, 1H), 7.15-7.29 (m, 2H), 7.70 (dd,
J=8.59, 5.56 Hz, 1H), 7.72-7.83 (m, 1H). [M+H] calc'd for
C.sub.26H.sub.30FN.sub.7O.sub.3, 508; found, 508.
Example 105
Synthesis of
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-morpholinoethanon-
e (Compound 102)
##STR00297##
[1277] A.
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyr-
ido[4,3-d]pyrimidin-5(6H)-one O-tert-butyldimethylsilyloxime
(105a)
[1278] A mixture of
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]p-
yrimidine-5(6H)-thione (31I, 366 mg, 1.0 mmol),
O-(tert-butyldimethylsilyl)hydroxylamine (588 mg, 4.0 mmol),
Hg(OAC).sub.2 (640 mg, 2.0 mmol) and toluene (5 mL) was heated at
100.degree. C. for 2 h. The mixture was cooled to r.t. and filtered
through celite. Filtrate concentrated and the resulting oily
residue was triturated with dry methanol to afford a pale yellow
solid. Filtered and dried to afford
((R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3--
d]pyrimidin-5(6H)-one O-tert-butyldimethylsilyloxime (105a, 384 mg,
80%) as a pale yellow solid. .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta. ppm 0.22 (s, 3H), 0.23 (s, 3H) 0.97 (s, 9H) 2.70 (s, 3H)
2.91 (dd, J=16.42, 8.08 Hz, 1H) 3.19 (ddd, J=16.36, 4.86, 1.26 Hz,
1H) 4.99 (ddd, J=7.77, 5.12, 2.02 Hz, 1H) 7.05 (td, J=8.27, 2.65
Hz, 1H) 7.33 (dd, J=8.08, 2.78 Hz, 1H) 7.39 (dd, J=8.72, 5.94 Hz,
1H). MS (ES) [M+H] calculated for C.sub.20H.sub.28BrFN.sub.5OSi,
480.12; found 480.30.
B. (R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydro
pyrido[4,3-d]pyrimidin-5(6H)-one oxime (105b)
[1279] To a solution of
((R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3--
d]pyrimidin-5(6H)-one O-tert-butyldimethylsilyloxime (105a, 384 mg,
0.8 mmol) in dioxane (2 mL) was added 1:9 TFA-H.sub.2O and the
reaction mixture stirred at rt for 2 h. The resultant sold was
filtered and washed with dioxane. The resultant solid was dried to
afford
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydro
pyrido[4,3-d]pyrimidin-5(6H)-one oxime (105b, 206 mg, 70%) as a
pale yellow solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
2.56 (s, 3H) 2.83 (dd, J=15.92, 4.55 Hz, 1H) 3.17 (dd, J=16.04,
5.94 Hz, 1H) 4.90 (q, J=4.97 Hz, 1H) 7.20 (d, J=1.52 Hz, 1H)
7.21-7.23 (m, 1H) 7.57 (ddd, J=8.34, 1.64, 1.39 Hz, 1H) 9.82 (s,
1H). MS (ES) [M+H] calculated for C.sub.14H.sub.14BrFN.sub.5O,
366.03; found 366.20.
C. (R,Z)-methyl
2-(2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]py-
rimidin-5(6H)-ylideneaminooxy)acetate (105c)
[1280] To a solution of
(R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydro
pyrido[4,3-d]pyrimidin-5(6H)-one oxime (105c, 150 mg, 0.4 mmol) in
dry DMF (1 mL) was added CsCO.sub.3 (195 mg, 0.6 mmol) and the
reaction mixture stirred at ambient temperature for 30 minutes.
Then methyl 2-bromoacetate (45 .mu.L, 0.48 mmol) was added and the
reaction mixture stirred for overnight. LCMS shows completion of
the starting material. The reaction mixture was poured on crushed
ice and the resultant sold was filtered and washed with cold water.
The resultant solid was dried to afford (R,Z)-methyl
2-(2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]py-
rimidin-5(6H)-ylideneaminooxy)acetate (105c, 172 mg, 99%) as a
light brown solid. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm
2.66 (s, 3H) 3.12-3.18 (m, 1H) 3.24-3.32 (m, 1H) 3.71 (s, 3H) 4.57
(s, 2H) 4.96 (ddd, J=8.40, 4.48, 1.77 Hz, 1H) 7.01 (td, J=8.27,
2.65 Hz, 1H) 7.23-7.29 (m, 1H) 7.39 (dd, J=8.84, 5.81 Hz, 0H). MS
(ES) [M+H] calculated for C.sub.17H.sub.18BrFN.sub.5O.sub.3,
438.05; found 438.00.
D.
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl--
7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)acetic acid
(105d)
[1281] A mixture of (R,Z)-methyl
2-(2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]py-
rimidin-5(6H)-ylideneaminooxy)acetate (105c, 175 mg, 0.4 mmol),
2-(6-methoxypyridin-2-yl)-6-phenyl-1,3,6,2-dioxazaborocane (298 mg,
1.0 mmol), Pd(dppf).sub.2Cl.sub.2 (32.5 mg, 0.04 mmol), 2N
Na.sub.2CO.sub.3 (1.0 mL, 2.0 mmol) in DMA (3 mL) was degassed with
N.sub.2 and heated at 85.degree. C. for over night. The reaction
mixture was cooled to ambient temperature, diluted with ethyl
acetate and filtered through celite. The filtrate was concentrated
to afford brown oil which was purified by preparative LCMS to
afford
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)acetic acid
(105d, 56 mg, 31%) as white solid. .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 2.79 (s, 3H) 3.16 (dd, J=17.05, 10.48 Hz,
1H) 3.45 (dd, J=17.05, 3.92 Hz, 1H) 3.88 (s, 3H) 4.59 (d, J=3.03
Hz, 2H) 4.96 (dd, J=10.36, 3.79 Hz, 1H) 5.90 (brs, 1H) 6.76 (d,
J=8.34 Hz, 1H) 7.02 (d, J=6.82 Hz, 1H) 7.14 (dd, J=9.09, 2.78 Hz,
1H) 7.19 (td, J=8.34, 2.78 Hz, 1H) 7.62 (dd, J=8.59, 5.56 Hz, 1H)
7.68 (dd, J=8.34, 7.33 Hz, 1H). MS (ES) [M+H] calculated for
C.sub.22H.sub.22FN.sub.6O.sub.4, 453.16; found 453.30.
E.
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl--
7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-morpholinoethan-
one (Compound 102)
[1282] To a solution of
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,-
8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)acetic acid
(105d, 0.05 mmol, 22.6 mg) in DMF (0.5 mL) was added HBTU (0.075
mmol, 28 mg), Et.sub.3N (0.125 mmol, 17 .mu.L) and morpholine (0.1
mmol, 8.3 .mu.L). The reaction mixture was stirred over night at
r.t. and LCMS shows completion of the reaction. Purified by prep
LCMS to afford the title compound
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4--
methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-1-morpholi-
noethanone (102, 5.7 mg, 22%) as off white solid. .sup.1H NMR (400
MHz, CHLOROFORM-d) .delta. ppm 2.83 (s, 3H) 3.15 (dd, J=17.31,
10.23 Hz, 2H) 3.43-3.51 (m, 2H) 3.63 (d, J=5.31 Hz, 2H) 3.65-3.71
(m, 4H) 3.89 (s, 3H) 4.71 (s, 2H) 4.97 (dd, J=10.36, 3.79 Hz, 1H)
5.96 (br. s., 1H) 6.77 (d, J=8.34 Hz, 1H) 7.03 (d, J=7.07 Hz, 1H)
7.14 (dd, J=9.35, 2.78 Hz, 1H) 7.19 (td, J=8.40, 2.65 Hz, 1H) 7.63
(dd, J=8.84, 5.56 Hz, 1H) 7.68 (dd, J=8.34, 7.33 Hz, 1H). MS (ES)
[M+H] calculated for C.sub.26H.sub.28FN.sub.7O.sub.4, 522.22; found
522.00.
[1283] The reaction schemes disclosed in the Example above was used
to prepare the compounds listed in the following table:
TABLE-US-00003 Compound M + H No. Structure & Name MW
(observed) 103 ##STR00298##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-
d]pyrimidin-5(6H)-ylideneaminooxy)-N,N-bis(2-
hydroxyethyl)acetamide 539.6 540 104 ##STR00299##
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-
2-yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-
d]pyrimidin-5(6H)-ylidene)aminooxy)-N,N-bis(2-
hydroxypropyl)acetamide 539.6567.6 568 105 ##STR00300##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-
d]pyrimidin-5(6H)-ylideneaminooxy)-l-(azetidin-1- yl)ethanone 491.5
492 106 ##STR00301##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-
d]pyrimidin-5(6H)-ylideneaminooxy)-1-(pyrrolidin-1- yl)ethanone
505.5 506 107 ##STR00302##
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylidene)aminooxy)-1-((S)-2-
(hydroxymethyl)pyrrolidin-1-yl)ethanone 535.6 536 108 ##STR00303##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylideneaminooxy)-1-(4-hydroxypiperidin-1- yl)ethanone 535.6
536 109 ##STR00304##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylideneaminooxy)-N-methyl-N-((6-methylpyridin-2-
yl)methyl)acetamide 570.6 571 110 ##STR00305##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylideneaminooxy)-N,N-bis(2- methoxyethyl)acetamide 567.6 568
111 ##STR00306##
(R,Z)-N-(2-amino-2-oxoethyl)-2-(2-amino-7-(4-fluoro-2-
(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-
dihydropyrido[4,3-d]pyrimidin-5(6H)-ylideneaminooxy)-
N-methylacetamide 522.5 523 112 ##STR00307##
2-((Z)-((R)-2-amino-7-(4-fIuoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylidene)aminooxy)-1-((R)-2-
(hydroxymethyl)pyrrolidin-1-yl)ethanone 535.6 536 113 ##STR00308##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylideneaminooxy)-N-(2-methoxyethyl)-N- methylacetamide 523.6
524 114 ##STR00309##
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylidene)aminooxy)-1-((R)-3-hydroxypyrrolidin-1- yl)ethanone
521.5 522 115 ##STR00310##
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylidene)aminooxy)-1-((R)-3-hydroxypiperidin-l- yl)ethanone
535.6 536 116 ##STR00311##
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylidene)aminooxy)-1-((S)-3-hydroxypyrrolidin-1- yl)ethanone
521.5 522 117 ##STR00312##
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylidene)aminooxy)-1-((S)-3-hydroxypiperidin-1- yl)ethanone
535.6 536 118 ##STR00313##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylideneaminooxy)-1-(3-hydroxyazetidin-1- yl)ethanone 507.5
508 119 ##STR00314##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylideneaminooxy)-1-(3,3-difluoropyrrolidin-l- yl)ethanone
541.5 542 120 ##STR00315##
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylidene)aminooxy)-1-((R)-3-fluoropyrrolidin-1- yl)ethanone
523.5 524 121 ##STR00316##
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylidene)aminooxy)-1-((S)-3-fluoropyrrolidin-1- yl)ethanone
523.5 524 122 ##STR00317##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylideneaminooxy)-1-(4-methoxypiperidin-1- yl)ethanone 549.6
550 123 ##STR00318##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylideneaminooxy)-1-(3,3-difluoroazetidin-1- yl)ethanone 527.5
528 124 ##STR00319##
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylidene)aminooxy)-1-(3-(methoxymethyl)piperidin-
l-yl)ethanone 563.6 564 125 ##STR00320##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-(dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylideneaminooxy)-N-methyl-N-(2-(methylamino)-
2-oxoethyl)acetamide 536.6 537 126 ##STR00321##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylideneaminooxy)-N-(isoxazol-3-ylmethyl)-N- methylacetamide
546.6 547 127 ##STR00322##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylideneaminooxy)-N-methyl-N-(thiazol-4- ylmethyl)acetamide
562.6 563 128 ##STR00323##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylideneaminooxy)-1-(pyrazin-2-yl)ethanone 557.6 558 129
##STR00324## 2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylidene)aminooxy)-1-(3-(dimethylamino)piperidin-
1-yl)ethanone 562.6 563 130 ##STR00325##
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylidene)aminooxy)-1-(2-methyltetrahydro-1H-
pyrrolo[3,4-c]pyridin-5(6H,7H,7aH)-yl)ethanone 574.6 575 131
##STR00326## (R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylideneaminooxy)-N-methyl-N-((5-methyl-1H-
pyrazol-3-yl)methyl)acetamide 559.6 560 132 ##STR00327##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylideneaminooxy)-1-(2-methyl-6,7-dihydro-3H-
imidazo[4,5-c]pyridin-5(4H)-yl)ethanone 571.6 572 133 ##STR00328##
2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylidene)aminooxy)-l-(3-(hydroxymethyl)pyrrolidin-
1-yl)ethanone 535.6 536 134 ##STR00329##
2-(2-((Z)-((R)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-
2-yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylidene)aminooxy)acetyl)hexahydropyrrolo[1,2-
a]pyrazin-6(7H)-one 574.6 575 135 ##STR00330##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylideneaminooxy)-1-(3-methoxyazetidin-1- yl)ethanone 521.5
522 136 ##STR00331##
(R,Z)-2-(2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-
yl)phenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-
5(6H)-ylideneaminooxy)-1-(4,4-difluoropiperidin-1- yl)ethanone
555.6 556
Example 106
Alternative synthesis of
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one oxime (Compound 61)
##STR00332## ##STR00333##
[1284] Step A. Synthesis of
(R)-5-(1H-benzo[d][1,2,3]triazol-1-yl)-7-(2-bromo-4-fluorophenyl)-4-methy-
l-7,8-dihydropyrido[4,3-d]pyrimidine-2-amine (Compound 106c)
[1285] In a 2-neck round-bottomed flask, under a blanket of
nitrogen was added
(R)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4-
,3-d]pyrimidin-5(6H)-one (106a, 1.00 g, 2.85 mmol),
1H-benzo[d][1,2,3]triazole (106b, 0.678 g, 5.70 mmol) and anhydrous
acetonitrile (14 mL). Phosphoryl trichloride (0.796 mL, 8.54 mmol)
was added slowly to the mixture and the reaction was heated in
75.degree. C. oil bath for 18 hours. By LC/MS about 7-10% of
compound 1 remained unreacted. The reaction mixture was
concentrated, then diluted with 80 mL of ethyl acetate and the
resulting mixture was added slowly to 40 mL of saturated sodium
bicarbonate. The layers were partitioned. The aqueous layer was
washed one more time with 40 mL of ethyl acetate. The organic
layers combined, washed with brine, dried over sodium sulfate, and
concentrated to a yellow-light brown solid, 1.72 g, contained about
0.37 g of excess benzotriazole. The crude material was taken on to
the next step without purification. MS (ES) [M+H] calc'd for
C.sub.20H.sub.15BrFN.sub.7, 452; found, 452.3-454.3. .sup.1H NMR
(400 MHz, CHLOROFORM-d) 61.96 (s, 3H), 2.74 (dd, J=16.42, 14.91 Hz,
1H), 3.13 (dd, J=16.55, 4.17 Hz, 1H), 5.20 (dd, J=14.91, 4.04 Hz,
1H), 5.69 (s, 2H), 7.03-7.12 (m, 1H), 7.38 (dd, J=8.21, 2.65 Hz,
1H), 7.47-7.52 (m, 1H), 7.56-7.63 (m, 1H), 7.74 (dd, J=8.84, 6.06
Hz, 1H), 8.16 (d, J=9.35 Hz, 2H).
Step B. Synthesis of
(7R)-7-(2-bromo-4-fluorophenyl)-4-methyl-5-(tetrahydro-2H-pyran-2-yloxyam-
ino)-7,8-dihydropyrido[4,3-d]pyrimidin-2-amine (Compound 106e)
[1286]
(R)-5-(1H-benzo[d][1,2,3]triazol-1-yl)-7-(2-bromo-4-fluorophenyl)-4-
-methyl-7,8-dihydropyrido[4,3-d]pyrimidine-2-amine (1.13 g, 2.50
mmol) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (0.322 g, 2.75
mmol) were combined in 15 mL of acetonitrile. Then acetic acid
(0.858 mL, 15.0 mmol) was added and the reaction mixture was
stirred at room temperature for 18 h. Next day, the reaction was
complete and it was concentrated in vacuo and then purified by
flash column chromatography, SiO.sub.2, gradient 30-100% ethyl
acetate/hexane. Obtained 0.838 g of compound 5, 74.5% yield. MS
(ES) [M+H] calc'd for C.sub.19H.sub.21BrFN.sub.5O.sub.2, 450;
found, 450.3-452.3. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta.
1.45-1.97 (m, 6H), 2.72 (s, 3H), 2.91 (ddd, J.sub.1=16.17, 10.86,
7.83 Hz, 1H), 3.05-3.26 (m, 1H), 3.58-3.71 (m, 1H), 3.86-4.08 (m,
1H), 4.92-5.06 (m, 1H), 5.25 (dd, J=5.81, 2.27 Hz, 1H), 5.63 (d,
J=4.04 Hz, 2H), 5.79-5.88 (d, J=36 Hz, 1H), 6.93-7.11 (m, J=16.07,
8.19, 8.19, 2.65 Hz, 1H), 7.28-7.34 (m, 1H), 7.35-7.44 (ddd, J=36
Hz, 1H).
Step C. Synthesis of
(7R)-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-5-(tetrahydro--
2H-pyran-2-yloxyamino)-7,8-dihydropyrido[4,3-d]pyrimidin-2-amine
(Compound 106 g)
[1287]
(7R)-7-(2-bromo-4-fluorophenyl)-4-methyl-5-(tetrahydro-2H-pyran-2-y-
loxyamino)-7,8-dihydropyrido[4,3-d]pyrimidin-2-amine (0.838 g, 1.86
mmol), 2-(6-methoxypyridin-2-yl)-6-phenyl-1,3,6,2-dioxazaborocane
(1.33 g, 4.47 mmol), sodium carbonate 2M solution (3.72 mL, 7.44
mmol) were combined in N,N-Dimethylacetamide (12 mL) and then the
mixture was purged with nitrogen for 5 minutes.
1,1'-bis(diphenylphosphino)ferrocenedichloro palladium(II)
dichloromethane complex (0.136 g, 0.186 mmol) was then added and
the reaction was heated in 85.degree. C. oil bath overnight. Next
day, the reaction was diluted with ethyl acetate 80 mL, washed with
brine (80 mL), dried over sodium sulfate, and concentrated to a
crude product which was then purified by flash column
chromatography, SiO.sub.2, gradient 20-100% ethyl acetate/hexane to
give a white solid, 1.11 g of product, contaminated with the
impurity of mass 182 (byproduct from the boronic ester, compound
6). MS (ES) [M+H] calc'd for C.sub.25H.sub.27FN.sub.6O.sub.3, 479;
found, 479.4.
Step D. Synthesis of
(R,Z)-2-amino-7-(4-fluoro-2(6-methoxypyridine-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one oxime (Compound 61)
[1288]
(7R)-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-5-(tetra-
hydro-2H-pyran-2-yloxyamino)-7,8-dihydropyrido[4,3-d]pyrimidin-2-amine
(0.891 g, 1.86 mmol) was dissolved in 10 mL of dioxane. 4M of HCl
in dioxane (1.86 mL, 7.45 mmol) was then added slowly to the above
stirred solution. After all the HCl was added, a yellow solid was
formed at the bottom of the reaction flask. The deprotection was
allowed to go for 30 minutes, then the supernatant was decanted.
Dichloromethane was added to wash the solid, then it was decanted.
This process was repeated a few times. No product was found in the
dioxane and dichloromethane washes. The solid product was then
purified on flash column chromatography, SiO.sub.2, gradient 2-15%
methanol/chloroform to give 0.404 g of product, 63.5% yield over 2
steps. MS (ES) [M+H] calc'd for C.sub.20H.sub.19FN.sub.6O.sub.2,
395; found, 395.3. .sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta.
2.60 (s, 3H), 3.09-3.19 (m, 1H), 3.29-3.34 (m, 1H), 3.91 (s, 3H),
5.45 (br. s., 1H), 6.82 (d, J=8.34 Hz, 1H), 7.16 (d, J=6.57 Hz,
1H), 7.19-7.30 (m, 2H), 7.55 (dd, J=8.59, 5.56 Hz, 1H), 7.79 (dd,
J=8.34, 7.33 Hz, 1H).
Example 107
Preparation of
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-d-
ihydropyrido[4,3-d]pyrimidin-5(6H)-one O--(S)-3,4-dihydroxybutyl
oxime benzoate Form A
[1289]
(R,Z)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-
-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
O--(S)-3,4-dihydroxybutyl oxime (Compound 37, 20 mg, a white
powder) was weighed in a reaction vessel equipped with a magnetic
stirring bar. Chloroform (5 mL) and benzoic acid in 1,4-dioxane
(340 .mu.L, 0.124 mol/L) were added, and the reaction mixture was
cooled at 5.degree. C. The solvent was evaporated with a gentle
stream of nitrogen, providing a paste.
[1290] Acetone (2.5 mL) was added to the residue. The mixture was
sonicated at room temperature until a solution was obtained.
Heptane (1 mL) was added and the reaction mixture was cooled at
5.degree. C. The solvent was evaporated with a gentle stream of
nitrogen yielding a solid.
[1291] The residual solid was characterized by powder X-ray
diffraction, differential scanning calorimetry (DSC) and
thermogravimetry. FIG. 2 shows the powder X-ray diffraction
diffractogram, which contains distinct lines characteristic of a
crystalline product. FIG. 3 shows an DSC thermogram which shows an
endotherm that starts at 128.degree. C. The solid possesses a
melting point of 128.degree. C.
[1292] In addition, the above reaction schemes and variations
thereof can be used to prepare the following compounds. It is
understood that recitation of a compound is intended to encompass
all of the different possible stereoisomers.
##STR00334## ##STR00335## ##STR00336## ##STR00337## ##STR00338##
##STR00339## ##STR00340## ##STR00341## ##STR00342##
Example A
Biological Assays
[1293] 1. Enzyme Binding (Fluorescence Polarization) Assay for
HSP90 Inhibitors.
[1294] a. Preparation of HSP90c Protein
[1295] This example describes cloning, expression and purification
of a protein comprising the N-terminal domain of HSP90.alpha.. It
should be noted that a variety of other expression systems and
hosts are also suitable for the expression of such protein, as
would be readily appreciated by one of skill in the art.
[1296] The sequence of human wild-type HSP90.alpha. is well known
in the art; see, Chen B. et al. Genomics 2005 86:627-637. The gene
encoding HSP90.alpha. can be isolated from RNA, cDNA or cDNA
libraries. In this case, the gene encoding residues 9-236 of image
clone 5270926 of HSP90.alpha. (ATCC) was isolated. This portion of
the gene encoding a section of human HSP90.alpha. that includes the
N-terminal nucleotide binding domain of human HSP90 was cloned into
pET28a vector (Novagen). The DNA sequence of the vector is shown in
SEQ ID NO: 1. Expression from this vector produced a protein
consisting of the recombinant N-terminal nucleotide binding domain
of HSP90.alpha. with a cleavable 6.times.-histidine tag and a
cleavage site at the N-terminus. The amino acid sequence of this
recombinant protein is shown in SEQ ID NO: 2.
[1297] Recombinant human N-terminal truncated
His.sub.6-HSP90.alpha. was expressed in E. coli (BL21) cells with
IPTG induction. Cell paste from 24.times.60 mL tubes (grown in a
multi-tube airlift fermentor) was lysed using an automated sample
lyser. Briefly, the pellet in each tube was suspended in 21 mL of
lysis buffer consisting of 50 mM Tris pH 7.9, 50 mM NaCl, 1 mM
MgCl.sub.2, 0.6 g/L Lysozyme (Sigma), 100 .mu.L/L Benzonase
(Novagen). After lysis, buffer was added; the tubes were sonicated
for 75 seconds, and then incubated for 20 minutes. After
incubation, 5 M NaCl was added to bring the final salt
concentration to 400 mM. The tubes were sonicated for 50 seconds
and then centrifuged at 3400 rpm for 50 min. The supernatants were
pooled and 4 ml of ProBond Ni resin (Invitrogen) was added. After
at least 30 minutes, the resin was spun down, washed with 25 mM
Tris pH 7.6, 400 mM NaCl, 20 mM imidazole, poured into a column and
washed with 10 column volumes of the same buffer. The protein was
eluted from the column using 3 column volumes of 25 mM Tris pH 7.6,
400 mM NaCl, 400 mM imidazole. The eluate was loaded onto a Supedex
200 column (GE Healthcare) equilibrated with 25 mM Tris pH 7.6, 250
mM NaCl, 0.25 mM TCEP, 1 mM EDTA and peak fractions were pooled and
concentrated to .about.6 mg/mL using 10 kDA MWCO centrifugal
concentrators (Millipore). Aliquots were flash frozen in liquid
nitrogen and stored at -80.degree. C. All purification was done at
4.degree. C.
[1298] b. Preparation of the Fluorescence Polarization Probe.
[1299] A fluorescein labeled small molecule was designed and
synthesized as a probe (TSD-FP probe) for the determination of the
binding affinity of the test compound to HSP90 proteins. The
synthesis of the small molecule,
(S,E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-me-
thyl-7,8-dihydroquinazolin-5(6H)-one O-2-aminoethyl oxime (Compound
24) was described in Examples 24 and 25 above. The TSD-FP probe was
prepared according to the following procedure:
##STR00343##
[1300] To a 4 mL vial containing a solution of Compound 24 (5 mg,
0.00908 mmol, 1.0 eq.) in dichloromethane (0.6 mL) and
triethylamine (6.3 .mu.L, 0.0454 mmol) was added a solution of
(5-((2,5-dioxopyrrolidin-1-yloxy)carbonyl)-2-(6-hydroxy-3-oxo-3H-xanthene-
-9-yl)benzoic acid (5-FAM, 4.7 mg, 0.01 mmol, 1.1 eq.) in
dichloromethane (0.4 mL); the mixture was stirred at room
temperature overnight. When the reaction was completed, as
determined by LC/MS, the reaction mixture was diluted with MeOH and
purified directly by preparative HPLC to give the TSD-FP probe as a
white solid (6.8 mg, 75%). ESI-MS: m/z 795.4 (M+H).sup.+.
[1301] c. Assaying the In Vitro Enzymatic Activity of HSP90
Inhibitors.
[1302] The inhibitory effect of the compounds of the invention
against HSP90.alpha. was determined by fluorescence polarization
assay. The assay was run in a black 384-well-plate and in an assay
buffer comprising 25 mM Hepes pH 7.3, 150 mM NaCl, 0.1 mM EDTA,
0.01% Brij35, 1 mM DTT.
[1303] To each test well, an aliquot of buffer, 2 .mu.l of test
compound in 10% DMSO, 4 .mu.l of 6.25 nM of TSD FP probe, 4 .mu.l
of 12.5 nM of purified HSP90.alpha. protein were added. For
positive control, 1 .mu.M geldanamycin (GM) was used instead of the
test compound (GM is a natural benzoquinone ansamycin that is known
to bind to the N-terminal ATP-binding pocket of HSP90 and inhibits
ATP binding and ATP-dependent chaperone activities). For negative
control, no inhibitor was added. The assay mixtures were incubated
at room temperature for 60 min and overnight (960 min). The
fluorescence intensity of the assay mixtures (both 60 min and
overnight incubation) was obtained using an Analyst HT (Molecular
Devices) with excitation wavelength of 485 nm and emission
wavelength of 535 nm.
[1304] d. Calculation of IC.sub.50 Values
[1305] IC.sub.50 value may be calculated by non-linear curve
fitting of the compound concentrations and FP signal to the
standard IC.sub.50 equation. See, J. Kim et al. "Development of a
Fluorescence Polarization Assay for the Molecular Chaperone Hsp90"
J. Biomolecular Screening 2004 9(5).
[1306] The percent inhibition of HSP90 at a given compound
concentration is defined as:
100%.times.[1-(FPcompound/FPblank)]
where FPcompound is the observed polarized fluorescence at a given
concentration of test compound and FPblank is the observed
polarized fluorescence in the presence of vehicle alone.
[1307] The pIC.sub.50 value (negative log of the molar
concentration of the compound that produces 50% inhibition) of a
test compound is calculated by non-linear least squares curve
fitting of the equation:
Percent Inhibition=100%/(1+(10-pIC.sub.50/10 log [I]))
to percent inhibition versus compound concentration. The 50%
inhibitory concentration (IC.sub.50) of a test compound is
calculated by raising 10 to the negative pIC.sub.50
(10-pIC.sub.50).
[1308] As reference, known HSP90 inhibitors, geldanamycin (GM) and
17 allylamino, 17-demethoxygeldanamycin (17-AAG), were assay and
the results summarized in Table 1. It is noted that these two
inhibitors showed a time dependence behavior of HSP90 binding which
are not common, among the small molecule inhibitors of the
invention.
TABLE-US-00004 TABLE 1 IC.sub.50 Values of Known HSP90 Inhibitors
Standard IC.sub.50 (nM) after IC.sub.50 (nM) after Compounds 1 hour
incubation overnight incubation Geldanamycin 90 10 17-AAG 400
110
[1309] 2. Cellular Viability Assay
[1310] BT-474, HT-29, K-562 and MKN-45 tumor cell lines were
maintained according to the suppliers (American Type Culture
Collection, Rockville, Md. or Human Science Research Resources
Bank, Osaka, Japan). Cells were seeded in 96-well tissue culture
microplates at 5,000-25,000 cells per well and cultured for 24
hours prior to addition of compounds or DMSO (dimethylsulfoxide)
vehicle. A sample where the cells were only treated with DMSO was
used a negative control and A sample where the cells were treated
with 17-AAG was used a positive control. After 72 hours of test
compound treatment, the conversion of tetrazolium salt MTS
(Promega, Madison, Wis.) by metabolically active cells was
determined through measuring the OD.sub.490 nm with a Spectramax
microplate reader (Molecular Devices, San Diego, Calif.). To
generate concentration-response curves, cells were treated in
duplicate with a range of serial compound dilutions (final DMSO
concentration was 0.5%). The percentage of viable cells per well
was determined by correcting for background and normalizing against
DMSO-treated cells. EC.sub.50 values for inhibition of cell
viability were calculated using XLfit4 Microsoft Excel
curve-fitting software.
[1311] 3. HSP70.beta. Induction Assay
[1312] The HSP70.beta./.beta.-galactosidase reporter vector was
purchased from Stressgen Bioreagents Corporation (Victoria, BC
Canada). This vector was transiently transfected into 2 million
HeLa cells per 10 cm.sup.2 dish according to the protocol provided
by Stressgen using the lipid based transfection reagent HeLaMONSTER
(Mirus Bio Corporation, Madison, Wis.). Cells were subsequently
plated in 96 well plates at 20,000 cells/well and after 24 hours of
recovery dosed with test compounds for 10 hours. To generate
concentration-response curves, cells were treated in duplicate with
a range of serial compound dilutions (final DMSO concentration was
0.5%). To measure .beta.-galactosidase activity, lysates were
prepared using the Galacto-Star System (Applied Biosystems,
Bedford, Mass.). Total non-infrared luminescence was read on an
EnVision plate reader (Perkin Elmer, Turku, Finland). EC.sub.50
values for HSP70.beta./.beta.-galactosidase induction were
calculated using XLfit4 Microsoft Excel curve-fitting software. A
sample where the cells were treated with DMSO only was used a
negative control, and a sample of 17-AAG was used as a positive
control.
[1313] 4. Western Blotting of the HSP90 Client Protein HER-2
[1314] 1 million SKOV3 cells (American Type Culture Collection,
Rockville, Md.) were seeded in 35 mm wells in McCoy's 5A medium
containing 10% fetal bovine serum. 24 hours after seeding, cells
were treated with compounds serially diluted 2.5-fold in DMSO
(final DMSO concentration was 0.5%). After 16 hours of test
compound incubation, whole cell lysates were prepared by lysing
cells in 62.5 mM Tris-HCl, pH 7, 1% SDS, 10% glycerol. Proteins
were resolved by SDS-PAGE and transferred to PVDF membranes.
Membranes were probed with the appropriate primary antibodies
followed by incubation with secondary IRDye 680- or
800CW-conjugated antibodies (Li-Cor, Lincoln, Nebr.). HER-2/ERBB2
was analyzed using monoclonal antibodies (Cell Signaling
Technologies, Danvers, Mass.). Total HSP70 levels were also
analyzed using a mouse monoclonal antibody (Stressgen, Ann Arbor,
Mich.). PCNA was used as a control for protein loading and was
detected by a monoclonal antibody (Calbiochem, San Diego, Calif.).
Blots were scanned on the Odyssey (Li-Cor, Lincoln, Nebr.) and
signals corresponding to PCNA, HER-2/ERBB2, were quantified using
Li-Cor software. Loss of total HER-2/ERBB2 protein EC.sub.50s were
obtained by curve-fitting the ratios of total HER-2/ERBB2 signal
over PCNA protein signal using XLfit4 Microsoft Excel curve-fitting
software.
Example B
In Vitro HSP90 Binding Affinity of Compound of the Invention
[1315] The enzyme activities of the compounds of the present
invention against HSP90 were determined using the method disclosed
Example A-1. The compounds of the invention are inhibitors of
HSP90; the IC50 values of the exemplified compounds are typically
less than 1 .mu.M and more typically less than 100 nM. The
IC.sub.50 values of selected compounds are reported in Table 2.
TABLE-US-00005 TABLE 2 IC.sub.50 of Exemplified Compounds Against
HSP90 Binding Affinity Compound No IC.sub.50(nM) 33 4 35 13 37 6 40
10 45 10 58 5 59 8 61 3 65 10 75 10 78 4 79 6 83 8 85 4 93 8 96 13
99 8
Sequence CWU 1
1
21690DNAArtificial SequenceHuman cDNA sequence encoding residues
9-236 of human HSP90 (including a start and a stop codon)
1atggaccaac cgatggagga ggaggaggtt gagacgttcg cctttcaggc agaaattgcc
60cagttgatgt cattgatcat caatactttc tactcgaaca aagagatctt tctgagagag
120ctcatttcaa attcatcaga tgcattggac aaaatccggt atgaaagctt
gacagatccc 180agtaaattag actctgggaa agagctgcat attaacctta
taccgaacaa acaagatcga 240actctcacta ttgtggatac tggaattgga
atgaccaagg ctgacttggt caataacctt 300ggtactatcg ccaagtctgg
gaccaaagcg ttcatggaag ctttgcaggc tggtgcagat 360atctctatga
ttggccagtt cggtgttggt ttttattctg cttatttggt tgctgagaaa
420gtaactgtga tcaccaaaca taacgatgat gagcagtacg cttgggagtc
ctcagcaggg 480ggatcattca cagtgaggac agacacaggt gaacctatgg
gtcgtggaac aaaagttatc 540ctacacctga aagaagacca aactgagtac
ttggaggaac gaagaataaa ggagattgtg 600aagaaacatt ctcagtttat
tggatatccc attactcttt ttgtggagaa ggaacgtgat 660aaagaagtaa
gcgatgatga ggctgaataa 6902249PRTArtificial Sequence1- 21 =
6x-histidine tag and cleavage site and a methionine 22-249 = Amino
acid sequence for residues 9-236 of human HSP90a 2Met Gly Ser Ser
His His His His His His Ser Ser Gly Leu Val Pro1 5 10 15Arg Gly Ser
His Met Asp Gln Pro Met Glu Glu Glu Glu Val Glu Thr 20 25 30Phe Ala
Phe Gln Ala Glu Ile Ala Gln Leu Met Ser Leu Ile Ile Asn 35 40 45Thr
Phe Tyr Ser Asn Lys Glu Ile Phe Leu Arg Glu Leu Ile Ser Asn 50 55
60Ser Ser Asp Ala Leu Asp Lys Ile Arg Tyr Glu Ser Leu Thr Asp Pro65
70 75 80Ser Lys Leu Asp Ser Gly Lys Glu Leu His Ile Asn Leu Ile Pro
Asn 85 90 95Lys Gln Asp Arg Thr Leu Thr Ile Val Asp Thr Gly Ile Gly
Met Thr 100 105 110Lys Ala Asp Leu Val Asn Asn Leu Gly Thr Ile Ala
Lys Ser Gly Thr 115 120 125Lys Ala Phe Met Glu Ala Leu Gln Ala Gly
Ala Asp Ile Ser Met Ile 130 135 140Gly Gln Phe Gly Val Gly Phe Tyr
Ser Ala Tyr Leu Val Ala Glu Lys145 150 155 160Val Thr Val Ile Thr
Lys His Asn Asp Asp Glu Gln Tyr Ala Trp Glu 165 170 175Ser Ser Ala
Gly Gly Ser Phe Thr Val Arg Thr Asp Thr Gly Glu Pro 180 185 190Met
Gly Arg Gly Thr Lys Val Ile Leu His Leu Lys Glu Asp Gln Thr 195 200
205Glu Tyr Leu Glu Glu Arg Arg Ile Lys Glu Ile Val Lys Lys His Ser
210 215 220Gln Phe Ile Gly Tyr Pro Ile Thr Leu Phe Val Glu Lys Glu
Arg Asp225 230 235 240Lys Glu Val Ser Asp Asp Glu Ala Glu 245
* * * * *